recent coverage on our projects
23-Apr-2021 – AZD1222
RTL Nieuws - Huisarts gooit 60 vaccins AstraZeneca weg: 'Opkomst onvoorstelbaar laag
"Twee weken geleden hebben wij onze grote prikdag gehad", vertelt Blanker, huisarts in Zwolle, aan RTL Nieuws. Het was vlak na het weekend dat bekend werd dat AstraZeneca niet meer aan 60-minners gegeven mocht worden. Er kwamen weinig mensen opdagen. Te weinig. "We hebben toen een grote no-show gehad."
23-Apr-2021 – AZD1222
AD- Grote Britse studie: Pfizer en AstraZeneca beschermen na één prik even goed
Zowel het AstraZeneca- als het Pfizer-vaccin zorgt al na één prik voor een sterk lagere kans om corona te krijgen. Allebei zijn ze bovendien werkzaam tegen de Britse variant. Maar: na één prik kun je nog steeds besmet raken met het virus en het is niet uit te sluiten dat je het ook nog door kan geven.
22-Apr-2021 – AZD1222
NOS- Onzuiverheden in AstraZeneca-vaccin mogelijk oorzaak zeldzame bijwerking
De zeer zeldzame bijwerking van het AstraZeneca-vaccin, trombose in combinatie met een verlaagd aantal bloedplaatjes, kan misschien wel worden voorkomen, denken Duitse wetenschappers.
22-Apr-2021- AZD1222
CTV News - Blood clots from AstraZeneca shot reach rate of 7.9 per million doses: British regulator
Britain's medicines regulator on Thursday said there had been 168 major blood clots following a dose of AstraZeneca's COVID-19 vaccine, a rate of 7.9 clots per million doses, a jump in incidence from the previous week's figure.
22-Apr-2021- AZD1222
ABC News - Europe won't block AstraZeneca vaccine shipment to PNG, Trade Minister says
Australian trade minister Dan Tehan says the European Union will not block the export of 1 million AstraZeneca COVID-19 vaccines to Papua New Guinea.
22-Apr-2021- GRAd-COV2
Wired - A che punto sono i vaccini italiani di Reithera e Takis?
Non sono tra i primi arrivati, non è detto abbiano performance al livello di quelli già in uso e si basano su piattaforme vaccinali diverse dall'mRna, su cui invece l'Unione europea parrebbe volere puntare. Per i vaccini targati Reithera e Takis la strada è tutt'altro che in discesa
22-Apr-2021 – NVX-COV2372
https://www.bbc.com/news/uk-england-tees-56836877
BBC News - Novavax: Billingham plant on track to make 60 million doses
A factory on Teesside making the new Novavax Covid-19 vaccine is on target to make the 60 million doses ordered by the UK, bosses have confirmed.
Fujifilm Diosynth Biotechnologies in Billingham began production in February ahead of approval for its use, which is expected within weeks.
22-Apr-2021 – NVX-COV2373
Sky News - COVID-19: 'I'm hoping collaboration can continue across borders' says Novavax vaccine maker
The British manufacturer of the next coronavirus vaccine likely to be approved for general use in the UK has called on international governments to cooperate to ensure the global rollout is not interrupted by disputes.
22-Apr-2021- NVX-COV2373
Observer - Is Novavax the Next COVID-19 Vaccine on the Block? How It Works & Why It’s Important
The global COVID-19 vaccine campaign is getting increasingly complicated. While the Moderna and Pfizer/BioNTech vaccines are rolling out in full speed in the U.S., public health experts have agreed that it will likely take a less expensive and easier to transport vaccine to get the rest of the world inoculated.
22-Apr-2021 – GRAd-COV2
https://www.agi.it/cronaca/news/2021-04-22/covid-vaccino-reithera-12279838/
Agenzia Italia -Il vaccino italiano Reithera sarà pronto dopo l'estate
Prosegue "a pieno ritmo" la sperimentazione del vaccino italiano ReiThera, basato sulla tecnologia proprietaria dell'adenovirus isolato dal gorilla, giunto in fase 2-3.
21-Apr-2021 – AZD1222
https://globalnews.ca/news/7776494/eu-covid-vaccine-astrazeneca-johnson-johnson/
Global News - EU won’t take extra 300M doses of AstraZeneca, Johnson & Johnson: source
The European Union won’t take up an extra 300 million doses of AstraZenecaand Johnson & Johnson COVID-19 vaccines that it has secured as options under existing contracts, a senior EU official told Reuters.
21-Apr-2021 – NVX-COV2373
https://denver.cbslocal.com/2021/04/21/novavax-covid-vaccine-colorado/
CBS Local - U.S Study Of Novavax COVID Vaccine Continues With 2 More Shots For Volunteers
Study of a promising COVID-19 vaccine by Novavax is continuing in the U.S. and Mexico. Now, clinical trial participants, including me, are rolling up our sleeves for a third shot and then, three weeks later, a fourth.
13-Apr-2021 – AZD122
https://www.bbc.com/news/world-europe-56724992
BBC - AstraZeneca: Irish health body recommends vaccine restriction
The Oxford-AstraZeneca vaccine should be limited to over-60s, the Republic of Ireland's National Immunisation Advisory Committee (NIAC) has said.
The body oversees the Covid-19 vaccine rollout programme in the Republic.
It said that the vaccine's benefits may vary by age and that, as other vaccines are available, it has revised its vaccine recommendations, reports RTÉ.
All AstraZeneca vaccination clinics planned for Tuesday should now be cancelled, it has also been advised.
13-Apr-2021 – NVX-COV2373
NPR - What is Novavax, Australia’s third COVID vaccine option? And when will we get it?
As AstraZeneca is no longer the preferred vaccine for Australian adults under 50, attention is turning to what other COVID-19 vaccine options are in our arsenal.
13-Apr-2021 – mAbCo19
https://www.fortuneita.com/2021/04/13/covid-rino-rappuoli-racconta-il-super-anticorpo-made-in-ita/
Fortune Health - Covid, Rino Rappuoli racconta il super anticorpo Made in Italy
UN ‘GIOIELLO’ della ricerca italiana, che promette di ‘spegnere’ l’infezione da Sars-Cov-2 prima che diventi un incendio. È il super anticorpo monoclonale made in Italy sviluppato dal team di Rino Rappuoli, scienziato italiano celebre nel mondo, ideatore di numerosi vaccini tra cui quello contro il meningococco B. Rappuoli, Chief scientist di Gsk Vaccines a Siena, è coordinatore del Monoclonal Antibody Discovery (Mad) Lab di Fondazione Toscana Life Sciences, impegnato nello sviluppo di un potente anticorpo contro Covid-19, che si sta dimostrando estremamente promettente.
12-Apr-2021 – AZD1222
DutchNews - Ministers ‘consider coronavirus vaccine rethink’ after AstraZeneca chaos
The government will announce if there is to be a change in the vaccination strategy at Tuesday’s press conference, following widespread criticism of the approach to the AstraZeneca vaccine, broadcaster NOS said on Monday evening.
12-Apr-2021 – COVID-eVax
Ill Cittadino - Il punto su Covid-eVax, il vaccino monzese “elettrico”: «Formula a dna, efficacia aumentata dalla elettroporazione»
Lo ha definito un virus “furbo” che sfugge a tutto ciò che facciamo, che potrebbe diventare endemico e, peggio ancora, potrebbe compiere altri salti di specie passando dall’uomo ad altri animali. Per Lucio Rovati, presidente e direttore scientifico della monzese Rottapharm Biotech, le uniche armi ora a disposizione nella lotta al Sars Cov 2 sono i vaccini.
11-Apr-2021 – AZD122
Reuters - AstraZeneca says it had positive meeting with EU over vaccine row
AstraZeneca had a positive meeting with the European Commission last week, the Anglo-Swedish company said after an Italian newspaper said the group had not replied to an EU letter of complaint over COVID-19 vaccines within a 20-day deadline.
9-Apr-2021 – AZD1222
Science the Wire - Amid India Surge, Gavi Asserts Serum Institute’s Obligation to Supply Vaccines
Amidst growing demand at home, the Serum Institute of India is legally bound to ship doses of the coronavirus vaccine to COVAX, a spokesperson of Gavi, which is co-leading the global vaccine-sharing facility, told Reuters.
8-Apr-2021 – AZD1222
https://www.fiercepharma.com/manufacturing/very-stressed-serum-institute-india-asks-government-for-vaccine-production-boost
FiercePharma - 'Very stressed' Serum Institute asks government for $400M vaccine production boost
With its production capacity “very stressed,” the world’s largest producer of vaccines is seeking relief from its government.
The Serum Institute of India has requested a grant of more than $400 million to beef up production of the AstraZeneca COVID-19 vaccine. The investment would allow SII to increase output from around 70 million doses per month to more than 100 million by the end of May.
8-Apr-2021 -AZD1222
De Telegraaf - Kabinet hakt knoop door over prikken met AstraZeneca
De Gezondheidsraad komt waarschijnlijk in de loop van donderdagavond met een advies over het coronavaccin van AstraZeneca. Dat vaccin wordt voorlopig niet toegediend aan mensen die jonger dan 60 jaar zijn, vanwege mogelijke bijwerkingen.
8-Apr-2021 – AZD1222
https://www.lc.nl/friesland/Friese-huisartsen-klaar-voor-prikken-met-AstraZeneca-26755378.html
Leeuwarder Courant - Friese huisartsen klaar voor prikken met AstraZeneca
De Friese huisartsen gaan hun patiënten tussen 60 en 65 jaar waarschijnlijk een dezer dagen uitnodigen voor een vaccinatie tegen het coronavirus. De weg lijkt vrij nu het Europees geneesmiddelenagentschap EMA de voordelen van AstraZeneca vindt opwegen tegen de nadelen.
8-Apr-2021 – AZD1222
https://www.ft.com/content/3dd76041-d8ac-4465-99a5-4569e8b9706e
Financial Times - Spain and Italy to restrict AstraZeneca’s Covid jab to over-60s
Spain and Italy have moved to limit the use of the Oxford/AstraZeneca vaccine to people aged above 60, in shifts that will complicate the countries’ efforts to step up their vaccination programmes.
8-Apr-2021 – NVX-COV2373
AFR - Novavax firms as third vaccine for Australia
Australia’s regulator is assessing early data about the Novavax vaccine, which has a high chance of becoming the country’s third vaccine against COVID-19.The Therapeutics Goods Administration in January granted a provisional determination to Biocelect Pty Ltd, on behalf of Novavax Inc.
7-Apr-2021 – AZD1222
https://www.nrc.nl/nieuws/2021/04/07/de-prikstop-schept-verwarring-a4038920
NRC- Opkomst AstraZeneca-vaccinatie Zuid-Holland gekelderd door verwarring
Huisartsen De opkomst van zestigers voor de AstraZeneca-prik keldert bij Zuid-Hollandse huisartsen sinds vrijdag. In Drenthe blijft de opkomst hoog. „Moet ik die prik wel nemen?” is een vraag die nu vaak gesteld wordt.
7-Apr-2021 – AZD1222
Dutch News - Rare blood clots may be a side effect of AstraZeneca vaccine, EMA says
There may be a link between a rare form of thrombosis and the AstraZeneca coronavirus vaccine but the advantages of the vaccine outweigh the disadvantages, the Amsterdam-based European Medicines Agency said on Wednesday afternoon.
7-Apr-2021 – AZD1222
The Guardian - The Guardian view on the AstraZeneca vaccine: confidence from clarity
Every day, people take medicines with known side-effects. The risk is accepted when weighed against the benefit. But Covid vaccines are unfamiliar. There is no record of use over time to build public confidence. Still, they have been tested and proven to offer protection against the virus. By all usual medical standards, they are safe. That remains true for the AstraZeneca vaccine, despite an evolving picture that side-effects might include a rare blood clotting disorder.
7-Apr-2021- GRAd-COV2
La Voce di Rovigo - Reithera e Sputnik, parte la sperimentazione a Ferrara
Manca poco all’avvio della sperimentazione del vaccino Reithera a Ferrara. Le dosi sono in arrivo nella Farmacia dell'ospedale "Sant’Anna", mentre l’azienda ospedaliera sta stilando l’elenco dei possibili candidati, che forse saranno reclutati in un numero ristretto rispetto alle attese iniziali (il gruppo potrebbe essere ridotto a chi ha 65 anni o più). Lo scrive La Nuova Ferrara.
7-Apr-2021 – GRAd-COV2
La Nuova Ferrara - Ferrara, vaccino Reithera sono ore decisive. E intanto Unife testa “Sputnik V”
Per il vaccino italiano si valuta la platea dei possibili candidati Ferrara, con Roma e San Marino, valuta anche il siero russo
6-Apr-2021 – NVX-COV2373
Bethesda - Novavax plan outlines expansion of Gaithersburg corporate campus
The biotechnology company Novavax, which is at the forefront of the COVID-19 vaccine development operation, has submitted a new initial site plan to the city of Gaithersburg with the hope of further expanding its corporate campus.
4-Apr-2021 – VPM1002
IOL- New TB vaccine on the cards
Bacillus Calmette–Guérin (BCG), a tuberculosis (TB) vaccine, has for more than a 100 years been the sole TB vaccine that has been administered to newborn babies to help prevent chances of being infected with the bacteria.
1-Apr-2021 – NVX-COV2373
CNN Health - How the Novavax Covid-19 vaccine works
At the headquarters of biotechnology company Novavax, scientists are developing what they hope could soon be another Covid-19 vaccine for the United States and the world. Data from the company's large-scale Phase 3 clinical trial of the vaccine in the US and Mexico are expected this month, but the timeline depends on how quickly it accumulates data on the prevalence of disease in trial areas.
1-Apr-2021 – Covid-eVAX
Il Mattino - Vaccino italiano al Pascale: il primo volontario è Alessandro, 26 anni
Ha preso ufficialmente il via con la prima iniezione, oggi al Pascale la sperimentazione del vaccino italiano anti Covid-19 ideato da Takis. Un vaccino interamente made in Italy che vede uniti tre ospedali, uno del Nord, il San Gerardo di Monza, uno del centro, lo Spallanzani di Roma e per il Sud il Pascale di Napoli. I tre centri sono coinvolti nella sperimentazione di fase I/II. La fase 1 coinvolgerà 80 volontari sani divisi in 4 gruppi con dosi diverse somministrate con o senza richiamo, mentre in fase 2 si raggiungeranno fino a 240 soggetti sulle dosi più promettenti
31-Mar-2021 – AZD1222
Algemeen Dagblad - Telefoon bij huisartsen roodgloeiend door onrust over AstraZeneca-vaccin: 'Wat als ik dit vaccin niet wil?’
De telefoon staat roodgloeiend bij menig huisarts in de regio Utrecht omdat mensen ongerust zijn over de veiligheid van het AstraZeneca-vaccin. „Sommige mensen geven aan een prik met dit vaccin niet meer te zien zitten door de commotie en vragen wat de andere opties zijn.”
31-Mar-2021 – AZD1222
De Volkskrant - Onderzoek onder zorgmedewerkers: tweederde krijgt griepsymptomen na prik met AstraZeneca
Tweederde van de zorgmedewerkers die deelnamen aan een onderzoek naar bijwerkingen, kreeg een dag na inenting met AstraZeneca te maken met griepsymptomen. Bij veel mensen waren die symptomen zo fiks dat ze niet konden werken. De negatieve berichten over AstraZeneca komen ongelegen nu de vaccinatiecampagne toch al zo moeizaam verloopt.
31-Mar-2021 – AZD1222
NOS.nl -Leeftijdsgrens voor AstraZeneca-vaccinatie in Duitsland, wat doet Nederland?
Duitsland past opnieuw het vaccinatiebeleid aan voor prikken met het AstraZeneca-vaccin, vanwege onrust over mogelijke bijwerkingen. Het land vaccineert daarom vanaf vandaag alleen 60-plussers met dit vaccin.
31-Mar-2021 – AZD1222
NRC - GGD: wijs nieuwe doelgroepen aan voor inenting met AstraZeneca
Koepelorganisatie GGD GHOR wil dat het ministerie van Volksgezondheid en het RIVM snel bepalen welke nieuwe doelgroepen er met het AstraZeneca-vaccin kunnen worden ingeënt. Op dit moment vaccineren de GGD’s zorgmedewerkers met dat vaccin, maar de afgelopen dagen werden onvoldoende afspraken ingepland om alle vaccins op te maken. Die doses blijven nu in de opslag liggen, omdat de GGD’s ze niet mogen gebruiken voor andere doelgroepen.
31-Mar-2021 – AZD1222
Nu.nl – EMA ziet geen link tussen AstraZeneca-vaccin en bloedproblemen
Het Europese geneesmiddelenbureau (EMA) heeft tot nu toe geen aanwijzingen voor een verband tussen het AstraZeneca-vaccin en bloedproblemen. Onderzoek naar een eventueel verband gaat door.
31-Mar-2021 – AZD1222
Business Insider - AstraZeneca's COVID-19 shot will come too late for the US
Dr. Ashish Jha, a top US public-health expert, earlier this month laid out what he thought was an unpopular opinion.
Shortly after AstraZeneca announced that its coronavirus vaccine was found to be safe and effective in a 32,000-volunteer US trial, Jha argued that the US should donate its supply of the shot to other countries, rather than reserve it for use domestically.
31-Mar-2021 – GRAd-COV2
https://www.cremonaoggi.it/2021/03/31/reithera-bellini-sto-bene-il-19-seconda-dose/
Cremona Oggi - ReiThera, Bellini: "Sto bene, il 19 seconda dose"
due giorni dalla somministrazione del vaccino sperimentale ReiThera, la consigliera Comunale Stella Bellini racconta di stare bene: “Ho avuto qualche linea di febbre e mal di testa ieri (martedì 20 marzo, ndr), ma sono tutti effetti che mi aspettavo. Oggi sto meglio”.
30-Mar-2021 – NVX-COV2373
Reuters- Novavax COVID-19 vaccine could be approved by UK in April, Evening Standard says
LONDON (Reuters) - Britain could approve Novavax’s COVID-19 vaccine next month, the chief investigator for the shot’s trial told the Evening Standard newspaper.
30-Mar-2021 – AZD1222
https://nltimes.nl/2021/03/30/netherlands-blew-chance-invest-astrazeneca-vaccine-report
NL Times - Netherlands blew a chance to invest in AstraZeneca vaccine: Report
When the University of Oxford asked the Netherlands for a ten-million euro investment at the Halix vaccine plant in Leiden, it opened the door for the country, and likely the entire European Union, to gain access to millions more Covid-19 vaccine doses compared to what AstraZeneca delivered to the EU in the first quarter of 2021. The university's scientists were days away from securing the backing of the pharmaceutical firm for its AZD 1222 vaccine in late April when they approached the Netherlands with the request, anonymous sources told broadcaster NOS.
30-Mar-2021- GRAd-COV2
Parma Today - Sperimentazione del vaccino ReiThera: si cercano volontari a Parma
Lo studio è promosso da ReiThera S.R.L., azienda biotecnologica che ha sviluppato e produce il vaccino in collaborazione con l’Istituto Nazionale per le Malattie Infettive “Lazzaro Spallanzani” (IRCCS Istituto di Ricovero e Cura a Carattere Scientifico pubblico). La fase 1 è conclusa. L’Azienda Ospedaliero-Universitaria di Parma partecipa allo studio di fase 2 allo scopo di valutare la sicurezza e l’efficacia del vaccino. Il progetto è coordinato dall’Istituto Spallanzani e condotto all’Ospedale di Parma dal Prof. Gabriele Missale, medico dell’Unità Operativa Malattie Infettive ed Epatologia, diretta dal Prof. Carlo Ferrari. In questa fase, la sperimentazione vede la partecipazione di 27 centri, di cui 26 in Italia e 1 in Germania, e la somministrazione del vaccino a 900 persone.
30-Mar-2021 – NVX-COV2373
https://www.bbc.com/news/uk-england-tees-56570168
BBC - Novavax: Deal agreed to 'fill and finish' 60 million doses in UK
Tens of millions of doses of the Novavax vaccine will now be produced and packaged in north-east England, the prime minister has announced.
Boris Johnson said a deal had been agreed with GlaxoSmithKline (GSK) to bottle 60 million doses at its facility in Barnard Castle, County Durham.
30-Mar-2021 – NVX-COV2373
The Times - Britain seeks Covid vaccine security by making 60m Novavax doses
Almost 60 million doses of a coronavirus vaccine shown to be effective against the South African variant will be made and packaged in Britain.
Boris Johnson called the Novavax jab a “significant new weapon in our armoury against Covid” as ministers plan autumn booster jabs for older people to prevent a damaging surge next winter.
29-Mar-2021 – NVX-COV2373
De Volkskrant - Live: Britse regering gaat zestig miljoen doses van Novavax-vaccin zelf maken • Janssen-vaccins worden vanaf 19 april aan EU geleverd
De Britse regering heeft een deal met farmaceut GlaxoSmithKline gesloten voor de productie van zestig miljoen doses van het Novavax-vaccin. Dat maakte Boris Johnson bekend.
29-Mar-2021 – NVX-COV2373
https://www.ft.com/content/55f1776f-84bb-45bd-83cc-bdc825817879
The Financial Times- GSK to help manufacture 60m doses of Novavax Covid vaccine in UK
British drugmaker GlaxoSmithKline will be part of the manufacturing process for up to 60m doses of the Covid-19 vaccine developed by US rival Novavax in an agreement set to boost UK production of coronavirus jabs.
29-Mar-2021 – NVX-COV2373
https://www.pharmaceutical-technology.com/news/serum-institute-novavax-vaccine/
Pharmaceutical Technology - Serum Institute to delay launch of Novavax vaccine in India
The Serum Institute of India (SII) has announced that the launch of the Covid-19 vaccine Covovax developed jointly by the company and Novavax is likely to be delayed to September in the country.
29-Mar-2021 – AZD1222
https://www.bnr.nl/nieuws/gezondheid/10436455/aarzeling-blijft-rond-toediening-vaccin-astrazeneca
BNR Nieuwsradio - AARZELING BLIJFT ROND TOEDIENING VACCIN ASTRAZENECA
Huisartsen ervaren nog altijd veel aarzeling bij patiënten rond het AstraZeneca-vaccin, meldt de Landelijke Huisartsen Vereniging aan BNR. Hoewel mensen in meerderheid uiteindelijk wél voor vaccinatie kiezen, moet daar vaak behoorlijk veel overredingskracht van de huisarts aan te pas komen. Het percentage mensen wat veel vertrouwen heeft in de werking van het vaccin daalde van 60 naar 50 procent
29-Mar-2021 -azd1222
Nu.nl - 'Britten zien AstraZeneca-vaccin meer als verlossing dan als twijfel'
In het Verenigd Koninkrijk wordt de strenge lockdown vanaf maandag versoepeld. Mensen mogen buiten met z'n zessen bij elkaar komen en buitensporten zijn weer toegestaan. De Britse premier Boris Johnson kwam eind februari met een routekaart voor versoepelingen. Nederland had ook zo'n kaart, maar bij ons is die in de prullenbak beland. Zorgt zo'n routekaart met uitzicht op betere tijden ook voor meer positiviteit onder de Britten? Daarover gaan we in gesprek met RTL Nieuws-correspondent Anne Saenen.
29-Mar-2021 – AZD1222
https://www.bbc.com/news/business-56570364
BBC - AstraZeneca vaccine - was it really worth it?
"It's appalling the way AstraZeneca has been treated. I wouldn't blame them if they were thoroughly fed up and decided to bow out of the covid vaccine business."
25-Mar-2021 – AZD1222
DutchNews.nl - AstraZeneca asks EMA to approve Leiden vaccine production plant
British-Swedish pharmaceuticals company AstraZeneca has asked the European Medicines Agency to approve vaccines produced at the Halix plant in Leiden for use in the EU.
25-Mar-2021 – mAbCo19
Siena News - La lezione di Rappuoli: “Con anticorpi e vaccini saremo liberi dal Covid nel 2021”
E ‘iniziata e si è conclusa con un paragone la lectio magistralis, in occasione del Capodanno senese nella sala del Mappamondo, di Rino Rappuoli, chief scientist di Gsk di Siena e direttore del Mad Lab di Tls: che cosa è cambiato a Siena dal 1348, anno della peste, al 2020, anno del covid? “Poco. Anche qualche mese fa abbiamo affrontato la pandemia con quarantene e distanziamento sociale -spiega-. L’unica grande differenza è che nel 2020 abbiamo prodotto ciò che ci permetterà di liberarci dal coronavirus nel 2021”.
25-Mar-2021 – GRAd-COV2
Ragusa News- ReiThera, ecco le prime “cavie” siciliane del vaccino italiano
I primi sette volontari si sono presentati ieri al Policlinico per l’avvio della sperimentazione siciliana sul vaccino italiano Reithera, di cui avevano dato notizia su Ragusanews: solo ad alcuni sarà iniettato però il siero, ad altri sarà somministrata una innocua soluzione fisiologica, così da avere un riscontro sul placebo. I "collaudatori" saranno in tutto 100.
24-Mar-2021- AZD1222
NOS.nl - 'Relatief veel bekende bijwerkingen na eerste prik met AstraZeneca'
Vrouwen tot 65 jaar die het AstraZeneca-vaccin krijgen, ervaren na de eerste prik ongeveer twee keer zo vaak bekende bijwerkingen als vrouwen uit dezelfde leeftijdsgroep die het Pfizer/BioNTech-vaccin krijgen. Dat stelt Bijwerkingencentrum Lareb op basis van onderzoek onder bijna 4000 vrouwen.
24-Mar-2021 – GRAd-COV2
Nuova Irpinia - Vaccino Reithera, al Moscati iniziata la sperimentazione sull’uomo
È iniziata al Moscati di Avellino la sperimentazione sull’uomo del vaccino ReiThera. Da oggi 50 volontari «sono stati arruolati per la fase decisiva della sperimentazione in corso presso il San Giuseppe Moscati. L’Azienda Ospedaliera di Avellino «è stata individuata tra i 27 centri clinici (26 in Italia e uno in Germania) chiamati a partecipare alla seconda fase dello studio», si ricorda in una nota.
24-Mar-2021 – GRAd-COV2
Affar Italiani - Vaccino italiano ReiThera, partita con grande adesione di volontari la seconda fase di sperimentazione
Entra oggi in fase avanzata di sperimentazione clinica il vaccino anti-Covid 'made in Italy' di ReiThera, società con sede a Castel Romano. Lo studio di Fase 2/3, denominato 'Covitar, ha già ricevuto l’autorizzazione dell’Agenzia italiana del farmaco ed è stato valutato positivamente dal Comitato etico dell’Istituto nazionale per le malattie infettive Spallanzani di Roma.
23-Mar-2021 – NVX-COV2373
https://www.gazettelive.co.uk/news/teesside-news/production-novavax-vaccine-gets-under-20237098
Gazette - Production of the Novavax vaccine gets under way in Billingham
Production of the Novavax covid-19 vaccine is already well under way in Billingham.Fujifilm Diosynth Technologies has begun manufacturing the jab, which is set to be the UK's fourth approved covid vaccine, the company's chief executive has confirmed.
23-Mar-2021 – AZD1222
European Biotechnology - AZD1222 claims 79% efficacy in pivotal US study
For exactly one day, the belief that AstraZeneca's COVID-19 vaccine AZD1222 may be better than its reputation lasted. But because the ailing vaccine manufacturer had apparently embellished the presentation of phase III results, the US authorities intervened. On Monday, AstraZeneca reported that In its ranomised phase III study, which enrolled 32,449 healthy adults at 88 sites in the US, Peru and Chile, AZD1222 reduced infections by 79% and prevented 100% of severe disease progression.
23-Mar-2021 – AZD1222
Pharmacy Times - Fauci: DSMB Challenge of New AstraZeneca COVID-19 Vaccine Data Is an ‘Unfortunate Incident’
Following a review of the latest interim data released by AstraZeneca on its US phase 3 clinical trial assessing the 2-dose AZD1222 COVID-19 vaccine, the Data and Safety Monitoring Board (DSMB) expressed concern at the inclusion of what may have been outdated data.
23-Mar-2021- AZD1222
https://www.miragenews.com/update-following-statement-by-niaid-on-azd1222-532925/
Mirage News - Update following statement by NIAID on AZD1222 US Phase III trial data
The numbers published yesterday were based on a pre-specified interim analysis with a data cut-off of 17 February.
23-Mar-2021 – AZD1222
Indian Express - Explained: Why interval between Covishield doses has been raised to 8 weeks
The government has decided to increase the interval between the first and second doses of Covishield to up to eight weeks in its ongoing vaccination drive against Covid-19. Covishield is Serum Institute of India’s version of AZD1222, the vaccine developed by AstraZeneca in collaboration with the University of Oxford.
23-Mar-2021 – AZD1222
Business Insider India - Clinical trials indicate AstraZeneca protects against COVID-19, says America's National Institutes of Health
Results from a large clinical trial in the US and South America indicate that the AstraZeneca Covid-19 vaccine is well-tolerated and protects against symptomatic Covid-19 disease, the American National Institutes of Health (NIH) said.
23-Mar-2021 – AZD1222
Hindustan Times - Centre tells states to widen gap between Covishield doses. Here’s why
The health ministry clarified that the revised time interval between two doses is applicable only to Covishield, the made-in-India version of the Oxford-AstraZeneca AZD1222 vaccine, and not to Covaxin, the indigenously developed shot.
22-Mar-2021 – NVX-COV2373
Yorkshire evening post - When will Novavax be approved in the UK? Date Covid vaccine could get approval - and how it compares to AstraZeneca
As the Covid vaccine rollout continues across the UK, attention turns to the next wave of jabs that could be deployed to help vaccinate against the deadly coronavirus.
22-Mar-2021 – GRAd-COV2
Gazzetta del Sud – Carofiglio volontario per il test del vaccino ReiThera: "Non mi sento un eroe"
E’ partita ufficialmente la sperimentazione del vaccino contro il Covid ReiTheraall’azienda ospedaliera Sant'Anna e San Sebastiano di Caserta. Tra i 5 volontari, sabaro scorso alle 9,30 per la somministrazione è arrivato anche lo scrittore Gianrico Carofiglio, così come aveva annunciato in un’intervista televisiva. «Non mi sento un eroe, quando ho saputo della sperimentazione mi è venuto spontaneo partecipare», ha detto ai cronisti.
22-Mar-2021 – AZD1222
Republic World - COVID: AstraZeneca Vaccine Shows 'no Evidence' For Increased Blood Clot Risk, Says Study
AstraZeneca on Sunday announced that its AZD1222 vaccine, co-developed by Oxford, has demonstrated 100 percent efficacy against the severe COVID-19 infection and hospitalization. The pharmaceutical company claimed that the US-led clinical trials on 32,000 participants in Chile and Peru also reaffirmed that the vaccine was safe and was “not associated with an increase in the overall risk of blood clots [thromboembolic events].
22-Mar-2021- AZD1222
Morningstar TOP NEWS: AstraZeneca jab validated as safe and effective by US study
AstraZeneca PLC on Monday announced that its vaccine, co-developed by Oxford University, is 100% effective against severe Covid-19 and at keeping people out of hospital with severe illness.
AstraZeneca shares were up 1.0% at 7,183.39 pence each in London on Monday morning.
22-Mar-2021- GRAd-COV2
https://qds.it/covid-a-palermo-via-alla-sperimentazione-del-vaccino-reithera/?refresh_ce
QDS.it - Covid, a Palermo via alla sperimentazione del vaccino ReiThera
E’ partita anche al Policlinico di Palermo la sperimentazione del vaccino italiano ReiThera.
22-Mar-2021 – AZD1222
Benzinga - AstraZeneca Reported AZD1222 US Phase III Trial Met Primary Efficacy endpoint in Preventing COVID-19 at Interim Analysis; Said Vaccine is 79% Effective at Preventing Symptomatic COVID-19
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.
18-Mar-2021- AZD1222
European Biotechnology - EMA recommends to continue AZD1222 vaccinations
After the stops of AstraZeneca's COVID-19 vaccine or specific batches of it in 13 EU member states, the EU regulatory authority EMA has analysed the incidence of rare thrombolytic events and potential causal links to the adenoviral vaccine AZD-1222 in the EU. Today, the authority in Amsterdam confirmed what its chief Emer Cooke had already indicated two days earlier: the EMA's upholds its recommendation that the benefits of vaccination by far outweigh the disadvantages. Previously the World Health Organisation has called on nations to continue vaccinations with AZD1222.
18-Mar-2021 – GRAd-COV2
Pharmaweb - ReiThera’s COVID-19 Vaccine Candidate Enters Phase 2/3 Clinical Study
ReiThera Srl, a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and medicinal products for advanced therapies, today announces the start of its Phase 2/3 clinical study of GRAd-COV2, its vaccine candidate against the novel coronavirus (SARS-CoV-2).
17-Mar-2021 – AZD1222
Biospectrum Asia - Daiichi Sankyo begins manufacture of the AstraZeneca COVID-19 Vaccine in Japan
Daiichi Sankyo Company, Ltd announced on March 12, 2021, that it has started manufacturing the AstraZeneca COVID-19 vaccine (AZD1222) in Japan. The marketing approval application for AZD1222 in Japan was submitted by AstraZeneca K.K. on February 5, 2021.
17-Mar-2021 – GRAd-COV2
https://www.zonedombratv.it/reithera-il-vaccino-italiano-ecco-come-funziona/
Zone Dombra TV- ReiThera, il vaccino italiano. Ecco come funziona
Il tema vaccino mai come in questo ultimo anno ha interessato le persone. L’argomento è uno dei più discussi dell’ultimo periodo. Con la campagna vaccinale aumenta la speranza di debellare il coronavirus. E arriva il vaccino italiano ReiThera.
17-Mar-2021 – GRAd-COV2
Giornale di Sicilia - Vaccino italiano Reithera, al Policlinico di Palermo la sperimentazione: 800 euro ai volontari
Il Policlinico «Paolo Giaccone» di Palermo, tra i centri clinici individuati per sperimentare il vaccino anticovid italiano GrAd-Cov.2 (meglio conosciuto come ReiThera), è pronto per la seconda fase del percorso che potrebbe già partire la prossima settimana. A dirlo è Antonio Cascio, direttore della Uoc di Malattie Infettive e Tropicali e professore all’Università di Palermo, intervistato da Insanitas.
17-Mar-2021 – GRAd-COV2
Secolo di Italia - Il vaccino italiano ReiThera verso la fase 2. “Efficace e ben tollerato”. La sperimentazione prosegue
A che punto è la sperimentazione del vaccino italiano della ReiThera? Il direttore del reparto di Malattie Infettive del policlinico di Palermo Antonio Cascio fotografa lo stato dell’arte in un’intervista al Giornale. Il policlinico palermitano, infatti, partecipa agli studi di seconda e terza fase sul vaccino della società biotecnologica italiana ReiThera. In collaborazione con l’istituto “Spallanzani”.
17-Mar-2021- GRAd-COV2
Younipa - Palermo, 800 euro ai volontari del vaccino Reithera, come candidarsi
Vaccino Reithera. Il Policlinico «Paolo Giaccone» di Palermo, tra i centri clinici individuati per sperimentare il vaccino anticovid italiano GrAd-Cov.2 (meglio conosciuto come vaccino ReiThera), è pronto per la seconda fase del percorso che potrebbe già partire la prossima settimana. A dirlo è Antonio Cascio, direttore della Uoc di Malattie Infettive e Tropicali e professore all’Università di Palermo, intervistato da Insanitas.
16-Mar-2021 -J.POD
Bioprocess Online - G-CON Manufacturing And Just – Evotec Biologics Complete Installation Of Cleanroom POD's
College Station, TX and Redmond, WA (PRWEB) - G-CON Manufacturing, the leader in prefabricated, flexible cleanroom solutions, announced today that it has successfully delivered and installed multiple PODs to Just – Evotec Biologics, a wholly-owned Seattle-based company of Evotec SE. The delivery advances the completion of the first J.POD® manufacturing facility in North America, a one-of-a-kind cGMP biomanufacturing facility that features small intensified bioprocessing operations housed inside G-CON cleanroom PODs. The news comes just weeks after Evotec’s announcement of Just – Evotec Biologics’ expanded contract with the Department of Defense for the manufacturing of anti-SARS-CoV-2 monoclonal antibodies.
16-Mar-2021 – NVX-COV2373
https://cnnphilippines.com/news/2021/3/16/Philippines-signs-supply-agreement-Novavax-vaccine.html
CNN Philippines - PH secures 30M Novavax doses
The Philippines has finally secured 30 million COVID-19 vaccine doses with US drugmaker Novavax, vaccine czar Carlito Galvez Jr. bared Tuesday.
In a virtual briefing with Presidential Spokesperson Harry Roque, Galvez said the supply agreement which covers the 30 million Covovax vaccine doses was signed during his meeting with the representatives of Serum Institute of India last week.
16-Mar-2021 – NVX-COV2373
https://www.biocentury.com/article/635019/gregory-glenn-on-next-steps-for-novavax-s-covid-19-vaccine
Biocentury - Gregory Glenn on next steps for Novavax’s COVID-19 vaccine
Novavax has proposed that FDA accept final data from a U.K. Phase III study of its COVID-19 vaccine candidate, supplemented by data from a Phase II study conducted in South Africa, as the basis for an emergency use authorization, the company’s president for R&D, Gregory Glenn, told BioCentury.
16-Mar-2021 – AZD1222
https://www.manilatimes.net/2021/03/16/news/national/astrazeneca-vouches-for-vaccines-safety/851613/
AstraZeneca vouches for vaccine’s safety
Manila Times- British-Swedish drugmaker AstraZeneca said there is no scientific evidence to back claims that its coronavirus disease 2019 (Covid-19) vaccine, AZD1222, triggered blood clotting or pulmonary embolism.
15-Mar-2021 – AZD1222
Why are countries suspending the AstraZeneca vaccine?
France, Germany and Italy are the latest countries to announce a temporary pause on the use of the Oxford/AstraZeneca coronavirus vaccine while reports of blood clots are investigated.
15-Mar-2021 – GRAd-COV2
Business Insider Italia - Vaccino italiano: quanti soldi pubblici ha speso l’Invitalia di Arcuri per il 27% di Reithera. E che poteri avrà
Per 15 milioni di euro, il mese scorso, l’azienda pubblica Invitalia guidata da Domenico Arcuri è diventata azionista al 27% di Reithera, la società al lavoro sul vaccino italiano contro il Covid-19, in collaborazione con l’Istituto Spallanzani. In questo modo, considerando anche i 49 milioni di finanziamenti annunciati alla fine di gennaio, sale a 64 milioni l’impegno complessivo di Invitalia (società di proprietà del ministero dell’Economia) su Reithera, che si inserisce nel solco tracciato dal decreto legge del 14 agosto 2020, che tra le altre cose aveva rifinanziato il Fondo per le emergenze nazionali anche con l’obiettivo di destinare risorse alla “ricerca e sviluppo e all’acquisto di vaccini e anticorpi monoclonali prodotti da industrie del settore, anche attraverso l’acquisizione di quote di capitale a condizioni di mercato”.
15-Mar-2021 – AZD1222
https://pharmaphorum.com/news/ireland-suspends-astrazeneca-covid-19-vaccine-shots/
Pharma Phorum - Ireland, Netherlands suspend AstraZeneca COVID-19 vaccinations
Ireland and the Netherlands have joined Norway, Denmark, Bulgaria and Iceland in suspending vaccinations with Oxford/AstraZeneca’s COVID-19 vaccine, shortly after the World Health Organization came out in support of the shot.
14-March-2021 – AZD1222
The Wire - India Expected to Review Covishield After Reports of Blood Clots After Vaccination
New Delhi: Indian drug regulators are expected to review data on one of the two candidate vaccines in its national COVID-19 vaccination drive after reports that some shot recipients had complained of unusual blood-related illnesses.
13-Mar-2021 – AZD1222
Hindustan Times- No clotting case in India after Oxford dose: Officials
No cases of adverse event involving blood clots have been reported in India in the case of the Oxford-AstraZeneca vaccine, according to top officials involved in the country’s coronavirus inoculation campaign, who also said a deeper review of post-vaccination side effects will be carried out next week.
13-Mar-2021 – NVX-COV2373
The Hindu - Coronavirus | Novavax reports 96.4% efficacy on original virus
Novavax, a U.S.-based biotechnology company developing a recombinant vaccine for COVID-19, announced a final efficacy of 96.4% against mild, moderate and severe disease caused by the original SARS-CoV-2 strain in a pivotal Phase 3 trial in the United Kingdom (U.K.).
12-Mar-2021 – AZD1222
Manila Times - PH downplays AstraZeneca ‘clotting’ reports, to continue vaccinations
THERE is no need to stop the distribution of the vaccines from AstraZeneca in the Philippines, the government said on Friday, amid reports of “clotting” experienced by recipients from several countries in Europe some of which allegedly resulted in deaths.
12-Mar-2021 – NVX-COV2373
Business Insider – Novavax surges 12% as its COVID-19 vaccine is found to be 96% effective in preventing the original virus strain
Shares in Novavax rose as much as 20% in premarket trading Friday after the company announced its coronavirus strain of the Covid-19 virus in a third stage trial conducted in the UK.
11-Mar-2021 – AZD1222
https://www.evaluate.com/vantage/articles/news/astras-covid-19-vaccine-woes-deepen
Evaluate - Astra’s Covid-19 vaccine woes deepen
Astrazeneca's PR battle with its Covid-19 vaccine is intensifying. AZD1222 had already faced questions about its efficacy, and now safety is under the spotlight – with the latest scare coming today from Denmark, which has suspended use of the jab as concerns about blood clots mount.
11-Mar-2021 – NVX-COV2373
https://time.com/5946225/novavax-covid-19-phase-3-results/
Time - Novavax Reports Its COVID-19 Vaccine is 96% Efficacious, Based on Phase 3 Trial Results
Novavax reported on March 11 that its COVID-19 vaccine is 96% efficacious in reducing mild, moderate or severe disease. The Maryland-based company joins the handful of manufacturers that have reported encouraging data on a COVID-19 vaccine; three, Pfizer-BioNTech, Moderna and Johnson & Johnson’s Janssen Pharmaceuticals, have already received emergency use authorization for their shots from the U.S. Food and Drug Administration
10-Mar-2021 – NVX-COV2373
The Wall Street Journal -Covid-19 Vaccines Targeting Multiple Variants Are in the Works at Moderna, Novavax
Researchers are trying to get ahead of variants like those identified in the U.K., South Africa and Brazil.
10-Mar-2021 – mAbCo19
https://www.repubblica.it/cronaca/2021/03/10/news/covid_vaccini-291508923/
La Repubblica - Covid, Rino Rappuoli:" Puntiamo ai nostri monoclonali". E una volta vaccinati "andranno fatti i richiami"
Paid content
10-Mar-2021 – NVX-COV2373
https://www.investing.com/news/jp-morgan-stick-to-their-buy-rating-for-novavax-2442163
Investing.com - J.P. Morgan Stick to Their Buy Rating for Novavax
J.P. Morgan analyst Eric Joseph maintained a Buy rating on Novavax (NASDAQ:NVAX) on Tuesday, setting a price target of $285, which is approximately 67.75% above the present share price of $169.9. Joseph expects Novavax to post earnings per share (EPS) of -$2.70 for the first quarter of 2021.
9-Mar-2021 – mAbCo19
https://www.lanazione.it/siena/cronaca/vaccini-e-anticorpi-la-capitale-è-qui-1.6111422
La Nazione - Vaccini e anticorpi La capitale è qui
Rino Rappuoli, chief scientist Gsk e padre degli anticorpi monoclonali di Tls, in questi tempi di Covid è entrato nel Pantheon dei ricercatori più ascoltati. Per il ministro della Salute, Roberto Speranza, per il presidente della Regione Eugenio Giani, per tutti i politici e le istituzioni che hanno visitato i laboratori di Toscana Life Sciences, Rappuoli è l’uomo che può contribuire a debellare un virus che ha piegato il mondo e neutralizzato molte sedicenti superpotenze. Da mesi punta tutto sugli anticorpi. E ora che sono finalmente iniziati i test clinici, Rappuoli ostenta un po’ più di certezze.
9-Mar-2021 – NVX-COV2373
Fox Business - Novavax CEO says 150M COVID vaccine doses can be manufactured per month
Novavax CEO and President Stanley C. Erck joined FOX Business' “Varney and Co.” to discuss the manufacturing capability and efficacy of his company’s two-shot coronavirus vaccine.
9-Mar-2021 – mAbCo19
La Repubblica - Pisa, via ai test degli anticorpi monoclonali AstraZeneca su due giovani volontari. Il professor Menichetti: "Noi i primi in Italia"
Paid content
9-Mar-2021 – GRAd-COV2
La Stampa - Anche a Latina la sperimentazione del vaccino Reithera: si cercano volontari
L' obiettivo è quello di produrre quanto prima il primo vaccino anti-Covid italiano. Così, dopo l'ospedale “Moscati” di Avellino, dalla prossima settimana, anche il Santa Maria Goretti di Latina, ospiterà la fase 2-3 della sperimentazione del vaccino anti-Covid (GrAd-CoV-2) sviluppato dall'azienda ReiThera insieme all'Inmi Spallanzani di Roma.
9-Mar-2021 – GRAd-COV2
Il Caffè - Cercasi volontari per testare vaccino ReiThera e donatori di plasma iperimmune
La lotta contro il covid affila ancora di più le proprie armi grazie alla scienza e alla ricerca. La Asl di Latina sta lavorando in prima linea sin dall’inizio dell’emergenza, ma stavolta fa un passo in più, perché sarà tra i centri italiani dove sarà avviata la sperimentazione del vaccino italiano ReiThera e dalla prossima settimana selezionerà circa 50 volontari.
6-Mar-2021 – GRAd-COV2
La Stampa - Covid, in autunno l’Italia produrrà i vaccini. Inizia la fase 2 della sperimentazione ReiThera
ROMA. Il vaccino italiano inizia la fase 2 della sperimentazione. Entro aprile si concluderà l’immunizzazione dei volontari. La via italiana al vaccino è sostenuta dai finanziamenti statali per ReiThera, secondo il contratto di sviluppo approvato dal consiglio di amministrazione di Invitalia. Per un investimento industriale di ricerca da 81 milioni di euro.
6-Mar-2021 – AZD1222
https://reliefweb.int/report/mali/covid-19-vaccines-arrive-covax-facility-becomes-reality-mali
Reliefweb -COVID-19 vaccines arrive as the COVAX Facility becomes a reality in Mali
Mali has just taken delivery of 396,000 doses of the vaccines against COVID-19. President Bah N’Daw led the official delegation to the international airport in Bamako to take delivery of the consignment.
6-Mar-2021 – AZD1222
https://www.manilatimes.net/2021/03/06/news/govt-races-to-beat-variants-mutations/847813/
The Manila Times - Govt races to beat variants, mutations
The Government is considering the simultaneous rollouts of the coronavirus vaccines of Sinovac and AstraZeneca to head off the growing threat of the virus’ new mutations.
5-Mar-2021 – mAbCo19
Les Echos -Covid : l'étude qui bouleverse nos certitudes sur la résistance du virus
Dans une expérience impressionnante ayant consisté à injecter la souche initiale du coronavirus SARS-CoV-2 dans le sérum riche en anticorps neutralisants d'un ancien malade du Covid-19, une équipe de scientifiques a montré qu'il suffisait de 80 jours à la sélection naturelle pour transformer cette souche initiale en un virus mutant, contre lequel les anticorps sont sans effet.
5-Mar-2021 – mAbCo19
Il Giornale - Monoclonali, via alla sperimentazione clinica. L'ipotesi: "Efficaci anche contro le varianti"
Gli anticorpi monoclonali «made in Italy», realizzati dal team dello scienziato Rino Rappuoli, cominciano finalmente la sperimentazione clinica. Il trial si svolgerà allo Spallanzani di Roma e nel Centro ricerche cliniche di Verona. Infialato dall'Istituto biochimico Giovanni Lorenzini, l'anticorpo «sarà testato, nei prossimi mesi, prima sui volontari sani (fase I) per verificarne la sicurezza, e poi su pazienti positivi al Covid-19 (fasi successive di sviluppo clinico) per l'ottimizzazione della dose e le verifiche di efficacia».
5-March-2021 – AZD1222
Manila Times - AstraZeneca vaccine eyed for senior health workers
Vaccine czar Carlito Galvez Jr. on Thursday said the AstraZeneca’s coronavirus vaccine from the Covax Facility might be allocated to elderly health care workers.
4-Mar-2021 – Covid-eVax
https://telenord.it/a-monza-napoli-e-roma-e-iniziato-studio-clinico-vaccino-italiano-contro-covid-19
Telenord - Vaccino italiano, Bonfanti: "Entro fine anno si concluderà fase due sperimentazione"
A Monza, Napoli e Roma è iniziato studio clinico vaccino italiano contro Covid-19.I primi volontari sani hanno ricevuto la dose iniziale del vaccino a DNA contro COVID-19 denominato COVID-eVax ideato da Takis e sviluppato in collaborazione con Rottapharm Biotech.
4-Mar-2021 – NVX-COV2373
News Medical Life Sciences -Novavax COVID-19 vaccine shows efficacy against South African SARS-CoV-2 variant
Researchers in the United States and South Africa report that the NVX-CoV2373 vaccine from Novavax has proved effective at preventing coronavirus disease (COVID-19) caused by the B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has recently emerged in South Africa.
4-Mar-2021 – mAbCo19
Go News - Covid, via alla sperimentazione clinica per la cura a base di anticorpi monoclonali
L’impegno contro il COVID-19 del Monoclonal Antibody Discovery (MAD) Lab di Fondazione Toscana Life Sciences prosegue con l’avvio degli studi clinici per la verifica della cura a base di anticorpi monoclonali. Toscana Life Sciences Sviluppo annuncia, infatti, che l’anticorpo monoclonale umano MAD0004J08, individuato dal team di ricerca coordinato dal Prof. Rino Rappuoli come il più promettente in risposta all’infezione da SARS-CoV-2, sarà sottoposto ai trial clinici.
4-Mar-2021 – mAbCo19
Corriere della Sera - Anticorpi monoclonali contro il Covid, via ai test sull’uomo in Italia. Rappuoli: «Potrebbero farci guarire in 3-4 giorni»
Dall’estate si potrà forse guarire dal Covid-19 con una semplice iniezione intramuscolare, fatta in ospedale, a casa o dal medico. Una volta che il liquido della fiala sarà iniettato, basteranno tre o quattro giorni per guarire e sconfiggere il Coronavirus.
4-March-2021 – AZD1222
https://pharmaphorum.com/news/germany-backtracks-on-az-covid-vaccine-age-restriction/
Pharma Phorum - Germany backtracks on AZ COVID vaccine age restriction
Germany has decided that AstraZeneca’s COVID-19 vaccine should be approved for use in the over-65s after all, reversing its earlier restriction in that age group.
The country’s drugs regulator previously limited use of the vaccine to the under-65s only, claiming that the data in the older age group was inadequate, even though the European Commission had approved the shot for all adults aged over 18.
3-Mar-2021 – AZD1222
https://en.interfax.com.ua/news/general/727697.html
Interfax Ukraine - Covishield and Oxford-AstraZeneca AZD1222 COVID-19 vaccines identical – UK Ambassador
British Ambassador to Ukraine Melinda Simmons emphasizes that the vaccines for the coronavirus disease COVID-19 Covishield and Oxford-AstraZeneca AZD1222 are identical, since the former is only the licensed name of the latter being produced in India.
2-Mar-2021 – mAbCo19
https://www.tpi.it/cronaca/covid-rino-rappuoli-cellule-monoclonali-intervista-video-20210302750632/
TPI - Ecco l’italiano che ci curerà dal virus: parla Rino Rappuoli | VIDEO
1-Mar-2021 – NVX-COV2373
The Jerusalem Post - Novavax COVID-19 shot could be cleared for U.S. use as early as May -CEO
Novavax Inc's chief executive said on Monday its COVID-19 vaccine could be cleared for use in the United States as soon as May if US regulators authorize it based on data from the company's British trial, which could be completed as soon as April.
1-Mar-2021- NVX-COV2373
Barron’s- Novavax Hopes to Start Supplying Covid Shots This Spring
Covid-19 cases are subsiding, vaccine megasites are opening across the country, and the U.S. government just authorized a third Covid vaccine. But most of America and the world remains unvaccinated, and investors have awarded a $15 billion capitalization to vaccine start-up Novavax, which hopes to seek U.S. authorization for its Covid entrant in the second quarter of 2021.
1-Mar-2021 – GRAd-COV2 and Covid-eVax
Il messaggero - Takis e Reithera, i vaccini italiani a che punto? Test, dosi necessarie, proprietà e tempi
Un centinaio nel mondo i vaccini già in distribuzione e somministrazione o in fase di sperimentazione, ma ora qualcosa si muove anche in Italia, e presto il nostro Paese produrrà vaccini senza doverli acquistare all'estero. La lotta al coronavirus passa dal Lazio, con tre imprese biotecnologiche impegnate sul vaccino: Reithera, Takis e Irbm, le prime due operanti nel distretto tecnologico di Castel Romano, mentre la terza è a Pomezia, nell’ex stabilimento del colosso farmaceutico Merck&Co.
1-Mar-2021 – NVX-COV2373
https://www.ft.com/content/22d3805e-c304-4d95-ae32-f559ff34886a
Financial Times - Novavax closes in on Covid triumph after 33 years of failure
Less than a year before the Covid-19 pandemic ravaged the world, Novavax was facing delisting from the Nasdaq. The pharmaceutical company had poured hundreds of millions of dollars into research and development for vaccines — and yet, at 33 years old, was approaching middle age without a single approved shot.
1-Mar-2021 – GRAd-COV2
India education diary - European Commission Approves €40 Million Italian Aid Measure To Support Coronavirus Related Research And Development Activities
The European Commission has approved a €40 million Italian aid measure to support coronavirus related research and development (R&D) by biotechnology company ReiThera S.r.l. The measure was approved under the State aid Temporary Framework.
1-Mar-2021 – Covid-eVax
https://www.ilcuoioindiretta.it/altre-news/2021/03/01/covid-evax-partita-la-sperimentazione-di-un-nuovo-vaccino-italiano/93293/
Il cuoio indiretta- Covid eVax, partita la sperimentazione di un nuovo vaccino italiano
Durante le prove di laboratorio il vaccino, a dna, ha provocato una forte risposta immunitariasia di tipo anticorpale sia cellulare.
1-Mar-2021
https://www.mbnews.it/2021/03/monza-ospedale-san-gerardo-vaccino-rottapharm-takis-covid/
MB News- Roma, Napoli e Monza per il Vaccino italiano anti Covid, al San Gerardo lo studio clinico
Il vaccino a DNA rappresenta una innovazione rispetto alle altre piattaforme tecnologiche già disponibili, quali quelle a RNA messaggero o a vettore virale. “Il DNA consente di evitare la catena del freddo nella conservazione e nel trasporto” ha dichiarato Luigi Aurisicchio, Amministratore delegato e Direttore Scientifico di Takis. “Per le sue caratteristiche, la produzione dell’antigene è prolungata nel tempo e il vaccino potrebbe funzionare bene già al primo ciclo. Inoltre, se necessario la somministrazione può essere ripetuta più volte per una risposta immunitaria più solida, anche grazie all’impiego della tecnica dell’elettroporazione sviluppata da un’altra azienda italiana, IGEA di Carpi, che facilita l’ingresso del DNA nelle cellule muscolari e funge anche da adiuvante, stimolando quindi i processi immunologici”.
1-Mar-2021 – Covid-eVax
https://www.blogo.it/post/covid-evax-vaccino-italiano-come-funziona
Blogo - COVID-eVax, il vaccino italiano a DNA entra in fase 1. Ecco come funzionerà
Ha preso il via oggi la fase 1 della sperimentazione di un vaccino anti-COVID tutto italiano, COVID-eVax, un vaccino ideato dalla Takis di Castel Romano, in provincia di Roma, e sviluppato in collaborazione con Rottapharm Biotech, con sede a Monza, con una tecnica diversa rispetto a quelle con RNA messaggero, come il vaccino di Pfizer/BioNTech e Moderna o a vettore virale, come quello di AstraZeneca.
26-Feb-2021 – NVX-COV2373
https://www.streetinsider.com/Corporate+News/Novavax+%28NVAX%29%2C+Takeda+%28TAK%29+Finalize+License+Agreement+for+Novavax’+COVID-19+Vaccine+Candidate+in+Japan%3B+Takeda+Initiates+Phase+12+Trial+in+Japan/18041963.html
Street Insider -Novavax (NVAX), Takeda (TAK) Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its collaboration with Takeda Pharmaceutical Company Limited, originally announcedin August. The companies have signed an exclusive license agreement for Takeda’s development, manufacturing and commercialization of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, in Japan. Additionally, Takeda dosed the first participants in a Phase 2 clinical trial to test the immunogenicity and safety of Novavax’ vaccine candidate in the Japanese population.
26-Feb-2021 – NVX-COV2373
https://www.fool.com/investing/2021/02/26/johnson-johnson-vs-novavax-which-vaccine-is-best-a/
The Motley Fool -Johnson & Johnson vs. Novavax: Which Vaccine Is Best Against New Strains?
Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) may soon be sharing the coronavirus vaccine market with two more companies. Johnson & Johnson and Novavax are approaching the finish line in this race. A U.S. Food and Drug Administration (FDA) committee meets today, Feb. 26, to discuss a possible Emergency Use Authorization (EUA) for the Johnson & Johnson candidate. A trial report released this week shows Johnson & Johnson's investigational vaccine fulfilled (and exceeded) efficacy and safety requirements. As for Novavax, the U.S., Europe, the U.K., and Canada have begun rolling reviews of the company's investigational vaccine
25-Feb-2021- GRAd-COV2
https://www.panorama.it/news/salute/reithera-vaccino-covid-sperimentazione
Panorama – sperimentazione in ritardo: il vaccino Reithera slitta a settembre
Era il 26 gennaio, un mese fa. Invitalia annunciava un investimento di 81 milioni di euro per il vaccino italiano Reithera che avrebbe accelerato i tempi per la sperimentazione.
24-Feb-2021 -NVX-COV2373
https://www.biospace.com/article/novavax-s-uphill-battle-to-vaccine-success/
Biospace - Novavax’s Uphill Battle to Vaccine Success
A week ago, Novavax announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to provide 1.1 billion doses of NVX-CoV2373, its COVID-19 vaccine candidate, for the COVAX Facility. The vaccine will be manufactured and distributed around the world by Novavax and Serum Institute of India (SII). SII has an existing deal with Gavi.
24-Feb-2021 – NVX-COV2373
https://www.japantimes.co.jp/news/2021/02/24/national/science-health/novavax-vaccine-japan/
The Japan Times - Takeda starts clinical trial of Novavax COVID-19 vaccine in Japan
Takeda Pharmaceutical Co. said Wednesday it had started a clinical trial of a COVID-19 vaccine developed by U.S. biotechnology firm Novavax Inc. in Japan, planning to domestically produce and supply it in the second half of 2021.
24-Feb-2021 – GRAd-COV2
https://www.ilmattino.it/napoli/cronaca/vaccino_italiano_ceinge_napoli_reithera-5788348.html
Il Mattino - Vaccino italiano, Ceinge di Napoli e Reithera rinnovano l'accordo di collaborazione
ll Ceinge, centro di biotecnologie avanzate di Napoli e ReiThera azienda italiana del tecnolopolo di Poezia che ha in fase di sperimentaaione un vaccino ad adenovirus vettore contro Covid 19 rinnovano la loro ultradecennale collaborazione.
23-Feb-2021 – mAbCo19
La Nazione - Vaccini e anticorpi monoclonali Rappuoli ospite on line del Rotary
A molti non basterebbe un volume, al professor Rino Rappuoli, ad di Gsk Vaccines di Siena e scienziato di caratura internazionale, sono bastate due frasi per fare il punto sulla pandemia e suoi progressi della scienza per combatterla: "Nel 2020 abbiamo combattuto la pandemia con quarantena, distanziamento e igiene, armi che erano in parte già presenti anche nel Medioevo; nel 2021 stiamo provando a riconquistare la libertà grazie a vaccini e anticorpi monoclonali”.
23-Feb-2021 – AZD1222
https://pharmaphorum.com/news/az-covid-jab-efficacy-debate-is-hindering-eus-vaccine-drive/
Pharma Phorum- AZ COVID jab efficacy debate is hindering EU’s vaccine drive
The spat between the EU and AstraZeneca over access to the company’s COVID-19 shot led to scathing remarks about its efficacy that now threaten to undermine the EU’s vaccination targets.
23-Feb-2021 – AZD1222
https://www.pharmacy.biz/mutations-could-make-covid-19-endemic/
Pharmacy Business - ‘Mutations could make Covid-19 endemic’
The recent SARS-CoV-2 virus variant in South Africa (B.1.351) underscores a critical weakness in combatting the Covid-19 epidemic and may prolong it indefinitely, according to the data and analytics company, GlobalData.
23-Feb-2021 – NVX-COV2373
The Wall Street Journal - Novavax Nears Covid-19 Vaccine Game Changer—After Years of Failure
In January of last year, employees of Novavax Inc. met at a local Maryland bar to discuss how they might salvage their careers. For decades, the small biotech had tried to develop an approved vaccine, with no success. The company had enough cash to survive only another six months or so and its shares traded under $4, with a market value of $127 million.
22-Feb-2021 – AZD1222
I Politics - ‘Complicated’ review of AstraZeneca vaccine nearly done: chief medical adviser
Health Canada’s “complicated” review of AstraZeneca’s COVID-19 vaccine is in its final stages, but still requires some “back and forth” between Canada’s regulator and the company, chief medical officer Dr. Supriya Sharma said on Monday.
22-Feb-2021 – mAbCo19
Go news - Covid-19, il punto di Rino Rappuoli a un anno dall'inizio della pandemia
A un anno dall’inizio dell’incubo pandemico, i presidenti Elisabetta Miraldi del Rotary Club Siena e Niccolò Mucerino Bucalossi del Rotary Club Valdelsa hanno voluto fare il punto su i vaccini e gli anticorpi monoclonali nella attuale guerra globale al Covid-19, invitando a una conviviale online il professor Rino Rappuoli, chief scientist e Head External R&D globale di GSK Vaccines e amministratore delegato della GSK Vaccines di Siena e socio onorario del Rotary Siena Est.
22-Feb-2021 – NVX-COV2373
https://www.reuters.com/article/us-health-coronavirus-novavax-idUKKBN2AM17O
Reuters - Novavax completes enrolling 30,000 people in U.S. trial of COVID-19 vaccine
Drug developer Novavax Inc said on Monday it has completed enrolling 30,000 volunteers in a late-stage study of its COVID-19 vaccine in the United States and Mexico.
22-Feb-2021 - AZD1222
https://www.nrc.nl/nieuws/2021/02/22/coronablog-22-februari-a4032690
NRC - AstraZeneca levert de komende twee weken ruim 200.000 minder vaccins
AstraZeneca levert de komende twee weken nog minder coronavaccins aan lidstaten van de Europese Unie dan eerder beloofd. In Nederland lopen 217.000 vaccindoses twee weken vertraging op. Dat heeft het RIVM maandag bekendgemaakt. De vertraging moet op zondag 7 maart goeddeels zijn ingelopen; dan is AstraZeneca van plan 211.000 doses extra te leveren. In januari maakte de Brits-Zweedse farmaceut al bekend in het eerste kwartaal van dit jaar 60 procent minder vaccins te kunnen leveren.
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
Siena Free - Diesse e AchilleS Vaccines insieme per le nuove terapie basate su anticorpi monoclonali
Diesse Diagnostica Senese S.p.a. e AchilleS Vaccines S.r.l. annunciano oggi la firma di un accordo strategico che porterà allo sviluppo congiunto da parte di Diesse, di test quantitativi rapidi di nuova generazione per i terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines.
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
About Pharma - Test per gli anticorpi monoclonali: partnership tra Diesse e AchilleS Vaccines
Un accordo strategico per lo sviluppo di test quantitativi per gli anticorpi monoclonali. È quello siglato tra Diesse Diagnostica Senese e AchilleS Vaccines. A darne notizia è una nota congiunta delle due aziende senesi.
19-Feb-2021 -mAbCo19 and Chorus diagnostic chewing gum
Il giunco - Anticorpi monoclonali: le nuove terapie saranno prodotte in un’azienda di Siena
Diesse Diagnostica Senese e AchilleS Vaccines annunciano oggi la firma di un accordo strategico che porterà allo sviluppo congiunto da parte di Diesse, di test quantitativi rapidi di nuova generazione per i terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines
19-Feb-2021 -mAbCo19 and Chorus diagnostic chewing gum
Toscana 24 -Alleanza senese per i test sugli anticorpi monoclonali
Diesse Diagnostica Senese e AchilleS Vaccines hanno firmato un accordo strategico che porterà allo sviluppo congiunto, da parte di Diesse, di test quantitativi rapidi di nuova generazione per i farmaci terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines. Proprio Av, startup incubata presso Toscana Life Sciences, ha finanziato e coordinato lo sviluppo industriale dell'anticorpo mAbCo19, "arma" anti-Covid sviluppata nel MadLab diretto da Rino Rappuoli.
19-Feb-2021 -GRAd-COV2
https://www.agi.it/cronaca/news/2021-02-19/vaccino-reithera-via-libera-fase-due-11472516/
Agenzia Italia - Via libera alla fase 2 per il vaccino di Reithera
"Sul vaccino ReiThera la novità è che finalmente l'Istituto Superiore di Sanità e l'Aifa ieri hanno dato l'ok alla fase due". Lo ha detto l'assessore alla Sanità della Regione Lazio, Alessio D'Amato, a margine dell'inaugurazione dell'acceleratore lineare per radioterapia presso il Policlinico Tor Vergata di Roma.
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
Siena Free - Diesse e AchilleS Vaccines insieme per le nuove terapie basate su anticorpi monoclonali
Diesse Diagnostica Senese S.p.a. e AchilleS Vaccines S.r.l. annunciano oggi la firma di un accordo strategico che porterà allo sviluppo congiunto da parte di Diesse, di test quantitativi rapidi di nuova generazione per i terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines.
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
Il giunco - Anticorpi monoclonali: le nuove terapie saranno prodotte in un’azienda di Siena
Diesse Diagnostica Senese e AchilleS Vaccines annunciano oggi la firma di un accordo strategico che porterà allo sviluppo congiunto da parte di Diesse, di test quantitativi rapidi di nuova generazione per i terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
Toscana 24 -Alleanza senese per i test sugli anticorpi monoclonali
Diesse Diagnostica Senese e AchilleS Vaccines hanno firmato un accordo strategico che porterà allo sviluppo congiunto, da parte di Diesse, di test quantitativi rapidi di nuova generazione per i farmaci terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines. Proprio Av, startup incubata presso Toscana Life Sciences, ha finanziato e coordinato lo sviluppo industriale dell'anticorpo mAbCo19, "arma" anti-Covid sviluppata nel MadLab diretto da Rino Rappuoli.
19-Feb-2021 -GRAd-COV2
https://www.agi.it/cronaca/news/2021-02-19/vaccino-reithera-via-libera-fase-due-11472516/
Agenzia Italia - Via libera alla fase 2 per il vaccino di Reithera
"Sul vaccino ReiThera la novità è che finalmente l'Istituto Superiore di Sanità e l'Aifa ieri hanno dato l'ok alla fase due". Lo ha detto l'assessore alla Sanità della Regione Lazio, Alessio D'Amato, a margine dell'inaugurazione dell'acceleratore lineare per radioterapia presso il Policlinico Tor Vergata di Roma.
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
Siena Free - Diesse e AchilleS Vaccines insieme per le nuove terapie basate su anticorpi monoclonali
Diesse Diagnostica Senese S.p.a. e AchilleS Vaccines S.r.l. annunciano oggi la firma di un accordo strategico che porterà allo sviluppo congiunto da parte di Diesse, di test quantitativi rapidi di nuova generazione per i terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines.
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
About Pharma - Test per gli anticorpi monoclonali: partnership tra Diesse e AchilleS Vaccines
Un accordo strategico per lo sviluppo di test quantitativi per gli anticorpi monoclonali. È quello siglato tra Diesse Diagnostica Senese e AchilleS Vaccines. A darne notizia è una nota congiunta delle due aziende senesi.
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
Il giunco - Anticorpi monoclonali: le nuove terapie saranno prodotte in un’azienda di Siena
Diesse Diagnostica Senese e AchilleS Vaccines annunciano oggi la firma di un accordo strategico che porterà allo sviluppo congiunto da parte di Diesse, di test quantitativi rapidi di nuova generazione per i terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
Toscana 24 -Alleanza senese per i test sugli anticorpi monoclonali
Diesse Diagnostica Senese e AchilleS Vaccines hanno firmato un accordo strategico che porterà allo sviluppo congiunto, da parte di Diesse, di test quantitativi rapidi di nuova generazione per i farmaci terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines. Proprio Av, startup incubata presso Toscana Life Sciences, ha finanziato e coordinato lo sviluppo industriale dell'anticorpo mAbCo19, "arma" anti-Covid sviluppata nel MadLab diretto da Rino Rappuoli.
19-Feb-2021 -GRAd-COV2
https://www.agi.it/cronaca/news/2021-02-19/vaccino-reithera-via-libera-fase-due-11472516/
Agenzia Italia - Via libera alla fase 2 per il vaccino di Reithera
"Sul vaccino ReiThera la novità è che finalmente l'Istituto Superiore di Sanità e l'Aifa ieri hanno dato l'ok alla fase due". Lo ha detto l'assessore alla Sanità della Regione Lazio, Alessio D'Amato, a margine dell'inaugurazione dell'acceleratore lineare per radioterapia presso il Policlinico Tor Vergata di Roma.
18-Feb-2021 - AZD1222
Bioprocess international - IDT Biologika latest to join AstraZeneca in COVID-19 response
CDMO IDT Biologika will expand its site in Dessau, Germany through a joint investment with AstraZeneca to support the latter’s COVID-19 vaccine.
AstraZeneca has signed a letter of intent with contract development manufacturing organization (CDMO) IDT Biologika to help produce its COVID-19 vaccine, AZD1222.
18-Feb-2021 - NVX-COV2373
Fierce Pharma - Novavax, coronavirus shot data in hand, strikes an eye-popping supply deal with global vaccine consortium
COVID-19 vaccine maker Novavax has at times flown under the radar as some of the world's leading drugmakers dominated headlines and raced toward rollouts. But an eye-popping new supply deal with international players is sure to turn heads.
15-Feb-2021 - NVX-COV2373
https://www.ft.com/content/ceebd562-7b50-427b-932f-40f2adfe5e26
The Financial Times- Novavax to complete US vaccine trial enrollment in record time
Novavax, one of the unexpected success stories of the Covid-19 vaccine race, is about to finish enrolling its US trial in record time, bringing it another step closer to fulfilling orders to inoculate 50m Americans.
15-Feb-2021 – GRAd-COV2
https://whtc.com/2021/02/15/pan-european-consortium-seeks-big-pharma-partner-for-covid-19-shot/
WHTC - Pan-European consortium seeks big pharma partner for COVID-19 shot
A pan-European consortium developing a COVID-19 vaccine is in talks with big pharma to support the late-stage development of its shot and ramp up manufacturing, the head of German biotech firm Leukocare told Reuters.
15-Feb-2021 – AZD1222
https://www.scientias.nl/oxford-vaccin-wordt-nu-ook-onder-kinderen-getest/
Scientias- Oxfordvaccin wordt nu ook onder kinderen getest
Ondertussen zijn er in de Europese Unie drie coronavaccins goedgekeurd: dat van Pfizer/BioNTech, Moderna en Oxford/Astrazenea. Maar in hoeverre werken ze eigenlijk bij kinderen? Dat is wat de makers van het Oxford-vaccin willen uitzoeken. Zij lanceren nu als eerste een studie om de werking van het vaccin onder kinderen en tieners te gaan testen.
13-Feb-2020 – Covid-eVAX
Il Sussidiaro - VACCINO ITALIANO/ Una tecnologia che vale l’immunità di gregge e un punto di Pil
L’Italia è tra i pochi paesi al mondo che può creare e produrre un vaccino completamente in autonomia e senza dipendere dall’estero. A beneficio dell’economia italiana, la produzione di un vaccino in loco, frutto della ricerca nostrana, porterà un punto di Pil in caso di successo.
13-Feb-2021 – GRAd-COV2
The Washington Post - The world needs more vaccines. But an Italian venture to fill the gap is facing novel obstacles.
If all goes according to plan, a small biotech company outside Rome will soon be cranking out millions of coronavirus vaccine doses a month. The company has finished an initial, small-scale trial. It has financial backing from the Italian government. It has an underground production facility so new that it smells of fresh paint.
11-Feb-2021 – AZD1222
Nu.nl - Mensen met ernstig overgewicht krijgen eerder coronavaccin
Mensen die morbide obees zijn, ofwel een BMI van 40 of hoger hebben, krijgen voorrang bij de COVID-19-vaccinatie met het AstraZeneca-vaccin. Ook mensen met het syndroom van Down en mensen die moeilijk kunnen ademhalen krijgen voorrang, zo bevestigt het ministerie van Volksgezondheid, Welzijn en Sport donderdag aan NU.nl na berichtgeving van de Landelijke Huisartsen Vereniging (LHV) en het AD.
11-Feb-2021 – V591
Endpoints news - After purging its own candidates, Merck says it's ready to assist in Covid-19 vaccine production
Days after quashing high hopes of a late but reliable addition to the global Covid-19 vaccine menu, Merck is searching for a way back to the action.
11-Feb-2021 – AZD1222
WHO - The Oxford/AstraZeneca COVID-19 vaccine: what you need to know
The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued interim recommendations for use of the Oxford/AstraZeneca COVID-19 vaccine (AZD1222). This article provides a summary of the interim recommendations; you may access the guidance document here.
11-Feb-2021 – AZD1222
https://edition.cnn.com/world/live-news/coronavirus-pandemic-vaccine-updates-02-11-21/index.html
CNN- WHO Africa encourages use of AstraZeneca vaccine despite variants
The head of the World Health Organization (WHO) in Africa has backed the use of the Oxford/AstraZeneca vaccine against Covid-19 even in countries reporting variants of the disease.
11-Feb-2021 – mAbCo19
Tuttoggi- Anticorpi monoclonali, la cura naturale che neutralizza il Covid | Verso la conclusione il lavoro di Rino Rappuoli
È ormai altissima l’aspettativa sugli sviluppi scientifici che porteranno a brevissimo alla sperimentazione (Trial) su esseri umani degli anticorpi monoclonali studiati e messi a punto dal Toscana Life Sciences di Siena, fondamentale laboratorio di ricerca tutto italiano guidato dal Dott. Rino Rappuoli
11-Feb-2021 – NVX-COV2373
https://www.reuters.com/article/idUSL1N2KH0Q1?edition-redirect=ca
Reuters - EU close to sealing supply deal with Novavax for COVID-19 vaccines - sources
The European Union could sign a supply deal with Novavax this week or next for the U.S. company’s COVID-19 vaccine candidate, two EU officials involved in the talks with the firm said.
9-Feb-2021 – NVX-COV2373
UMB News - Novavax Vaccine Demonstrates Strong Immune Response
The vaccine was found to generate a robust immune response in animals exposed to the vaccine with strong data indicating safety and efficacy, according to the study published recently in the journal Nature Communications. The results have been used to begin testing the vaccine in human trials in the United States with a Phase 3 trial that recently launched at UMSOM’s Center for Vaccine Development and Global Health (CVD).
9-Feb-2021 – NVX-COV2373
https://www.fox5dc.com/video/898571
Fox 5- Update on Novavax COVID vaccine
A top company tells FOX 5 that the Novavax vaccine is more than 95 percent effective against the original strain of the COVID-19 virus.
8-Feb-2021 – AZD1222
FiercePharma - AstraZeneca, Oxford race to update COVID-19 vaccine as study flags weak action against variant
It didn’t take long before a morale boost for AstraZeneca’s COVID-19 vaccine was overshadowed by disappointment over its waned protection against a newly emerged coronavirus variant.
A new study has found AZ’s COVID-19 shot offered “minimal protection” against mild to moderate disease caused by the B.1.351 variant, which was first identified in South Africa, the University of Oxford, the original developer of the vaccine, said Sunday.
8-Feb-2021 – COVID-eVax
Reuters - Italian DNA-based COVID-19 vaccine candidate could start clinical trials in March - developer
Italy’s second COVID-19 vaccine candidate, COVID-eVax, is likely to start trials in early March after it was approved by the national drug regulator last week, one of the biotech firms leading the project said on Monday.
8-Feb-2021 - GRAd-COV2
La Repubblica - Maggiorenne, sano e consapevole: l'identikit del volontario per il vaccino ReiThera in Puglia
Le prime adesioni sono già arrivate. Si tratta di una decina di manifestazioni di interesse spontanee da parte di coloro che vorrebbero sottoporsi alla sperimentazione del vaccino ReiThera che sarà avviata a marzo dall'Asl della provincia di Barletta- Andria- Trani. E a breve, non appena saranno formalizzate le procedure, potrebbero arrivarne molte altre.
8-Feb-2021 - AZD1222
NRC- Zuid-Afrika schort vaccinatie op met AstraZeneca-vaccin
De Zuid-Afrikaanse regering heeft zondag het gebruik van het vaccin van fabrikant AstraZeneca (het ‘Oxford-vaccin’) voorlopig opgeschort. Dat deed ze omdat uit pril onderzoek naar voren komt dat het vaccin nauwelijks lijkt te beschermen tegen infectie met de besmettelijkere Zuid-Afrikaanse variant van het coronavirus, B.1.351. Ook blijkt dat de antistoffen die het vaccin opwekt minder goed werken tegen die variant, die voor het eerst opkwam in dat land en daar nu vrijwel alle besmettingen voor zijn rekening neemt.
8-Feb-2021 - GRAd-COV2
La Repubblica - Maggiorenne, sano e consapevole: l'identikit del volontario per il vaccino ReiThera in Puglia
Le prime adesioni sono già arrivate. Si tratta di una decina di manifestazioni di interesse spontanee da parte di coloro che vorrebbero sottoporsi alla sperimentazione del vaccino ReiThera che sarà avviata a marzo dall'Asl della provincia di Barletta- Andria- Trani. E a breve, non appena saranno formalizzate le procedure, potrebbero arrivarne molte altre.
8-Feb-2021 - AZD1222
NRC- Zuid-Afrika schort vaccinatie op met AstraZeneca-vaccin
De Zuid-Afrikaanse regering heeft zondag het gebruik van het vaccin van fabrikant AstraZeneca (het ‘Oxford-vaccin’) voorlopig opgeschort. Dat deed ze omdat uit pril onderzoek naar voren komt dat het vaccin nauwelijks lijkt te beschermen tegen infectie met de besmettelijkere Zuid-Afrikaanse variant van het coronavirus, B.1.351. Ook blijkt dat de antistoffen die het vaccin opwekt minder goed werken tegen die variant, die voor het eerst opkwam in dat land en daar nu vrijwel alle besmettingen voor zijn rekening neemt.
8-Feb-2021 - GRAd-COV2
La Repubblica - Maggiorenne, sano e consapevole: l'identikit del volontario per il vaccino ReiThera in Puglia
Le prime adesioni sono già arrivate. Si tratta di una decina di manifestazioni di interesse spontanee da parte di coloro che vorrebbero sottoporsi alla sperimentazione del vaccino ReiThera che sarà avviata a marzo dall'Asl della provincia di Barletta- Andria- Trani. E a breve, non appena saranno formalizzate le procedure, potrebbero arrivarne molte altre.
8-Feb-2021 - AZD1222
NRC- Zuid-Afrika schort vaccinatie op met AstraZeneca-vaccin
De Zuid-Afrikaanse regering heeft zondag het gebruik van het vaccin van fabrikant AstraZeneca (het ‘Oxford-vaccin’) voorlopig opgeschort. Dat deed ze omdat uit pril onderzoek naar voren komt dat het vaccin nauwelijks lijkt te beschermen tegen infectie met de besmettelijkere Zuid-Afrikaanse variant van het coronavirus, B.1.351. Ook blijkt dat de antistoffen die het vaccin opwekt minder goed werken tegen die variant, die voor het eerst opkwam in dat land en daar nu vrijwel alle besmettingen voor zijn rekening neemt.
7-Feb-2021 - GRAd-COV2
Siena News- Rappuoli: “Entro la fine del 2021 pandemia sotto controllo ma non tiriamo troppo la corda o si spezza”
“Quanto ci vorrà a fare i vaccini? Questa era la domanda più frequente durante i primi mesi di pandemia. Ebbene, abbiamo battuto tutti i record, a differenza delle aspettative, siamo riusciti a produrre vaccini in 10 mesi”.Queste, le parole di Rino Rappuoli, Chief di Gsk, a margine del convegno virtuale proposto dagli organizzatori di Wine&Siena. Proprio dal padre dei vaccini arriva un messaggio di speranza: “Entro la fine dell’anno avremo controllato la pandemia”.
7-Feb-2021 - GRAd-COV2
Siena News- Rappuoli: “Entro la fine del 2021 pandemia sotto controllo ma non tiriamo troppo la corda o si spezza”
“Quanto ci vorrà a fare i vaccini? Questa era la domanda più frequente durante i primi mesi di pandemia. Ebbene, abbiamo battuto tutti i record, a differenza delle aspettative, siamo riusciti a produrre vaccini in 10 mesi”.Queste, le parole di Rino Rappuoli, Chief di Gsk, a margine del convegno virtuale proposto dagli organizzatori di Wine&Siena. Proprio dal padre dei vaccini arriva un messaggio di speranza: “Entro la fine dell’anno avremo controllato la pandemia”.
7-Feb-2021 - GRAd-COV2
Siena News- Rappuoli: “Entro la fine del 2021 pandemia sotto controllo ma non tiriamo troppo la corda o si spezza”
“Quanto ci vorrà a fare i vaccini? Questa era la domanda più frequente durante i primi mesi di pandemia. Ebbene, abbiamo battuto tutti i record, a differenza delle aspettative, siamo riusciti a produrre vaccini in 10 mesi”.Queste, le parole di Rino Rappuoli, Chief di Gsk, a margine del convegno virtuale proposto dagli organizzatori di Wine&Siena. Proprio dal padre dei vaccini arriva un messaggio di speranza: “Entro la fine dell’anno avremo controllato la pandemia”.
6-Feb-2021 - GRAd-COV2
La Repubblica - Burioni boccia la sperimentazione del vaccino ReiThera in Puglia: "Rischiosa"
Roberto Burioni boccia la sperimentazine del vaccino ReiThera annunciata dall'Asl Bat, che coinvolgerà 40 volontari fra Andria e dintorni nell'ambito di un programma nazionale dell'azienda farmaceutica italiana. Il virologo ha scritto un tweet nel quale spiega che "sottoporre pazienti alla sommistrazione di un vaccino sperimentale è un rischio".
6-Feb-2021 - GRAd-COV2
La Repubblica - Burioni boccia la sperimentazione del vaccino ReiThera in Puglia: "Rischiosa"
Roberto Burioni boccia la sperimentazine del vaccino ReiThera annunciata dall'Asl Bat, che coinvolgerà 40 volontari fra Andria e dintorni nell'ambito di un programma nazionale dell'azienda farmaceutica italiana. Il virologo ha scritto un tweet nel quale spiega che "sottoporre pazienti alla sommistrazione di un vaccino sperimentale è un rischio".
4-Feb-2021 - Covid-eVax
La Repubblica -Il secondo vaccino italiano è pronto per i test. Prodotto da Takis e Rottapharm
Un secondo vaccino italiano è pronto per la sperimentazione sull’uomo. Lo ha messo a punto l’azienda Takis di Castel Romano (Roma), che lavora al suo sviluppo insieme alla Rottapharm Biotech di Monza. L’Aifa, Agenzia italiana del farmaco, ha affidato la richiesta al proprio comitato etico, che darà presto il via libera. Le vaccinazioni di prova potranno partire nel corso del mese e dare risultati in primavera per quanto riguarda la fase uno e in estate per la fase due. I primi 80 volontari sono già stati arruolati in tre ospedali del nord (il san Gerardo di Monza), del centro (lo Spallanzani di Roma) e del sud (l’istituto Pascale di Napoli). “Vogliamo essere un vaccino di tutta l’Italia” sorride Luigi Aurisicchio, amministratore delegato e direttore scientifico di Takis.
29-Jan-2021 – AZD1222
De Telegraaf - Toezichthouder EMA komt met oordeel over derde coronavaccin
Over het vaccin is de laatste tijd veel te doen. De Europese Unie heeft voor dit jaar 400 miljoen doses AZD1222 besteld, waarvan er 11,7 miljoen naar Nederland zouden gaan. Voor eind maart zou AstraZeneca de eerste 80 miljoen doses moeten leveren, waarvan 4,5 miljoen aan Nederland. Tot woede van Brussel zegt de farmaceut nu slechts 31 miljoen doses te kunnen leveren. Dat zou komen door een haperende productie bij een fabriek in Wallonië.
29-Jan-2021 – AZD1222
The Manila Times - AstraZeneca vaccine approved for rollout
The Philippine Food and Drug Administration (FDA) has given Emergency Use Authorization (EUA) to British-Swedish drugmaker AstraZeneca for its coronavirus disease 2019 (Covid-19) vaccine.
29-Jan-2021 – NVX-COV2373
https://www.rtlnieuws.nl/nieuws/nederland/artikel/5211490/corona-covid-vaccin-novavax-effectief
RTL Nieuws - Ook Novavax-vaccin lijkt voor 90 procent effectief
Het vaccin van het Amerikaanse biotechbedrijf Novavax beschermt bij negen op de tien mensen tegen Covid-19, stelt het bedrijf op basis van een klinische test in het Verenigd Koninkrijk. Het is een van de acht vaccins die een rol speelt in de Nederlandse vaccinatiestrategie.
29-Jan-2021 – NVX-COV2373
Het Parool - Ook Novavax claimt coronavaccin met hoge effectiviteit
Het coronavaccin van het Amerikaanse biotechbedrijf Novavax beschermt bij negen op de tien mensen tegen Covid-19, stelt het bedrijf op basis van een klinische test in het Verenigd Koninkrijk. Het middel zou bijna net zo effectief zijn tegen de Britse variant van het virus, zou uit voorlopige resultaten blijken.
29-Jan-2021 -NVX-COV2373
De Volkskrant - Ook Novavax claimt effectiviteit van 90 procent
Het coronavaccin van het Amerikaanse biotechbedrijf Novavax beschermt bij negen op de tien mensen tegen Covid-19, stelt het bedrijf op basis van een klinische test in het Verenigd Koninkrijk. Het middel zou bijna net zo effectief zijn tegen de Britse variant van het virus, zou uit voorlopige resultaten blijken.
29-Jan-2021 – NVX-COV2373
https://edition.cnn.com/2021/01/29/europe/novavax-covid-vaccine-uk-sa-trials-gbr-intl/index.html
CNN- Novavax says Covid-19 vaccine is 89% effective in UK trial, but less so in South Africa
A new Covid-19 vaccine from Novavax was found to be 89.3% effective in a clinical trial conducted in the UK and appears to offer protection against some variants of the coronavirus, the American biotech firm has announced.
29-Jan-2021 – NVX-COV2373
New Scientist - Novavax coronavirus vaccine found 89 per cent effective in trials
A coronavirus vaccine developed by the US firm Novavax has been shown to be 89 per cent effective in preventing covid-19 in phase III clinical trials. The vaccine is made from nanoparticles containing spike proteins from the virus, which are produced by genetically modified insect cells. The nanoparticles cannot replicate or cause covid-19, but they enable the body’s immune system to recognise the viral proteins and make antibodies against them.
29-Jan-2021 – NVX-COV2373
Times of India - Serum Institute applies to conduct local trial for Novavax Vaccine
29-Jan-2021 – NVX-COV2373
https://www.timesofisrael.com/novavax-says-its-vaccine-appears-96-effective-but-less-so-against-variants/
The times of Israel - Novavax says its vaccine appears 96% effective, but less so against variants
Novavax Inc. said Thursday that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well — against new mutated versions of the virus circulating in that country and South Africa.
29-Jan-2021 – AZD1222
https://www.dvhn.nl/extra/Coronavaccin-AstraZeneca-krijgt-positief-oordeel-van-Europese-medicijnwaakhond-maar-nog-altijd-discussie-over-de-levering-26446919.html
Dagblad van het Noorden - Coronavaccin AstraZeneca krijgt positief oordeel van Europese medicijnwaakhond (maar nog altijd discussie over de levering)
Het Europees Geneesmiddelenbureau (EMA) is positief over het coronavaccin dat AstraZeneca en de Universiteit van Oxford hebben ontwikkeld. Daarmee is de weg vrij voor de Europese Commissie om het middel toe te laten. Het is het derde vaccin dat een positief oordeel van de toezichthouder krijgt.
29-Jan-2021 – NVX-COV2373
Bloomberg - Novavax Sees U.K. Vaccine Approval First; in Talks With FDA
A new Covid-19 vaccine from Novavax Inc. is likely to get its first approval in the U.K., and the company is discussing with U.S. regulators whether trial data from other countries could be part of the shot’s review, Chief Executive Officer Stan Erck said.
28-Jan-2021 – AZD1222
https://wnl.tv/2021/01/28/nederland-heeft-bijna-12-miljoen-doses-besteld-bij-astrazeneca/
WNL - Nederland heeft bijna 12 miljoen doses besteld bij AstraZeneca
De farmaceut AstraZeneca lag vorig jaar ruim op kop in de race om als eerste een coronavaccin op de markt te brengen. Voor het kabinet was dat aanleiding om alvast een grote bestelling te doen. Nederland zou in de loop van dit jaar 11,7 miljoen doses van het middel AZD1222 krijgen, waarvan 4,5 miljoen al voor eind maart. Van dat optimisme is nu weinig over: AstraZeneca is afgetroefd door twee rivalen, kan waarschijnlijk minder leveren dan verwacht en tot overmaat van ramp is niet duidelijk of het middel wel genoeg werkt bij ouderen, terwijl dat nou juist de meest kwetsbare groep is.
28-Jan-2021 – NVX-COV2373
Novavax-coronavaccin heeft volgens farmaceut effectiviteit van 90 procent
Nu.nl - Het coronavaccin van het Amerikaanse biotechbedrijf Novavax beschermt negen op de tien mensen tegen het coronavirus, stelt het bedrijf op basis van een klinische test in het Verenigd Koninkrijk. Het middel zou bijna net zo effectief zijn tegen de Britse variant van het virus, beweert het bedrijf op basis van de recentste onderzoeksresultaten.
28-Jan-2021 – NVX-COV2373
https://www.ft.com/content/1978fc50-99f0-4aab-88cb-15dd1ba14c95
Financial Times - Novavax’s Covid-19 vaccine shown to be 89% effective
Novavax’s Covid-19 vaccine is 89 per cent effective and works against new variants of the virus, according to interim data published from clinical trials in the UK and South Africa.
28-Jan-2021 – NVX-COV2373
Forbes - Novavax Covid Vaccine Is Highly Effective Against U.K. Variant But Struggled In South Africa, Data Shows
A Covid-19 vaccine candidate from Novavax offers strong protection against a more contagious coronavirus variant first discovered in the United Kingdom, but it’s somewhat less effective against a rapidly spreading mutation from South Africa, according to early data released Thursday, marking the latest vaccine to face some efficacy issues as new strains of the virus evolve.
28-Jan-2021 – NVX-COV2373
https://www.telegraaf.nl/nieuws/1458711489/live-novavax-claimt-coronavaccin-met-hoge-effectiviteit
De Telegraaf - Novavax claimt coronavaccin met hoge effectiviteit
Ook nu er een begin is gemaakt met vaccineren, blijft het uit China overgewaaide coronavirus mondiaal voor ontwrichting zorgen. De besmettingen en ziekenhuiscijfers zijn in Nederland nog niet extreem, maar de mutanten baren zorgen. De Britse variant houdt op het ’eiland’ flink huis en ook de Braziliaanse en Zuid-Afrikaanse zijn in aantocht. Tegelijkertijd zuchten economie en maatschappij onder verstikkende maatregelen. Volg in dit live-blog het laatste coronanieuws
27-Jan-2021 – AZD1222
https://www.spektrum.de/news/astrazeneca-impfstoff-verwirrung-um-die-wirksamkeit-von-azd1222/1824223
Spektrum- Verwirrung um die Wirksamkeit des AstraZeneca-Impfstoffs
Über 65-Jährige sollen durch den Impfstoff von AstraZeneca (AZD1222) nur unzureichend geschützt sein. Bei ihnen solle die Wirkung nur bei rund acht Prozent liegen. Diese Behauptung war kürzlich in diversen Medienberichten zu lesen. Zwar werde weiterhin damit gerechnet, dass das Mittel in der Europäischen Union zugelassen wird – es sei jedoch möglich, dass es für besagte Altersgruppe nicht in Frage kommt, hieß es etwa im »Handelsblatt« weiter.
27-Jan-2021- GRAd-COV2
https://www.ilfattoquotidiano.it/2021/01/27/reithera-palu-aifa-dopo-settembre-alcune-milioni-di-dosi-del-vaccino-italiano-speranza-giusto-entrare-nel-capitale-con-soldi-pubblici/6079852/
Il Fatto Quotidiano - Reithera, Palù (Aifa): “Dopo settembre alcune milioni di dosi del vaccino italiano”. Speranza: “Giusto entrare nel capitale con soldi pubblici”
Perché il vaccino di Reithera sia disponibile, ha detto il presidente dell'Agenzia italiana del farmaco, "ci vorrà ancora qualche mese" perché "è stata appena conclusa la fase 1". Quindi ha specificato: "Non sarà utile in questa fase critica, ma sicuramente più avanti"
27-Jan-2021 – GRAd-COV2
https://www.thelocal.it/20210127/covid-19-italian-reithera-vaccine-set-to-be-available-from-september
The Local- Covid-19: Italian ReiThera vaccine set to be available from September
A Covid-19 vaccine developed by Italian company ReiThera is expected to be available from September, Italian pharmaceutical agency AIFA said on Wednesday.
26-Jan-2021 – AZD1222
https://www.mdr.de/wissen/corona-impfung-astrazeneca-vektor-virus-100.html
Mitteldeutscher Rundfunk - ASTRAZENECA-IMPFSTOFF: NICHT GEEIGNET FÜR MENSCHEN ÜBER 65?
Am kommenden Freitag entscheidet die EMA über die Zulassung des Corona-Impfstoffs von AstraZeneca und schon vorher gibt es Konflikte. Denn es gibt Lieferschwierigkeiten und Vorwürfe, dass die Impfung bei älteren Menschen nicht wirken würde. Seine Funktionsweise ist anders, als die der schon zugelassenen mRNA-Vakzine.
25-Jan-2021- GRAd-COV2
https://www.meteo.it/notizie/vaccino-italiano-spallanzani-reithera-6900fe3c
Meteo - A che punto siamo con il "vaccino italiano" di Spallanzani e ReiThera
È stato annunciato a inizio gennaio il successo della prima fase di sperimentazione, ma restano ancora diversi aspetti da definire
25-Jan-2021 – mABCo19
Il tirreno - Super farmaco anti-Covid, Rappuoli: "Sarà pronto tra aprile e maggio"
"Il farmaco" anti Covid a base di anticorpi monoclonali "è infialato e pronto per le prove cliniche, e con leggerissimo ritardo dovrebbe essere a disposizione per aprile/maggio". Lo annuncia, nel corso di un evento on line, il professor Rino Rappuoli a capo dell'equipe che nei laboratori senesi della Fondazione Toscana Life Sciences sta lavorando a una terapia anti Covid.
23-Jan-2021 – NVX-COV2373
https://www.entrepreneur.com/article/363991
The entrepreneur - Curevac and Novavax Vaccines Against Covid-19 Will Begin Phase 3 in Mexico
The Secretary of Foreign Affairs, Marcelo Ebrard , shared on his Twitter account that the CUREVAC (German) and Novavax (USA ) vaccines would start phase 3 in Mexico and that the necessary doses for this will arrive next week.
21-Jan-2021 – AZD1222
Der Spiegel - Größter Impfstoffhersteller der Welt meldet Fabrikbrand
In Indien steht ein Produktionsstandort des Serum Institute in Flammen, das auch den Corona-Impfstoff von AstraZeneca herstellt. Laut Firmenangaben soll das Feuer aber keine Folgen für die Produktion haben.
21-Jan-2021 – AZD1222
Bioprocess international - Oxford vaccine fill-finish site threatened by severe floods
Storm Christopher has caused – and continues to cause – severe damage across North Wales, and yesterday hit a facility producing the Oxford-AstraZeneca vaccine (AZD1222) run by Wockhardt UK.
22-Jan-2021 – NVX-COV2373
The Sydney Morning Herald - Sydney startup to help vaccine hopeful Novavax roll out jab
Multibillion-dollar US vaccine maker Novavax has selected a Sydney company to help it secure approval for its coronavirus vaccine and plan for its Australian rollout, in a significant boost for the local biotech sector.
20-Jan-2021 – NVX-COV2373
https://www.fiercepharma.com/vaccines/novavax-sees-covid-vaccine-trial-dropout-as-pfizer-moderna-shots-rollout-gears-up
Fierce Pharma - Novavax sees some COVID-19 vaccine trial dropout as Pfizer, Moderna rollouts gear up
As more supplies of Pfizer-BioNTech and Moderna’s authorized COVID-19 vaccines arrive, many states are expanding their reach beyond the elderly and into the 65-plus crowd. That broader rollout has created some problems for clinical trials of other experimental shots.
18-Jan-2021 – Covivaxx
Hindustan times - SII to dispatch Covishield to multiple countries by month-end
The city-based Serum Institute of India (SII), largest vaccine manufacturer, has provided 11 million Covishield doses to the central government
16-Jan-2021 – AZD1222
https://www.enca.com/news/oxford-scientists-how-we-developed-our-covid-19-vaccine-record-time
ENCA- Oxford scientists: how we developed our COVID-19 vaccine in record time
The pandemic is only a year old, but we already have multiple vaccines available to fight COVID-19 – including the vaccine developed by the team we’re part of at the University of Oxford.
18-Jan-2021- AZD1222
Der Standard- Kurz will rasche Zulassung von Astra-Zeneca-Impfstoff, doch es gibt noch Unklarheiten
In Brüssel herrscht Sorge, ob jenes Vakzin, mit dem man die breite Bevölkerung gegen Covid-19 impfen will, auch für über 55-Jährige zugelassen wird. Dazu kommen Lieferengpässe bei Pfizer
17-Jan-2021 - mAbCo19
Corriere della sera - Covid e variante brasiliana, Rappuoli: «Sono possibili reinfezioni, ma i vaccini dovrebbero difenderci»
L’11 gennaio scorso il ministro della Salute del Giappone ha annunciato di aver isolato una nuova variante di Sars-CoV-2 in 4 persone arrivate dal Brasile. L’ultima, in ordine di tempo. Sabato 16 gennaio l’Italia ha deciso di bloccare i voli da quel Paese, dopo che questa variante (qui tutti i dettagli) ha aggravato la già pesante situazione della pandemia in Brasile (raccontata qui).
17-Jan-2021 - AZD1222
https://www.thenews.com.pk/print/775576-oxford-astrazeneca-s-covid-19-vaccine-allowed-in-pakistan
The news international -Oxford-Astrazeneca’s Covid-19 vaccine allowed in Pakistan
The Drug Regulatory Authority of Pakistan (DRAP) on Saturday gave emergency use authorization to Oxford-Astrazeneca’s AZD1222 in Pakistan following recommendations by a six-member panel of health experts. A private firm has been allowed to import the COVID-19 vaccine in the country.
16-Jan-2021 - AZD1222
https://www.enca.com/news/oxford-scientists-how-we-developed-our-covid-19-vaccine-record-time
ENCA - Oxford scientists: how we developed our COVID-19 vaccine in record time
The pandemic is only a year old, but we already have multiple vaccines available to fight COVID-19 – including the vaccine developed by the team we’re part of at the University of Oxford.
15-Jan-2021- mAbCo19
Abruzzo live - Coronavirus, Rappuoli: su anticorpi gli Usa sono avanti. Per Trump usati 8 grammi, nostre dosi inferiori
L’Aquila. Sugli anticorpi monoclonali le americane Eli Lilly e Regeneron “sono più avanti. Non hanno ancora avuto l’approvazione definitiva, ma la Fda ha dato l’ok per l’emergency use, più o meno l’equivalente del nostro uso compassionevole. Noi invece iniziamo in febbraio la fase 1 e saremo pronti tra aprile e maggio. Prima di giugno potremmo avere l’approvazione”. Lo ha detto all’ANSA Rino Rappuoli, direttore scientifico di Gsk Vaccines e coordinatore della ricerca sugli anticorpi di Toscana Life Sciences.
15-Jan-2021 - NVX-COV2373
Fox21 - U Of M Medical School Participating In Novavax Phase 3 Trials
Clinical trials for Phase 3 of the Novavax COVID-19 vaccine are starting soon.The University of Minnesota Medical School is one of a hundred institutions participating in the study. Medical researchers say after undergoing the first two stages of clinical trials, Novavax vaccine shows promise.
13-Jan-2021 -NVX-COV2373, AZD1222
7 News- What are Australia's COVID-19 vaccines, and when will they be available?
Australians will start to be vaccinated against coronavirus in February, following new advice provided to the federal government. Australia has entered into four separate agreements for the supply of COVID-19 vaccines if they are proven safe and effective
13-Jan-2021- NVX-COV2373
https://www.sueddeutsche.de/politik/coronavirus-weltweit-neuinfektionen-usa-1.5170366
Süddeutsche Zeitung - 226 954 neue Infektionen in den USA
Die EU-Arzneimittelbehörde will bis Ende Januar über Astra-Zeneca-Impfstoff entscheiden.
13-Jan-2021 – mAbCo19
Intoscana - La ricerca contro il Covid-19: dalle Coop in arrivo 1 milione e mezzo di euro per i monoclonali
L’obiettivo era raccogliere 1 milione e mezzo di euro ed è stato superato in poco più di un mese: dal 1 dicembre del 2020 al 10 gennaio sono 150mila le persone che hanno contribuito alla raccolta fondi a sostegno della terapia contro il Covid-19 basata sugli anticorpi monoclonali della Fondazione Toscana Life Sciences.
13-Jan-2021 – mAbCo19
Siena News - Covid, Rappuoli: “Monoclonali e vaccini efficaci contro le varianti inglese e sudafricana”
“Credo che i vaccini e gli anticorpi monoclonali riescano a contenere sia la variante inglese che la variante sudafricana del coronavirus”. Lo ha detto il coordinatore del Mad Lab di Tls Rino Rappuoli durante la conferenza per presentare i risultati della campagna di raccolta fondi promossa da Unicoop Firenze, Coop Alleanza 3.0, Coop Centro Italia, Unicoop Tirreno, Coop Unione Amiatina e Coop Reno a favore della ricerca scientifica della Fondazione Toscana Life Sciences.
12-Jan-2021 – AZD1222
RND - Astra Zeneca: Das ist über den Corona-Impfstoff AZD1222 bekannt
Der britisch-schwedische Arzneimittelkonzern Astra Zeneca hat die Zulassung seines Corona-Impfstoffs in der Europäischen Union (EU) beantragt. Wird das vom Pharmaunternehmen und der Universität in Oxford gemeinsam entwickelte Vakzin genehmigt, wäre es das dritte zugelassene Präparat gegen Covid-19 in der EU. Anders als bei den bisher zugelassenen Vakzinen handelt es sich dabei nicht um einen mRNA-Impfstoff. Und auch in vielen anderen Aspekten unterscheidet sich der Impfstoff AZD1222 von den Präparaten von Biontech/Pfizer und Moderna.
12-Jan-2021 – AZD1222
https://www.gelbe-liste.de/nachrichten/zulassungsantrag-azd1222-astrazeneca
Gelbe Liste - Zulassungsantrag für AZD1222 in EU
Die EMA gab heute bekannt, dass sie einen Antrag auf bedingte Zulassung für das Inverkehrbringen des von AstraZeneca und der Universität Oxford entwickelten Corona-Impfstoffs erhalten hat. Seit Anfang Oktober 2020 befindet sich der Impfstoff im „Rolling-Review“-Verfahren der EMA.
12-Jan-2021 – AZD1222
Free press journal - 'Covishield' FAQ: Serum Institute answers all your queries ahead of COVID-19 vaccination drill
Ahead of the nationwide inoculation exercise against coronavirus disease (COVID-19) across India, the Serum Institute has issued a fact-sheet to answer all the Frequently Asked Questions (FAQs) that vaccine beneficiaries might have in preparation of the drill.
11-Jan-2021 -mAbCo19
https://www.lanazione.it/siena/cronaca/sicurezza-vaccino-covid-1.5902398
La Nazione - Vaccini antiCovid, Rappuoli: "Sulla sicurezza fatti più test del solito"
Nonostante i tempi estremamente rapidi nella sperimentazione dei vaccini anti-Covid, "la quantità di test eseguiti è stata superiore a quelli fatti abitualmente per gli altri vaccini".
11-Jan-2021 – NVX-COV2373
Forbes - Moderna Releases Details Of New Vaccine Deals While Novavax Moves To Phase 3
Novavax, a tiny Maryland-based biotech firm, is hoping 2021 is the year it will reach the major leagues in the global race for a Covid-19 vaccine. While Pfizer, its partner BioNTech, and Moderna received the first vaccine authorizations with mRNA technology, Novavax is hot on their heels with a different option.
11-Jan-2021 – NVX-COV2373
Howard University Newsroom - RECRUITMENT FOR THE HOWARD UNIVERSITY CLINICAL TRIAL IS NOW OPEN TO THE PUBLIC
Howard University announces its participation as a Phase 3 COVID-19 clinical trial site to evaluate the safety and effectiveness of a new coronavirus vaccine developed by Maryland-biotechnology company, Novavax.
11-Jan-2021 – NVX-COV2373
The Economic Times - EU seeks more Moderna COVID-19 vaccines, eyes deals with Valneva, Novavax
The European Union is in talks with Moderna to order more of its COVID-19 vaccine despite the company seeking a higher price, and is also trying to close COVID-19 vaccine deals with Valneva and Novavax, according to two EU officials and an internal document.
10-Jan-2021 – NVX-COV2373
Channel News Asia - Philippines secures 30 million Novavax COVID-19 vaccine doses
The Philippines has secured 30 million doses of a COVID-19 vaccine developed by US drug maker Novavax, officials said Sunday (Jan 10), as the country braces for a surge in infections after a huge religious event.
10-Jan-2021 – mAbCo19
Il Tirreno - Nel laboratorio toscano del super farmaco anti-Covid: i segreti dell'anticorpo J-08, i test sull'uomo e quando sarà pronto
Siena, il team di Rappuoli ha trovato i monoclonali più potenti per mettere a punto una terapia con cui sconfiggere il Coronavirus: come funziona e le previsioni sull'arrivo negli ospedali
8-Jan-2021 – AZD1222
https://www.nytimes.com/interactive/2020/health/oxford-astrazeneca-covid-19-vaccine.html
The New York Times - How the Oxford-AstraZeneca Vaccine Works
The University of Oxford partnered with the British-Swedish company AstraZeneca to develop and test a coronavirus vaccin known as ChAdOx1 nCoV-19 or AZD1222. A clinical trial revealed the vaccine was 62 to 90 percent effective, depending on the initial dosage. Despite some uncertainty over trial results, Britain authorized the vaccine for emergency use in December, and India authorized a version of the vaccine called Covishield on January 3, 2021.
7-Jan-2021 – NVX-COV2373
News4SA- UT Health looking for participants in Phase 3 Novavax COVID vaccine trial
People living in San Antonio will now have the opportunity to participate in the Phase 3 trial for the Novavax COVID-19 vaccine. UT Health and University Health says they started enrolling the first participants Thursday afternoon. They hope to enroll 500 people locally.
7-Jan-2021 – NVX-COV2373
News4Jax- Jacksonville clinical research center begins trials on another COVID-19 vaccine
While the Pfizer and Moderna COVID-19 vaccines continue to be administered across the United States under an emergency authorization status, the Jacksonville Center for Clinical Research has just begun clinical trials for the Novavax vaccine.
7-Jan-2021 – GRAd-COV2
https://tg24.sky.it/salute-e-benessere/2021/01/07/reithera-vaccino-italiano-covid
Sky Tg24- Reithera, Sky TG24 nella fabbrica del vaccino italiano anti-Covid.
L’azienda specializzata in biotecnologie, con sede alle porte di Roma, sta lavorando sul vaccino anti-Covid GRAd-CoV2, che rappresenta la risposta italiana ai vaccini di Pfizer e di Moderna. Dopo la fase 1 di sperimentazione “il vaccino Reithera ha dimostrato di essere sicuro e di avere capacità di indurre risposta immunitaria”, come confermato da Giuseppe Ippolito, direttore scientifico dell'Ospedale Spallanzani di Roma
6-Jan-2021 – NVX-COV2373
Barron’s -Novavax Has Covid-19 Vaccine News Coming Out Soon. That Could Be Good for the Stock.
Covid-19 vaccine makers Moderna and Pfizer are rushing to supply enough vaccine doses to staunch the pandemic’s still-climbing global death toll. Biotech company Novavax may be able to provide a glimmer of hope early this quarter, when data from its first Phase 3 trial of its Covid-19 vaccine is expected to be released.
6-Jan-2021 – AZD1222
Biopharma reporter – Oxford-AstraZeneca COVID-19 vaccine granted emergency use authorization in multiple countries
AstraZeneca officially announced today the Serum Institute of India had obtained emergency use authorization in India for its COVID-19 vaccine.
6-Jan-2021 -GRAd-COV2
Huffpost - ReiThera, prime consegne vaccino italiano entro fine del 2021
“L’obiettivo è quello di concludere la sperimentazione entro l’estate, per poi presentare la richiesta di autorizzazione alle agenzie regolatorie. Ovviamente per fare tutto questo servono le risorse”. Così la presidente di ReiThera Antonella Folgori, l’azienda del vaccino Made in Italy, su La Stampa.
6-Jan-2021 – mAbCo19
https://www.repubblica.it/salute/2021/01/06/news/covid_i_guariti_non_sono_immuni_al_virus_mutato-281310046/
La Repubblica - Covid, cosa succede quando i guariti incontrano il virus mutato
L’immunità naturale, quella sviluppata dopo aver superato la malattia, potrebbe non proteggere da una seconda infezione se Sars-Cov-2 è mutato. Lo dimostra uno studio condotto dal gruppo di Rino Rappuoli. Attenzione, però: è un lavoro in laboratorio e non si riferisce alle persone vaccinate
6-Jan-2021 – GRAd-COV2
https://www.lagone.it/2021/01/06/ben-tollerato-e-sicuro-positivi-i-primi-giudizi-sul-vaccino-italiano-rei-thera/
Lagone - “ben tollerato e sicuro”. positivi i primi giudizi sul vaccino italiano rei thera
Lusinghieri gli esiti della prima fase di sperimentazione. “Oltre il 94% dei soggetti nella fascia d’età 18-55 anni vaccinati con una sola dose ha prodotto anticorpi, ed oltre il 90% ha sviluppato anticorpi con potere neutralizzante nei confronti del virus”.
6-Jan-2021 - GRAd-COV2
https://www.ilmessaggero.it/video/salute/vaccino_italiano_reithera_puntiamo_100_milioni_di_dosi-5682572.html
Il Messagero - Codiv, vaccino italiano Reithera: «Puntiamo a 100 milioni di dosi»
«Puntiamo a sviluppare 100 mln dosi di vaccino per anno. Il vaccino è stabile ad una temperatura tra 2 e 8 gradi». Lo ha detto la presidente dell'azienda Reithera sviluppatrice del vaccino italiano, Antonella Folgore, alla presentazione dei risultati della Fase 1 della sperimentazione del Vaccino GRAd-CoV2
6-Jan-2021- GRAd-COV2
https://www.ilmessaggero.it/video/salute/vaccino_reithera_arcuri_giornata_importante_italia_punta_indipendenza-5682594.html
Il Messagero- Vaccino ReiThera, Arcuri: «Giornata importante, Italia punta a indipendenza»
«È una giornata molto importante. In una situazione come questa dobbiamo cercare di dipendere il meno possibile degli altri e produrre in maniera propria. In queste settimane dipendiamo completamente da vaccini stranieri e combattiamo per avere il maggior numero possibile di vaccini, ma l'Italia punta all'indipendenza». Così il commissario straordinario per l'emergenza COVID-19, Domenico Arcuri, durante la conferenza stampa sugli esiti e risultati della Fase 1 della sperimentazione del vaccino ReiThera GRAd-CoV2. «Il governo ha destinato una quantità di risorse sufficienti per lo sviluppo successivo di Reithera ed entrerà nel capitale dell'azienda per la successiva fase 2 e fase 3. L'azienda ha già presentato una proposta di investimento», ha aggiunto Arcuri.
6-Jan-2021 – GRAd-COV2
https://www.mondopalermo.it/news/il-vaccino-italiano-reithera-e-monodose-e-si-conserva-tra-2-e-8-gradi/
Mondo Palermo - IL VACCINO ITALIANO REITHERA È MONODOSE E SI CONSERVA TRA 2 E 8 GRADI
Ieri all’Istituto Spallanzani di Roma sono stati presentati i risultati della prima fase di sperimentazione del GRAd-COV2, il vaccino italiano prodotto dalla ReiThera di Castel Romano. Erano presenti il commissario straordinario per l’emergenza Covid, Domenico Arcuri e il presidente del Consiglio superiore di sanità (ISS), Franco Locatelli. Si tratta di un vaccino monodose che si conserva ad una temperatura tra i 2 e gli 8 gradi. L‘obiettivo produttivo stimato è di cento milioni di dosi all’anno. Nei soggetti a cui è stato inoculato nella prima fase di sperimentazione sull’uomo, non c’è stato nessun effetto indesiderato o grave.
6-Jan-2021 – AZD1222
https://indianexpress.com/article/india/coronavirus-vaccination-drive-icmr-covaxin-bharat-biotech-7134363/
The Indian Express - Ready for vaccination within 10 days of approval: Ministry
The Union Health Ministry said on Tuesday that stakeholders at the Centre and states were prepared to roll out the mass immunisation programme against Covid-19 within 10 days of the vaccines getting approval.The decision on rolling out India’s biggest adult vaccination drive will, however, be taken by the central government, it said.
5-Jan-2021 – mAbCo19
https://www.lanazione.it/siena/cronaca/mano-tesa-da-unicoop-fi-al-mad-lab-della-fondazione-tls-1.5879751
La Nazione - Mano tesa da UniCoop.Fi al Mad Lab della Fondazione Tls
Uniti nel sostenere i ricercatori del Mad Lab della Fondazione Toscana Life Sciences di Siena, coordinato dal professor Rino Rappuoli, scienziato di fama mondiale. Il noto laboratorio da marzo scorso ha indirizzato le proprie competenze nell’individuazione di anticorpi monoclonali umani capaci di curare il Covid-19.
5-Jan-2021 – GRAd-COV2
https://www.lacnews24.it/italia-mondo/reithera-il-vaccino-anticovid-italiano-e-efficace-come-pfizer-e-moderna_129792/
LACnews24 - ReiThera, il vaccino anti-Covid italiano «è efficace come Pfizer e Moderna»
Il vaccino italiano anti-Covid prodotto da ReiThera è efficace come quello di Pfizer e Moderna. A dirlo il direttore scientifico dell’Inmi Spallanzani di Roma, Giuseppe Ippolito, che ha presentato i risultati della Fase 1 della sperimentazione della cura contro il Covid-19.
5-Jan-2021 – GRAd-COV2
https://www.reuters.com/article/us-health-coronavirus-italy-reithera/italy-to-invest-in-biotech-reithera-to-support-covid-19-vaccine-development-idUSKBN29A17V
Reuters - Italy to invest in biotech ReiThera to support COVID-19 vaccine development
Italy will invest in local biotech company ReiThera to support the development of its COVID-19 vaccine, a senior official said on Tuesday after the government called results of a Phase 1 trial encouraging.
5-Jan-2021- GRAd-COV2
https://uk.reuters.com/article/health-coronavirus-italy-reithera/update-1-italy-to-invest-in-biotech-reithera-to-support-covid-19-vaccine-development-idUKL8N2JG2MB
Reuters- Italy to invest in biotech ReiThera to support COVID-19 vaccine development
Italy will invest in local biotech company ReiThera to support the development of its COVID-19 vaccine, a senior official said on Tuesday after the government called results of a Phase 1 trial encouraging.
4-Jan-2021 – AZD1222
http://www.koreaherald.com/view.php?ud=20210104000871
The Korea Herald - Korea begins approval process for AstraZeneca vaccine
AstraZeneca’s COVID-19 vaccine (AZD1222) will be reviewed for potential approval in South Korea within the next 40 days, Korea’s Ministry of Food and Drug Safety announced Monday
4-Jan-2021 – AZD1222
https://www.zenopa.com/news/2856/vaccine-developers-respond-to-remarks-regarding-their-vaccines-effectiveness-against-the-new-strain-of-covid
Zenopa - Vaccine developers respond to remarks regarding their vaccines' effectiveness against the new strain of Covid
Several vaccine developers have responded to remarks regarding their vaccines' effectiveness against the new strain of COVID-19. Ugur Sahin, BioNTech Chief Executive Officer, whose Pfizer partnered vaccine has been approved in the UK, US and EU, believes the vaccine will continue to work against the new strain.
1-Jan-2021 -AZD1222
https://www.hindustantimes.com/india-news/sii-s-covishield-approval-efficacy-cost-and-all-about-astrazeneca-s-covid-19-vaccine/story-2XrMT3hOEfuMhDOi4GViOK.html
Hindustan Times - SII’s Covishield approval: Efficacy, cost and all about AstraZeneca’s Covid-19 vaccine
A government’s expert panel has reportedly approved the vaccine, developed by AstraZeneca and Oxford University, for emergency use in India to provide immunity against the coronavirus disease (Covid-19). According to news agency Reuters, a subject expert committee, set up by Drugs Controller General of India (DCGI) to vet Covid-19 vaccine proposals, recommended granting emergency use authorisation to AstraZeneca’s vaccine AZD1222, dubbed in India as Covishield.
1-Jan-2020 – AZD1222
https://www.indiatvnews.com/news/world/coronavirus-oxford-astrazeneca-covid-19-vaccine-serum-institute-covishield-all-you-need-to-know-675389
India TV- Here's what you need to know about Oxford Covid-19 vaccine
With the UK giving the green light to the Covid-19 vaccine developed by Oxford University and drugmaker AstraZeneca, India is also expected to follow suit soon as a meeting of the decision-making body began on Friday, giving new hope of beginning the end of the pandemic as the New Year ushers in.
31-Dec-2020 – AZD1222
https://www.biospace.com/article/warp-speed-head-slaoui-predicts-astrazeneca-vaccine-won-t-be-used-in-the-u-s-until-april/
Biospace- AstraZeneca Vaccine Not Likely to Receive U.S. EUA Until April, Warp Speed Chief Says
The United Kingdom authorized AstraZeneca’s COVID-19 vaccine on Wednesday, but it could be April at the earliest before the drug will likely be administered in the United States, Operation Warp Speed’s chief said.
31-Dec-2020 – NVX-COV2373
https://www.nytimes.com/interactive/2020/health/novavax-covid-19-vaccine.html
The NY Times - How the Novavax Vaccine Works
The Maryland-based company Novavax has developed a protein-based coronavirus vaccine called NVX-CoV2373. The vaccine produced strikingly high levels of antibodies in early clinical trials. In September, the vaccine entered a Phase 3 clinical trial in the United Kingdom, and another one in the United States at the end of December. Those trials will show whether the vaccine is safe and effective.
29-Dec-2020 -AZD1222
https://www.lanazione.it/siena/cronaca/coronavirus-1.5861016
La Nazione - "Il virus cambia, andiamo più veloci"
Per ora lo studio è pubblicato su una piattaforma scientifica, ’biorxiv’, che potrebbe essere il passaggio propedeutico alla pubblicazione su Science o su altre riviste prestigiose.
28-Dec-2020 – NVX-COV2373
National Institutes of Health - Phase 3 trial of Novavax investigational COVID-19 vaccine opens
The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by Novavax, Inc., of Gaithersburg, Maryland.
25-Dec-2020 – V591
https://www.verywellhealth.com/merck-covid-19-vaccine-5093294
VeryWellHealth - An Overview of the Merck COVID-19 Vaccine
Merck, one of the largest pharmaceutical companies in the world, focused its early efforts in the fight against the coronavirus disease 2019 (COVID-19) on looking for ways to treat people who were sick. Now, the U.S. company is working on the vaccine development.
23-Dec-2020 – AZD1222
https://www.nst.com.my/news/nation/2020/12/651722/astrazeneca-selling-covid-19-vaccine-malaysia-no-profit
The Straits Times - AstraZeneca selling Covid-19 vaccine to Malaysia at no profit
With Malaysia and AstraZeneca having entered an agreement for the supply of 6.4 million doses of the University of Oxford's potential Covid-19 vaccine called AZD1222, the company confirms they are providing the vaccine at no profit.
22-Dec-2020 – Cape Biologix
https://www.news.uct.ac.za/article/-2020-12-22-uct-spin-off-receives-millions-in-european-funding
UCT spin-off receives millions in European funding
Cape Bio Pharms has received a multimillion-rand capital injection to fast-track the production of affordable plant-based rapid diagnostic COVID-19 test kits.
17-Dec-2020 – NVX-COV2373
https://www.reuters.com/article/us-health-coronavirus-newzealand-novavax-idUSKBN28R01S
Reuters - Novavax enters deal with New Zealand for 10.7 million doses of COVID-19 vaccine candidate
Biotechnology company Novavax Inc said it had entered an agreement with the government of New Zealand for 10.7 million doses of its COVID-19 vaccine candidate.
17-Dec-2020 – NVX-COV2373
Reuters - EU concludes preliminary talks to buy up to 200 million doses of Novavax COVID vaccine
The European Union has concluded preliminary talks with U.S. firm Novavax to secure up to 200 million doses of its COVID-19 vaccine candidate, a Commission spokesman said on Thursday.
17-Dec-2020 – NVX-COV2373
https://investorplace.com/2020/12/nvax-stock-still-make-vaccines-great-again/
Investor Place - Novavax Can Still Make Coronavirus Vaccines Great Again
It was the one-two punch (from the same arm, as it turned out) that chagrined many a novel coronavirus vaccine contender. First, Pfizer (NYSE:PFE) came up with a long-term solution that was 90%-plus effective, then Moderna (NASDAQ:MRNA) followed shortly thereafter. Both utilize messenger-RNA, which greatly contributed to their success over rivals like Novavax (NASDAQ:NVAX). But this approach is also why you can’t completely discount NVAX stock.
17-Dec-2020 – NVX-COV2373
Ekathimerini.com - EU concludes preliminary talks to buy up to 200 mln doses of Novavax Covid vaccine
The European Union has concluded preliminary talks with U.S. firm Novavax to secure up to 200 million doses of its COVID-19 vaccine candidate, a Commission spokesman said on Thursday.
17- Dec-2020 – NVX-COV2373
Dagblad van het Noorden - Europa dicht bij de aankoop van nog een coronavaccin. Het Amerikaanse Novavax moet 200 miljoen doses gaan leveren
De Europese Commissie is dicht bij de aankoop van nog een coronavaccin. De verkennende gesprekken met het Amerikaanse Novavax zijn afgerond, laat de commissie weten. Ze wil 100 miljoen doses kopen en een optie op nog eens zoveel.
17-Dec-2020 – AZD1222
https://www.nytimes.com/interactive/2020/health/oxford-astrazeneca-covid-19-vaccine.html
The New York Times - How the Oxford-AstraZeneca Vaccine Works
The University of Oxford partnered with the British-Swedish company AstraZeneca to develop and test a coronavirus vaccine known as ChAdOx1 nCoV-19 or AZD1222. A clinical trial revealed the vaccine was up to 90 percent effective, depending on the initial dosage. But uncertainty over the results has clouded its prospects.
15-Dec-2020 – AZD1222
https://www.manilatimes.net/2020/12/15/news/headlines/astrazeneca-seeks-vaccine-approval/811014/
The Manila Times - AstraZeneca seeks vaccine approval
After withdrawing its application for clinical trials in the Philippines, AstraZeneca is negotiating with the country’s vaccine regulators for an emergency use authorization (EUA) for its vaccine.
14-Dec-2020 – AZD1222
Europe Pharmaceutical Review - AstraZeneca to test combination of AZD1222 and Sputnik V vaccines
AstraZeneca has agreed to use one of the Sputnik V vaccine components in combination with its own COVID-19 vaccine to try and boost the efficacy of AZD1222 in humans.
“Today we announce a clinical trial programme to assess the safety and immunogenicity of a combination of AZD1222, developed by AstraZeneca and Oxford University, and Sputnik V, developed by Russian Gamaleya Research institute,” AstraZeneca said.
14-Dec-2020 – AZD1222
Hospital Healthcare Europe - AZD1222 vaccine has acceptable efficacy and safety profile
The highly anticipated vaccine (AZD1222) produced by a collaboration between Oxford University and AstraZeneca has become the first to have its interim study data published and appears to be as effective as reported in various media outlets.
14-Dec-2020 – mAbCo19
Siena News - Anticorpi monoclonali, Rappuoli: “Con questa cura guariti dal covid in 2 giorni”
L’ anticorpo monoclonale “in una persona positiva nello stadio iniziale della malattia, velocizza la guarigione in due o tre giorni ed è protetta per sei mesi dal Covid. Poi la protezione svanisce”.
13-Dec-2020 – COVID-eVAX
Il Meteo - CORONAVIRUS: VACCINO, ne arriverà uno tutto ITALIANO, al via la SPERIMENTAZIONE.
In attesa della somministrazione del VACCINO contro il CORONAVIRUS dell'azienda farmaceutica PFIZER, un nuovo vaccino tutto italiano è pronto ad essere testato. Lucio Rovati, presidente e direttore scientifico di Rottapharm Biotech, già durante la prima ondata dell’emergenza sanitaria ha messo a disposizione di Takis, società biotecnologica romana, "il supporto tecnico dei nostri manager scientifici, costituendo un team di elevate competenze cliniche, di tossicologia, farmacologia e nello sviluppo di prodotti biologici".
13-Dec-2020 – PLX-PAD
The Jerusalem Post - Pluristem to terminate Phase III study of critical limb ischemia (CLI)
While the CLI study was unsuccessful, Yanay said the company is maintaining a forward-thinking attitude, looking toward the development of other treatments it has in the works.
11-Dec-2020 – NVX-COV2373
M live - Ann Arbor VA hospital to conduct Novavax COVID-19 vaccine trial
The VA Ann Arbor Healthcare System will be one of two VA medical centers in the nation to launch clinical trials for the investigational COVID-19 vaccine developed by Novavax, according to a release from the U.S. Department of Veterans Affairs.
10-Dec-2020 – PLX-PAD
NASA-partnered Pluristem crashes to Earth as it axes leading therapy
Israeli biotech Pluristem is canning its experimental phase 3 critical limb ischemia therapy after an outside review said it was no good.
10-Dec-2020 - mAbCo19
Libero quotidiano - Coronavirus, fiale di monoclonali per guarire in 48 ore. Il microbiologo Rappuoli: "Basterà una puntura fatta in casa”
Fiale di monoclonali che consentono di guarire dal Covid in 48 ore, "basterà una puntura fatta in casa, poi basta contagi". E' questa la cura cui sta lavorando il microbiologo Rino Rappuoli, coordinatore scientifico del Mad (Monoclonal antibody discovery) della fondazione toscana Life Sciences. Dopo aver raccolto gli anticorpi dal sangue delle persone convalescenti, lo scienziato ha isolato in laboratorio le cellule che producono queste difese naturali e ha selezionato quelle super potenti, per poi riprodurle su scala industriale e poterle reiniettare.
10-Dec-2020 - mAbCo19
Il Sussidiario - https://www.ilsussidiario.net/news/monoclonali-guariscono-covid-in-48-ore-rappuoli-dose-anticorpi-protegge-6-mesi/2103554/
Non solo prevenzione ma anche terapia contro il Covid. Oltre al vaccino, l’attenzione è focalizzata in questo momento anche sull’uso di anticorpi monoclonali. Il microbiologo Rino Rappuoli, coordinatore scientifico del Mad (Monoclonal antibody discovery) della fondazione Life Sciences sta lavorando proprio su questa promettente cura.
10-Dec-2020 - NVX-COV2373
FX street - NVAX Stock Price: Novavax Inc drops as big name biotech companies inch closer to EUA for COVID-19 vaccine
NVAX has been somewhat forgotten in the race for Emergency Use Authorization (EUA) of its COVID-19 vaccine, taking a backseat to some of the biotech giants who are anticipating approval over the next couple of weeks. Novavax dropped 4.08% on Wednesday alongside a broader market selloff as US stimulus talks hit another wall in Congress. Investors do not have much to complain about considering shares are still up nearly 3000% over the past 52-weeks, with more to come in 2021 once its COVID-19 vaccine is approved for distribution.
10-Dec-2020 - NVX-COV2373
Oxford Mail - Novavax Covid vaccine trial recruits in Oxfordshire
US biotech company Novavax is running trials in Oxford as part of more than 15,203 participants recruited across the UK. It is the largest double blind, placebo-controlled Covid-19 vaccine trial to be undertaken in the country so far.
9-Dec-2020 - AZD1222
European Pharmaceutical Review - AZD1222 vaccine for COVID-19 is safe and effective in Phase III trials
An interim analysis reveals the AZD1222 vaccine candidate against COVID-19 is safe and effectively prevents immunised individuals from contracting symptomatic COVID-19 or severe disease requiring hospitalisation. The interim analysis for efficacy was based on 11,636 participants accruing 131 symptomatic infections in Phase III trials conducted in the UK and Brazil by Oxford University.
9-Dec-2020 - NVX-COV2373
https://dc.citybizlist.com/article/642516/why-novavax-stock-crushed-it-in-november
Citybizlist - Why Novavax Stock Crushed It in November
Shares of the COVID-19 vaccine developer Novavax (NASDAQ:NVAX) jumped by a healthy 73% during the month of November, according to data from S&P Global Market Intelligence. To put this sizable northward move into the proper context, the iShares Nasdaq Biotechnology ETF gained a far more modest 10.9% over the course of November.
8-Dec-2020 - PLX-PAD
https://seekingalpha.com/article/4393565-pluristem-moment-of-truth
Seeking Alpha - Pluristem - Moment Of Truth
For a biotechnology company there is always that defining moment where it presents the results of a super critical clinical trial which will define the fate of the company and will determine whether the sometimes decades long research was worth the huge resources and funds or whether it all goes down to the drain.That moment is here and now for Pluristem (PSTI).
8-Dec-2020 – AZD1222
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext
The Lancet - Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
8-Dec-2020 – AZD1222
https://www.handelsblatt.com/unternehmen/industrie/corona-pandemie-zwischenanalyse-impfstoff-von-astra-zeneca-ist-sicher-und-wirksam/26699012.html?ticket=ST-8938600-oidobq9Tr2kI5DQVMEta-ap3
Handelsblatt - Zwischenanalyse: Impfstoff von Astra-Zeneca ist sicher und wirksam
Der britische Pharmakonzern Astra-Zeneca hat die Daten der Zwischenanalyse aus seiner fortgeschrittenen Corona-Impfstoffstudie in der Fachzeitschrift „The Lancet“ veröffentlicht. Damit können Experten in aller Welt die Daten zum gemeinsam mit der Universität Oxford entwickelten Impfstoff einsehen.
8-Dec-2020 – AZD1222
Der Standard - Erste Resultate zu Corona-Impfstoff von Astra Zeneca stimmen zuversichtlich
Zum ersten Mal sind Resultate zur Wirksamkeit eines Covid-19-Impfstoffs in einer begutachteten Fachzeitschrift veröffentlicht worden. Das Vakzin AZD1222 sei sicher und biete nach Gabe zweier Dosen einen Schutz von etwa 70 Prozent gegen die Erkrankung, schreibt das Team um Andrew Pollard von der Universität Oxford im Fachblatt "The Lancet".
8-Dec-2020 – AZD1222
Berliner Zeitung - AstraZeneca: Erstmals Resultate zu Corona-Impfstoff in Fachjournal publiziert
Auf derartige Daten warten Wissenschaftler in aller Welt: Zum ersten Mal sind Resultate zur Wirksamkeit eines Covid-19-Impfstoffs in einer begutachteten Fachzeitschrift veröffentlicht worden. Es ist der Impfstoff AZD1222, den die Oxford University zusammen mit dem Astra-Zeneca-Konzern entwickelt, zu dem nun eine solche Publikation aus der entscheidenden klinischen Phase 3 vorliegt. Ähnliche Veröffentlichungen der beiden ebenfalls weit vorangekommenen Hersteller Moderna und Biontech sind zwar angekündigt, aber noch nicht erschienen.
5-Dec-2020 - Cape Biologix
https://www.biznews.com/news/2020/12/05/inside-covid-19-3
Biz news - Inside Covid-19: Meet two remarkable SA women in the spotlight for putting others first
BizNews journalist Linda van Tilburg looks at an entrepreneurial Cape company that has developed a rapid Covid-19 test from a cousin of the tobacco plant. The company is one of five attracting investment from the University Technology Fund, a South African vehicle aimed at commercialising technologies and innovations developed at home. We speak to Cape Bio Pharms founder Belinda Shaw.
3-Dec-2020 - Cape Biologix
https://www.biznews.com/inside-covid-19/2020/12/03/inside-covid-19-3
Biznews - Inside Covid-19: Meet two remarkable SA women in the spotlight for putting others first
In this episode of Inside Covid-19, we look at two SA success stories as the world fights the biggest global health crisis in living memory. BizNews journalist Linda van Tilburg looks at an entrepreneurial Cape company that has developed a rapid Covid-19 test from a cousin of the tobacco plant.
3-Dec-2020 - COVID-eVAX
Ansa - Covid, in Italia si lavora al vaccino contro le varianti del virus
Dopo la prima generazione, ormai vicina all'approvazione da parte delle agenzie regolatorie, dei vaccini contro il Covid-19, si cominciano già a studiare quelli in grado di contrastare le nuove varianti del virus SARS-CoV-2, La Takis si prepara infatti alla sperimentazione clinica di fase 1 del vaccino COVID-eVax, basato sulla sequenza genetica del virus SARS-CoV-2 circolato in Cina ad inizio 2020.
2-Dec-2020 - NVX-COV2373
https://www.jpost.com/israel-news/two-dozen-red-zones-named-tuesday-as-criteria-changed-650916
The Jerusalem Post - Israel in negotiations with Novavax to purchase COVID-19 vaccine
Israel is in negotiations with the Maryland-based biotech company Novavax to receive its vaccine candidate, Prime Minister Benjamin Netanyahu said Wednesday.
2-Dec-2020 -v591
Fierce Pharma - Merck cashes in on Moderna COVID-19 vaccine enthusiasm with sale of equity stake
When Merck invested $100 million in cash and stock in Moderna back in 2015, and then another $125 million three years later, the term “mRNA” was barely known outside of biotech circles.But now that Moderna’s mRNA vaccine to prevent COVID-19 is nearing the finish line—contributing to the collective worldwide sigh of relief that an end to the pandemic may be in sight—Merck’s early investment in the company looks rather prescient.
30-Nov-2020 - GRAd-COV2
Il Dolomiti - Coronavirus, Mirian Fadelli volontaria per il test sul nuovo vaccino: “Nessun effetto collaterale”
Da Roma arriva il via libera per procedere con la fase 2 per la sperimentazione del vaccino contro il coronavirus dell'italiana Reithera. Tra il primo gruppo di volontari sani, tra 18 e 55 anni, che si sono sottoposti all'inoculazione c’è Mirian Fadelli: “Ho deciso di farlo perché credo fortemente nella scienza e nella medicina”
30-Nov-2020 - NVX-COV2373
Finanzen.net - Corona-Impfstoffstudie von US-Biopharmakonzern Novavax verzögert sich - Novavax-Aktie in Grün
Für die Zulassung in den USA und Mexiko starte die Phase III der klinischen Studie voraussichtlich in den kommenden Wochen, teilte Novavax am Montag in Gaithersburg (Maryland) mit. Bisher hatte das Unternehmen mit dem Start bis Ende November gerechnet. Novavax hat nach eigenen Angaben durch das Impfprogramm der US-Regierung 1,6 Milliarden US-Dollar (1,3 Mrd Euro) erhalten, um die Bereitstellung eines sicheren und wirksamen Vakzins zu beschleunigen. In Großbritannien stünden nun rund 15 000 Teilnehmer für die Phase III der dortigen Versuchsstudie fest.
30-Nov-2020 - mAbCo19
https://www.lanazione.it/covid-rino-rappuoli-anticorpi-monoclonali-pronti-per-marzo-2021-1.5766617
La Nazione - Covid, Rino Rappuoli: "Anticorpi monoclonali pronti per marzo 2021"
Dovrebbero arrivare a marzo le prime dosi di anticorpi monoclonali 'made in Italy' da distribuire alla popolazione. Entro fine anno, infatti, la Fondazione Toscana life sciences inizierà i test sulle persone. A fare il punto e' il coordinatore della ricerca, Rino Rappuoli, questa mattina nel corso di una conferenza stampa indetta da Coop Alleanza 3.0 e Unicoop Firenze. "Stiamo lavorando per avere i monoclonali disponibili su larga scala per marzo 2021", conferma Rappuoli.
30-Nov-2020 - mAbCo19
Contro Radio - Covid: Rappuoli, entro primavera avremo anticorpi potenti e costi accessibili
Gli anticorpi monoclonali “in genere sono per malattie gravi come tumori, malattie
infiammatorie, autoimmuni, e costano tantissimo, a volte decine di migliaia di dollari o euro per trattamento”, invece “i nostri anticorpi sono stati studiati in modo da essere molto potenti, in modo che bastino quantità piccole, quindi i costi saranno molto più accessibili”. Lo ha affermato Rino Rappuoli, direttore
scientifico di Gsk Vaccines e coordinatore del progetto di ricerca sugli anticorpi monoclonali presso Toscana Life Sciences.
30-Nov-2020 - NVX-COV2373
Reuters - Novavax delays U.S. COVID-19 vaccine trial again, now sees start in the coming weeks
Vaccine maker Novavax Inc said on Monday it has pushed back the start of a U.S.-based, late-stage trial for its experimental COVID-19 vaccine and now expects it to begin in the coming weeks instead of November.
26-Nov-2020- AZD1222
Ruhr24.de - Corona-Impfstoffe: Unterschiede zwischen Biontech, Astra Zeneca und Moderna einfach erklärt
Dortmund – Maske tragen, Abstand halten, Kontaktbeschränkungen. Der Wunsch nach Lockerungen und nach einem baldigen Ende der Coronavirus-Pandemieist groß. Aktuell gibt es drei heiße Impfstoff-Kandidaten, die die angespannte Corona-Dynamik vielleicht bald entspannen könnten. Die drei Wirkstoffe wurden von verschiedenen Firmen entwickelt und unterscheiden sich in der Wirkweise.
25-Nov-2020 – AZD1222
https://www.gv.com/news/vaccitech-adrian-hill-covid-19-vaccine/
GV- Vaccitech Co-Founder Professor Adrian Hill on Developing a COVID-19 Vaccine
Following this week's news that AstraZeneca, the University of Oxford, and our portfolio company Vaccitech's vaccine for COVID-19 is highly effective and safe, my colleague Vidu Shanmugarajah and I invited Vaccitech co-founder Professor Adrian Hill to talk with our portfolio CEOs about the battle against the pandemic. Here Adrian recounts the story behind his search for a vaccine, results from late-stage clinical trials, the challenges of manufacturing and global distribution — and what has to happen next to stop the virus.
25-Nov-2020 - VPM1002
Neue Presse - MHH testet Corona-Impfstoff – besser als Biontech & Co.?
Derzeit überschlagen sich die Meldungen über Corona-Impfstoffe. Dabei könnte es sein, dass es ihn schon längst gibt. Die MHH forscht jetzt mit der Fortentwicklung eines bewährten Tuberkulose-Mittels. Und dieser Impfstoff könnte viel besser wirken als die angekündigten Mittel gegen Covid-19.
25-Nov-2020 - AZD1222
RTL- Warum der Impfstoff von Astrazeneca die Welt endlich von Corona befreien könnte
Die Biotech-Pioniere Biontech und Moderna beherrschen mit ihren Covid-19-Impfstoffen die Schlagzeilen. Diese Medikamente werden wohl hauptsächlich an die reichen Industrieländer gehen. Die Hoffnung vor allem ärmerer Länder ruht unter anderem aber viel mehr auf Astrazeneca und der Universität Oxford.
24-Nov-2020 -AZD1222
AstraZeneca: Halbe Dosis – bessere Wirksamkeit
AstraZeneca hat neue Daten zu seinem Corona-Impfstoffkandidaten vorgelegt. Das Besondere: Die beiden untersuchten Impfschemata scheinen unterschiedlich wirksam zu sein: Zwei volle Dosen schützen mit einer rund 70-prozentigen Wahrscheinlichkeit vor Covid-19. Wird bei der ersten Injektion nur die halbe Dosis verabreicht, so entsteht ein Infektionsschutz von 90 Prozent.
24-Nov-2020 - AZD1222
https://www.n-tv.de/wissen/Die-drei-Top-Corona-Impfstoffe-im-Vergleich-article22189430.html
NTV -Die drei Top-Corona-Impfstoffe im Vergleich
Kampf mit dem Coronavirus Sars-CoV-2 scheint sich das Blatt zugunsten der Menschheit zu wenden: Innerhalb von rund zwei Wochen geben die westlichen Entwickler Biontech/Pfizer, Moderna und Astrazeneca/Universität Oxford Erfolge mit ihren Impfstoffkandidaten bekannt. Das Positive: Alle drei Vakzine wirken gegen den Erreger. Dennoch gibt es markante Unterschiede zwischen den drei Impfstoffen.
24-Nov-2020 -AZD1222
https://www.n-tv.de/wirtschaft/Astrazeneca-macht-den-Impfstoff-fuer-die-Massen-article22187188.html
NTV - Astrazeneca macht den Impfstoff für die Massen
Die Biotech-Pioniere Biontech und Moderna beherrschen mit ihren Impfstoffen die Schlagzeilen. Diese Medikamente werden wohl hauptsächlich an die reichen Industrieländer gehen. Die Hoffnung vor allem ärmerer Länder ruht unter anderem aber viel mehr auf Astrazeneca und der Universität Oxford.
24-Nov-2020 - AZD1222
https://indianexpress.com/article/explained/simply-put-how-far-from-a-vaccine-now-7063054/
Explained: How far are we from a Covid-19 vaccine now?
AstraZeneca Oxford vaccine trials put efficacy at 62% when two full doses are given, and 90% when first shot is half a dose. How does it compare to other vaccines, and what does it mean for Covishield in India?
24-Nov-2020 - GRAd-COV2
Corriere Etneo - Coronavirus, va avanti il vaccino italiano di Reithera: “E’ ben tollerato e induce risposta immunitaria”
ReiThera fa sapere infatti che il suo candidato vaccino Grad-Cov2 contro Covid-19 “è ben tollerato e induce risposta immunitaria nei soggetti sani di età compresa tra i 18 e i 55 anni”. La Fase 1 – che valuta il candidato vaccino su 90 volontari sani – avanza ora nei soggetti più anziani, tra i 65 e gli 85 anni.
24-Nov-2020 - GRAd-COV2
Il Fatto Quotidiano - Vaccino Covid, Reithera: “Nostro candidato ben tollerato e induce risposta immunitaria. Ora al via i test sugli anziani”
Lo studio è stato disegnato ed è condotto in collaborazione con l’Istituto nazionale per le malattie infettive Lazzaro Spallanzani di Roma. "L'arruolamento dei volontari più anziani sta procedendo come previsto e prevediamo di comunicare entro la fine dell’anno i primi risultati dello studio" dice l'ad Antonella Folgori
24-Nov-2020 - GRAd-COV2
https://www.ilmessaggero.it/salute/focus/vaccino_covid_azienda_roma_reithera_news-5604983.html
Il messaggero - Vaccino Covid, Reithera: «Ben tollerato, ora Fase 1 sui soggetti più anziani»
Sul vaccino anti Covid avanza anche la ricerca italiana. ReiThera, azienda di Castel Romano, fa sapere infatti che il suo candidato vaccino Grad-Cov2 contro Covid-19 «è ben tollerato e induce risposta immunitaria nei soggetti sani di età compresa tra i 18 e i 55 anni». La Fase 1 - che valuta il candidato vaccino su 90 volontari sani - avanza ora nei soggetti più anziani, tra i 65 e gli 85 anni. L'azienda ha comunicato infatti oggi l'aggiornamento sullo studio clinico di Fase 1 del suo candidato vaccino, attualmente in corso.
24-Nov-2020 - GRAd-COV2
https://www.scienceboard.net/index.aspx?sec=ser&sub=def&pag=dis&ItemID=1754
Science Board - ReiThera touts phase I COVID-19 vaccine results
ReiThera is highlighting positive phase I clinical trial results for its COVID-19 vaccine candidate, GRAd-COV2. The first phase of the trial includes a cohort of healthy volunteers between the ages of 18 and 55. This phase is now advancing to include healthy subjects between the ages of 65 and 85; its phase II/III will explore effective vaccine dose. The vaccine is based on a proprietary replication-defective simian adenoviral vector that encodes the full-length coronavirus spike protein, according to the firm.
23-Nov-2020 - mAbCo19
Siena News- Covid, Rappuoli: “Vaccini e anticorpi monoclonali nel 2021 ci ridaranno la nostra libertà”
“Nel 2021 saremmo capaci di controllare la pandemia da covid grazie ai vaccini e agli anticorpi monoclonali”, lo ha detto in una videoconferenza il microbiologo e scienziato senese Rino Rappuoli ospite all’Accademia dei Fisiocritici per parlare di vaccini e anticorpi monoclonali che verranno usati contro il coronavirus.
23-Nov-2020 - AZD1222
Deutsche Apotheker Zeitung - AZD1222 erzeugt robuste Immunität auch bei Senioren
Der Corona-Impfstoff von AstraZeneca scheint auch bei älteren Menschen eine robuste Immunität zu erzeugen und tendenziell verträglicher zu sein als bei Jüngeren, zu diesem Fazit kommen Wissenschaftler bei einer Zwischenauswertung von ChAdOx1 nCoV-19 (AZD1222) in „The Lancet“. Dies ist in zwei Punkten interessant: Denn ältere Menschen haben ein erhöhtes Risiko für schwere und tödliche COVID-19-Verläufe, jedoch reagiert ihr Immunsystem aufgrund von Immunoseneszenz meist schlechter auf eine Impfung als das von jüngeren Menschen.
23-Nov-2020 - AZD1222
The Japan Times - AstraZeneca and Oxford say COVID-19 vaccine shows 70% efficacy
British drug group AstraZeneca and the University of Oxford on Monday said their jointly-developed vaccine against COVID-19 has shown “an average efficacy of 70 percent” in trials.
22-Nov-2020 - NVX-COV2373
Daily Mail - Novavax vaccine stops coronavirus spreading between monkeys – raising hopes of a jab that will eliminate virus as well as stopping people falling ill
A company in the global race to produce a Covid-19 vaccine has raised hopes that its jab could stop humans spreading the virus to each other following successful trials in monkeys. Novavax told The Mail on Sunday that its vaccine 'prevented infection' between rhesus macaque monkeys in testing
20-Nov-2020 - AZD1222
https://www.genengnews.com/news/astrazeneca-oxford-covid-19-vaccine-shows-positive-phase-ii-results/
Gen eng news - AstraZeneca-Oxford COVID-19 Vaccine Shows Positive Phase II Results
Researchers from AstraZeneca, the University of Oxford, and several collaborating institutions have published Phase II data showing that their COVID-19 vaccine candidate AZD1222—one of several leading vaccines in development against the virus—has similar immunogenicity across all age groups after the second “boost” dose, including older adults where the vaccine showed fewer adverse effects.
20-Nov-2020 -AZD1222
Cambridge Network - AstraZeneca's COVID-19 vaccine shows promise among older people in trials
Strong immune responses were demonstrated across all age groups and boosted after a second dose.Interim results from the ongoing Phase II/III COV002 trial of AZD1222 in the UK, led by the University of Oxford demonstrated lower local and systemic reactions in older adults (≥56-69 years and ≥70 years) than younger adults (≥18-55 years) and generated similar robust immune responses against the SARS-CoV-2 virus across all adult age groups.
20-Nov-2020 - AZD1222
http://www.koreaherald.com/view.php?ud=20201120000748
Korea Herald- AstraZeneca vaccine results to be out around Christmas, SK Bioscience already manufacturing
AstraZeneca and Oxford University’s co-developed COVID-19 vaccine AZD1222 has shown immune response in older adults enrolled in a phase 2 clinical trial of the drug.
Phase 3 clinical trial results are anticipated to be released around Christmas, the researchers said Friday.
20-Nov-2020 - AZD1222
Nasdaq -AZN's Covid Jab & Immunosenescence, PFE/BNTX To Seek Emergency Nod For Vaccine, QURE Aces HOPE-B
Today's Daily Dose brings you news about the encouraging immune response triggered by AstraZeneca's Covid-19 vaccine candidate in older adults, the first combination regimen authorized for emergency use by FDA for COVID-19, Pfizer/BioNTech mulling to file for emergency use approval of their COVID-19 shot, and uniQure's gene therapy trial results in Hemophilia B patients.
20-Nov-2020 - mAbCo19
Il Giornale -Un super anticorpo anti Covid "Pronti a distribuirlo in Italia"
Starebbe arrivando un super anticorpo capace di combattere il Covid e presto potrebbe essere distribuito in Italia.
20-Nov-2020 - mAbco19
https://www.today.it/scienze/anticorpi-monoclonali-italia-quando.html
Today - Anticorpi monoclonali: quando arriva la cura contro il coronavirus in Italia
Lo scienziato Rino Rappuoli ha annunciato che è in corso di definizione un accordo con il Ministero della Salute per la distribuzione da marzo (ma solo in casi di emergenza)
17-Nov-2020 - AZD1222
https://in.reuters.com/article/uk-factcheck-vaccine-idUSKBN27W2I7
Reuters- Fact check: Lung tissue of an ‘aborted male foetus’ is not in the vaccine for coronavirus
A Facebook video discussing the Oxford AstraZeneca vaccine for COVID-19 has falsely claimed it contains tissue from an aborted human foetus.
16-Nov-2020 - GRAd-COV2
https://www.radioradio.it/2020/11/ranucci-vaccino-coronavirus-di-lorenzo-big-pharma/?cn-reloaded=1
RadioRadio- Contratti segreti sul vaccino: lo Stato italiano paga, Big Pharma guadagna miliardi ► Ranucci (Report)
Tutti lo cercano, tutti attendono il fatidico annuncio: la caccia al vaccino contro il coronavirus sarebbe forse come lo sbarco sulla Luna per la nazione che lo trovasse. Non si spiegherebbero altrimenti le estenuanti ricerche nei laboratori di tutto il mondo che in queste ore fanno i conti con Big Pharma. La celebre multinazionale starebbe infatti provando ad attribuire gli oneri di un risarcimento dovuto a disfunzioni o effetti collaterali agli Stati nazionali: una lotta in cui è inclusa anche l’Italia.
11-Nov-2020 - NVX-COV2373
Washington Business Journal - Novavax mulls up to $500M raise as Covid, flu programs move forward
Novavax has experienced “accelerated expansion … in every functional area,” CEO Stanley Erck said on a Nov. 9 company earnings call.
11-Nov-2020 - NVX-COV2373
https://www.kbtx.com/2020/11/10/novavax-covid-19-vaccine-receives-designated-fast-track-from-fda/
KBTX-TV - Novavax COVID-19 Vaccine receives designated fast track from FDA
Novavax vaccine is the latest company to get fast track designation from the U.S Food and Drug Administration (FDA).This is the same company that will use the FUJIFILM Diosynth biotechnologies and the Texas A&M Innovation Center to help manufacture their product.
11-Nov-2020 - mAbCo19
In Toscana - Toscana Life Sciences: a Siena il polo d’eccellenza nella ricerca farmacologica
Arriva da Siena la nuova speranza di cura e prevenzione contro il Covid-19. La Fondazione Toscana Life Sciences infatti ha individuato gli anticorpi monoclonali in grado di combattere il Coronavirus, grazie al lavoro del Monoclonal Antibody Discovery (MAD) Lab della fondazione senese, coordinato dallo scienziato e pioniere dei vaccini Rino Rappuoli che riceverà, insieme al presidente di TLS Fabrizio Landi, il Pegaso d’Oro della Regione Toscana.
11-Nov-2020 - COVID-eVAX
https://www.ilgiorno.it/monza-brianza/cronaca/covid-vaccino-1.5701818
Il Giorno - Covid: vaccino made in Monza, a gennaio la sperimentazione
Vaccino anti-Covid, pronti allo studio clinico sui primi volontari. "In questi giorni invieremo la documentazione alle autorità sanitarie e a inizio gennaio partiremo con la Fase 1 al San Gerardo di Monza, allo Spallanzani di Roma (che si occuperà anche di tutte le valutazioni di laboratorio) e all’oncologico Pascale di Napoli".
9-Nov-2020 - NVX-COV2373
Bloomberg - Prognosis: Novavax Covid-19 Vaccine Gets Fast-Track Tag From FDA
Novavax Inc.’s experimental Covid-19 vaccine received a fast-track designation from U.S. regulators as the drugmaker prepares to launch a large, late-stage study before the end of the month, the company said on Monday.
9-Nov-2020 - AZD1222
Morningstar- CSL Begins Manufacturing Of Astra's AZD1222 Covid-19 Vaccine Candidate
CSL Ltd on Sunday confirmed it will start manufacturing the AZD1222 Covid-19 vaccine candidate from the University of Oxford and AstraZeneca PLC at its advanced manufacturing facility in Broadmeadows, Australia.
5-Nov-2020 - AZD1222
BioPharma Reporter - Only ‘small chance’ of distributing the AZD1222 vaccine in the UK before Christmas
Late-stage trial results on Astra Zeneca’s Covid-19 Vaccine could be ready by December
5-Nov-2020 - AZD1222
Sixth tone - COVID Vaccines, Tests Take Center Stage at Shanghai Trade Expo
With the COVID-19 pandemic still spreading rapidly across the globe, several companies are showcasing their health care-related products and services at the third annual China International Import Expo (CIIE), which kicked off Thursday in Shanghai.
5-Nov-2020 - AZD1222
Finanztreff.de - Astrazeneca erwartet noch 2020 Studienergebnis zu Covid-19-Impfstoff
LONDON (Dow Jones)Der Pharmakonzern Astrazeneca befindet sich mit seiner klinischen Studie zu einem Impfstoff gegen das Coronavirus im Plan. Ergebnisse sollen noch in diesem Jahr vorliegen, und eine Auslieferung der Impfdosen soll nach einer Genehmigung durch die Behörden "schnell" erfolgen, wie der britische Konzern ankündigte.
5-Nov-2020 - AZD1222
https://www.thelocal.it/20201105/italy-seeks-volunteers-for-covid-19-vaccine-trial
The Local It - Italy seeks volunteers for Covid-19 vaccine trial
Volunteers in Italy could receive the first doses in December, as scientists begin a Phase 3 clinical trial of the vaccine developed by Oxford University and AstraZeneca pharmaceutical group and partly manufactured and bottled by two Italian companies near Rome.
5-Nov-2020 - NVX-COV2373
Brisbane times - Experts hail addition of two more vaccines to Australia's virus 'portfolio'
The expert in charge of two separate Australian clinical trials of coronavirus vaccine candidates says the latest vaccine agreement announced by the federal government is vital in helping the country eventually reopen fully next year.
4-Nov-2020 - AZD1222
Fierce Biotech - Trial chief tips AstraZeneca COVID-19 vaccine for 2020 data drop
AstraZeneca has a good chance of delivering late-phase data on its COVID-19 vaccine this year, the chief investigator of the Oxford Vaccine Trial said. The timing gives AstraZeneca a “small chance” of being able to start distributing the AZD1222 vaccine in the U.K. before Christmas.
3-Nov-2020 - mAbCo19
https://www.theflorentine.net/2020/11/03/covid-19-monoclonal-antibody-treatment-developed-in-siena/
The Florentine -Covid-19: Monoclonal antibody treatment developed in Siena
A monoclonal antibody treatment to heal Covid-19 patients and prevent infection is being developed in Siena, Tuscany. The announcement was made on television programme “Che tempo che fa?” by Professor Rino Rappuoli, Chief Scientist and Head External R&D di GSK Vaccines in Siena.
2-Nov-2020 - AZD1222
Pharma Forum - UK could get COVID-19 vaccines early next year, ahead of European countries
COVID-19 vaccines could be approved and available early next year in the UK ahead of European countries, after its national regulator began its own rolling reviews of shots from AstraZeneca and Moderna.
2-Nov-2020 - NVX-COV2373
Washington business journal - Novavax buys new real estate as Covid-19 program drives growth
Gaithersburg’s Novavax Inc. has secured new real estate to support its growth, fueled by its Covid-19 and seasonal flu programs. The local biotech said early Monday it has purchased a 9.7-acre parcel at 14 Firstfield Road in Gaithersburg through its affiliate, 14 Firstfield Holdings LLC. There, Novavax “plans to develop in the future to accommodate growth of the Company.” It did not immediately disclose a purchase price, which is not yet public.
2-Nov-2020 - NVX-COV2373
WTOP News - Novavax to expand in Montgomery County, add hundreds of jobs
Gaithersburg, Maryland-based Novavax, one of several companies advancing a potential COVID-19 vaccine, will open a new research and development and manufacturing facility in Gaithersburg, and will add at least 400 new jobs, the majority of them by next spring.
2-Nov-2020 - AZD1222
https://www.fr.de/wissen/kein-kompletter-schutz-aber-ein-kuerzerer-infekt-90088168.html
Frankfurter Rundschau - Kein kompletter Schutz – aber ein kürzerer Infekt
Die ersten Impfstoffe werden wohl kaum die Ansteckung eines Geimpften mit dem neuen Coronavirus verhindern. „Die Daten aus den Tierstudien deuten darauf hin, dass nur im Einzelfall einen Schutz vor Infektion mit Sars-CoV-2 durch die Impfung erreicht wird“, sagt Klaus Cichutek, Präsident des Paul-Ehrlich-Institutes, der deutschen Behörde, die für die Zulassung von Impfstoffen zuständig ist. Warum ist das so und was bringt ein Impfstoff dann überhaupt?
1-Nov-2020 - AZD1222
VOA News - Britain Starts Accelerated Review for AstraZeneca's Potential COVID-19 Vaccine
AstraZeneca Plc said on Sunday Britain's health regulator had started an accelerated review of its potential coronavirus vaccine."We confirm the MHRA's (Medicines and Healthcare Products Regulatory Agency) rolling review of our potential COVID-19 vaccine," an AstraZeneca spokesman said.
, coordinato da Rino Rappuoli a Siena. Si è arrivati alla scelta del candidato migliore su cui puntare durante la fase di sviluppo e produzione dei tre anticorpi migliori (selezionati a luglio scorso), che valuta sia la capacità dell'anticorpo di legare la proteina spike e di inattivare il virus, sia la resa da un punto di vista dello sviluppo e produzione della terapia contro il virus.
30-Oct-2020 - AZD1222
Geneng News - U.S. Army Awards $599M in Contracts for AstraZeneca Vaccine, Lilly Antibody vs. COVID-19
The U.S. Army will spend a combined $599 million to procure two leading COVID-19 candidates—AstraZeneca’s vaccine AZD1222, co-developed with the University of Oxford and a spinout company; and Eli Lilly’s neutralizing antibody bamlanivimab (LY-CoV555).
30-Oct-2020- AZD1222
Indian Express - Explained: Is death in Brazil a blow for AstraZeneca-Oxford Covid-19 vaccine candidate?
There has been a death in the late-stage clinical trials of a Covid-19 vaccine being developed by University of Oxford and Swedish-British drugmaker AstraZeneca. What happened and what does this mean for the trials of the closely watched candidate, a version of which is at the forefront of India’s own Covid-19 vaccine race?
30-Oct-2020 - VPM1002
Money Control - Explainer: What the ICMR study tells us about the effectiveness of the BCG vaccine against Covid-19
Governments around the world are keen to know if the nearly century-old vaccine can be used to prevent Covid-19. It’s not hard to see why — the safety of the BCG vaccine has long been established. Moreover, it is very cheap and production can be scaled up easily
29-Oct-2020 - AZD1222 & NVX-COV2373
Pharmalive - pharma companies strike deals to deliver millions of covid-19 vaccines by 2021 leading pharmaceutical giants – including moderna, pfizer and astrazeneca – are racing ahead to develop and distribute a covid-19 vaccine.
29-Oct-2020- mAbCo19
AGI - "Ancora 3 mesi e avremo la cura con anticorpi". La revisione di Rappuoli
L'amministratore delelgato di Glaxo Vaccines è fiducio: "Dopo l'arruolamento in un mese-un mese e mezzo contiamo di avere i risultati in base ai quali poter chiedere l'autorizzazione al commercio"
29-Oct-2020 -mAbCo19
055 Firenze - Pegaso d'Oro a Rino Rappuoli e a Fabrizio Landi della Fondazione Toscana Life Sciences
Il primo Pegaso d'Oro della nuova Giunta regionale della Toscana, guidata da Eugenio Giani, sarà consegnato allo scienziato Rino Rappuoli e al presidente della Fondazione Toscana Life Sciences, Fabrizio Landi. Entrambi, spiega la Regione, sono al centro di una nuova strategia scientifica per sconfiggere il Covid 19, su cui lo stesso Governo italiano sta investendo in modo significativo, per accelerare i risultati della ricerca di un vaccino, che dovrebbe proteggerci definitivamente dalla pandemia in corso.
29-Oct-2020 - GRAd-COV2
I24 News - Israel agrees to buy coronavirus vaccines from Italy
Rome-based biotech company ReiThera is currently developing a coronavirus vaccine at the capital's Spallanzani Institute for infectious diseases. Human trials, expected to last six months, began in August.
27-OCt-2020 - V591
Business Standard -Merck says early data from Covid-19 vaccines expected this year
Merck & Co Inc on Tuesday said it expects to report results from early-stage studies of two potential COVID-19 vaccines before the end of the year and has advanced an experimental antiviral drug into late-stage testing.
28-Oct-2020 - AZD1222
https://www.dw.com/en/covid-19-difficult-trade-offs-in-astrazeneca-vaccine-development/a-55421164
DW - COVID-19: Difficult trade-offs in AstraZeneca vaccine development
The Oxford vaccine ChAdOx1 is seen as a promising candidate to combat COVID-19. But critics believe that research is going too fast and that risks could be being played down. What is true about the accusations?
27-Oct-2020 - AZD1222
The Guardian - Oxford Covid vaccine works in all ages, trials suggest
One of the world’s leading Covid-19 experimental vaccines produces an immune response in older adults as well as the young, its developers say, raising hopes of protection for those most vulnerable to the coronavirus that has caused social and economic chaos around the world.
27-Oct-2020 - v591
Business standard - Merck says early data from Covid-19 vaccines expected this year
Merck & Co Inc on Tuesday said it expects to report results from early-stage studies of two potential COVID-19 vaccines before the end of the year and has advanced an experimental antiviral drug into late-stage testing.
27-Oct-2020- NVX-COV2373
CNBC- Novavax delays U.S. trial of Covid-19 vaccine candidate to November
Novavax on Tuesday delayed the start of a late-stage U.S. trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing process.
27-Oct-2020 -NVX-COV2373
https://www.deaandeelhouder.nl/nieuws/2020/10/27/novavax-breidt-coronavaccinstudie-in-vk-uit/
De aandeelhouder -Novavax breidt coronavaccinstudie in VK uit
Novavax heeft ruim 5.500 proefpersonen gerekruteerd voor de Fase 3 studie naar een coronavaccin die het in Verenigd Koninkrijk uitvoert en wil dit onderzoek uitbreiden naar 15.000 vrijwilligers. Dit meldde het Amerikaanse farmaceutische bedrijf dinsdagmiddag.
27-OCt-2020 - mAbCo19
https://startupitalia.eu/139528-20201027-rappuoli-chi-e-biografia
Startup Italia - Rino Rappuoli, chi è il “papà” dei super anticorpi contro il Covid
Rino Rappuoli è uno dei più importanti e riconosciuti microbiologi italiani e mondiali. Noto alla comunità scientifica per la scoperta del vaccino contro meningococco B e C e quello contro la pertosse, oggi Rappuoli è a capo del progetto della fondazione non profit Toscana Life Sciences – TLS -, per la ricerca sugli anticorpi monoclonali in grado di rendere immuni per sei mesi dal Covid. Sempre in Toscana, lo scienziato direttore scientifico e capo del comparto di ricerca e sviluppo nella divisione vaccini della casa farmaceutica britannica GlaxoSmithKline– GLS – a Rosia, in provincia di Siena.
26-Oct-2020 - AZD1222
Aljazeera -Oxford vaccine prompts immune response in elderly: AstraZeneca
An experimental COVID-19 vaccine being developed in the United Kingdom produces an immune response in both younger and older adults, British drug maker AstraZeneca said, raising hopes in the fight against the coronavirus pandemic.
26-Oct-2020 - AZD1222
https://pharmaphorum.com/news/az-jj-coronavirus-vaccine-trials-okay-to-restart-in-us/
PharmaPhorum - AZ, J&J COVID-19 vaccine trials okay to restart in US
US trials of AstraZeneca’s experimental COVID-19 vaccine AZD1222 have been cleared to restart by the FDA, several weeks after testing was suspended following a serious adverse reaction in one patient who received the shot.
26-Oct-2020 - AZD1222
Scandasia - AstraZeneca to produce COVID-19 vaccine AZD1222 for Thailand and South East Asia
The Swedish Embassy, on 12 October 2020, expressed that they were delighted to witness the signing ceremony of the Letter of Intent on the manufacturing and supply of the University of Oxford’s potential COVID-19 vaccine AZD1222 for Thailand and South East Asia among the Thailand’s Ministry Of Public Health, Siam Bioscience Co., Ltd., SCG and British – Swedish biopharmaceutical company, Astrazeneca (Thailand) Ltd. Photo from the signing ceremony on 12 October 2020 at Thailand’s Ministry of Public Health
26-Oct-2020 - AZD1222
Pharmazeutische Zeitung -Astra-Zenecas Corona-Impfstoffstudie in den USA läuft wieder
Nach einer fast siebenwöchigen Unterbrechung setzt der Pharmakonzern Astra-Zeneca seine klinischen Studien für den mit der Universität Oxford entwickelten Corona-Impfstoff AZD1222 auch in den USA wieder fort.
25-Oct-2020 -
mAbCo19
RAI TV Che Tempo Che Fa - Rino Rappuoli, scientific director of the vaccines division of GSK of Rosia (Siena)
25-Oct-2020 - PLX-PAD
The Jerusalem Post - Pluristem names members of coronavirus Steering Committee
Israeli bio-pharmaceutical firm Pluristem officially formed a Steering Committee for its clinical program for its treatment of coronavirus complicated by acute respiratory distress syndrome (ARDS).
25-Oct-2020 - mAbCo19
Siena News - Covid, Rappuoli: “A marzo prime dosi del farmaco con anticorpi monoclonali”
“Incominciare le prove cliniche prima di Natale, finirle entro febbraio e a marzo avere il farmaco a disposizione, le prime decine di migliaia di dosi e poi averne sempre di più”, così è intervenuto nella trasmissione “Che tempo che fa?” il direttore scientifico della divisione vaccini Gsk e capo del laboratorio Mad Lab Rino Rappuoli. Il progetto di ricerca sugli anticorpi monoclonali contro il covid è iniziato questa primavera e vi collaborano INMI Spallanzani, Toscana Life Sciences, VisMederi, università di Siena e Imperial College di Londra.
25-Oct-2020 -mAbCo19
Corriera Dell Umbria - Coronavirus, Rappuoli (Gsk), annuncia a Che Tempo che fa: "Farmaco a marzo, migliaia di dosi" | Video
23-Oct-2020 - AZD1222, NVX-CoV2373
India Today - Readying 1 billion doses of 5 coronavirus vaccines, says SII's Adar Poonawalla
Serum Institute of India (SII) is reportedly readying one billion doses of five coronavirus vaccines worldwide with CEO Adar Poonawalla saying that the plan is to launch at least one vaccine every quarter likely by 2021 beginning.
23-Oct-2020 - AZD1222
Frankfurter Allgemeine - Corona-Impfung mit Fragezeichen
Weltweit wird in Rekordtempo an einem Corona-Impfstoff geforscht. Doch die Zulassungsstudien werden von einem Todesfall und quälenden Unsicherheiten überschattet.
23-October-2020 - AZD1222
Republic World - Oxford COVID-19 Vaccine Doing 'everything Expected'; Says Study Calling It 'good News'
The Oxford University COVID-19 vaccine, which is currently undergoing Phase III, clinical trial with Pharma Giant AstraZeneca is doing “everything expected”, an independent analysis stated on October 22. The analysis, which was conducted by researchers from Bristol University, examined vaccine candidates ChAdOx1 and also AZD1222, to see “what it does when it gets inside a human cell.”
22-Oct-2020 - AZD1222
https://www.aerztezeitung.de/Nachrichten/Toter-bei-COVID-19-Impfstoffstudie-413949.html
AerzteZeitung - Toter bei COVID-19-Impfstoffstudie?
Der COVID-19-Impfstoffkandidat „AZD1222“ von der Universität Oxford und AstraZeneca gilt als einer der vielversprechendsten Kandidaten weltweit. Nun soll in der klinischen Phase-III-Studie ein Proband gestorben sein.
21-Oct-2020 - AZD1222
PMLive - AZ’s US-based COVID-19 vaccine trial could restart this week
The US arm of AstraZeneca’s (AZ) COVID-19 vaccine, which was put on hold in September after a study participant developed a serious illness, could resume this week.
20-Oct-2020 - V591
Oe24 - Corona-Impfung: Wiener war Österreichs erster Tester
Die erste Corona-Impfung hat Alex P. (32) aus Wien bereits schadlos überstanden. Insgesamt nehmen 25 Probanden aus ganz Österreich an der Studie teil.
19-Oct-2020 - PLX-PAD
https://www.calcalistech.com/ctech/articles/0,7340,L-3862812,00.html
Ctech - The Genesis Prize Foundation and Start-Up Nation Central announce finalists in COVID-19 startup competition
21 of Israel's most promising startups are shortlisted for a competition highlighting the global potential of Israeli innovation. “The shortlisted companies epitomize the best of what Israeli innovation has to offer to help tackle the global crisis.”
19-Oct-2020 - PLX-PAD (from minute 7.20, in Hebrew)
https://www.youtube.com/watch?v=QL2AlnLUtPM&ab_channel=כאןחדשות-תאגידהשידורהישראלי
Israeli TV Channel 11 - CEO and President, Yaky Yanay’s COVID19 interview on the World Today program broadcast on Israeli TV Channel 11
15-Oct-2020 -PLX-PAD
The Jerusalem Post - Pluristem to enroll participants for GvHD treatment at Sourasky
Israeli biotech company Pluristem received clearance to move forward with Cohort II enrollment for its investigator-led Phase I/II study for the treatment of steroid-refractory chronic graft vs. host disease (GvHD).
14-Oct-2020 - mAbCo19
https://www.lanazione.it/siena/cronaca/anticorpi-monoclonali-1.5609119
La Nazione - Covid, a Siena individuato l'anticorpo monoclonale più potente. Al via test
Si chiama MAD0004J08, ed è l'anticorpo monoclonale che si è dimostrato più potente contro il virus: i test clinicipartiranno entro fine 2020. Lo annuncia il Monoclonal Antibody Discovery Lab di Fondazione Toscana Life Sciences, coordinato da Rino Rappuoli a Siena. Si è arrivati alla scelta del candidato migliore su cui puntare durante la fase di sviluppo e produzione dei tre anticorpi migliori (selezionati a luglio scorso), che valuta sia la capacità dell'anticorpo di legare la proteina spike e di inattivare il virus, sia la resa da un punto di vista dello sviluppo e produzione della terapia contro il virus.
17-Oct-2020 -mAbCo19
Sienanews - Coronavirus, Rappuoli: “Fuori dalla pandemia nel 2021”
Così, risponde Rino Rappuoli, capo della ricerca sui vaccini all’Imperial College di Londra, a una intervista del Quotidiano.net. Il riferimento è, ovviamente, a riguardo del coronavirus, tema tornato di grande attualità, purtroppo, a causa della forte impennata dei contagi nel nostro Paese, ma anche nel resto d’Europa. Ebbene, il professore e Chief Scientist and Head External R&D di Gsk Vaccines a Siena ha rassicurato un po’ la popolazione relativamente a una possibile cura del Covid-19.
17-Oct-2020 - mAbCo19
https://www.blitzquotidiano.it/salute/rino-rappuoli-vaccini-3228490/
Blitz quotidiano - Rino Rappuoli, il prof dei vaccini: “Fuori dalla pandemia entro il 2021 grazie a vaccini e anticorpi monoclonali”
Rino Rappuoli non ha dubbi, il nostro Paese tornerà a respirare tra un anno: “Fuori dalla pandemia entro il 2021 grazie a vaccini e anticorpi monoclonali”. Secondo Rino Rappuoli, microbiologo italiano, Medaglia d’oro al merito della sanità pubblica nel 2005, l’Italia uscirà dalla pandemia entro il 2021 grazie a vaccini e anticorpi monoclonali.
19-Oct-2020 - J.POD
Manager Magazin - Gates-Stiftung steckt Geld in Covid-19-Forschung von Evotec
Prominente Unterstützung für den MDax-Konzern Evotec: Für die Forschung gegen die Corona-Krankheit Covid-19 erhält das Unternehmen eine Finanzspritze der Stiftung von Microsoft-Gründer Bill Gates.
19-Oct-2020 - J.POD
https://www.finanztreff.de/nachrichten/evotec-und-bill-gates+erste-kaufsignale/22120859
Finanztreff.de - Evotec und Bill Gates – erste Kaufsignale
Der Wirkstoff-Forscher Evotec bekommt eine Förderung von der Stiftung von Microsoft-Gründer Bill Gates. Anleger reagieren positiv – und die Evotec-Aktie liefert erste Kaufsignale.Mit der Geldspritze, über deren Höhe keine Angabe gemacht wurde, soll die Entwicklung und Herstellung von Antikörpern gegen die Lungenkrankheit Covid-19 in den USA vorangetrieben werden, wie Evotec am Montag mitteilte.
19-Oct-2020 - J.POD
pharmiweb - JUST - EVOTEC BIOLOGICS RECEIVES GRANT TO ENABLE AN ANTIBODY PRODUCT FOR THE PREVENTION OF COVID-19
Evotec SE today announced that its Seattle-based subsidiary, Just - Evotec Biologics, Inc., received a grant from the Bill & Melinda Gates Foundation (Seattle, WA) as part of the COVID-19 Therapeutics Accelerator to enable the development and production of monoclonal antibody ("mAb") candidates for the prevention of severe COVID-19 in vulnerable populations in low and middle income countries.
17-Oct-2020 - AZD1222
Live mint - COVID-19 vaccine may be ready by December, to be available in market by March: SII official
Serum Institute of India can produce 700-800 million vaccine dosages every year once things are streamlined, executive director of SII said. The vaccine is likely to provide protection for about a year, AstraZeneca CEO Pascal Soriot said
16-Oct-2020 - mAbCo19
OKSiena - INDIVIDUATO A SIENA ANTICORPO MONOCLONALE PIÙ POTENTE CONTRO COVID-19
Scelto l’anticorpo monoclonale più potente contro il coronavirus e, per questo, candidato farmaco per la terapia per sconfiggere Covid-19. Ad annunciarlo il Monoclonal Antibody Discovery Lab di Fondazione Toscana Life Sciences con sede a Siena e coordinato dallo scienziato Rino Rappuoli.
13-Oct-2020 - AZD1222
https://www.sknvibes.com/news/newsdetails.cfm/113257
SKN Vibes - Mexico ensures vaccine for more than 100 million Mexicans
The Government of Mexico formalized pre-purchase contracts for COVID-19 vaccine with AstraZeneca, CanSino Biologics and Pfizer to cover more than 100 million Mexicans. In the framework of the press conference led by President Andrés Manuel López Obrador, the Secretary of Foreign Affairs, Marcelo Ebrard Casaubon, reported on the progress in Mexico's strategy to guarantee universal access and fair prices to the vaccine against COVID- 19. This week, the Government of Mexico signed three pre-purchase contracts with the pharmaceutical companies AstraZeneca, CanSino Biologics and Pfizer to acquire sufficient doses of vaccines to cover, together with those obtained in the COVAX mechanism, up to 116 million Mexican people.
13-Oct-2020 - NVX-CoV2373
Yorkshire Evening Post - Hundreds take part in Novavax Covid-19 vaccine study in University of Leeds The Edge sports hall
The trial is the first Phase Three study to test the effectiveness of the new Novavax COVID-19 vaccine.Volunteers will be receiving the vaccine in the University of Leeds' The Edge Sports Hall.Half of the volunteers will be given the vaccine and the other half a placebo, or "dummy" injection.
9-Oct-2020 - NVX-CoV2373
FXstreet- NVAX Stock Price: Novavax Inc. gains as COVID-19 vaccines hit front-page news after President Trump’s recovery
It has been a historic year for biotech firms as the emergency need for a COVID-19 vaccine has put many small firms on the radars of investors. NASDAQ:NVAX is at the top of that list and after gaining over 4600% year to date, the stock still could have room to move if the results of its Phase 3 clinical trials are successful.
9-Oct-2020 - NVX-CoV2373
CBS Baltimore - 10K Volunteers Participating In Novavax COVID-19 Vaccine Trial In UK
A big step in the race for a coronavirus vaccine- Gaithersburg-based Novavax has kicked off the late-stage trial of its potential vaccine in the UK. It’s testing the effectiveness of the shot among 10,000 people.
8-Oct-2020 – AZD1222
https://ipolitics.ca/2020/10/08/canada-could-order-astrazenecas-covid-vaccine-before-end-of-2020/
iPolitics - Canada could order AstraZeneca’s COVID vaccine before end of 2020
The Canadian government could pre-order doses of the COVID-19 vaccine that’s furthest along in Health Canada’s authorization process before the end of the year, if the vaccine continues to show promising results in its clinical trials.
8-Oct-2020 – Chorus
Radio Siena TV- Diesse Diagnostica Senese, nuovo test per la diagnosi sierologica precoce di Covid-19
Prosegue l’impegno di DIESSE nella lotta alla pandemia, offrendo un nuovo ed efficace supporto all’identificazione dello stato di salute dei pazienti. Il nuovo test sierologico sviluppato da DIESSE consente di rilevare la presenza di anticorpi totali (IgG, IgM ed IgA) contro il virus SARS-CoV-2 con valori di sensibilità e specificità superiori al 99% con metodica automatizzata sulla piattaforma Chorus.
8-Oct-2020 – Chorus
https://www.gonews.it/2020/10/08/covid-diesse-kit-diagnosi/
Go news - Covid-19, dalla senese Diesse un nuovo kit per la diagnosi
Prosegue l’impegno di DIESSE nella lotta alla pandemia, offrendo un nuovo ed efficace supporto all’identificazione dello stato di salute dei pazienti. Il nuovo test sierologico sviluppato da DIESSE consente di rilevare la presenza di anticorpi totali (IgG, IgM ed IgA) contro il virus SARS-CoV-2 con valori di sensibilità e specificità superiori al 99% con metodica automatizzata sulla piattaforma Chorus.
7-Oct-2020 -PLX-PAD
The Jerusalem Post - Phase II COVID-19 placenta cellular therapy trial to launch in Israel
The Haifa-based company Pluristem announced announced Wednesday that it has received approval from the Health Ministry to expand an existing Phase II clinical trial of its treatment for COVID-19 to Israel.
6-Oct-2020 – AZD1222
https://www.fool.com/investing/2020/10/06/astrazenecas-coronavirus-vaccine-is-already-being/
The Motley Fool - AstraZeneca's Coronavirus Vaccine Is Already Being Reviewed for Approval in Canada and Europe. Why Not in the U.S.?
It wasn't all that long ago that many people saw AstraZeneca (NYSE:AZN) as the leader in the race to develop a coronavirus vaccine. The U.K.-based drugmaker partnered with the University of Oxford and got off to a fast start.
6-Oct-2020 – AZD1222
Fierce Pharma - Oxford Biomedica earns U.K. nod for 4th manufacturing suite to boost COVID-19 production
Among the contract manufacturers enjoined in the race for a COVID-19 vaccine, Oxford Biomedica has forged a close relationship with AstraZeneca given its choice location. Now, the company is one step closer to running at full speed with the U.K.'s nod for a new production suite.
3-Oct-2020 – PLX-PAD
Gulf News - Abu Dhabi Stem Cells Centre collaborating with Israeli firm for COVID-19 therapies
Abu Dhabi: UAE's Abu Dhabi Stem Cells Centre (ADSCC) is collaborating with Israeli regenerative medicine company, Pluristem, to advance COVID-19 therapies.
In a statement, ADSCC said it was working to administer Pluristem developed PLX cells via a nebuliser to COVID-19 patients. The collaboration will allow ADSCC to expand its stem cell therapy options with the novel PLX cells, while also enabling Pluristem to leverage the ADSCC’s nebuliser administration experience to develop a new treatment delivery model for PLX cells.
2-Oct-2020 – AZD1222
Market Screener - AstraZeneca : COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India
The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
2-Oct-2020 – PLX-PAD
The Jerusalem Post -Israeli and Emirati companies join forces to develop COVID-19 treatment
Israeli Pluristem Therapeutics Inc. (PSTI,) and Emirati Abu Dhabi Stem Cells Center (ADSCC) unveiled their first joint projects at the Malta Conferences Foundation, a global conference that brings together scientists and researchers from Middle East countries in order to improve the quality of life and regional political stability, while meeting the scientific and technological challenges of the region.
1-Oct-2020 – GRAd-COV2
Start Magazine - Sanofi, Irbm, Reithera: il ruolo dell’Italia per il vaccino anti Covid
Anche l’Italia ha un ruolo chiave per lo sviluppo, la produzione e il confezionamento dei vaccini anti Covid. Oggi lo stabilimento Sanofi di Anagni ha inaugurato le linee di produzione del farmaco sviluppato dalla francese Sanofi in collaborazione con la casa farmaceutica britannica Gsk (che ha lo zampino anche nella fondazione Tls che sarà finanziata dal governo Conte). In Italia verrà infialato, presso la Catalent di Anagni, il vaccino messo a punto dall’Università di Oxford in collaborazione con l’italiana Irbm e prodotto da Astrazeneca. E sempre in Italia, Reithera, di proprietà di Keires Ag, società del settore finanziario con sede a Basilea, ha sviluppato, in collaborazione con lo Spallanzani, un vaccino che viene testato e prodotto nel nostro Paese.
30-Sep-2020 – NVX-COV2373
Bioprocess international - Novavax and J&J ink COVID-19 vaccine fill/finish deals
As Novavax progresses its COVID-19 vaccine candidate through the clinic, the firm has inked numerous deals with contract development and manufacturing organizations (CDMOs) to ensure it will be ready for large-scale production.
The latest focuses on the fill and finish of the Phase II candidate, NVX-CoV2373, with a deal in place with Par Sterile Products – a subsidiary of Endo International.
29-Sep-2020 – NVX-COV2373
The New Indian Express- COVID-19: Mysuru’s JSS Hospital likely to start human trials of Novavax
Mysuru’s JSS Hospital is likely to start phase 2 and 3 trials of the Covid-19 vaccine candidate, Novavax.
The hospital consented to carry out the trial after Pune-based Serum Institute of India approached the hospital, adding another feather to its cap.
23-Sept-2020 – VPM1002
Frankfurter Rundschau - Kampf gegen Corona: Alter Impfstoff könnte den Durchbruch bringen
Ein altbekanntes Vakzin verhindert laut einer Studie Atemwegsinfekte – und könnte auch gegen Mutationen des Coronavirus wirksam sein. Ein gegen Tuberkulose entwickelter Impfstoff könnte auch gegen das Coronavirus helfen. In verschiedenen klinischen Studien soll jetzt die Wirksamkeit gegen Covid-19 getestet werden. Auch ein in den USA entwickelter Antikörper könnte den Durchbruch in der Forschung für einen Impfstoff bringen.
23-Sept-2020 – mAbCo19
Il Cittadino - Coronavirus: AchilleS Vaccines è partner strategico di TLS
SIENA. AchilleS Vaccines e Fondazione Toscana Life Sciences (TLS) hanno siglato un Joint Venture Agreement orientato al finanziamento e alla gestione dello sviluppo industriale del prodotto MAbCo19, frutto della ricerca su anticorpi monoclonali umani come soluzione terapeutica al SARS-CoV-2.
21-Sept-2020 – AZD1222
The week – Human trials of Oxford coronavirus vaccine paused over ‘spinal-cord disease fears’
Human trials of the Oxford coronavirus vaccine are facing delays in the US after a participant suffered a rare neurological condition, according to a leaked document.
15 Sept-2020 – NVX-COV2373
Fierce Pharma - Novavax adds antigens to COVID-19 production pact with Indian vaccines giant
Despite a lackluster history of taking vaccines to market, Maryland's Novavax is streaking through clinical trials for its promising COVID-19 shot candidate. Going commercial is a whole other beast, however, and Novavax is now expanding one of its key manufacturing deals to aid the cause.
14-Sept-2020 – AZD1222
Fierce Biotech - AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine
Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the U.K.
Announced over the weekend, the U.K. Big Pharma said its vaccine, known as AZD1222, “has resumed in the U.K. following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.”
14-Sept-2020 – GRAd-Cov2
ADNKronos - Covid, ReiThera: "Per vaccino corsa contro il tempo"
ReiThera è "coinvolta a pieno ritmo nel raggiungimento di questo importante obiettivo: si tratta di una vera e propria corsa contro il tempo per verificare la sicurezza, l’immunogenicità e l’efficacia del vaccino sull’uomo affinché possa essere messo a disposizione di tutto il Paese nel più breve tempo possibile".
12-Sept-2020 – V591
Reuters - Merck starts recruitment for COVID-19 vaccine trial
U.S. drugmaker Merck & Co Inc has begun recruiting participants to its early-stage COVID-19 vaccine study, according to the government database clinicaltrials.gov.
12-Sept-2020 – AZD1222
https://www.channelnewsasia.com/news/world/astrazeneca-trials-of-covid-19-vaccine-resuming-13105804
Channel News Asia - AstraZeneca resumes UK trials of COVID-19 vaccine halted by patient illness
AstraZeneca has resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs, the company said on Saturday (Sep 12).
09-Sep-2020- AZD1222
The Wire (India) COVID-19: AstraZeneca Halts Oxford Vaccine Trial After a Report of Adverse Effects
The British-Swedish pharma company AstraZeneca has temporarily halted phase 3 clinical trials of the AZD1222 COVID-19 vaccine after a trial participant reportedly developed severe adverse reactions, STAT News has reported. Reuters quoted company spokeswoman Michele Meizell: “Our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee.”
09-Sep-2020- AZD1222
The Conversation AU: Halting the Oxford vaccine trial doesn’t mean it’s not safe – it shows they’re following the right process
Only days after the federal government announced a A$1.7 billion vaccine deal to roll out COVID-19 vaccines to Australians in 2021, one of the two candidates has halted its phase 3 trials after a participant became ill. The AZD1222 vaccine, considered one of the frontrunners in the global race for a COVID-19 vaccine, was developed by the University of Oxford and has been undergoing testing with British-Swedish pharmaceutical company AstraZeneca.
09-Sep-2020- Grad-Cov 2
https://www.rfi.ro/social-124714-italia-accelereaza-testarea-propriul-vaccin-anticovid
RFI Romania: Italia accelerează testarea pe om a propriul vaccin anticovid (Italy is accelerating human testing for its own vaccine)
Italy is accelerating the human testing of Grad-Cov 2 vaccine. The vaccine is produced and patented by a company in Rome and would be approved for widespread use in the spring, if the test results allow. Meanwhile, more and more volunteers from the age of 18 are receiving doses of the Italian vaccine. At the Borgo Roma hospital in Verona, 6 volunteers aged between 18 and 54 have already received their dose of Grad-Cov 2 vaccine, developed, produced and patented by the Italian biotechnology company, ReiThera. This is the first of three phases of the Italian human vaccine testing. Tomorrow the number of vaccinated volunteers will be double so that a total of 43 people will receive the vaccine at the hospital in Verona. One third of the volunteers are doctors, nurses or medical students. Volunteers will be monitored for six months and if during this time they did not register side effects and produced antibodies - "we can say that we are on the right track in finding the vaccine," says Stefano Milleri, director of the Center for Clinical Research.
07-Sep-2020- mAbCo19
http://www.quotidianosanita.it/regioni-e-asl/articolo.php?articolo_id=87730
Quotidiano Sanità: Speranza in visita al polo Toscana Life Sciences. Rossi: “Verrà da Siena il nuovo farmaco per curare il coronavirus”(Speranza visits the Toscana Life Sciences hub. Rossi: "The new drug to cure the coronavirus will come from Siena")
The new drug that will allow Covid to be treated will come from Siena. The president of the Tuscany Region, Enrico Rossi, is convinced of this , and today he visited together with the Minister of Health, Roberto Speranza, the headquarters of Toscana Life Sciences, the Sienese technology and research center, financed iby the Tuscany Region. For Rossi, “TLS is the only center in Italy that can boast hundreds of pharmaceutical patents and that can compete globally with all the countries that are fighting against Covid”.
07-Sep-2020-mAbCo19
Siena News: L’Italia punta su Tls, 50 milioni di euro per la produzione del farmaco anticovid (Italy is betting on Toscana Life Sciences (Tls), 50 million euros for the production of the anticovid drug)
Fifty million euro funding for the anticovid drug, with a potential to rise to 80 million. These are the funds that the Italian Government will invest in the project to be developed in the Tls laboratories. The drug will be produced in the Menarini plants in Florence.
07-Sep-2020- nvx-cov2373
http://www.koreabiomed.com/news/articleView.html?idxno=9129
Korea BioMedical review: Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
The New England Journal of medicine published the paper "Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine". The results show that at 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum.
01-Sep-2020- AZD1222
European Pharmaceutical review: Phase III testing of AstraZeneca’s AZD1222 vaccine has begun in the US
A multi-site, Phase III clinical trial evaluating AZD1222, an investigational COVID-19 vaccine, has begun in the US. The trial will enrol approximately 30,000 adult volunteers (aged 18 plus) at 80 US sites to evaluate if the candidate vaccine can prevent symptomatic COVID-19. The 30,000 participants in the double-blind US trial will be randomly assigned to either the investigational vaccine group or the placebo group in a ratio of 2:1. After an initial screening, participants will receive two injections of either the investigational vaccine or a saline placebo approximately four weeks apart. The trial is primarily designed to determine if AZD1222 can prevent symptomatic COVID-19 after two doses. However, it will also evaluate if the vaccine candidate can prevent SARS-CoV-2 infection regardless of symptoms and if it can preclude severe COVID-19. It will also assess if the experimental vaccine can reduce the incidence of emergency department visits due to COVID-19.
31-Aug-2020 - AZD1222
BusinessWire: Development of COVID-19 Vaccine AZD1222 Expands Into US Phase III Clinical Trial Across All Adult Age Groups
AZD1222 development expanded into a Phase III clinical trial in the US to assess its safety, efficacy and immunogenicity. Trial centers across the US are recruiting up to 30,000 adults aged 18 years or over from diverse racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions, including those living with HIV, and who are at increased risk of infection from the SARS-CoV-2 virus.
31-Aug-2020 - Grad-CoV2
Sputnik News: Grad-CoV2, candidato vaccino italiano in sperimentazione al Policlinico di Verona (Grad-CoV2, Italian vaccine candidate being tested at the Verona Polyclinic).
The trial of the Italian Grad-CoV2 vaccine candidate to verify the immune response to the Sars-CoV2 virus, starts on Monday 31 August at the Policlinico di Verona. Today the first three volunteers will receive the injection, out of a total of 70 chosen from the many applicants.
31-Aug-2020 - NVX-CoV2373
NASDAQ: Novavax Inks Deal With Canadian Government To Sell Up To 76 Mln Doses Of Its COVID-19 Vaccine
(RTTNews) - Biotechnology company Novavax, Inc. (NVAX) announced Monday it has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, Novavax' COVID-19 vaccine. Novavax and Canada expect to finalize an advance purchase agreement under which Novavax will supply doses of NVX-CoV2373 to Canada beginning as early as the second quarter of 2021.
31-Aug-2020 - NVX-CoV2373
CNBC: Canada to purchase 76 million doses of Novavax coronavirus vaccine.
The company says Novavax said it expects to finalize an agreement that would see it begin to supply Canada with doses “as early as the second quarter of 2021,” the company said. The company’s vaccine, called NVX-CoV2373, is currently in phase two trials. Novavax has previously said it could begin late-stage trials as early as October.
29-Aug-2020 - PLX-PAD
Jerusalem Post: FDA clears Haifa-based Pluristem’s COVID-19 Expanded Access Program
The US Food and Drug Administration has approved the use of Pluristem’s PLX-PAD cells in patients who are suffering from acute respiratory distress syndrome brought on by COVID-19, but who do not qualify for the company’s clinical trial.
26-Aug-2020 - Grad-CoV2
EU Reporter: Mexico signs up to Italian vaccine trial for Coronavirus – minister
Mexico is due to take part in clinical trials of an Italian vaccine GRAd-COV2 being developed by the National Institute for Infectious Diseases ‘Lazzaro Spallanzani’ in Rome.against the coronavirus. The Lazzaro Spallanzani institute this week announced it would conduct trials on 90 volunteers over the coming weeks, with the hope a vaccine may be available by spring of next year. Ebrard did not say when Mexico would begin the trials of the vaccine.
24-Aug-2020- Grad-CoV2
S.I.R. Agenzia D’Informazione: Coronavirus Covid-19: iniziata allo Spallanzani la sperimentazione sull’uomo di GRAd-CoV2, il candidato vaccino italiano contro Sars-CoV-2 (Coronavirus Covid-19: human experimentation of GRAd-CoV2, the Italian vaccine candidate against Sars-CoV-2, started at Spallanzani)
The human trial of GRAd-CoV2, the Italian vaccine candidate against Sars-CoV-2, began this morning at the National Institute of Infectious Diseases (Inmi) "Lazzaro Spallanzani" in Rome. made, produced and patented by the Italian biotechnology company ReiThera. The experiment, developed by a team of Spallanzani researchers and clinicians in collaboration with ReiThera, will be carried out on ninety volunteers divided into two age groups: 45 between 18 and 55 years, as many over the age of 65.
24-Aug-2020- NVX-CoV2373
Globe NewsWire: Novavax Initiates Phase 2 Portion of Phase 1/2 Clinical Trial of COVID-19 Vaccine
Novavax, Inc. a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the first volunteers have been enrolled in the Phase 2 portion of its ongoing clinical trial to evaluate the immunogenicity and safety of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The Phase 2 clinical trial expands on the age range of the Phase 1 portion by including older adults 60-84 years of age as approximately 50 percent of the trial’s population.24-Aug-2020 – GRAd-COV2
Corriere della sera - Vaccino anti Covid allo Spallanzani: oggi iniziano i test di Reithera sull’uomo
Antonella Folgori, ad di Reithera, annuncia l’avvio della sperimentazione del vaccino per il coronavirus pensato in Italia che sarà condotta dallo Spallanzani con dosi studiate e preparate nello stabilimento di Castel Romano
24-Aug-2020 – NVX-COV2373
Reuters - Novavax starts enrollment for phase two of COVID-19 vaccine trial
Novavax Inc said on Monday it has begun enrolling volunteers for the second phase of an ongoing clinical trial of its COVID-19 vaccine candidate, with interim data expected in the fourth quarter of 2020.
20-Aug-2020 – NVX-COV2373
Washington Business Journal - Novavax lease brings newly converted Gaithersburg lab building to full occupancy
Gaithersburg-based Novavax Inc. (NASDAQ: NVAX), which has secured a multibillion-dollar commitment to develop a Covid-19 vaccine, recently inked a lease for lab space at 704 Quince Orchard Road, co-owner Scheer Partners announced Thursday.
19-Aug-2020 – PLX-PAD
https://www.israel21c.org/israelis-and-emiratis-to-develop-covid-stem-cell-therapy/
Israel21c- Israelis and Emiratis to develop Covid stem-cell therapy
Fast on the heels of the agreement between Israel and the United Arab Emirates (UAE) to establish full diplomatic relations, Haifa-based Pluristem Therapeutics signed a non-binding memorandum of understanding (MoU) with the Abu Dhabi Stem Cells Center to advance cell therapies for diseases including Covid-19.
17-Aug-2020 – PLX-PAD
https://en.globes.co.il/en/article-pluristem-teams-with-1001339557
Globes - The two sides have signed an MOU on cooperation in developing stem cell-based therapies for coronavirus and other diseases.
The normalization agreement between Israel and the United Arab Emirates (UAE) has not yet been signed, but several Israeli healthcare companies from the two countries are cementing scientific and business ties that they had already started forming discretely.
17-Aug-2020 – NVX-COV2373
MarketWatch - Novavax starting trial of COVID-19 vaccine in South Africa
Novavax NVAX, +6.15% said it's beginning a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, its COVID-19 vaccine candidate. The Bill & Melinda Gates Foundation providing $15 million grant toward trial, said Novavax, which last week agreed to sell its vaccine to the U.K. government if successful.
17-Aug-2020 – NCX-COV2373
Biopharma-reporter – UK strikes deals with J&J, Novavax to source 90m COVID-19 vaccines
UK government reaches agreements to buy millions of COVID-19 vaccines from Johnson & Johnson and Novavax, bringing total stockpile up to 340 million.
17-Aug-2020 – NVX-COV2373
Washington Business Journal - Novavax is racking up Covid-19 vaccine deals for global markets. And the stock shows.
This agreement is the latest in a string the Gaithersburg biotech has inked in the past week.
17-Aug-2020 – NVX-COV2373
The Hill - Novavax coronavirus vaccine candidate begins phase two trials
Novavax on Monday announced it would proceed with phase two clinical trials to determine if its coronavirus vaccine candidate showed positive results for patients.
17-Aug-2020 – NVX-COV2373
The Wall Street Journal - Covid-19 Vaccine Candidate From Novavax Starts Midstage Trial
The Phase 2 study will test the safety and efficacy of the vaccine in South Africa, with 2,665 healthy adults and another 240 who are HIV positive
17-Aug-2020 – PLX-PAD (in Hebrew)
N12 - An interview with Pluristem’s CEO, Yaky Yanay, on Israeli TV
N12 News Israel, discuss the latest milestone #UAE #Israel collaboration with ADSCC Abu dhabi Stem Cells Center to advance cell therapies for the benefit of patients throughout the world.
16-Aug-2020 – AZD1222
Yahoo finance - AstraZeneca Clinches First Supply Deal With EU For Covid-19 Vaccine
AstraZeneca has reached an agreement with the European Commission (EC) to supply up to 400 million doses of its AZD1222 COVID-19 vaccine candidate. AstraZeneca (AZN) said that the agreement builds on the existing accord with Europe’s Inclusive Vaccines Alliance spearheaded by Germany, France, Italy and the Netherlands. The new agreement will give all EU member states the option to access the vaccine candidate in an equal manner at no profit during the coronavirus pandemic. The terms also allow EU member states to redirect doses to other European countries.
14-Aug-2020 – NVX-COV2373
Washington Business Journal- Novavax is racking up Covid-19 vaccine deals for global markets. And the stock shows. (paid content)
14-Aug-2020 – AZD1222
https://www.fiercepharma.com/pharma/astrazeneca-europe-ink-covid-vaccine-supply-deal-for-400m-doses
Fierce Pharma- Busy AstraZeneca inks yet another big COVID-19 vaccine deal, this time with EU
As Johnson & Johnson, Sanofi and GlaxoSmithKline move ahead in advanced COVID-19 vaccine supply negotiations with the EU, AstraZeneca has signed into the union’s first finalized agreement.
14-Aug-2020 – AZD1222
https://www.wsj.com/articles/eu-secures-coronavirus-vaccine-deal-with-astrazeneca-11597418453
The Wall Street Journal - EU Secures Coronavirus Vaccine Deal With AstraZeneca
The European Union, seeking to catch up with other parts of the world for access to coronavirus treatments, agreed with AstraZeneca PLC to buy as many as 400 million doses of the U.K. drugmaker’s Covid-19 vaccine now in development.
14-Aug-2020 – VPM1002
The Economic Times – TB vaccine shows encouraging results against coronavirus in phase-3 clinical trials
India may have hope in a fourth vaccine being tested as a preventive and immunity booster against Covid-19. VPM1002, a tuberculosis vaccine, is showing encouraging results against the coronavirus infection in Phase-III clinical trials being conducted in Germany.
14-Aug-2020 - NVX-COV2373
Reuters - Novavax to deliver 60 million doses of COVID-19 vaccine candidate to UK
U.S. drug developer Novavax Inc (NVAX.O) said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373.
14-Aug-2020 – NVX-COV2373
Yahoo finance - Novavax Inks UK Supply Deal For 60M Doses Of Its Covid-19 Vaccine Candidate
Novavax said on Friday that the US drug developer has entered into a purchase agreement with the UK government for the supply of 60 million doses of NVX-CoV2373, its COVID-19 vaccine, sending shares up 6% in pre-market trading.
13-Aug-2020 – NVX-COV2373
https://en.yna.co.kr/view/AEN20200813009500320?section=news
Yonhap news - SK Bioscience to manufacture Novavax's coronavirus vaccine candidate
SEOUL, Aug. 13 (Yonhap) -- SK Bioscience Co., a vaccine unit of South Korea's SK Group, said Thursday that it has secured a deal to manufacture a component of the U.S.-based biotechnology company Novavax Inc.'s experimental coronavirus vaccine.
10-Aug-2020 – NVX-COV2372
Boston Business Journal - Takeda enters Covid-19 vaccine race with $285M manufacturing deal
After declining to develop a Covid-19 vaccine of its own, Takeda Pharmaceutical Co. Ltd. is lending its manufacturing expertise in the field to another startup.
8-Aug-2020 – AZD1222
Business Standard - Serum Institute to provide Covid vaccine to 92 countries at Rs 250 a dose
Serum Institute of India (SII) has inked a pact with the Bill and Melinda Gates Foundation, as well as Gavi, The Vaccine Alliance, to make 100 million doses of a potential vaccine. This is for low- and medium-income countries, and with a price cap of Rs 250 a dose.
7-August-2020 – GRAd-COV2
Italia Sera - Vaccino antiCovid: dal 24 agosto lo Spallanzani avvierà i primi test sull’uomo del ‘Grad-Cov2’
”Sono arrivate le prime dosi del vaccino made in Italy” all’Istituto Spallanzani di Roma per la “sperimentazione sull’uomo” che, ha aggiunto, prenderà il via “dal 24 agosto”.
7-Aug-2020- AZD1222
Deutsche Apotheker Zeitung - AstraZeneca will Covid-19-Vakzine zum Selbstkostenpreis anbieten
Es ist noch nicht so weit mit einem Corona-Impfstoff. Trotzdem müssen sich die Regierungen schon jetzt Gedanken über den Zugang zu den Vakzinen und über die voraussichtlichen Kosten machen. Aus Sicht der Hersteller ist der Preis auch ein wesentliches Wettbewerbsinstrument. AstraZeneca meint, dass sein COVID-19-Impfstoff eventuell nur ein paar Dollar kosten könnte. Damit könnten Moderna und Pfizer wohl bei weitem nicht mithalten.
5-Aug-2020 - NVX-CoV2373
https://www.nytimes.com/2020/08/04/world/coronavirus-cases.html#link-1228a480
The New York Times - Novavax sees encouraging results from two studies of its experimental vaccine.
Novavax, the little-known Maryland company that received a $1.6 billion deal from the federal government for its experimental coronavirus vaccine, announced encouraging results in two preliminary studies on Tuesday.
5-Aug-2020 - NVX-CoV2373
Handelsblatt - Hersteller Novavax: Gute Ergebnisse nach ersten Tests von Corona-Impfstoff
Ein experimenteller Coronavirus-Impfstoff der US-Biotech-Firma Novavax hat nach Angaben des Herstellers bei ersten Tests ermutigende Ergebnisse gezeigt. In der ersten Phase der klinischen Tests hätten alle Probanden Antikörper gegen den Erreger Sars-CoV-2 entwickelt, erklärte das Unternehmen am Dienstag (Ortszeit). Bei den 131 Teilnehmern im Alter von 18 bis 59 Jahren habe es keine schweren Nebenwirkungen gegeben, hieß es weiter. Die Ergebnisse der in Australien durchgeführten Tests wurden jedoch noch nicht von unabhängigen Forschern geprüft und veröffentlicht.
5-Aug-2020 - NVX-CoV2373
https://video.foxbusiness.com/v/6178362555001/?playlist_id=3166411554001#sp=show-clips
Fox Business - Novavax R&D head: ‘Hopeful’ coronavirus vaccine can be deployed in December
Novavax Research and Development President Dr. Gregory Glenn on the next steps for the company’s coronavirus vaccine.
4-Aug-2020 – V591 (formerly COVAX)
Bioprocess International - Merck betting on ‘swish-and-swallow’ and single administration COVID vaccines
A recombinant vesicular stomatitis virus-based COVID-19 vaccine may be active when administered orally, says Merck as it begins clinical manufacture from facilities in Pennsylvania.
4-Aug-2020 – GRAd-COV2
Gazetta delle milia - UniCredit eroga il primo finanziamento leasing in Italia con Garanzia Sace a favore di ReiThera Srl
Le nuove risorse finanziarie saranno utilizzate sempre nell’ambito degli investimenti sul fronte della ricerca scientifica di un vaccino contro il virus Covid-19 e per l’acquisto di specifici macchinari destinati alla produzione, al confezionamento e distribuzione del vaccino stesso.
3-Aug-2020 - PLX-PAD
Disney-ABC - Broadway Set Designer Survives Covid-19 After 46 Days On Ventilator
Ed Pierce and his wife Pixie talk about his “Hail Mary” life-saving treatment that they both credit with saving his life during his COVID-19 battle.
30-July-2020 – AZD1222
https://uk.reuters.com/article/us-astrazeneca-results-vaccine-liability-idUKKCN24V2EN
Reuters - AstraZeneca to be exempt from coronavirus vaccine liability claims in most countries
AstraZeneca has been granted protection from future product liability claims related to its COVID-19 vaccine hopeful by most of the countries with which it has struck supply agreements, a senior executive told Reuters.
27-July-2020 – VPM1002
Express Pharma - SII enrols 6000 subjects for efficacy trial of rBCG vaccine, VPM1002 against COVID-19
The DBT-BIRAC supported trial aims to evaluate the ability of VPM1002 in reducing infection incidence and severe disease outcomes of COVID-19 among high-risk persons of advanced age or co-morbidities and high-exposure healthcare workers
27-July-2020 – mAbCo19
OMAR- Tre diversi anticorpi monoclonali anti-SARS-CoV-2 saranno prodotti per i primi test sull’uomo
Il MAD (Monoclonal Antibody Discovery) LAB di Fondazione Toscana Life Sciencesannuncia di aver terminato la fase di discovery di anticorpi monoclonali umani in risposta all’infezione da SARS-CoV-2, per l’impiego a scopo profilattico/terapeutico e come esca molecolare per la ricerca di antigeni per lo sviluppo di vaccini. Sono 3 gli anticorpi selezionati a partire da più di 4000 candidati ottenuti dal sangue di pazienti convalescenti o guariti da COVID-19, ricevuto grazie alla collaborazione con INMI Spallanzani e, successivamente, con la Azienda Ospedaliero-Universitaria Senese e che, dopo essere stati oggetto di domanda di brevetto, potranno essere prodotti per i test clinici.
27-July-2020 – NVX-CoV2373
bizjournals - Novavax adds Fujifilm to growing manufacturing roster for Covid-19 vaccine
Novavax Inc. (NASDAQ: NVAX) is looking to get its Covid-19 vaccine through clinical trials with help from global contract development and manufacturing organization Fujifilm Diosynth Biotechnologies.
24-July-2020 – mAbCo19
La Nazione Siena - "I nostri anticorpi prima del vaccino La cura senese contro l’epidemia"
La dottoressa Sala a capo del laboratorio Tls che ha individuato tre proteine monoclonali molto efficaci.
24-Jul-2020
Reuters - EU eyes COVID-19 vaccines at less than $40, shuns WHO-led alliance
The European Union is not interested in buying potential COVID-19 vaccines through an initiative co-led by the World Health Organisation as it deems it slow and high-cost, two EU sources told Reuters, noting the bloc was in talks with drugmakers for shots cheaper than $40.
22-July-2020 – mAbCo19
https://www.gazzettadisiena.it/anti-covid-19-rappuoli-a-siena-vogliamo-fare-qualcosa-di-speciale/
Gazzetta di Siena - Anti Covid 19, Rappuoli: “A Siena vogliamo fare qualcosa di speciale”
Lo scienziato sugli anticorpi monoclonali: “A Siena abbiamo effettivamente selezionato tre anticorpi che sono mille volte più potenti degli altri”
21-July-2020
Times of India - Possible but not certain Covid-19 vaccine rolled out this year – Oxford developer
The university of Oxford’s possible Covid-19 vaccine could be rolled out by the end of the year but there is no certainty that will happen, the lead developer of the vaccine said on Tuesday.
21-July-2020 – AZD1222
The New York Times - South Korea's SK Bioscience in Deal With AstraZeneca on Vaccine
South Korea's SK Bioscience has agreed to manufacture AstraZeneca's experimental COVID-19 vaccine to help the British company build global supplies of the vaccine that has shown promise against the new coronavirus, it said on Tuesday.
21-July-2020 – AZD1222
Hindustan Times - How was AZD1222 made, when is first dose expected: Things to know about Oxford University’s Covid-19 vaccine
The researchers on Monday announced the results of the first phase of a Covid-19 vaccine developed by the University of Oxford. The vaccine appears safe and induces a strong immune response within the body, the results published in leading scientific journal The Lancet show.
20-July-2020 – plant based protein
https://allafrica.com/stories/202007200987.html
South Africa: UCT to Boost COVID-19 Testing Capability in SA
The University of Cape Town's (UCT) Biopharming Research Unit (BRU), under the leadership of Professor Ed Rybicki, has received government funding to assist in the production of diagnostic reagents for COVID-19.
20-July-2020 – AZD1222
https://www.pharmaceutical-business-review.com/news/azd1222-astrazeneca-oxford-trial/
Pharmaceutical business review - AZD1222 delivers strong immune response in phase I/II Covid-19 vaccine trial
AstraZeneca said that the AZD1222 vaccine candidate (formerly ChAdOx1 nCoV-19) licensed from the Oxford University has shown strong immune responses against the SARS-CoV-2 virus in all participants in a phase I/II trial.
20-July-2020 – AZD1222
NRC - Vaccins uit China en Oxford zijn veilig en roepen afweerreactie op
De eerste proeven in vrijwilligers met twee experimentele vaccins tegen Covid-19 laten zien dat beide middelen een krachtige afweer oproepen tegen het nieuwe coronavirus SARS-CoV-2 en dat ze veilig zijn zonder al te veel bijwerkingen. Dat is het hoopvolle nieuws dat maandag online werd gepubliceerd door het medische vakblad The Lancet.
20-July-2020 – AZD1222
The Economist - Trials of a vaccine and new drug raise hope of beating covid-19
IN EARLY JANUARY researchers at Oxford University started work on a vaccine for covid-19. At that time the illness was a tiny outbreak without a proper name. Six months on, with more than 600,000 people dead, the Oxford team is leading a race to develop a vaccine that could halt the pandemic. The vaccine has been raced into production around the world by AstraZeneca, a British-Swedish drug company, and billions of doses are planned. But two key questions remain: is it safe and does it work? The first glimmers of the answers have just arrived, with the publication in the Lancet on July 20th of a paper about a trial of the Oxford vaccine, which began in April and involved 1,000 volunteers.
20-July-2020 -AZD1222
Bloomberg - Oxford Vaccine Shows Early Promise But Market Is Unconvinced
A coronavirus vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, and is now set to move into larger trials that are likely to be decisive on how effective they truly are.
20-July-2020 -AZD1222
RTL Nieuws - Veelbelovende eerste resultaten van coronavaccin dat Nederland heeft besteld
Het coronavaccin dat al in grote hoeveelheden door Nederland is ingekocht is veilig, heeft weinig bijwerkingen en zorgt ervoor dat het immuunsysteem het virus aanvalt. Dat blijkt uit de eerste testresultaten van de Universiteit van Oxford.
20-July-2020 – AZD1222
Times Now News - Oxford’s COVID-19 vaccine phase 1 data expected today; Serum Institute to begin human trials from next month
The Lancet medical journal is expected to publish the phase 1 clincial trial data of Oxford and AstraZeneca's COVID-19 vaccine candidate, AZD1222 COVID-19 vaccine, formerly called ChAdOx1 nCoV-19, today, July 20. On Thursday, July 16, media reports in the UK said the team of researchers at Oxford have discovered that the vaccine could offer ‘double protection’ against the novel coronavirus (SARS-CoV-2) following early stage human trials. Meanwhile, vaccine maker Serum Institute of India (SII) has reportedly said it would start human trials of the Oxford- AstraZeneca’s coronavirus vaccine candidate from next month.
20-July-2020 – AZD1222
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext
The Lancet - Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2.
20-July-2020 – VPM1002
Welt - Wie ein Tuberkulose-Impfstoff auch gegen Covid-19 helfen könnte
In Studien wird aktuell untersucht, ob der Tuberkulose-Impfstoff auch gegen Sars-CoV-2 Viren helfen kann. Prof. Stefan Kaufmann erklärt, wie man auf diese Idee gekommen ist.
19-July-2020 – AZD1222
News Medical Life Sciences - Oxford University and AstraZeneca to publish eagerly-anticipated COVID-19 trial results today
The coronavirus pandemic is still rapidly spreading across the globe, infecting more than 14.44 million people. With more than 188 countries and territories affected, scientists are racing to develop a vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19).
18-July-2020 – AZD1222
Financial Express - Oxford-AstraZeneca Coronavirus vaccine: Serum Institute says it will take a long time to reach everyone
“It will be a long time before everyone gets a vaccine because of the number of doses that needs to be administered,” said Adar Poonawalla, CEO, Serum Institute, who has partnered with Oxford-AstraZeneca to support in COVID-19 vaccine development.
18-July-2020 -mAbCo19
Canale3 - COVID-19: conclusa la fase di discovery per il progetto MabCo19 di Toscana Life Sciences: 3 gli anticorpi monoclonali che saranno prodotti per i test clinici.
Il MAD (Monoclonal Antibody Discovery) LAB di Fondazione Toscana Life Sciences annuncia di aver terminato la fase di discovery di anticorpi monoclonali umani in risposta all’infezione da SARS-CoV-2, per l’impiego a scopo profilattico/terapeutico e come esca molecolare per la ricerca di antigeni per lo sviluppo di vaccini. Sono 3 gli anticorpi selezionati a partire da più di 4000 candidati ottenuti dal sangue di pazienti convalescenti o guariti da COVID-19, ricevuto grazie alla collaborazione con INMI Spallanzani e, successivamente, con la Azienda Ospedaliero-Universitaria Senese e che, dopo essere stati oggetto di domanda di brevetto, potranno essere prodotti per i test clinici.
17-July-2020 – PLX-PAD
https://www.calcalistech.com/ctech/articles/0,7340,L-3840111,00.html
Ctech- Israel third only to U.S. and China in Covid-19 solutions, says life sciences expert
We don't talk anymore about devices or drugs. We talk about healthtech convergence, which for me is the future," explains Dr. Laurent Choppe, Managing Partner at Cukierman & Co. Life Sciences
16-July-2020 – NVX-CoV2373
https://www.nytimes.com/2020/07/16/health/coronavirus-vaccine-novavax.html
The New York Times - How a Struggling Company Won $1.6 Billion to Make a Coronavirus Vaccine
Novavax just received the Trump administration’s largest vaccine contract. In the Maryland company’s 33-year history, it has never brought a vaccine to market.
16-July-2020 – VPM1002
MDR Thüringen - Thüringer Forscher testen Tuberkulose-Mittel gegen Covid-19
Ein Erfurter Forschungs-Institut testet einen Tuberkulose-Impfstoff gegen die Covid-19-Infektion. Wie das Unternehmen Socratec der Thüringer Allgemeinen mitteilte, wurde das Mittel eigentlich gegen Tuberkulose entwickelt. Bei den Tests soll nun herausgefunden werden, ob es auch bei einer Infektion mit dem Corona-Virus wirkt. Die Forscher hoffen demnach, dass ein schwerer Verlauf der Corona-Infektion abgemildert werden kann. Das Mittel soll bei älteren Menschen und Mitarbeitern von Krankenhäusern und Arztpraxen getestet werden.
15-July-2020 – AZD1222
Bloomberg - Covid Vaccine Front-Runner Is Months Ahead of Her Competition
The University of Oxford candidate, led by Sarah Gilbert, might be through human trials in September. AstraZeneca has lined up agreements to produce 2 billion doses. Could this be the one?
14-July-2020 – AZD1222
Fierce Biotech - AstraZeneca taps IQVIA to 'warp speed' its U.S. pandemic vaccine research
Operation Warp Speed is living up to its name as, under the project, one of the COVID-19 vaccine front-runners AstraZeneca is teaming up with life science services company IQVIA to boost its work on the shot.
11-July-2020 – AZD1222 & NVX-CoV2373
India Today- The vaccine candidates that come as a ray of hope during the Covid pandemic
More than 150 vaccine candidates from 12 countries, including India, are in the race to counter the deadly Covid-19 that has infected over 1.2 crore people and killed more than 5.5 lakh worldwide in a little over six months. Of them, a dozen vaccines have entered the clinical trial phase.
10-July-2020 – NVX-CoV2373
Yahoo Finance - Can Novavax Win FDA Approval for COVID-19 Vaccine Before Year End? Analyst Weighs In
After initially being excluded from the U.S. government’s Operation Warp Speed (OWS) program, Novavax (NVAX) joined the list of companies eligible for federal support.
On July 7, the vaccine specialist announced it will receive $1.6 billion from the federal government to support the development of its COVID-19 vaccine candidate, NVX-CoV2373.
8-July-2020 - NVX-CoV2373
15min.lt (source BNS): AV skyrė 2 mlrd. JAV dolerių dviem bendrovėms, kuriančioms vaistus nuo COVID-19. (The US has allocated $ 2 billion. USD for two companies developing COVID-19 drugs)
The U.S. federal government has allocated $ 2 billion. USD to two pharmaceutical companies to support the development and production of experimental drugs and a possible vaccine against coronavirus infection COVID-19. After receiving this funding, the company intends to produce 100 million. vaccine doses - this is expected to happen by the end of this year.
8-July-2020 - NVX-CoV2373
https://www.apteka.ua/article/554207
Apteka Online: Правительство США финансирует создание вакцин и биопрепаратов против COVID-19. (The US government finances the creation of vaccines and biological products against COVID - 19)
The US government is funding the development of vaccines and biological products. Novavax reportedly received 1.6Billion dollars to finance the development and launch of the large-scale production of an experimental vaccine against COVID-19.
8-July-2020 - NVX-CoV2373
https://finance.sina.com.cn/stock/usstock/c/2020-07-08/doc-iirczymm1279040.shtml
Sina.com.cn: 开盘：关注疫情与复苏前景 美股小幅高开. (US stocks opened slightly higher following the epidemic situation and recovery prospects)
Novavav is working on a vaccine that is one of more than 130 candidate coronavirus vaccines worldwide. If the clinical trial is successful, it will provide 100 million doses of vaccine by the end of 2020. The US epidemic situation is grim, with more than 60,000 newly diagnosed cases yesterday, of which nearly half came from 4 states including Arizona.
8-July-2020 - NVX-CoV2373
https://www.industriepharma.fr/covid-19-novavax-recoit-1-6-mrd-du-gouvernement-americain,112331
Industrie Pharma: Covid-19 : Novavax reçoit 1,6 Mrd $ du gouvernement américain. (Covid-19: Novavax receives $ 1.6 billion from the US government)
After CEPI (Coalition for Epidemic Preparedness Innovations) last June , the American government has provided funding to the American biotech Novavax for its Covid-19 vaccine project. Called "Warp Speed", this operation includes aid amounting to 1.6 billion dollars (1.4 billion €), ensuring the United States gets the first 100 million doses in the event of proven effectiveness. This funding will be used to complete the clinical development of NVX-CoV2373, a vaccine candidate developed from antigens derived from the SARS-Cov-2 protein Spike. The phase III clinical trial of this active ingredient is scheduled for fall 2020, after the phase I / II immunogenicity and safety results expected by the end of July, and should include up to 30,000 participants.
8-July-2020 - NVX-CoV2373
El Pais (Brazil): EUA pagam 1,6 bilhão de dólares à Novavax para acelerar a produção de uma vacina contra a covid-19 (US pays $ 1.6 billion to Novavax to accelerate the production of a vaccine against covid-19)
The United States government has allocated $ 1.6 billion (about $ 8.61 billion) to the biotechnology company Novavax to accelerate its production of the coronavirus vaccine. The investment is part of the Operation Warp Speed program , created in mid-May to provide financial support to companies that are developing the most promising treatments to control the pandemic. Novavax, which has never launched a product on the market, said on Tuesday that it will use the money to complete studies of the latest testing stages, manufacture on a large scale and deliver 100 million doses in late 2020 and early 2021, if the test results show that the vaccine (NVX-CoV2373) is safe and effective.
8-July-2020 - NVX-CoV2373
NASDAQ: CRVS, HEPA Jump On COVID-19 Drug Bandwagon, LVGO In Good Health, NVAX Joins $100 Stock Price Club
Shares of Novavax Inc. (NVAX) climbed more than 30 percent on Tuesday, following news that the Company has been selected to participate in Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 in 2021. The Company's COVID-19 vaccine candidate NVX-CoV2373 is under a phase I/II trial, with preliminary immunogenicity and safety results from the phase I portion of the trial expected in July 2020. If the results are promising, the phase II portion of the trial will be initiated quickly. The Coalition for Epidemic Preparedness Innovations has provided up to $388 million in funding to support the phase I/II trial.
8-July-2020 -mAbCo19
Siena News: Covid-19, Rino Rappuoli: “Stiamo facendo progressi, a fine anno potremmo avere il vaccino” (Rino Rappuoli: We’re making progress. By the end of the year we could have a vaccine)
We are making progress on the new vaccine and if we are lucky we will have it ready by the end of the year says Rino Rappuoli, CEO of GSK Vaccines during the presentation of the new Smart Lab structure of the company. Rappuoli is considered one of the top experts in the world.
07-July-2020 – AZD1222
DAZ.online - COVID-19-Impfstoffe: ein Kandidat in Phase 3, zweiter folgt
Nach der aktuellen „Draft landscape of COVID-19 candidate vaccines“ der WHO vom 6. Juli 2020 hat die Zahl der COVID-19-Impfstoffkandidaten, die in der klinischen Erprobung angekommen sind, weiter zugenommen. Mittlerweile sind es 19 Kandidaten, davon zehn in den Phasen 3, 2 und 1/2.
07-July-2020 – NVX-COV2373
Bloomberg - Novavax Covid Vaccine Gets $1.6 Billion in U.S. Funding
Novavax Inc., one of the front-runners in the race to develop a Covid-19 vaccine, will receive $1.6 billion from the U.S. government, the biggest contribution yet from the Operation Warp Speed program.
6-July-2020 – PLX-PAD
https://www.israel21c.org/13-promising-covid-treatments-emerging-from-israel/
Israel21c - 13 promising Covid treatments emerging from Israel
In parallel to vaccine research, there’s an urgent need for effective treatments for the respiratory disease caused by the SARS-CoV-2 coronavirus.
5-July-2020- PLX-PAD
https://www.tikkunolamisrael.com
Tikkun Olam: Israel vs COVID-19
How is one of the planet's smallest countries helping to tackle the world's biggest challenge?
5-July-2020 – AZD1222
News medical life sciences - Oxford COVID-19 vaccine trials move to stage 3 human trials
Scientists across the globe are racing to develop an effective and safe vaccine against severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2). The coronavirus pandemic has marked its 11th million cases, and without a vaccine, cases are expected to continue to rise for the foreseeable future. Sarah Gilbert, professor of vaccinology at the University of Oxford, and one of the scientists leading the vaccine initiative told the U.K.'s Science and Technology Committee last week that their candidate vaccine has progressed to the phase III trial in the United Kingdom.
5-July-2020 – NVX-CoV2373
The Print - CanSino, Moderna, Novavax: A list of Covid vaccines under clinical trials across the world
New Delhi: With the coronavirus pandemic continuing to claim thousands of lives across the globe every day, the Indian Council of Medical Research (ICMR) has decided to fast-track clinical trials of the indigenous Covid-19 vaccine, which it is producing with the Bharat Biotech International Limited (BBIL).
4-July-2020 – AZD1222
First post - Oxford's vaccine offers ‘good duration of immunity’ to COVID-19 compared to no vaccine: lead researcher
Oxford University, experts think, is the most likely to come up with a viable vaccine candidate for COVID-19, which has caused havoc around the world. Even the World Health Organisation has pegged them as the leading candidate for a viable vaccine.
2-July-2020 – NVX-CoV2373
Yahoo Finance - Novavax Announces Updates to Leadership Team
Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Frank Czworka as Senior Vice President, Global Sales, with responsibility for leading sales planning and distribution. Novavax also announced the promotion of Brian Webb to Senior Vice President, Manufacturing, with responsibility for overseeing antigen manufacturing and supply activities in support of Novavax’ vaccine candidates.
1-July-2020 - AZD1222
Reuters - Oxford COVID-19 vaccine developers encouraged by immune response but cautious on timeframe
A leading scientist behind the University of Oxford’s potential COVID-19 vaccine said on Wednesday the team has seen the right sort of immune response in trials but declined to give a firm timeframe for when it could be ready.
1-July-2020 - AZD1222
International Business Times - WHO Reveals Coronavirus Vaccine 'Leading Candidate', Already In Phase 3 Clinical Trials
For the World Health Organization (WHO), however, the winner is clear -- AZD1222 from the University of Oxford and AstraZeneca. WHO chief scientist Dr. Soumya Swaminathan revealed AZD1222 appears "probably the leading candidate." She gave two reasons for her statement.
30-June-2020- NVX-CoV2373
Fierce Pharma - Novavax hires new manufacturing chief to take COVID-19, flu vaccine hopefuls across the finish line
With its COVID-19 vaccine hopeful cycling through clinical trials, shot maker Novavax is working to flesh out its executive team to help lead the company to the commercial stage. But you can't get regulatory approval without a sturdy manufacturing operation—and now Novavax has hired an exec to get that operation in order.
29-June-2020 – AZD1222
Fierce Pharma - AstraZeneca reaches supply deal with Brazilian government to produce millions of doses of COVID-19 shot
As COVID-19 continues to rampage across the globe, Brazil stands alongside the U.S. as the countries hardest hit with new infections and deaths. But AstraZeneca and its vaccine hopeful could be coming to save the day now that the drugmaker and Brazilian government have reached a new supply pact.
26-June-2020 – GRAd-COV2
The New York Times - Brazil University in Talks to Test Italian Coronavirus Vaccine
The Federal University of Sao Paulo (Unifesp) is in talks to test a potential coronavirus vaccine developed by Italian researchers, the dean of the Brazilian university told Reuters.
25-June-2020 – PLX-PAD
Theater Mania - Edward Pierce's Miracle: How a Broadway Set Designer Beat Covid and Made Medical History
Pierce is the first American to receive a placental cell transplant to fight the insidious virus that left him on a ventilator for five weeks.
25-June-2020 - GRAd-COV2
Startmag.it – Reithera, chi è l’azienda finanziata da Unicredit per il vaccino anti Covid
Unicredit scommette sul vaccino anti-Covid dell’azienda biotecnologica italiana Reithera (prodotto in collaborazione con Sgs). Dal gruppo bancario capeggiato dall’amministratore delegato, Jean-Pierre Mustier, è arrivato un finanziamento di 5 milioni di euro per accelerare nella ricerca dell’antidoto. Tutti i dettagli.
23-June-2020 – GRAd-COV2
Affari Italiani – Reithera, chi è l’azienda finanziata da Unicredit per il vaccino anti Covid
Liberare il potenziale dei progetti innovativi. Questo l’obiettivo di ReiThera srl che ottiene da UniCredit un finanziamento da 5 milioni di euro, grazie alle garanzie rilasciate dal Fondo Centrale di Garanzia, per nuovi investimenti sul fronte della ricerca scientifica innovativa mirata all’individuazione di un vaccino contro il virus Covid 19.
23-June-2020 – AZD1222
https://www.sciencefocus.com/news/oxford-vaccine-trial-on-pigs-boosts-coronavirus-immune-response/
BBC Science Focus – Oxford vaccine: trial on pigs ‘boosts coronavirus immune response’
Two doses of a coronavirus vaccine candidate created by UK researchers produce a greater antibody response than a single dose, a study in pigs has shown. The ChAdOx1 nCoV-19 (AZD1222) vaccine, developed by the University of Oxford, is currently undergoing human trials and it is hoped an effective vaccine could be ready later this year.
23-June-2020 – AZD1222
Euro weekly news - Coronavirus Vaccine: UK Scientists “very positive” after Trials with Two Doses
After a study in pigs, it was found that two doses of a coronavirus vaccine made by UK researchers produced a greater antibody response than a single dose.
The technical name for the drug is ChAdOx1 nCoV-19 (also known as the AZD1222) vaccine and was developed by the University of Oxford.
23-June-2020 – VPM1002
VPM - Hope for the elderly in the corona pandemic – First participants receive VPM1002 in a late-stage phase III clinical trial in Germany
Vakzine Projekt Management GmbH (VPM) announces that the first participants have been enrolled last week in the phase III trial to test the efficacy of the vaccine candidate VPM1002 in preventing COVID-19 and other respiratory diseases. The large-scale, multicentre clinical trial has started in Berlin and will soon be rolled out to other sites in Germany. The clinical trial will include elderly participants.
22-June-2020 – NVX-COV2373
Washington Business Journal - Novavax charges ahead with $200M in fresh capital — and a familiar face on its board
Novavax Inc. plans to advance its Covid-19 vaccine candidate with new additions to the company and about $200 million in new funds from selling convertible preferred stock — the latest cash infusion for the Gaithersburg vaccine maker.
19-June-2020 – mAbCo19
https://www.bioworld.com/articles/435911-other-news-to-note-for-june-19-2020
Bioworld - Other news to note for June 19, 2020
Achilles Vaccines srl, of Siena, Italy, has received an investment from the EU Malaria Fund (EUMF) that will support development of a novel malaria vaccine produced on its technology platform designed to transform bacteria into an efficient delivery system of bio antigenic molecules to produce low-cost, safe and self-adjuvanting fit-for-purpose vaccines. The funding, with support from Fondazione TLS, will also be used to advance the company’s project to develop a human monoclonal antibody against COVID-19.
19-June-2020 – mAbCo19
La Nazione- Rossi e l’orgoglio di Fondazione Mps La corsa di AchilleS
"Siamo particolarmente soddisfatti di essere la prima fondazione italiana a partecipare al Malaria Fund, con un milione di euro". Carlo Rossi, presidente della Fondazione MPS. "Un investimento importante, con una visione di lungo termine, che ci consente di perseguire due obiettivi in questo delicato momento: continuare a sostenere la ricerca scientifica, in particolare su quelle malattie con elevato impatto in termini di salute pubblica, ed attrarre nuove risorse sul nostro territorio con benefici durevoli a favore della comunità. – prosegue Rossi - Siamo molto soddisfatti, inoltre, della decisione di destinare parte delle risorse alla ricerca su Covid-19, un’altra sfida sanitaria globale che richiede un enorme impegno collettivo".
19-June-2020 – mAbCo19
La Nazione - "L’Europa ha bisogno di impianti Pronti a investire 280 milioni"
Holm Keller, manager del Malaria Fund, alla consegna dei finanziamenti per la start up senese sui vaccini
19-Jun-2020 - mAbCo19
Canale 3 TV - Eu Malaria Fund: presentato a Siena il primo investimento europeo in Italia in AchilleS Vaccines per la lotta contro malaria e Covid -19
EU Malaria Fund (EUMF) ha presentato oggi a Siena, nella sede della Fondazione Monte dei Paschi di Siena, il suo primo investimento in AchilleS Vaccines. Un finanziamento per lo sviluppo di un nuovo vaccino contro la malaria, attraverso l’utilizzo di una piattaforma tecnologica combinata, in grado di trasformare i batteri – portatori di molecole potenzialmente nocive per la salute umana – in un efficiente sistema di distribuzione di molecole bio-antigene, in grado di produrre vaccini a basso costo, sicuri ed autoimmunizzanti.
19-Jun-2020 - mAbCo19
Antenna Radio Esse - 46 milioni ad AchilleS Vaccines da EU Malaria Fund per la ricerca su Covid-19 e malaria
La start up senese AchilleS Vaccines usufruirà per i suoi progetti di un finanziamento di 46 milioni da parte del nuovo fondo europeo Malaria Fund. Uno di questi riguarda proprio lo sviluppo di un anticorpo monoclonale contro il coronavirus, mentre l’altro progetto riguarda la realizzazione di un nuovo vaccino a basso costo contro la malaria.
18-Jun-2020 - mAbCo19
Radio Siena TV - L’Europa premia i vaccini senesi con 46 milioni: AchilleS Vaccines riceve finanziamenti per lotta a malaria e Covid
EU Malaria Fund ha presentato oggi nella sede della Fondazione Monte dei Paschi di Siena il suo primo investimento in AchilleS Vaccines: Italia primo paese a beneficiarne
17-June-2020 – NVX-CoV2373
Benzinga - Novavax Beefs Up Executive Team As It Sprints In The Coronavirus Vaccine Race
The company said Wednesday it has appointed AstraZeneca plc veteran Filip Dubovsky as SVP and Chief Medical Officer, overseeing its medical and clinical affairs and related activities
16-June-2020 – AZD1222
Daily Mail - AstraZeneca boss claims Oxford University's experimental Covid-19 vaccine is likely to protect humans for a YEAR
The boss of British pharma giant AstraZeneca today claimed its unproven Covid-19 vaccine may protect people from catching the disease for a year. Its AZD1222 jab, developed by Oxford University, is currently being trialled on more than 10,000 people but there is no scientific evidence it works.
16-June-2020 – NVX-CoV2373
https://baltimore.cbslocal.com/2020/06/16/novavax-coronavirus-vaccine-latest/
CBS Baltimore - Gaithersburg-Based Novavax Raising $200M To Fund COVID-19, Flu Vaccine Efforts
The Gaithersburg-based company Novavax announced this week it plans to raise around $200 million to not only fund its coronavirus vaccine work, but also its flu vaccine, NanoFlu.
16-June-2020 – AZD1222
Skynews - Coronavirus: Oxford University vaccine to provide protection 'for about a year', says drugmaker
A coronavirus vaccine being developed in the UK will provide protection against the disease "for about a year", according to the drugmaker currently carrying out trials.
14-June-2020 - AZD1222
https://www.timesofisrael.com/astrazeneca-agrees-to-make-experimental-covid-19-vaccine-for-europe/
The Times of Israel - AstraZeneca agrees to make experimental COVID-19 vaccine for Europe
Drugmaker AstraZeneca struck a deal Saturday to supply up to 400 million doses of an experimental COVID-19 vaccine to European Union countries, the latest in a series of agreements as scientists, governments and pharmaceutical companies race to combat the virus.
13-June-2020 - AZD1222
https://www.bnnbloomberg.ca/astrazeneca-reaches-vaccine-supply-deal-with-four-eu-nations-1.1449944
BNN Bloomberg - AstraZeneca reaches vaccine supply deal with four EU nations
AstraZeneca Plc and four European Union countries said they reached an agreement to distribute a coronavirus vaccine. The Netherlands, Germany, France and Italy concluded a contract with the U.K. drugmaker to provide 300 million to 400 million doses of a possible vaccine in stages starting from the end of 2020, the Dutch government said in a statement on Saturday.
13-June-2020 - AZD1222
De Volkskrant - Nederland sluit aan in de rij: het eerste mogelijke coronavaccin is gereserveerd
Als het de universiteit van Oxford en medicijnenfabrikant AstraZeneca lukt om nog dit jaar een vaccin tegen het coronavirus te ontwikkelen, staat Nederland vooraan in de rij. Samen met Duitsland, Frankrijk en Italië zijn bij voorbaat 300 miljoen doses gereserveerd. Dat heeft minister De Jonge (Volksgezondheid) zaterdag aan de Tweede Kamer geschreven.
12-June-2020 – mAbCo19
Milano Finanza - EU Malaria Fund e Fondazione Mps finanziano AchilleS Vaccines
La scale-up italiana, incubata presso Toscana Life Sciences, si aggiudica tre progetti di ricerca sulla malaria e altre malattie infettive, e uno sul Covid-19 da parte del fondo EU Malaria Fund
11-June-2020 - mAbCo19
Corriere di Siena - Siena, arrivano 10 milioni per la Achilles Vaccines: progetti contro Coronavirus e malaria
Quarantasei milioni di euro in cinque anni, oltre dieci subito, destinati a tre progetti di ricerca sulla malaria e altre malattie infettive e uno relativo al Covid-19.
11-June-2020 - PLX-PAD
Streetinsider - Pluristem Therapeutics (PSTI) Reports Activation of Clinical Sites & Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial
Pluristem Therapeutics Inc. (NASDAQ: PSTI) announced today the activation of clinical sites and initiation of enrollment in its Phase II U.S. Food and Drug Administration (FDA) study of PLX cells for the treatment of severe COVID-19 complicated by Acute Respiratory Distress Syndrome (ARDS). The Company is focused on expanding to clinical sites throughout the U.S. in accordance with the changing dynamic spread of the COVID-19 pandemic, using its advanced operational capabilities and cold chain agility. The trial is expected to include up to 25 sites.
9-June-2020 - mAbCo19
MedicalExcellence.tv -Ricerca malaria e Covid-19: EU Malaria Fund finanzia AchilleS Vaccines con il sostegno di Fondazione MPS
AchilleS Vaccines, scale-up italiana incubata presso Toscana Life Sciences, si aggiudica il finanziamento di ben tre progetti di ricerca sulla malaria e altre malattie infettive, e di uno relativo al Covid-19, da parte del fondo EU Malaria Fund, grazie anche ad un importante investimento della Fondazione Monte dei Paschi di Siena.
9-June-2020- AZD 1222/ NVX-CoV2373
https://abcnews.go.com/Health/lab-peoples-arms-list-covid-19-vaccines-studied/story?id=71145250
ABC News - Out of the lab and into people’s arms: A list of COVID-19 vaccines that are being studied in clinical trials
The world's leading drug companies, universities and governments are racing to develop a vaccine for COVID-19, the disease that has taken more than 400,000 lives globally. Of the 133 candidates being explored, ten have been approved for human trials, according to the World Health Organization.
9-June-2020- NVX-CoV2373
https://finance.yahoo.com/news/novavax-inks-dod-contract-operation-235503847.html
Yahoo Finance - After Novavax Inks DoD Contract, Is Operation Warp Speed Ahead? Top Analyst Weighs In
On June 4, Novavax (NVAX) revealed it will receive $60 million from the U.S. Department of Defense (DoD) to further the advancement of its experimental vaccine candidate, NVX-CoV2373, in the U.S., through JPEOCBRND-EB (Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies). As per the terms of the agreement, NVAX will work with multiple biologics contract development manufacturing organizations (CDMO) based in the U.S. to increase the scale of antigen and Matrix-M adjuvant production, which are both components of the vaccine. The end goal is to produce 10 million doses for the DoD in 2020, which will then be used in either a Phase 2/3 trial or under an Emergency Use Authorization (EUA).
9-June-2020- AZD 1222
Times of India - Coronavirus vaccine latest update: AstraZeneca close to "rolling out" COVID-19 vaccine, Oxford vaccine gets the go-ahead for clinical trials in Brazil and more updates
COVID-19 cases have topped the seven million mark today (June 08) globally. India too is seeing a surge in the number of cases every day. While there still is a long way to go before we put the pandemic behind us, trials and research are going on at warp speed to attend to the crisis at large. Many potential treatments have shown promising results in the clinical trial stage, while some are carrying on production. We recap all the recent development as the world waits for a COVID-19 vaccine with bated breath
9-June-2020 – mAbCo19
Radio Siena TV - Ricerca Covid-19: l’Europa investe nella ricerca senese con il finanziamento a AchilleS Vaccines
Il più grande finanziamento start-up del biotech italiano: 46 milioni in 5 anni, l’EU Malaria Fund finanzia AchilleS Vaccines con il sostegno di Fondazione Mps e la collaborazione di TLS
8-June-2020- VPM 1002
https://www.modernghana.com/news/1007659/jymwrites-using-tb-vaccine-in-treating-the-new.html
Modern Ghana - JymWrites: Using TB Vaccine In Treating The New COVID 19
The Bacillus Calmette-Guérin (BGC) vaccine has been protecting against the deadliest forms of tuberculosis (TB) for the past 100 years. Even though the safety and effectiveness of the vaccine were hugely debated over the decades, research indicates that its effectiveness level is around 70-80% against the most severe forms of TB. A dose of the vaccine is given to newborn babies living in countries with a high TB rate.
Also, scientists in Germany have developed a new tuberculosis vaccine (VPM1002) by genetically modifying the BGC that could help control the new coronavirus. Several studies have been initiated and the results are promising, the BCG has already proven to be effective against other infections. Given that the world is urgently looking for ways to treat and prevent the new coronavirus until we can develop a vaccine, attention is being turned to the BCG vaccine and the new VPM1002
8-June-2020 – mAbCo19
https://www.lanazione.it/siena/cronaca/il-malaria-fund-della-ue-punta-risorse-su-siena-1.5198836
La Nazione - Il Malaria Fund della Ue punta risorse su Siena
I segreti della AchilleS Vaccines la start up senese che è riuscita ad avere il finanziamento più ingente per il suo progetto
5-June-2020 – NVX-CoV2373
Washington Business Journal - Novavax’s latest win? A $60M contract for its Covid-19 vaccine
Novavax Inc. just scored even more support for its coronavirus vaccine program. The Gaithersburg company said late Thursday it won a Department of Defense contract worth up to $60 million to help manufacture its Covid-19 vaccine candidate, NVX CoV2373. The funding, from the Defense Health Program, would back the production of multiple pieces of the vaccine, to be manufactured in the U.S., according to Novavax’s (NASDAQ: NVAX) announcement.
5-June-2020 – AZD1222
Daily Mail - Pharmaceutical giant AstraZeneca reveals it is ALREADY manufacturing Oxford University's experimental vaccine in India, the UK and Europe amid plans to distribute 2BILLION doses as early as September if it works
A British pharmaceutical giant is already manufacturing an unproven coronavirusvaccine as it hopes to dish out hundreds of millions of doses by September.
AstraZeneca has started to mass-produce the experimental AZD1222 jab, developed by Oxford University, at factories in India, Oxford, Switzerland and Norway.
5-June-2020 – AZD1222
The next web - Bill Gates commits $750M to help Oxford vaccinate the world against COVID-19
The Bill and Melinda Gates Foundation has contributed $750 million towards the manufacturing and distribution a potential COVID-19 vaccine developed by Oxford University.
4-June-2020 – NVX-CoV2373
Bloomberg - Overlooked Covid-19 Vaccine Runners Up Defended by Wall Street
Don’t give up hope for Novavax Inc. and Inovio Pharmaceuticals Inc., Wall Street analysts said after the two failed to appear on a Trump administration list of Covid-19 vaccine developers picked for Operation Warp Speed.
4-June-2020 – AZD1222
The Guardian - AstraZeneca doubles capacity for potential Covid-19 vaccine to 2bn doses
AstraZeneca has doubled the manufacturing capacity for its potential Covid-19 vaccine to 2bn doses after striking a number of deals that include two health organisations backed by Bill and Melinda Gates.
4-June-2020 – NVX-CoV2373
Welt - Schützt eine ausrangierte Tuberkuloseimpfung vor Covid-19?
Um Patienten vor schweren Verläufen von Covid-19 zu schützen, greifen Forscher zu ungewöhnlichen Mitteln. In Hannover soll nun ein Impfstoff verwendet werden, der sich in seinem ursprünglichen Einsatzgebiet nicht gut bewährt hat. Er soll jedoch die Körperabwehr verbessern.
4-June-2020 - AZD1222
The Telegraph - How close are we to a coronavirus vaccine? Latest news on UK and US trials
Alok Sharma, the Business Secretary, said that the clinical trial at the University of Oxford is progressing well and, if it proves successful, the doses could be ready by the end of the summer.
3-June-2020 – NVX-CoV2373
Financial Post – Novavax partners with contract drugmaker for COVID-19 vaccine manufacturing
An add-on component of Novavax’s vaccine that could help enhance the immune response against the coronavirus would be manufactured by privately held AGC Biologics, the contract drugmaker said. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Saumyadeb Chakrabarty)
3-June-2020 - COVID-eVax
Ansa - Takis, Rottapharm in vaccine deal
Italian biotech companies Takis and Rottapharm Biotech on Wednesday reached a deal to develop a vaccine against the coronavirus conceived by Takis and called COVID-eVax.
Within the framework of the accord, a statement said, Rottapharm Biotech will place at Takis's disposal its experience in the development of innovative drugs and financial support up to at least the completion of phases one and two of clinical trials.
2-June-2020 - AZD1222
Daily Mail - Drugs to treat Covid-19 are 'essential' because a vaccine will take YEARS to roll out and multiple waves of the virus are inevitable when air travel resumes, Wellcome Trust expert warns
British firm AstraZeneca said it fully expected to have millions of doses of its AZD1222 vaccine, being developed by Oxford University, ready by September.
28-May-2020 - Plant based protein production
https://www.news.uct.ac.za/article/-2020-05-28-harnessing-plant-power-to-curb-covid-19
University of Cape Town News - Harnessing plant power to curb COVID-19
Here’s a different reason for tobacco to be in the news. Cape Bio Pharms, a biotech company with its origins in the Biopharming Research Unit (BRU) at the University of Cape Town (UCT), has joined the global effort to create a fast and affordable antibody test for COVID-19, using a relative of the tobacco plant.
28-May-2020 - AZD1222
The New York Times - AstraZeneca Partners With Oxford Biomedica to Expand COVID-19 Vaccine Manufacturing Capacity
AstraZeneca has partnered with British cell therapy company Oxford Biomedica to make its experimental COVID-19 vaccine, as the drugmaker looks to bolster its manufacturing capacity to produce one billion doses.
28-May-2020 - COVAX
https://de.reuters.com/article/idDEKBN2341SX
Reuters- Wiener Biotechfirma Themis verspricht weltweiten Zugang zu Corona-Impfstoff
Der vom US-Pharmariesen Merck & Co übernommene österreichische Impfstoffhersteller Themis Bioscience will das von ihm entwickelte potentielle Covid-19-Medikament weltweit zur Verfügung stellen.
27-May-2020 - NVX-CoV2373
Reuters - Novavax aims to make one billion COVID-19 vaccine doses after buying plant
Novavax Inc is buying a manufacturing plant from privately held Serum Institute of India, the world’s largest maker of vaccines by volume, as the U.S. company aims to produce 1 billion doses of its COVID-19 vaccine candidate next year.
27-May-2020- PLX-PAD
Cell & Gene Therapy Insights - Cell therapy’s role in defeating Covid-19
YAKY YANAY was appointed as President from February 2014 and as CEO from June 2019, after a period of being Co-CEO since March 2017. Mr Yanay served in variety of executive positions in Pluristem since 2006 including Chief Financial Officer, Chief Operating Officer and Executive Vice President. He is the former Co-Chairman and current board member of Israel Advanced Technology Industries (IATI), the largest umbrella organization representing Israel’s life science and high-tech industries.
26-May-2020 - VPM1002
Vakzine Projekt Management - SARS-CoV-2 study kicks off in Germany: First participant enrolled in Phase III clinical trial of VPM1002 focused on healthcare workers battling the COVID-19 pandemic
Vakzine Projekt Management GmbH (VPM) announced that the first participant has been enrolled on May 25th in a phase III study to investigate whether the vaccine candidate VPM1002 is effective against respiratory diseases like COVID-19.
26-May-2020 - NVX-CoV2373
CNBC - Front-line coronavirus workers could be vaccinated as soon as this year, Novavax CEO says
Workers on the front lines of the coronavirus pandemic will be first to receive a vaccine and that could come as soon as later this year, Stanley Erck, CEO of vaccine development company Novavax, said Tuesday.
26-May-2020 – COVAX
Reuters - Merck to buy Austrian vaccine maker as it jumps into COVID-19 race
Merck & Co Inc (MRK.N), which has largely kept to the sidelines of the race for COVID-19 treatments, said it was buying Austrian vaccine maker Themis Bioscience and would collaborate with research nonprofit IAVI to develop two separate vaccines.
26-May-2020 – NVX-CoV2373
https://www.wsj.com/articles/novavax-coronavirus-vaccine-begins-human-testing-11590438240
Bloomberg - Novavax Coronavirus Vaccine Begins Human Testing
Novavax Inc. said Monday it started the first human study of its experimental coronavirus vaccine, making it one of at least 10 shots now being tested in people globally for Covid-19.
26-May 2020 – NVX-CoV2373
https://www.sbs.com.au/news/first-australian-human-trials-of-potential-coronavirus-vaccine-start-in-melbourne
SBSNews - First Australian human trials of potential coronavirus vaccine start in Melbourne
More than 100 volunteers in Melbourne and Brisbane have been lined up to take part in the first phase of a human trial of a potential coronavirus vaccine.
26-May-2020 – COVAX
Bloomberg - Merck Unveils Virus Vaccine Candidates While Warning on Timeline
Merck & Co. moved to bolster the global fight against the coronavirus, unveiling plans for a pill to treat the infection and two vaccines to prevent it.
26-May-2020 – COVAX
Forbes - Merck Jumps Into The Race For A Coronavirus Vaccine
New Jersey-based pharmaceutical Merck announced three initiatives Tuesday to fight the novel coronavirus, including teaming up with nonprofit scientific research firm IAVI to develop a vaccine, as companies around the world race to find an effective treatment against the virus.
26-May-2020 – COVAX
https://www.wsj.com/articles/merck-does-deals-to-develop-coronavirus-vaccines-drug-11590489902
The Wall Street Journal - Merck Does Deals to Develop Coronavirus Vaccines, Drug
Drugmaker is buying a privately held Austrian company to obtain one vaccine, joining with other groups on a second vaccine and an antiviral
25-May-2020 – NVX-CoV2373
Bloomberg - Novavax Jumps After Starting Covid-19 Vaccine Study
Novavax Inc. jumped at much as 18% on Tuesday after initiating testing of its coronavirus vaccine candidate in people. The biotech anticipates providing a first look in July at what sort of immune responses are generated.
25-May-2020 – VPM1002
Göttinger Tageblatt - MPI-Forscher: Tuberkulose-Impfstoff könnte gegen Corona-Virus helfen
Stefan Kaufmann wird Emeritus-Direktor am Göttinger Max-Planck-Institut für biophysikalische Chemie. Er entwickelte einen Impfstoff gegen Tuberkulose, der als Zwischenlösung bei Covid-19 dienen könnte.
25-May-2020 – NVX-CoV2373
Forbes - Novavax Is Beginning Clinical Trials Of Its Coronavirus Vaccine
Novavax, a biotech company focused on developing vaccines against infectious diseases, announced Monday that it is beginning a phase 1 clinical trial of its Covid-19 vaccine candidate in Australia. Results of the trial are expected in July 2020.
25-May-2020 - COVAX
https://www.mrknewsroom.com/news-release/research-and-development-news/merck-acquire-themis
Merck - Merck to Acquire Themis
Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur.
24-May-2020 – AZD1222
Hindustan Times - Oxford’s Covid-19 vaccine trial has 50% chance of success: Project leader
The University of Oxford’s Covid-19 vaccine trial has only a 50% chance of success as the coronavirus seems to be fading rapidly in Britain, the professor co-leading the development of the vaccine has said. Oxford’s Jenner Institute has tied up with biopharma major AstraZeneca Plc to produce the vaccine on a mass scale if the results are successful. The experimental vaccine, known as ChAdOx1 nCoV-19, is one of the front-runners in the global race to provide protection against the new coronavirus causing the coronavirus pandemic.
24-May-2020 – AZD1222
Bloomberg - Oxford University Vaccine Trials Run Into Hurdle
The Oxford University team in charge of developing a coronavirus vaccine said a decline in the infection rate will make it increasingly difficult to prove whether it’s been successful, the Telegraph reported. “It’s a race against the virus disappearing, and against time,” Professor Adrian Hill, director of the university’s Jenner Institute, told the newspaper. “We said earlier in the year that there was an 80% chance of developing an effective vaccine by September. But at the moment, there’s a 50% chance that we get no result at all.”
22-May-2020 - ChAdOx1 nCoV-19, COVAX, NVX-CoV2373
The Times of India - How one Indian company could be world's door to a Covid-19 vaccine
If the world is to gain access to a vaccine for Covid- 19, there's a good chance it will pass through the doors of Serum Institute of India.
22-May-2020 - ChAdOx1 nCoV-19
http://www.ox.ac.uk/news/2020-05-22-oxford-covid-19-vaccine-begin-phase-iiiii-human-trials
Oxford University - Oxford COVID-19 vaccine to begin phase II/III human trials
niversity of Oxford researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers.
22-May-2020 - ChAdOx1 nCoV-19
The Telegraph - Coronavirus latest news: Vaccine trial extended to 10,000 people including over 70s and children
Researchers have begun recruiting volunteers for the next two phases in clinical trials they hope could bring a coronavirus vaccine this year. Work began in January on the vaccine, which uses a virus taken from chimpanzees and has been developed by the University of Oxford's Jenner Institute and the Oxford Vaccine Group. Now scientists want to recruit up to 10,260 people across the country for phases II and III, which involve vastly increasing the number of volunteers and expanding the age range to include older adults and children.
22-May-2020 - mAbCo19
Corriere Di Siena - Vaccino Coronavirus, professor Rappuoli: "Nostro patto per riuscire a produrre un miliardo di dosi". Il video
Un patto tra giganti della farmaceutica per arrivare a produrre un miliardo di dosi di vaccino anti Coronavirus entro il 2021. E’ stato Rino Rappuoli, direttore scientifico e responsabile delle ricerche sui vaccini di Gsk, a svelare l’ambizioso progetto durante Meet the future, programma online de La Repubblica. Parlando dell’emergenza per il Covid-19 e della ricerca di un vaccino, in corso praticamente in tutto il mondo, Rappuoli si è detto abbastanza fiducioso: a suo avviso saranno più di uno i progetti che andranno a buon fine. Un problema non indifferente, però, sarà l’altissimo numero di dosi di cui si avrà bisogno se davvero la campagna di vaccinazione dovrà essere mondiale. Occorrono miliardi di fiale. La soluzione a cui sta pensando Gsk è quella di utilizzare gli adiuvanti che permettono di garantire l’effetto di un vaccino pur usando solo un decimo della dose.
22-May-2020 - ChAdOx1 nCoV-19
The Print India - Covid vaccine could come by 2020-end but realistic time-frame would be 2 yrs: Adar Poonawalla
Vaccines for Covid-19 are at least two years away, but a few may get ready by the end of the year, said Adar Poonawalla, chief executive of Serum Institute of India, the world’s largest vaccine producer. Pune-based SII, which produces 150 crore vaccine doses a year across the globe, is working on three vaccine candidates developed by the UK’s University of Oxford, US-based Codagenix and Austrian biotech firm Themis. Of these, if the vaccine currently under trials by Oxford University in collaboration with British pharma giant AstraZeneca succeeds, it may become the first to come out by the end of the year.
22-May-2020 - ChAdOx1 nCoV-19
Live Mint - Vaccine development is like a rollercoaster, says Serum Institute CEO
Adar Poonawalla, CEO, Serum Institute of India (SII), said on Thursday that developing a vaccine is like a rollercoaster ride with ups and downs. " Sometimes we fail, sometimes we succeed, but we must be patient and not jump to conclusions too early. We must wait for all phase 3 trials to be completed," Poonawalla said in a tweet. There have been reports that one of the strong candidates for a potential vaccine for Covid-19 being tested by researchers at the Oxford University has failed to protect monkeys from being infected by the virus. However, the potential vaccine helped to protect the monkeys from pneumonia.
22-May-2020 - ChAdOx1 nCoV-19
Times of India - Coronavirus vaccine current update: Oxford vaccine failure to Moderna's favourable results, here is the latest status of COVID-19 vaccines and drugs
The vaccine being developed by Oxford University uses a weakened strain of the common cold virus, known as adenovirus which causes infections in Chimpanzees. They have combined it with the genetical material of the spike protein of SARS-CoV-2. The vaccine candidate was developed within 3 months and showed promising results in animal trials. However, recent reports have confirmed that the potential vaccine ‘ChAdOx1 nCoV-19’, ’was not able to prevent infection in rhesus macaque monkeys. As of now, the vaccine seems to be partially effective as it protected the animals from developing viral pneumonia but could not stop the COVID-19 infection.
21-May-2020 - NVX-CoV2373
https://finance.yahoo.com/news/novavax-covid-19-vaccine-candidate-001437548.html
Yahoo Finance - Novavax’s COVID-19 Vaccine Candidate Could Be the One, Says Top Analyst
Wall Street has been looking at Novavax (NVAX) of late, and investors clearly like what they see. Over the past 5 months, Novavax stock skyrocketed over 1000% (that's not a typo) and remains relatively close to its 52-week high. The company’s speedy development of a possible COVID-19 vaccine has been behind the stock’s dazzling performance. The company developed vaccines against coronaviruses such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS), for which preclinical testing demonstrated strong immunogenicity and 100% protection. This was also the case for Ebola, with the NVAX vaccine candidate proving effective in primate studies.
21-May-2020 - ChAdOx1 nCoV-19
https://www.nytimes.com/2020/05/21/health/coronavirus-vaccine-astrazeneca.html
New York Times - $1.2 Billion From U.S. to Drugmaker to Pursue Coronavirus Vaccine
The Trump administration announced a grant to AstraZeneca, which has licensed a potential vaccine that is in trials by Oxford University. Scientists at Oxford University are proceeding on an accelerated timetable for a potential coronavirus vaccine in Britain, in partnership with AstraZeneca. Expanding its pursuit of an inoculation against the coronavirus, the U.S. Department of Health and Human Services said on Thursday it would provide “up to $1.2 billion” to the drug company AstraZeneca to develop a potential vaccine from a laboratory at Oxford University. The deal with AstraZeneca is the fourth and by far the largest vaccine research agreement that the department has disclosed. The money will pay for a Phase 3 clinical trial of a potential vaccine in the United States this summer with about 30,000 volunteers.
21-May-2020- ChAdOx1 nCoV-19
https://www.ft.com/content/4b216c2e-2558-4308-b9c2-bf805b08e949
Financial Times - AstraZeneca books orders for 400m doses of Oxford vaccine
Drugmaker AstraZeneca has secured orders for at least 400m doses of an as yet unproven Covid-19 vaccine being developed with Oxford university and would begin delivering them in September. The company said it had also received more than $1bn in funding from the Biomedical Advanced Research and Development Authority (Barda), a unit of the US health department, to develop the coronavirus vaccine.
21-May-2020 - PLX-PAD
The Daily Beast - How Edward Pierce, Broadway ‘Wicked’ Designer, Fought COVID-19—and Made Medical History
Broadway designer Edward Pierce is the first American to receive placental cell treatment for COVID-19. He and wife Pixie tell Tim Teeman about survival, guilt, and making history.
21-May-2020 - PLX-PAD
The Daily Mail - Broadway set designer makes medical history after becoming first American to receive placental cell treatment for coronavirus under FDA's 'compassionate use' rules
Edward Pierce, 49, is acclaimed Broadway scenic designer for plays like Wicked. Pierce fell ill with COVID-19 and was treated at a hospital in Teaneck, New Jersey . Doctors grew concerned as his condition deteriorated due to organ failure. There was little hope, so his wife agreed to use an untested method. Pierce was administered placental cells in around 15 parts of his body. Within 10 days, he was off a ventilator and breathing on his own. The placental cell therapy was developed by an Israeli biotechnology firm. Pierce was given treatment as part of 'compassionate use' .
20-May-2020- NVX-CoV2373
https://www.skynews.com.au/details/_6157799654001
Sky News - COVID-19 vaccine trial to begin human testing in Australia
Phase one of a coronavirus vaccine trial - which will see 131 people from Melbourne and Sydney injected with the trial drug - is set to begin in less than a week. The vaccine was developed in the United States and is the first human clinical trial to run in Australia.
18-May-2020 - ChAdOx1 nCoV-19
TimesNowNews India - Potential Oxford COVID-19 vaccine fails to prevent coronavirus infection in animal trials
New Delhi: Oxford University’s COVID-19 vaccine failed to prevent the monkeys from being infected with the novel coronavirus in trials, dashing the UK's hopes of a safe and effective vaccine this year. The vaccine is among the top candidates that are currently being tested on humans. But detailed results from the animal trials showed that the ChAdOx1 nCoV-19 vaccine did not stop rhesus macaque monkeys from contracting the virus, and it does not stop the animals from spreading the infection to others as well.
18-May-2020 - PLX-PAD
TrialSite News - Regenerative Therapy out of Israel Shows Promise for COVID-19 Patients Fighting ARDS
75% of those COVID-19 patients treated by the company’s regenerative therapy were off any mechanical ventilation after 28 days of treatment. Under a compassionate use program in Israel, in addition to an FDA Single Patient Expanded Access Program in the United States, treated patients were in Intensive Care Units (ICU), on invasive mechanical ventilation and were suffering from Acute Respiratory Distress Syndrome (ARDS) at the time of treatment.
18-May-2020 - ChAdOx1 nCoV-19
The Telegraph - Doubts over Oxford vaccine as it fails to stop coronavirus in animal trials
Experts warn that vaccine may only be 'partially effective' after results of a trial in rhesus macaque monkeys.
18-May-2020 - ChAdOx1 nCoV-19
sky news - Coronavirus vaccine: How is Oxford vaccine being trialled and when will we know if it works?
The government says 30 million doses could be available across the UK in September if the medical trial turns out well.
18-May-2020 - mAbCo19
About Pharma - Produzioni del vaccino per Covid, Rappuoli: “Bisogna investire milioni sugli impianti”
Per preparare milioni se non miliardi di dosi serviranno investimenti titanici e tutto dipenderà da questo. Rino Rappuoli, direttore scientifico GlaxoSmithKline Vaccines spiega come la sperimentazione non sia l’unico ostacolo da superare, bensì anche la capacità produttiva delle singole aziende. Non tutte potranno farlo e la selezione rischia di essere impietosa.
17-May-2020 - ChAdOx1 nCoV19
NASDAQ/RTT News: AstraZeneca To Make 30 Mln Doses Of Coronavirus Vaccine By Sept If Successful
AstraZeneca will make up to 30 million doses of the Oxford coronavirus vaccine by September if the vaccine is successful. As part of a global licensing agreement between Oxford University and AstraZeneca, the UK-based pharmaceutical company will deliver 100 million doses in total. Sharma announced a new funding of 84 million pounds for two universities to increase production of their potential vaccines.
17-May-2020 - AZD1222
The Times - Race to find coronavirus vaccine has rivals working together
Vaccitech, which was founded by two Oxford professors, Adrian Hill and Sarah Gilbert, in 2016, is part of a consortium that is, so far, Britain’s best hope in the race to find a vaccine. In partnership with Oxford University, Astra Zeneca and other biotech companies, Vaccitech wants to deliver millions of doses of the vaccine.
17-May-2020 – AZD1222
Bloomberg - AstraZeneca Aims for 30 Million U.K. Vaccine Doses by September
AstraZeneca Plc will make as many as 30 million doses of coronavirus vaccine available to the U.K. by September and has committed to delivering 100 million doses this year. The U.K. will be the first country to get access to the vaccine should it be successful.
16-May-2020 - PLX-PAD
The Jerusalem Post - Israel’s Pluristem: 75% of treated COVID-19 patients off ventilators
The Haifa-based regenerative medicine company that has been treating COVID-19 patients with its biological therapeutic products reported that 75% of those treated were off any mechanical ventilation within 28 days.
16-May-2020 - Plant-based protein production
IOL - South African researchers making giant strides in fight against Covid-19
Cape Bio Pharms used a distant cousin of tobacco, Nicotiana benthamiana, as a bioreactor to produce antibodies and antigens
15-May - ChAdOx1 nCoV19
NIH: Investigational ChAdOx1 nCoV-19 vaccine protects monkeys against COVID-19 pneumonia
A single dose of ChAdOx1 nCoV-19, an investigational vaccine against SARS-CoV-2, has protected six rhesus macaques from pneumonia caused by the virus, according to National Institutes of Health scientists and University of Oxford collaborators. The findings posted in preprint server bioRxiv are not yet peer-reviewed but are being shared to assist the public health response to COVID-19. Based on these data, a Phase 1 trial of the candidate vaccine began on April 23 in healthy volunteers in the United Kingdom.
15-May-2020 – NVX-CoV2373
Bloomberg TV - Novavax Could Deliver 100M Covid-19 Vaccine Doses By End of Year, Says R&D Head
Novavax Inc.'s vaccine is one of at least 100 potential candidates trying to curb the spread of the virus that causes Covid-19. The biotech company recently received a funding of $388-million from the Coalition for Epidemic Preparedness Innovation, making it the biggest investment ever from the group. Dr. Gregory Glenn, Novavax's president of research and development, speaks on "Bloomberg Technology."
14-May-2020 PLX-PAD
https://www.nytimes.com/2020/05/14/theater/patti-lupone-marianne-elliott-company.html
The New York Times - The Show’s Delayed, but They’re Still Keeping ‘Company’
By trans-Atlantic email, Patti LuPone and the Broadway director Marianne Elliott talk fear, sadness, camaraderie and the ethics of buying eggs from a Trump supporter; ith a side note on the Pluristem PLX-PAD clinical trial.
14-May-2020 – mAbCo19
https://horizon-magazine.eu/article/aim-find-monoclonal-hunt-antibody-treat-covid-19.html
Horizon Magazine - The aim is to find the monoclonal’: the hunt for the antibody to treat Covid-19
Transfusing antibodies from Covid-19 survivors into seriously ill patients could provide a quick treatment win, but a more selective approach may both treat and prevent the disease. A single, highly-effective antibody that is mass-produced like a drug could combine the benefits of antivirals and a vaccine for at-risk individuals such as health workers.
14-May-2020 – mAbCo19
https://www.lanazione.it/siena/cronaca/coronavirus-anticorpi-1.5147927
La Nazione- Trovati 17 anticorpi che uccidono il virus
I primi successi della ricerca Fondazione Tls-Spallanzani. Le anticipazioni di Rappuoli, le speranze della ’senior scientist’ Claudia Sala
14-May-2020 – PLX-PAD
Israeli Life Sciences - Pluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, today reported an update on the status of COVID-19 infected patients treated with PLX cells under a compassionate use program in Israel and the FDA Single Patient Expanded Access Program in the U.S. All treated patients were in Intensive Care Units (ICU), on invasive mechanical ventilation and suffered from Acute Respiratory Distress Syndrome (ARDS) at the time of treatment. As of today, a total of 18 patients were treated in Israel and in the U.S., of which 8 (1 in the U.S. and 7 in Israel) so far have completed a 28-day follow up period.
13-May-2020 – ChAdOx1-nCoV19 - NVX-CoV2372
CNBC - Scientists race to find a cure or vaccine for the coronavirus. Here are the top drugs in development
Below is a list of the leading vaccines and drugs in development to battle Covid-19.
13-May-2020 - mAbCo19
Corriere di Siena - Farmaco anti Coronavirus, Tls conferma importanti progressi. Il punto sulla ricerca a Siena
Farmaco anti Coronavirus, Toscana Life Sciences conferma gli importanti progressi nella ricerca annunciati dal coordinatore del gruppo di lavoro, Rino Rappuoli, nel corso di una intervista a RaiNews24.
13-May-2020 - mAbCo19
il Cittadino - Covid-19: tra qualche mese pronto un farmaco contro l’infezione
Gsk, Tls e Spallanzani stanno lavorando agli anticorpi monoclonali
12-May-2020 – NVX-CoV2372
CNBC - Novavax CEO talks receiving $384 million in CEPI funding for coronavirus vaccine candidate
Novavax CEO Stanley Erck discussed the biotech company’s efforts to develop a Covid-19 vaccine, including millions in funding to help clinical trials and production
12-May-2020 - mAbCo19
RAI News - Rappuoli: funzionano i nostri anticorpi monoclonali, la cura contro il Covid19
C'è una importante svolta sul fronte della cura di Covid19: Rino Rappuoli, uno dei microbiologi più citati e noti al mondo, il padre del vaccino contro meningococco B e C e quello contro la pertosse, è riuscito a trovare degli anticorpi monoclonali che funzionano contro il nuovo coronavirus. Spiega di cosa si tratti e le prospettive per arrivare ad un vaccino nell’intervista a Gerardo D’Amico
12-May-2020 – Plant based protein production
News24 - WATCH | CT company uses plants to create antigens to test for Covid-19
Cape Bio Pharms is using biotechnology to manufacture Covid-19 proteins in plants. These proteins, called antigens, are used in rapid diagnostic test kits that detect antibodies against the virus in a person's blood, indicating whether they have been exposed to the virus.
12-May-2020 - mAbCo19
https://www.ilsole24ore.com/art/la-cura-made-italy-il-sangue-guariti-ADbVV3P?refresh_ce=1
isole24ore - La cura made in Italy con il sangue dei guariti
Dalla partnership tra Spallanzani e Fondazione Toscana Life Science lo sviluppo di un farmaco. Si punta a produrlo per la primavera del 2021, ma ora servono gli investimenti dell’industria. Di Barbara Gobbi
12-May-2020 – COVAX
https://science.orf.at/stories/3200746/
ORF - Mit dem Masernvirus zum Covid-Impfstoff
Zahlreiche Forschungsgruppen weltweit arbeiten intensiv an einem Impfstoff gegen SARS-CoV-2, auch in Österreich. Die Wiener Biotech-Firma Themis verwendet das Masernvirus, um das Immunsystem auf das neuartige Coronavirus aufmerksam zu machen.
11-May-2020 - VPM1002
https://www.dw.com/en/can-a-tuberculosis-vaccine-help-combat-covid-19/a-53388220
Deutsche Welle - Can a tuberculosis vaccine help combat COVID-19?
VPM1002 is the name of a new tuberculosis vaccine that could possibly help control the novel coronavirus. Scientists at Germany's Max Planck Institute for Infection Biology have developed the vaccine by genetically modifying BCG. Now, scientists are also testing the vaccine for its efficacy against COVID-19. Its precursor has already proven to be effective against other infections. Several studies have been initiated and seem promising.
11-May-2020 - ChAdOx1 nCoV-19
https://indianexpress.com/article/explained/coronavirus-covid-19-vaccine-6402085/
The Indian Express - Covid-19 vaccine: The search for a coronavirus cure
The University of Oxford is researching whether a vaccine that was originally developed for MERS, another coronavirus, could be administered during this pandemic. Called ChAdOx1 nCoV-19, this vaccine would help the body recognise the “spikes” of the virus which are made of protein. As it was already being developing for MERS, it passed the initial stages and is now in the clinical trial phase.
10-May-2020 - GRAd-COV2
Il tempo - Coronavirus, presto test sull'uomo per il vaccino tutto made in Italy
ReiThera Srl ha annunciato i risultati ottenuti dai test del suo vaccino anti-COVID19 negli animali. Stefania Capone, direttore della ricerca preclinica di ReiThera ha dichiarato che una singola somministrazione di vaccino ha indotto una forte risposta immunitaria sia per quanto riguarda gli anticorpi contro il Coronavirus, che sono in grado di prevenire l'infezione, sia per quanto riguarda le cellule T che eliminano il virus già entrato nell'organismo.
10-May-2020 - PLX-PAD
https://en.globes.co.il/en/article-fda-covid-19-trial-nod-boosts-pluristem-1001327952
Globes - FDA Covid-19 trial nod boosts Pluristem
The FDA has cleared Pluristem's application for a Phase II study of its PLX cells in the treatment of severe Covid-19 cases. Pluristem has been treating patients suffering from severe complications caused by COVID-19, such as ARDS and inflammatory complications, in the US and Israel through compassionate use programs. Preliminary data from these compassionate use programs in Israel were reported on April 7, 2020. A Clinical Trial Authorization (CTA) has also been filed in Europe for a Phase II COVID-19 trial, with the first European clinical sites planned in Germany and Italy.
9-May-2020 - ChAdOx1 nCoV-19
https://thenewdaily.com.au/life/wellbeing/2020/05/09/oxford-coronavirus-vaccine-trial/
The New Daily - Coronavirus vaccine trial: Oxford scientists shoot for one million doses by September
Can the safety of a vaccine be established in large enough numbers within the next four to five months? This is the plan of the Oxford University team who are working at unprecedented speed to develop a vaccine against COVID-19. By September, all going well, the Oxford scientists will begin jabbing a million arms with their new vaccine called ChAdOx1 nCoV-19.
8-May-2020 - PLX-PAD
The Jerusalem Post - Israel's Pluristem FDA approved for study in treatment of severe COVID-19
Israel’s Pluristem Therapeutics’ PLX cells therapy has been cleared by the US Food and Drug Administration for a Phase II study in the treatment of severe COVID-19 cases complicated by Acute Respiratory Distress Syndrome.
7-May-2020 PLX-PAD
https://sciencebusiness.net/covid-19/regenerating-bodys-healing-mechanisms-covid-19-patients
Science Business - Regenerating the body’s healing mechanisms for COVID-19 patients
EU-backed Israeli biotech company treats COVID-19 patients with innovative cell therapy. An innovative treatment developed by Pluristem, a regenerative medicine company based in Israel, is showing promise. The company recently signed a non-dilutive financing agreement of €50 million with the European Investment Bank to support the further development of Pluristem’s regenerative cell therapy platform, with a focus on the company’s COVID-19 treatment.
6-May-2020 – PLX-PAD
http://www.xinhuanet.com/english/2020-05/06/c_139033131.htm
Xinhua net - Roundup: Israeli hi-tech firms focus on seeking solutions to COVID-19 challenges
In face of the challenges posed by the COVID-19 pandemic, the Israeli hi-tech industry has focused its efforts on seeking innovative solutions. Pluristem Therapeutics, a company based in the northern Israeli city of Haifa, announced last week it had received a grant of 50 million U.S. dollars from the European Investment Bank (EIB) to further advance its stem cell therapy in curing COVID-19 patients. Pluristem specializes in creating regenerative medicines using full-term placenta cells.
6-May-2020 – plant based protein production
https://ewn.co.za/2020/05/06/covid-19-claims-10-more-lives-in-sa-bringing-death-toll-to-148
Eyewitness News - COVID-19 CLAIMS 10 MORE LIVES IN SA, BRINGING DEATH TOLL TO 148
‚In the Western Cape - Biotechnology firm , Cape Bio Pharms (a spin-off of the Biopharming Research Unit at UCT) is producing plant-based antigens. to be used in conjunction with rapid diagnostic test kits’
5-May-2020 - PLX-PAD
https://www.eib.org/en/stories/placenta-cell-therapy-cure-covid-19
EIB Blog - Placenta cells to fight COVID-19
Can placenta cell therapy cure COVID-19? Israeli-European firm Pluristem is on track to show how placenta cells help the body heal itself.
5-May-2020: Plant-based protein Production
Creamer Media’s Engineering News - Cape Town company joins global efforts to develop plant-based Covid-19 test kits
Cape Bio Pharms, a spin-off company of the Biopharming Research Unit at the University of Cape Town, has partnered with international biotechnology companies to address the international problem of accessibility to affordable reagents and rapid Covid-19 serology testing, with the launch of its Plants Against Corona initiative.
4-May 2020 – ChAdOx1 nCoV-19
https://www.nrc.nl/nieuws/2020/05/04/welk-vaccin-gaat-ons-verlossen-van-dit-virus-a3998583
NRC - De wedloop om hét vaccin
Het is de heilige graal, dé uitweg uit deze pandemie: een coronavaccin. Meer dan negentig prototypen zijn op dit moment in ontwikkeling in laboratoria in een kleine twintig landen. Deze race tegen de klok moet alle records breken. Maar gaat het ook lukken? En vooral: wanneer?
2-May-2020 - ChAdOx1 nCoV-19
Libero Quotidiano - Giuseppe Conte "ha detto no". Dagospia, bomba sul governo: il vaccino anti-coronavirus poteva essere italiano
Il vaccino anti-coronavirus poteva essere italiano, ma Giuseppe Conte ha detto no. E ora, forse, ci ritroveremo a doverlo chiedere alla Gran Bretagna. Dagospia, con un pesantissimo Dago-report, sgancia la bomba sul governo accendendo i fari sulle ricerche condotte in partnership tra lo Jenner Institute della Oxford University e la società IRBM di Pomezia, uno dei fiori all'occhiello della scienza di casa nostra che ha iniziato a lavorare fin da subito per trovare l'arma contro il Covid19.
2-May-2020 - PLX-PAD
https://www.mako.co.il/news-channel12?subChannelId=52d3d5d1b5331710VgnVCM100000700a10acRCRD&vcmid=fd695d064a6d1710VgnVCM100000700a10acRCRD (original in hebrew)
https://www.pluristem.com/pluristem-video/ (original with English subtitles provided by the company)
N12 - Israeli treatment of Corona based on placental cells
Weekend prime time TV news
1-May-2020 - ALL
WHO - WHO and European Investment Bank strengthen efforts to combat COVID-19 and build resilient health systems to face future pandemics
In the context of the COVID-19 pandemic, the EIB is currently assessing over 20 projects in the field of vaccine development, diagnostic and treatment, leading to potential investments in the 700 million EUR range.
30-April-2020 -PLX-PAD
https://www.calcalistech.com/ctech/articles/0,7340,L-3814051,00.html
Ctech - European Investment Bank, Israel Innovation Authority Collaborate on Medical Investments
As part of the collaboration, European Investment Bank has provided Pluristem GmbH, the German subsidiary of Israel-based medical company Pluristem, with a debt loan of €50 million (approximately $54 million)
30-Apr-2020 - VPM1002
The Lancet - Considering BCG vaccination to reduce the impact of COVID-19
By Tedros A Ghebreyesus, among others. In addition to its specific effect against tuberculosis, the BCG vaccine has beneficial nonspecific (off-target) effects on the immune system that protect against a wide range of other infections and are used routinely to treat bladder cancer.1, 2 This has led to the suggestion that vaccination with BCG might have a role in protecting health-care workers and other vulnerable individuals against severe coronavirus disease 2019 (COVID-19).
30-Apr-2020 - PLX-PAD
http://www.israelnationalnews.com/News/News.aspx/279444
Israel National News 7 - €50 loan from European Investment Bank to Israeli company Pluristem
Pluristem is a regenerative medicine company with a focus on novel biological products.
30-Apr-2020 - PLX-PAD
https://www.my9nj.com/video/679516
my9 news - NJ hospital pioneers COVID-19 treatment
Holy Name Medical Center in Teaneck, NJ, is the first to use a breakthrough COVID-19 treatment.
30-Apr-2020 - PLX-PAD
Jerusalem Post - European Investment Bank to assist Israeli bio-convergence research
The European Investment Bank (EIB) and the Israel Innovation Authority (IIA) signed a cooperation agreement on Thursday to pursue investment in the field of bio-convergence for healthcare.
30-Apr-2020 - PLX-PAD
European Commission - New collaboration in innovation and therapies for COVID-19 with Israel
On 30 April 2020 the European Investment Bank (EIB) and the Israel Innovation Authority (IIA) signed a cooperation agreement (MoU) to jointly pursue investment opportunities in the domain of bio-convergence in health.
30-Apr-2020 – ChAdOx1 nCoV-19
BBC News - Oxford 'started developing coronavirus vaccine in January'
Pharmaceutical giant AstraZeneca is to manufacture and distribute a coronavirus vaccine that is being developed by the University of Oxford, if the treatment proves effective. AstraZeneca's chief executive Pascal Soriot tells the BBC why his firm has chosen to back Oxford in developing a vaccine.
28-Apr-2020 - ChAdOx1 nCoV-19
The Economist - An Indian firm starts mass-producing an unproven covid-19 vaccine
On April 21, Adar Poonawalla, boss of the Serum Institute of India, one of the world’s largest producers of vaccines, arrived at work full of optimism about a new vaccine for covid-19, created by the Jenner Institute at Oxford University. In normal times the products that Mr Poonawalla manufactures are proven, effective vaccines. They have regulatory approval, and an order has been placed for them. These are not normal times.
28-Apr-2020 - ChAdOx1 nCoV-19
Algemeen Dagblad - ‘Coronavaccin met Nederlands tintje mogelijk in september al op de markt’
Hoopvol nieuws in sombere coronatijden: wetenschappers van de universiteit van Oxford zeggen dat ze in september een werkend vaccin tegen het virus op de markt kunnen brengen. Er zitten meerdere Nederlandse tintjes aan het vaccin.
27-Apr-2020 – ChAdOx1 nCoV-19
https://www.nytimes.com/2020/04/27/world/europe/coronavirus-vaccine-update-oxford.html
The New York Times - In Race for a Coronavirus Vaccine, an Oxford Group Leaps Ahead
As scientists at the Jenner Institute prepare for mass clinical trials, new tests show their vaccine to be effective in monkeys.
27-Apr-2020 - PLX-PAD
Deutschlandradio - Informationen am Morgen: Kurz vor Impfstoff?
Israel sieht sich als Forschungshochburg gegen COVID-19.
26-April-2020 – NVX-CoV2373
https://www.thesun.co.uk/news/11482679/one-third-americans-think-government-hiding-coronavirus-cure/
The Sun - CORON-SPIRACY - One-third of Americans think government hiding virus cure despite no evidence
SUSPICIOUS Americans reckon a coronavirus vaccine has been created, but that it's being "withheld from the public", a joint study shows
24-Apr-2020 - PLX-PAD
Jerusalem Post - Israel's Pluristem secures €50m. EU financing to boost COVID-19 treatment
Haifa-based Pluristem has secured €50 million ($54m.) in financing from the European Union's European Investment Bank (EIB) to advance its pioneering regenerative cell therapy platform, with a focus on the clinical development of a placenta-based treatment for complications associated with COVID-19.
24-April-2020 – VPM1002
Reuters - Reasons for hope: the drugs, tests and tactics that may conquer coronavirus
With much of the world living in lockdown, the spread of the new coronavirus, SARS-CoV-2, that was first detected in China late last year is beginning to slow in some places. As of April 23, 2.7 million had been infected and 192,000 killed by COVID-19, the disease caused by the virus.
23-Apr-2020 – ChAdOx1 nCoV-19
The New York Times - European Firms Step Up COVID-19 Vaccines Work, UK Team Starts Human Trials
Scientists in Britain began clinical trials of a potential COVID-19 vaccine on Thursday as other vaccine developers across Europe also stepped up work on experimental shots against the disease caused by the new coronavirus.
23-Apr-2020 - ChAdOx1 nCoV-19
BBC - Coronavirus: First patients injected in UK vaccine trial
The first human trial in Europe of a coronavirus vaccine has begun in Oxford. Two volunteers were injected, the first of more than 800 people recruited for the study. Half will receive the Covid-19 vaccine, and half a control vaccine which protects against meningitis but not coronavirus.
23-Apr-2020 - COVAX
https://tvthek.orf.at/profile/Eco/11523082/Eco/14049277
ORF - Magazin ECO: Wettlauf der Forscher, teure Suche nach dem Wirkstoff
Weltweit forschen unzählige Teams an Universitäten und in Pharma-Unternehmen mit Hochdruck an einem Impfstoff oder einem Medikament gegen das Coronavirus. Üblicherweise dauert es zehn bis 15 Jahre bis neue Mittel marktreif sind. Diesmal muss es viel schneller gehen. Auch in Österreich stellt die Regierung Geld zur Verfügung, um die Entwicklung von Medikamenten voranzutreiben.
20 Apr-2020 - ChAdOx1 nCoV-19
Daily Mail - Oxford scientist leading Britain's coronavirus vaccine race urges Government to help produce millions of doses amid hopes jab could be ready by September
An Oxford scientists leading Britain's coronavirus vaccine race has urged the Government to help produce millions of doses before it has proven to be effective.
19-Apr-2020 - ChAdOx1 nCoV-19
https://www.bbc.co.uk/iplayer/episode/m000hk96/the-andrew-marr-show-19042020
(available inside the UK only)
BBC: The Andrew Marr Show
Andrew Marr is joined by Professor Sarah Gilbert, vaccinologist at Oxford University
17-Apr-2020 - VPM1002
https://magazin-forum.de/de/node/18512#article
FORUM: „Etwa 50 Impfstoffe in der Entwicklung“
Prof. Dr. Stefan H. E. Kaufmann hat einen Tuberkulose-Impfstoff entwickelt, der gute Aussichten auf einen Einsatz gegen SARS-CoV-2 hat. Mit FORUM spricht der Biologe über die Entwicklung von spezifischen Impfstoffen sowie Einsatzmöglichkeiten seines Impfstoffs VPM1002.
16 April 2020 - PLX-PAD
https://newyork.cbslocal.com/2020/04/16/coronavirus-placenta-cell-therapy-treatment/
CBS: Coronavirus Update: Hospital In New Jersey Is First In USA To Try Placenta Cell Therapy On A COVID-19 Patient
A New Jersey hospital is the first in the country to try a therapy on a coronavirus patient that utilizes cells from new moms.
Photos from inside Holy Name Medical Center’s ICU show a historic effort to fight the coronavirus: A 49-year-old patient is injected with placenta cells derived from a healthy live birth.
16 April 2020 -PLX-PAD
Bloomberg: Holy Name Medical Center Uses Placenta Cells to Treat Covid-19
Michael Maron, chief executive officer at Holy Name Hospital in Teaneck, New Jersey, discusses progress on an experimental treatment the hospital is using. He speaks with Bloomberg's Emily Chang.
14-April-2020 – PLX-PAD
https://video.foxbusiness.com/v/6149349682001/#sp=show-clips
Fox Business - Placenta coronavirus treatment offers hope: Dr. Ravit Barkama
Holy Name Medical Center Clinical Development Assistant Vice President Dr. Ravit Barkama provides insight into a possible new coronavirus treatment that uses cells taken from a placenta after a baby is born
14 April 2020 - PLX-PAD
Jerusalem Post: Israeli COVID-19 treatment with 100% survival rate tested on US patient
After one week, six critically ill patients in Israel survived. Four of them showed improvement in respiratory parameters.
13 April 2020 - PLX-PAD
https://nypost.com/2020/04/13/could-stem-cells-from-a-babys-placenta-treat-covid-19/#content-wrapper
New York Post: Stem cells from a baby’s placenta may save life of coronavirus victim in NJ
Doctors in New Jersey are battling the coronavirus in one 49-year-old male patient with a revolutionary new treatment — injections of cells from babies’ placentas. The procedure, which was approved by the Food and Drug Administration only on Friday, was carried out Saturday and may be the first of its kind to take place in the entire US.
12-April-2020 -PLX-PAD
The Jerusalem Post - Israeli COVID-19 treatment shows 100% survival rate - preliminary data
Six critically ill coronavirus patients in Israel who are considered high-risk for mortality have been treated with Pluristem’s placenta-based cell-therapy product and survived, according to preliminary data provided by the Haifa-based company.
11 April - ChAdOx1 nCoV-19
Bloomberg: Prognosis. Coronavirus Vaccine Could Be Ready in Six Months: Times
A vaccine against the coronavirus could be ready by September, according to a scientist leading one of Britain’s most advanced teams.
Sarah Gilbert, professor of vaccinology at Oxford University, told The Times on Saturday that she is “80% confident” the vaccine would work, and could be ready by September. Experts have warned the public that vaccines typically take years to develop, and one for the coronavirus could take between 12 to 18 months at best.
11 April - ChAdOx1 nCoV-19
The Times: ‘Many of us have been saying for years that we need more vaccines’
But the Oxford professor closing in on a treatment for Covid-19 isn’t angry, she just wants to do her bit to help.
10 April – NVX-CoV2372
https://www.fox5dc.com/news/montgomery-county-biotech-company-working-on-covid-19-vaccine
FOX5: Montgomery County biotech company working on COVID-19 vaccine
A biotech company in Montgomery County says it's ready to start taking its coronavirus vaccine program to a new phase earlier than they expected, as the company is still working on securing more funding and support for the program.
9-April-2020
BioSpace - Preliminary Data from Pluristem’s PLC Cell Program Shows Promise in COVID-19
The world continues to wait with bated breath for a treatment for COVID-19, and Pluristem Therapeutics appears to be on the cusp of providing some hope. Preliminary data from Israel is showing promise for the company’s experimental treatment.
8 April - PLX-PAD
The Jerusalem Post: Israeli COVID-19 treatment shows 100% survival rate - preliminary data
Six critically ill patients in Israel who were considered high-risk for mortality have been treated with Pluristem’s placenta-based cell-therapy product and survived, according to preliminary data. The patients were treated at three different Israeli medical centres for one week under the country’s compassionate use program and were suffering from acute respiratory failure and inflammatory complications associated with COVID-19. Four of the patients also demonstrated failure of other organ systems, including cardiovascular and kidney failure.
8 April – NVX-CoV2373
https://www.nytimes.com/2020/04/08/health/coronavirus-vaccines.html
The New York Times: More Coronavirus Vaccines and Treatments Move Toward Human Trials
Just three months after the start of the coronavirus pandemic, several biotech companies are beginning trials of promising vaccines and treatments.
7 April – Hydroxychloroquine & Quinine
https://www.zdf.de/verbraucher/volle-kanne/medikamente-gegen-covid-100.html
ZDF: Medikamenten-Tests gegen Covid-19. Ein Lösungsansatz mit altbekannten Mitteln?
Europäische Forschungseinrichtungen beginnen mit klinischen Tests von vier Methoden zur Behandlung von Covid-19-Patienten. Dafür nehmen rund 3200 Probanden Medikamente gegen Ebola, Malaria und HIV ein. Dr. Christoph Specht ist hierzu im Gespräch.
7 April – PLX-PAD
Reuters: Pluristem Reports 100% Survival Rate In 7 COVID-19 Patients
PLURISTEM REPORTS PRELIMINARY DATA FROM ITS COVID-19 COMPASSIONATE USE PROGRAM, TREATING SEVEN PATIENTS WITH ACUTE RESPIRATORY FAILURE
7 April – PLX-PAD
Wallstreet-online: Pluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure
All treated patients were in Intensive Care Units (ICU) on ventilators and suffered from Acute Respiratory Distress Syndrome (ARDS). 100% survival rate for all seven patients.
6 April - VPM1002
https://www.zdf.de/nachrichten/heute-journal/heute-journal-vom-06042020-100.html ZDF Heute Journal: Immun-Booster gegen Sars COV2
magazin coverage at 19:39 min
3 April - VPM1002
CNN: Germany testing tuberculosis drug as coronavirus treatment
A microbiologist in Germany believes that the use of an updated version of a 100-year-old Tuberculosis vaccine may work as an intermediate treatment for Covid-19. CNN's Frederik Pleitgen reports.
3 April - COVAX
Wiener Zeitung: Impfstoff mit Österreich-Komponente
Das Wiener Bioscience-Unternehmen Themis spielt bei der Entwicklung eines Covid-19-Impfstoffs eine Schlüsselrolle.
3 April - VPM1002
Frankfurter Allgemeine Zeitung: Die Zwischenlösung im Kampf gegen Covid-19
Ein alter Impfstoff gegen Tuberkulose soll nun Ärzte und Pflegekräfte vor schweren Verläufen von Covid-19 schützen. Damit er wirksamer ist, wurde er jetzt aufgerüstet. Doch der Wirkstoff ist nur eine Zwischenlösung.
2 April - VPM1002
Reuters: Explainer - How an old tuberculosis vaccine might help fight the new coronavirus
There is no vaccine against the novel coronavirus, called SARS-CoV-2, that is spreading rapidly around the world. But scientists in several countries are testing a century-old tuberculosis (TB) vaccine to see if it might boost the immune system to reduce respiratory symptoms in people who get new coronavirus infections.
1 April - COVAX
https://www.nytimes.com/2020/04/01/world/europe/coronavirus-science-research-cooperation.html
The New York Times: Covid-19 Changed How the World Does Science, Together
Never before, scientists say, have so many of the world’s researchers focused so urgently on a single topic. Nearly all other research has ground to a halt.
1 April– VPM1002
Berliner Zeitung: Hilfe gegen Covid-19: Neue Impfung soll Abwehr gegen Corona verbessern
Sein in Berlin entwickelter Tuberkulose-Impfstoff könnte gefährdete Personengruppen vor einer Corona-Infektion schützen, sagt der Immunologe Stefan Kaufmann. Es handle sich dabei aber nur um eine Übergangslösung.
30 March – PLX-PAD
The Jerusalem Post: Israeli company uses placenta cells to treat critical COVID-19 patients
Pluristem Therapeutics, a Haifa-based regenerative-medicine company, has treated its first three coronavirus patients in Israel with its placenta-based cell-therapy product.
28 March 2020 - Hydroxychloroquine & Quinine
https://www.makanisi.org/coronavirus-la-rdc-terre-du-quinquina-au-centre-des-enjeux-mondiaux/
Makanisi: Coronavirus. la RDC, terre du quinquina, au centre des enjeux mondiaux
Face au Covid-19, des traitements associant la chloroquine, produit synthétique inspiré de la formule chimique de la quinine, seraient prometteurs. La RDC dispose, au Kivu, de vastes plantations de quinquina, un arbre dont l’écorce contient de la quinine, réputée pour ses propriétés antipaludiques. Dans la crise sanitaire actuelle, le pays pourrait avoir une carte à jouer. Les explications d’Etienne Erny, directeur général de la Pharmakina, le géant de cette filière dans le pays
27 March – Hydroxychloroquine & Quinine
Frankfurter Allgemeine Zeitung : Bisher nur grobe Vermutungen
Der Tropenmediziner Peter Kremsner will herausfinden, ob ein Malariamittel gegen Covid-19 hilft.
25 March - Hydroxychloroquine & Quinine
Radio Okapi: Coronavirus. la Task force va réfléchir sur l'opportunité d’appuyer la PHARMAKINA pour fabriquer la chloronique
Le Président de la République, Felix Tshisekedi a promis, mardi 24 février, que la « Task force » qu’il dirige va réfléchir avec le comité de pilotage de la lutte contre le coronavirus sur les contours et l’opportunité d’appuyer la PHARMAKINA.
21 March - ChAdOx1 nCoV-19
ITV: Coronavirus - How scientists are racing to find a Covid-19 vaccine
The first steps towards a coronavirus vaccine in the UK start next week, but a vaccine for all is still a year away at best. Scientists at Public Health England invited the cameras in to their usually off-limits Porton Down research labs. They’re the highest containment laboratories in the UK that handle the really nasty stuff, like Ebola, Marburg disease and the much milder, but much more threatening SARS-CoV-2, the virus that causes COVID-19.
20 March - ChAdOx1 nCoV-19
https://www.newsweek.com/countries-coronavirus-vaccine-trials-covid-19-before-end-year-1493362
Newsweek: 3 Countries Starting Coronavirus Vaccine Trials in global race to stop COVID-19 before end of year.
In the three months since the covid-19 pandemic started, scientists around the world have raced to create the first vaccine against it, with trials either starting or poised to in the U.S., China, and Europe.
20 March - ChAdOx1 nCoV-19
https://www.mirror.co.uk/news/uk-news/coronavirus-vaccine-trials-starting-uk-21723248
Mirror: Coronavirus vaccine trials starting in UK next month in major pandemic breakthrough
Trials of a coronavirus vaccine could begin within the next month, the Government's health agency has said, as it prepares to start evaluating a drug developed by Oxford University. Scientists at Public Health England could give the go-ahead for human testing well ahead of the usual time frame for drug development.
20 March - ChAdOx1 nCoV-19
https://www.telegraph.co.uk/news/2020/03/20/coronavirus-vaccine-trials-could-start-uk-within-month/
The Telegraph: Coronavirus vaccine trials could start in UK within a month
Trials of a coronavirus vaccine could begin within the next month, the Government's health agency has said, as it prepares to start evaluating a drug developed by Oxford University.
20 March– Cape Bio Pharms
https://www.enca.com/news/watch-race-covid-19-local-test-kits
ENCA: The race for COVID-19 local test kits
Diagnostic test kits for the coronavirus are in high demand - but all of them are imported.
A South African company is looking to potentially change that and fast. A cheaper, locally produced kit would separate the seasonal flu sufferer from a person infected with COVID-19, alleviating the strain on our healthcare system. Cape Bio Pharm is introducing spike proteins into plants, which are reproducing them but to what end?
20 March– VPM1002
https://magazin.spiegel.de/SP/2020/14/170213712/index.html
Der Spiegel No 14: Alarm im ganzen Körper
Der Berliner Max-Planck-Forscher Stefan Kaufmann hat einen neuen Impfstoff gegen Tuberkulose entwickelt. Der könnte vielleicht sogar vor Covid-19 schützen.
No preview available
19 March– ChAdOx1 nCoV-19
https://www.theguardian.com/society/2020/mar/19/uk-drive-develop-coronavirus-vaccine-science
The Guardian: Trials to begin on Covid-19 vaccine in UK next month
Researchers at Oxford University, led by Prof Sarah Gilbert, are planning a safety trial on humans of what is expected to be the UK’s first coronavirus vaccine next month. Provided that it goes smoothly, they will move directly into a larger trial to assess how effective the vaccine is at protecting against the infection.
17 March– PLX-PAD
Reuters: Israel to weigh "compassionate use" of Pluristem therapy for COVID-19
Israel’s Health Ministry has approved a request by Pluristem Therapeutics to seek case-by-case permission for compasstional treatment of COVID-19 patients with its stem cell therapy, the company said on Tuesday.
15 March – PLX-PAD
The Jerusalem Post: Israeli cell therapy could treat respiratory effects caused by coronavirus
A regenerative medicine company based in Haifa, Israel, says its placenta-based cell therapy product could be used to treat hundreds of patients who are suffering from respiratory and inflammatory complications associated with the COVID-19 coronavirus.
recent coverage on our projects
10-Mar-2021 – mAbCo19
https://www.repubblica.it/cronaca/2021/03/10/news/covid_vaccini-291508923/
La Repubblica - Covid, Rino Rappuoli:" Puntiamo ai nostri monoclonali". E una volta vaccinati "andranno fatti i richiami"
Paid content
10-Mar-2021 – NVX-COV2373
https://www.investing.com/news/jp-morgan-stick-to-their-buy-rating-for-novavax-2442163
Investing.com - J.P. Morgan Stick to Their Buy Rating for Novavax
J.P. Morgan analyst Eric Joseph maintained a Buy rating on Novavax (NASDAQ:NVAX) on Tuesday, setting a price target of $285, which is approximately 67.75% above the present share price of $169.9. Joseph expects Novavax to post earnings per share (EPS) of -$2.70 for the first quarter of 2021.
9-Mar-2021 – mAbCo19
https://www.lanazione.it/siena/cronaca/vaccini-e-anticorpi-la-capitale-è-qui-1.6111422
La Nazione - Vaccini e anticorpi La capitale è qui
Rino Rappuoli, chief scientist Gsk e padre degli anticorpi monoclonali di Tls, in questi tempi di Covid è entrato nel Pantheon dei ricercatori più ascoltati. Per il ministro della Salute, Roberto Speranza, per il presidente della Regione Eugenio Giani, per tutti i politici e le istituzioni che hanno visitato i laboratori di Toscana Life Sciences, Rappuoli è l’uomo che può contribuire a debellare un virus che ha piegato il mondo e neutralizzato molte sedicenti superpotenze. Da mesi punta tutto sugli anticorpi. E ora che sono finalmente iniziati i test clinici, Rappuoli ostenta un po’ più di certezze.
9-Mar-2021 – NVX-COV2373
Fox Business - Novavax CEO says 150M COVID vaccine doses can be manufactured per month
Novavax CEO and President Stanley C. Erck joined FOX Business' “Varney and Co.” to discuss the manufacturing capability and efficacy of his company’s two-shot coronavirus vaccine.
9-Mar-2021 – mAbCo19
La Repubblica - Pisa, via ai test degli anticorpi monoclonali AstraZeneca su due giovani volontari. Il professor Menichetti: "Noi i primi in Italia"
Paid content
9-Mar-2021 – GRAd-COV2
La Stampa - Anche a Latina la sperimentazione del vaccino Reithera: si cercano volontari
L' obiettivo è quello di produrre quanto prima il primo vaccino anti-Covid italiano. Così, dopo l'ospedale “Moscati” di Avellino, dalla prossima settimana, anche il Santa Maria Goretti di Latina, ospiterà la fase 2-3 della sperimentazione del vaccino anti-Covid (GrAd-CoV-2) sviluppato dall'azienda ReiThera insieme all'Inmi Spallanzani di Roma.
9-Mar-2021 – GRAd-COV2
Il Caffè - Cercasi volontari per testare vaccino ReiThera e donatori di plasma iperimmune
La lotta contro il covid affila ancora di più le proprie armi grazie alla scienza e alla ricerca. La Asl di Latina sta lavorando in prima linea sin dall’inizio dell’emergenza, ma stavolta fa un passo in più, perché sarà tra i centri italiani dove sarà avviata la sperimentazione del vaccino italiano ReiThera e dalla prossima settimana selezionerà circa 50 volontari.
6-Mar-2021 – GRAd-COV2
La Stampa - Covid, in autunno l’Italia produrrà i vaccini. Inizia la fase 2 della sperimentazione ReiThera
ROMA. Il vaccino italiano inizia la fase 2 della sperimentazione. Entro aprile si concluderà l’immunizzazione dei volontari. La via italiana al vaccino è sostenuta dai finanziamenti statali per ReiThera, secondo il contratto di sviluppo approvato dal consiglio di amministrazione di Invitalia. Per un investimento industriale di ricerca da 81 milioni di euro.
6-Mar-2021 – AZD1222
https://reliefweb.int/report/mali/covid-19-vaccines-arrive-covax-facility-becomes-reality-mali
Reliefweb -COVID-19 vaccines arrive as the COVAX Facility becomes a reality in Mali
Mali has just taken delivery of 396,000 doses of the vaccines against COVID-19. President Bah N’Daw led the official delegation to the international airport in Bamako to take delivery of the consignment.
6-Mar-2021 – AZD1222
https://www.manilatimes.net/2021/03/06/news/govt-races-to-beat-variants-mutations/847813/
The Manila Times - Govt races to beat variants, mutations
The Government is considering the simultaneous rollouts of the coronavirus vaccines of Sinovac and AstraZeneca to head off the growing threat of the virus’ new mutations.
5-Mar-2021 – mAbCo19
Les Echos -Covid : l'étude qui bouleverse nos certitudes sur la résistance du virus
Dans une expérience impressionnante ayant consisté à injecter la souche initiale du coronavirus SARS-CoV-2 dans le sérum riche en anticorps neutralisants d'un ancien malade du Covid-19, une équipe de scientifiques a montré qu'il suffisait de 80 jours à la sélection naturelle pour transformer cette souche initiale en un virus mutant, contre lequel les anticorps sont sans effet.
5-Mar-2021 – mAbCo19
Il Giornale - Monoclonali, via alla sperimentazione clinica. L'ipotesi: "Efficaci anche contro le varianti"
Gli anticorpi monoclonali «made in Italy», realizzati dal team dello scienziato Rino Rappuoli, cominciano finalmente la sperimentazione clinica. Il trial si svolgerà allo Spallanzani di Roma e nel Centro ricerche cliniche di Verona. Infialato dall'Istituto biochimico Giovanni Lorenzini, l'anticorpo «sarà testato, nei prossimi mesi, prima sui volontari sani (fase I) per verificarne la sicurezza, e poi su pazienti positivi al Covid-19 (fasi successive di sviluppo clinico) per l'ottimizzazione della dose e le verifiche di efficacia».
5-March-2021 – AZD1222
Manila Times - AstraZeneca vaccine eyed for senior health workers
Vaccine czar Carlito Galvez Jr. on Thursday said the AstraZeneca’s coronavirus vaccine from the Covax Facility might be allocated to elderly health care workers.
4-Mar-2021 – Covid-eVax
https://telenord.it/a-monza-napoli-e-roma-e-iniziato-studio-clinico-vaccino-italiano-contro-covid-19
Telenord - Vaccino italiano, Bonfanti: "Entro fine anno si concluderà fase due sperimentazione"
A Monza, Napoli e Roma è iniziato studio clinico vaccino italiano contro Covid-19.I primi volontari sani hanno ricevuto la dose iniziale del vaccino a DNA contro COVID-19 denominato COVID-eVax ideato da Takis e sviluppato in collaborazione con Rottapharm Biotech.
4-Mar-2021 – NVX-COV2373
News Medical Life Sciences -Novavax COVID-19 vaccine shows efficacy against South African SARS-CoV-2 variant
Researchers in the United States and South Africa report that the NVX-CoV2373 vaccine from Novavax has proved effective at preventing coronavirus disease (COVID-19) caused by the B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has recently emerged in South Africa.
4-Mar-2021 – mAbCo19
Go News - Covid, via alla sperimentazione clinica per la cura a base di anticorpi monoclonali
L’impegno contro il COVID-19 del Monoclonal Antibody Discovery (MAD) Lab di Fondazione Toscana Life Sciences prosegue con l’avvio degli studi clinici per la verifica della cura a base di anticorpi monoclonali. Toscana Life Sciences Sviluppo annuncia, infatti, che l’anticorpo monoclonale umano MAD0004J08, individuato dal team di ricerca coordinato dal Prof. Rino Rappuoli come il più promettente in risposta all’infezione da SARS-CoV-2, sarà sottoposto ai trial clinici.
4-Mar-2021 – mAbCo19
Corriere della Sera - Anticorpi monoclonali contro il Covid, via ai test sull’uomo in Italia. Rappuoli: «Potrebbero farci guarire in 3-4 giorni»
Dall’estate si potrà forse guarire dal Covid-19 con una semplice iniezione intramuscolare, fatta in ospedale, a casa o dal medico. Una volta che il liquido della fiala sarà iniettato, basteranno tre o quattro giorni per guarire e sconfiggere il Coronavirus.
4-March-2021 – AZD1222
https://pharmaphorum.com/news/germany-backtracks-on-az-covid-vaccine-age-restriction/
Pharma Phorum - Germany backtracks on AZ COVID vaccine age restriction
Germany has decided that AstraZeneca’s COVID-19 vaccine should be approved for use in the over-65s after all, reversing its earlier restriction in that age group.
The country’s drugs regulator previously limited use of the vaccine to the under-65s only, claiming that the data in the older age group was inadequate, even though the European Commission had approved the shot for all adults aged over 18.
3-Mar-2021 – AZD1222
https://en.interfax.com.ua/news/general/727697.html
Interfax Ukraine - Covishield and Oxford-AstraZeneca AZD1222 COVID-19 vaccines identical – UK Ambassador
British Ambassador to Ukraine Melinda Simmons emphasizes that the vaccines for the coronavirus disease COVID-19 Covishield and Oxford-AstraZeneca AZD1222 are identical, since the former is only the licensed name of the latter being produced in India.
2-Mar-2021 – mAbCo19
https://www.tpi.it/cronaca/covid-rino-rappuoli-cellule-monoclonali-intervista-video-20210302750632/
TPI - Ecco l’italiano che ci curerà dal virus: parla Rino Rappuoli | VIDEO
1-Mar-2021 – NVX-COV2373
The Jerusalem Post - Novavax COVID-19 shot could be cleared for U.S. use as early as May -CEO
Novavax Inc's chief executive said on Monday its COVID-19 vaccine could be cleared for use in the United States as soon as May if US regulators authorize it based on data from the company's British trial, which could be completed as soon as April.
1-Mar-2021- NVX-COV2373
Barron’s- Novavax Hopes to Start Supplying Covid Shots This Spring
Covid-19 cases are subsiding, vaccine megasites are opening across the country, and the U.S. government just authorized a third Covid vaccine. But most of America and the world remains unvaccinated, and investors have awarded a $15 billion capitalization to vaccine start-up Novavax, which hopes to seek U.S. authorization for its Covid entrant in the second quarter of 2021.
1-Mar-2021 – GRAd-COV2 and Covid-eVax
Il messaggero - Takis e Reithera, i vaccini italiani a che punto? Test, dosi necessarie, proprietà e tempi
Un centinaio nel mondo i vaccini già in distribuzione e somministrazione o in fase di sperimentazione, ma ora qualcosa si muove anche in Italia, e presto il nostro Paese produrrà vaccini senza doverli acquistare all'estero. La lotta al coronavirus passa dal Lazio, con tre imprese biotecnologiche impegnate sul vaccino: Reithera, Takis e Irbm, le prime due operanti nel distretto tecnologico di Castel Romano, mentre la terza è a Pomezia, nell’ex stabilimento del colosso farmaceutico Merck&Co.
1-Mar-2021 – NVX-COV2373
https://www.ft.com/content/22d3805e-c304-4d95-ae32-f559ff34886a
Financial Times - Novavax closes in on Covid triumph after 33 years of failure
Less than a year before the Covid-19 pandemic ravaged the world, Novavax was facing delisting from the Nasdaq. The pharmaceutical company had poured hundreds of millions of dollars into research and development for vaccines — and yet, at 33 years old, was approaching middle age without a single approved shot.
1-Mar-2021 – GRAd-COV2
India education diary - European Commission Approves €40 Million Italian Aid Measure To Support Coronavirus Related Research And Development Activities
The European Commission has approved a €40 million Italian aid measure to support coronavirus related research and development (R&D) by biotechnology company ReiThera S.r.l. The measure was approved under the State aid Temporary Framework.
1-Mar-2021 – Covid-eVax
https://www.ilcuoioindiretta.it/altre-news/2021/03/01/covid-evax-partita-la-sperimentazione-di-un-nuovo-vaccino-italiano/93293/
Il cuoio indiretta- Covid eVax, partita la sperimentazione di un nuovo vaccino italiano
Durante le prove di laboratorio il vaccino, a dna, ha provocato una forte risposta immunitariasia di tipo anticorpale sia cellulare.
1-Mar-2021
https://www.mbnews.it/2021/03/monza-ospedale-san-gerardo-vaccino-rottapharm-takis-covid/
MB News- Roma, Napoli e Monza per il Vaccino italiano anti Covid, al San Gerardo lo studio clinico
Il vaccino a DNA rappresenta una innovazione rispetto alle altre piattaforme tecnologiche già disponibili, quali quelle a RNA messaggero o a vettore virale. “Il DNA consente di evitare la catena del freddo nella conservazione e nel trasporto” ha dichiarato Luigi Aurisicchio, Amministratore delegato e Direttore Scientifico di Takis. “Per le sue caratteristiche, la produzione dell’antigene è prolungata nel tempo e il vaccino potrebbe funzionare bene già al primo ciclo. Inoltre, se necessario la somministrazione può essere ripetuta più volte per una risposta immunitaria più solida, anche grazie all’impiego della tecnica dell’elettroporazione sviluppata da un’altra azienda italiana, IGEA di Carpi, che facilita l’ingresso del DNA nelle cellule muscolari e funge anche da adiuvante, stimolando quindi i processi immunologici”.
1-Mar-2021 – Covid-eVax
https://www.blogo.it/post/covid-evax-vaccino-italiano-come-funziona
Blogo - COVID-eVax, il vaccino italiano a DNA entra in fase 1. Ecco come funzionerà
Ha preso il via oggi la fase 1 della sperimentazione di un vaccino anti-COVID tutto italiano, COVID-eVax, un vaccino ideato dalla Takis di Castel Romano, in provincia di Roma, e sviluppato in collaborazione con Rottapharm Biotech, con sede a Monza, con una tecnica diversa rispetto a quelle con RNA messaggero, come il vaccino di Pfizer/BioNTech e Moderna o a vettore virale, come quello di AstraZeneca.
26-Feb-2021 – NVX-COV2373
https://www.streetinsider.com/Corporate+News/Novavax+%28NVAX%29%2C+Takeda+%28TAK%29+Finalize+License+Agreement+for+Novavax’+COVID-19+Vaccine+Candidate+in+Japan%3B+Takeda+Initiates+Phase+12+Trial+in+Japan/18041963.html
Street Insider -Novavax (NVAX), Takeda (TAK) Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its collaboration with Takeda Pharmaceutical Company Limited, originally announcedin August. The companies have signed an exclusive license agreement for Takeda’s development, manufacturing and commercialization of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, in Japan. Additionally, Takeda dosed the first participants in a Phase 2 clinical trial to test the immunogenicity and safety of Novavax’ vaccine candidate in the Japanese population.
26-Feb-2021 – NVX-COV2373
https://www.fool.com/investing/2021/02/26/johnson-johnson-vs-novavax-which-vaccine-is-best-a/
The Motley Fool -Johnson & Johnson vs. Novavax: Which Vaccine Is Best Against New Strains?
Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) may soon be sharing the coronavirus vaccine market with two more companies. Johnson & Johnson and Novavax are approaching the finish line in this race. A U.S. Food and Drug Administration (FDA) committee meets today, Feb. 26, to discuss a possible Emergency Use Authorization (EUA) for the Johnson & Johnson candidate. A trial report released this week shows Johnson & Johnson's investigational vaccine fulfilled (and exceeded) efficacy and safety requirements. As for Novavax, the U.S., Europe, the U.K., and Canada have begun rolling reviews of the company's investigational vaccine
25-Feb-2021- GRAd-COV2
https://www.panorama.it/news/salute/reithera-vaccino-covid-sperimentazione
Panorama – sperimentazione in ritardo: il vaccino Reithera slitta a settembre
Era il 26 gennaio, un mese fa. Invitalia annunciava un investimento di 81 milioni di euro per il vaccino italiano Reithera che avrebbe accelerato i tempi per la sperimentazione.
24-Feb-2021 -NVX-COV2373
https://www.biospace.com/article/novavax-s-uphill-battle-to-vaccine-success/
Biospace - Novavax’s Uphill Battle to Vaccine Success
A week ago, Novavax announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to provide 1.1 billion doses of NVX-CoV2373, its COVID-19 vaccine candidate, for the COVAX Facility. The vaccine will be manufactured and distributed around the world by Novavax and Serum Institute of India (SII). SII has an existing deal with Gavi.
24-Feb-2021 – NVX-COV2373
https://www.japantimes.co.jp/news/2021/02/24/national/science-health/novavax-vaccine-japan/
The Japan Times - Takeda starts clinical trial of Novavax COVID-19 vaccine in Japan
Takeda Pharmaceutical Co. said Wednesday it had started a clinical trial of a COVID-19 vaccine developed by U.S. biotechnology firm Novavax Inc. in Japan, planning to domestically produce and supply it in the second half of 2021.
24-Feb-2021 – GRAd-COV2
https://www.ilmattino.it/napoli/cronaca/vaccino_italiano_ceinge_napoli_reithera-5788348.html
Il Mattino - Vaccino italiano, Ceinge di Napoli e Reithera rinnovano l'accordo di collaborazione
ll Ceinge, centro di biotecnologie avanzate di Napoli e ReiThera azienda italiana del tecnolopolo di Poezia che ha in fase di sperimentaaione un vaccino ad adenovirus vettore contro Covid 19 rinnovano la loro ultradecennale collaborazione.
23-Feb-2021 – mAbCo19
La Nazione - Vaccini e anticorpi monoclonali Rappuoli ospite on line del Rotary
A molti non basterebbe un volume, al professor Rino Rappuoli, ad di Gsk Vaccines di Siena e scienziato di caratura internazionale, sono bastate due frasi per fare il punto sulla pandemia e suoi progressi della scienza per combatterla: "Nel 2020 abbiamo combattuto la pandemia con quarantena, distanziamento e igiene, armi che erano in parte già presenti anche nel Medioevo; nel 2021 stiamo provando a riconquistare la libertà grazie a vaccini e anticorpi monoclonali”.
23-Feb-2021 – AZD1222
https://pharmaphorum.com/news/az-covid-jab-efficacy-debate-is-hindering-eus-vaccine-drive/
Pharma Phorum- AZ COVID jab efficacy debate is hindering EU’s vaccine drive
The spat between the EU and AstraZeneca over access to the company’s COVID-19 shot led to scathing remarks about its efficacy that now threaten to undermine the EU’s vaccination targets.
23-Feb-2021 – AZD1222
https://www.pharmacy.biz/mutations-could-make-covid-19-endemic/
Pharmacy Business - ‘Mutations could make Covid-19 endemic’
The recent SARS-CoV-2 virus variant in South Africa (B.1.351) underscores a critical weakness in combatting the Covid-19 epidemic and may prolong it indefinitely, according to the data and analytics company, GlobalData.
23-Feb-2021 – NVX-COV2373
The Wall Street Journal - Novavax Nears Covid-19 Vaccine Game Changer—After Years of Failure
In January of last year, employees of Novavax Inc. met at a local Maryland bar to discuss how they might salvage their careers. For decades, the small biotech had tried to develop an approved vaccine, with no success. The company had enough cash to survive only another six months or so and its shares traded under $4, with a market value of $127 million.
22-Feb-2021 – AZD1222
I Politics - ‘Complicated’ review of AstraZeneca vaccine nearly done: chief medical adviser
Health Canada’s “complicated” review of AstraZeneca’s COVID-19 vaccine is in its final stages, but still requires some “back and forth” between Canada’s regulator and the company, chief medical officer Dr. Supriya Sharma said on Monday.
22-Feb-2021 – mAbCo19
Go news - Covid-19, il punto di Rino Rappuoli a un anno dall'inizio della pandemia
A un anno dall’inizio dell’incubo pandemico, i presidenti Elisabetta Miraldi del Rotary Club Siena e Niccolò Mucerino Bucalossi del Rotary Club Valdelsa hanno voluto fare il punto su i vaccini e gli anticorpi monoclonali nella attuale guerra globale al Covid-19, invitando a una conviviale online il professor Rino Rappuoli, chief scientist e Head External R&D globale di GSK Vaccines e amministratore delegato della GSK Vaccines di Siena e socio onorario del Rotary Siena Est.
22-Feb-2021 – NVX-COV2373
https://www.reuters.com/article/us-health-coronavirus-novavax-idUKKBN2AM17O
Reuters - Novavax completes enrolling 30,000 people in U.S. trial of COVID-19 vaccine
Drug developer Novavax Inc said on Monday it has completed enrolling 30,000 volunteers in a late-stage study of its COVID-19 vaccine in the United States and Mexico.
22-Feb-2021 - AZD1222
https://www.nrc.nl/nieuws/2021/02/22/coronablog-22-februari-a4032690
NRC - AstraZeneca levert de komende twee weken ruim 200.000 minder vaccins
AstraZeneca levert de komende twee weken nog minder coronavaccins aan lidstaten van de Europese Unie dan eerder beloofd. In Nederland lopen 217.000 vaccindoses twee weken vertraging op. Dat heeft het RIVM maandag bekendgemaakt. De vertraging moet op zondag 7 maart goeddeels zijn ingelopen; dan is AstraZeneca van plan 211.000 doses extra te leveren. In januari maakte de Brits-Zweedse farmaceut al bekend in het eerste kwartaal van dit jaar 60 procent minder vaccins te kunnen leveren.
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
Siena Free - Diesse e AchilleS Vaccines insieme per le nuove terapie basate su anticorpi monoclonali
Diesse Diagnostica Senese S.p.a. e AchilleS Vaccines S.r.l. annunciano oggi la firma di un accordo strategico che porterà allo sviluppo congiunto da parte di Diesse, di test quantitativi rapidi di nuova generazione per i terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines.
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
About Pharma - Test per gli anticorpi monoclonali: partnership tra Diesse e AchilleS Vaccines
Un accordo strategico per lo sviluppo di test quantitativi per gli anticorpi monoclonali. È quello siglato tra Diesse Diagnostica Senese e AchilleS Vaccines. A darne notizia è una nota congiunta delle due aziende senesi.
19-Feb-2021 -mAbCo19 and Chorus diagnostic chewing gum
Il giunco - Anticorpi monoclonali: le nuove terapie saranno prodotte in un’azienda di Siena
Diesse Diagnostica Senese e AchilleS Vaccines annunciano oggi la firma di un accordo strategico che porterà allo sviluppo congiunto da parte di Diesse, di test quantitativi rapidi di nuova generazione per i terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines
19-Feb-2021 -mAbCo19 and Chorus diagnostic chewing gum
Toscana 24 -Alleanza senese per i test sugli anticorpi monoclonali
Diesse Diagnostica Senese e AchilleS Vaccines hanno firmato un accordo strategico che porterà allo sviluppo congiunto, da parte di Diesse, di test quantitativi rapidi di nuova generazione per i farmaci terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines. Proprio Av, startup incubata presso Toscana Life Sciences, ha finanziato e coordinato lo sviluppo industriale dell'anticorpo mAbCo19, "arma" anti-Covid sviluppata nel MadLab diretto da Rino Rappuoli.
19-Feb-2021 -GRAd-COV2
https://www.agi.it/cronaca/news/2021-02-19/vaccino-reithera-via-libera-fase-due-11472516/
Agenzia Italia - Via libera alla fase 2 per il vaccino di Reithera
"Sul vaccino ReiThera la novità è che finalmente l'Istituto Superiore di Sanità e l'Aifa ieri hanno dato l'ok alla fase due". Lo ha detto l'assessore alla Sanità della Regione Lazio, Alessio D'Amato, a margine dell'inaugurazione dell'acceleratore lineare per radioterapia presso il Policlinico Tor Vergata di Roma.
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
Siena Free - Diesse e AchilleS Vaccines insieme per le nuove terapie basate su anticorpi monoclonali
Diesse Diagnostica Senese S.p.a. e AchilleS Vaccines S.r.l. annunciano oggi la firma di un accordo strategico che porterà allo sviluppo congiunto da parte di Diesse, di test quantitativi rapidi di nuova generazione per i terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines.
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
Il giunco - Anticorpi monoclonali: le nuove terapie saranno prodotte in un’azienda di Siena
Diesse Diagnostica Senese e AchilleS Vaccines annunciano oggi la firma di un accordo strategico che porterà allo sviluppo congiunto da parte di Diesse, di test quantitativi rapidi di nuova generazione per i terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
Toscana 24 -Alleanza senese per i test sugli anticorpi monoclonali
Diesse Diagnostica Senese e AchilleS Vaccines hanno firmato un accordo strategico che porterà allo sviluppo congiunto, da parte di Diesse, di test quantitativi rapidi di nuova generazione per i farmaci terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines. Proprio Av, startup incubata presso Toscana Life Sciences, ha finanziato e coordinato lo sviluppo industriale dell'anticorpo mAbCo19, "arma" anti-Covid sviluppata nel MadLab diretto da Rino Rappuoli.
19-Feb-2021 -GRAd-COV2
https://www.agi.it/cronaca/news/2021-02-19/vaccino-reithera-via-libera-fase-due-11472516/
Agenzia Italia - Via libera alla fase 2 per il vaccino di Reithera
"Sul vaccino ReiThera la novità è che finalmente l'Istituto Superiore di Sanità e l'Aifa ieri hanno dato l'ok alla fase due". Lo ha detto l'assessore alla Sanità della Regione Lazio, Alessio D'Amato, a margine dell'inaugurazione dell'acceleratore lineare per radioterapia presso il Policlinico Tor Vergata di Roma.
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
Siena Free - Diesse e AchilleS Vaccines insieme per le nuove terapie basate su anticorpi monoclonali
Diesse Diagnostica Senese S.p.a. e AchilleS Vaccines S.r.l. annunciano oggi la firma di un accordo strategico che porterà allo sviluppo congiunto da parte di Diesse, di test quantitativi rapidi di nuova generazione per i terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines.
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
About Pharma - Test per gli anticorpi monoclonali: partnership tra Diesse e AchilleS Vaccines
Un accordo strategico per lo sviluppo di test quantitativi per gli anticorpi monoclonali. È quello siglato tra Diesse Diagnostica Senese e AchilleS Vaccines. A darne notizia è una nota congiunta delle due aziende senesi.
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
Il giunco - Anticorpi monoclonali: le nuove terapie saranno prodotte in un’azienda di Siena
Diesse Diagnostica Senese e AchilleS Vaccines annunciano oggi la firma di un accordo strategico che porterà allo sviluppo congiunto da parte di Diesse, di test quantitativi rapidi di nuova generazione per i terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines
19-Feb-2021 - mAbCo19 and Chorus diagnostic chewing gum
Toscana 24 -Alleanza senese per i test sugli anticorpi monoclonali
Diesse Diagnostica Senese e AchilleS Vaccines hanno firmato un accordo strategico che porterà allo sviluppo congiunto, da parte di Diesse, di test quantitativi rapidi di nuova generazione per i farmaci terapeutici basati su anticorpi monoclonali che verranno sviluppati da AchilleS Vaccines. Proprio Av, startup incubata presso Toscana Life Sciences, ha finanziato e coordinato lo sviluppo industriale dell'anticorpo mAbCo19, "arma" anti-Covid sviluppata nel MadLab diretto da Rino Rappuoli.
19-Feb-2021 -GRAd-COV2
https://www.agi.it/cronaca/news/2021-02-19/vaccino-reithera-via-libera-fase-due-11472516/
Agenzia Italia - Via libera alla fase 2 per il vaccino di Reithera
"Sul vaccino ReiThera la novità è che finalmente l'Istituto Superiore di Sanità e l'Aifa ieri hanno dato l'ok alla fase due". Lo ha detto l'assessore alla Sanità della Regione Lazio, Alessio D'Amato, a margine dell'inaugurazione dell'acceleratore lineare per radioterapia presso il Policlinico Tor Vergata di Roma.
18-Feb-2021 - AZD1222
Bioprocess international - IDT Biologika latest to join AstraZeneca in COVID-19 response
CDMO IDT Biologika will expand its site in Dessau, Germany through a joint investment with AstraZeneca to support the latter’s COVID-19 vaccine.
AstraZeneca has signed a letter of intent with contract development manufacturing organization (CDMO) IDT Biologika to help produce its COVID-19 vaccine, AZD1222.
18-Feb-2021 - NVX-COV2373
Fierce Pharma - Novavax, coronavirus shot data in hand, strikes an eye-popping supply deal with global vaccine consortium
COVID-19 vaccine maker Novavax has at times flown under the radar as some of the world's leading drugmakers dominated headlines and raced toward rollouts. But an eye-popping new supply deal with international players is sure to turn heads.
15-Feb-2021 - NVX-COV2373
https://www.ft.com/content/ceebd562-7b50-427b-932f-40f2adfe5e26
The Financial Times- Novavax to complete US vaccine trial enrollment in record time
Novavax, one of the unexpected success stories of the Covid-19 vaccine race, is about to finish enrolling its US trial in record time, bringing it another step closer to fulfilling orders to inoculate 50m Americans.
15-Feb-2021 – GRAd-COV2
https://whtc.com/2021/02/15/pan-european-consortium-seeks-big-pharma-partner-for-covid-19-shot/
WHTC - Pan-European consortium seeks big pharma partner for COVID-19 shot
A pan-European consortium developing a COVID-19 vaccine is in talks with big pharma to support the late-stage development of its shot and ramp up manufacturing, the head of German biotech firm Leukocare told Reuters.
15-Feb-2021 – AZD1222
https://www.scientias.nl/oxford-vaccin-wordt-nu-ook-onder-kinderen-getest/
Scientias- Oxfordvaccin wordt nu ook onder kinderen getest
Ondertussen zijn er in de Europese Unie drie coronavaccins goedgekeurd: dat van Pfizer/BioNTech, Moderna en Oxford/Astrazenea. Maar in hoeverre werken ze eigenlijk bij kinderen? Dat is wat de makers van het Oxford-vaccin willen uitzoeken. Zij lanceren nu als eerste een studie om de werking van het vaccin onder kinderen en tieners te gaan testen.
13-Feb-2020 – Covid-eVAX
Il Sussidiaro - VACCINO ITALIANO/ Una tecnologia che vale l’immunità di gregge e un punto di Pil
L’Italia è tra i pochi paesi al mondo che può creare e produrre un vaccino completamente in autonomia e senza dipendere dall’estero. A beneficio dell’economia italiana, la produzione di un vaccino in loco, frutto della ricerca nostrana, porterà un punto di Pil in caso di successo.
13-Feb-2021 – GRAd-COV2
The Washington Post - The world needs more vaccines. But an Italian venture to fill the gap is facing novel obstacles.
If all goes according to plan, a small biotech company outside Rome will soon be cranking out millions of coronavirus vaccine doses a month. The company has finished an initial, small-scale trial. It has financial backing from the Italian government. It has an underground production facility so new that it smells of fresh paint.
11-Feb-2021 – AZD1222
Nu.nl - Mensen met ernstig overgewicht krijgen eerder coronavaccin
Mensen die morbide obees zijn, ofwel een BMI van 40 of hoger hebben, krijgen voorrang bij de COVID-19-vaccinatie met het AstraZeneca-vaccin. Ook mensen met het syndroom van Down en mensen die moeilijk kunnen ademhalen krijgen voorrang, zo bevestigt het ministerie van Volksgezondheid, Welzijn en Sport donderdag aan NU.nl na berichtgeving van de Landelijke Huisartsen Vereniging (LHV) en het AD.
11-Feb-2021 – V591
Endpoints news - After purging its own candidates, Merck says it's ready to assist in Covid-19 vaccine production
Days after quashing high hopes of a late but reliable addition to the global Covid-19 vaccine menu, Merck is searching for a way back to the action.
11-Feb-2021 – AZD1222
WHO - The Oxford/AstraZeneca COVID-19 vaccine: what you need to know
The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued interim recommendations for use of the Oxford/AstraZeneca COVID-19 vaccine (AZD1222). This article provides a summary of the interim recommendations; you may access the guidance document here.
11-Feb-2021 – AZD1222
https://edition.cnn.com/world/live-news/coronavirus-pandemic-vaccine-updates-02-11-21/index.html
CNN- WHO Africa encourages use of AstraZeneca vaccine despite variants
The head of the World Health Organization (WHO) in Africa has backed the use of the Oxford/AstraZeneca vaccine against Covid-19 even in countries reporting variants of the disease.
11-Feb-2021 – mAbCo19
Tuttoggi- Anticorpi monoclonali, la cura naturale che neutralizza il Covid | Verso la conclusione il lavoro di Rino Rappuoli
È ormai altissima l’aspettativa sugli sviluppi scientifici che porteranno a brevissimo alla sperimentazione (Trial) su esseri umani degli anticorpi monoclonali studiati e messi a punto dal Toscana Life Sciences di Siena, fondamentale laboratorio di ricerca tutto italiano guidato dal Dott. Rino Rappuoli
11-Feb-2021 – NVX-COV2373
https://www.reuters.com/article/idUSL1N2KH0Q1?edition-redirect=ca
Reuters - EU close to sealing supply deal with Novavax for COVID-19 vaccines - sources
The European Union could sign a supply deal with Novavax this week or next for the U.S. company’s COVID-19 vaccine candidate, two EU officials involved in the talks with the firm said.
9-Feb-2021 – NVX-COV2373
UMB News - Novavax Vaccine Demonstrates Strong Immune Response
The vaccine was found to generate a robust immune response in animals exposed to the vaccine with strong data indicating safety and efficacy, according to the study published recently in the journal Nature Communications. The results have been used to begin testing the vaccine in human trials in the United States with a Phase 3 trial that recently launched at UMSOM’s Center for Vaccine Development and Global Health (CVD).
9-Feb-2021 – NVX-COV2373
https://www.fox5dc.com/video/898571
Fox 5- Update on Novavax COVID vaccine
A top company tells FOX 5 that the Novavax vaccine is more than 95 percent effective against the original strain of the COVID-19 virus.
8-Feb-2021 – AZD1222
FiercePharma - AstraZeneca, Oxford race to update COVID-19 vaccine as study flags weak action against variant
It didn’t take long before a morale boost for AstraZeneca’s COVID-19 vaccine was overshadowed by disappointment over its waned protection against a newly emerged coronavirus variant.
A new study has found AZ’s COVID-19 shot offered “minimal protection” against mild to moderate disease caused by the B.1.351 variant, which was first identified in South Africa, the University of Oxford, the original developer of the vaccine, said Sunday.
8-Feb-2021 – COVID-eVax
Reuters - Italian DNA-based COVID-19 vaccine candidate could start clinical trials in March - developer
Italy’s second COVID-19 vaccine candidate, COVID-eVax, is likely to start trials in early March after it was approved by the national drug regulator last week, one of the biotech firms leading the project said on Monday.
8-Feb-2021 - GRAd-COV2
La Repubblica - Maggiorenne, sano e consapevole: l'identikit del volontario per il vaccino ReiThera in Puglia
Le prime adesioni sono già arrivate. Si tratta di una decina di manifestazioni di interesse spontanee da parte di coloro che vorrebbero sottoporsi alla sperimentazione del vaccino ReiThera che sarà avviata a marzo dall'Asl della provincia di Barletta- Andria- Trani. E a breve, non appena saranno formalizzate le procedure, potrebbero arrivarne molte altre.
8-Feb-2021 - AZD1222
NRC- Zuid-Afrika schort vaccinatie op met AstraZeneca-vaccin
De Zuid-Afrikaanse regering heeft zondag het gebruik van het vaccin van fabrikant AstraZeneca (het ‘Oxford-vaccin’) voorlopig opgeschort. Dat deed ze omdat uit pril onderzoek naar voren komt dat het vaccin nauwelijks lijkt te beschermen tegen infectie met de besmettelijkere Zuid-Afrikaanse variant van het coronavirus, B.1.351. Ook blijkt dat de antistoffen die het vaccin opwekt minder goed werken tegen die variant, die voor het eerst opkwam in dat land en daar nu vrijwel alle besmettingen voor zijn rekening neemt.
8-Feb-2021 - GRAd-COV2
La Repubblica - Maggiorenne, sano e consapevole: l'identikit del volontario per il vaccino ReiThera in Puglia
Le prime adesioni sono già arrivate. Si tratta di una decina di manifestazioni di interesse spontanee da parte di coloro che vorrebbero sottoporsi alla sperimentazione del vaccino ReiThera che sarà avviata a marzo dall'Asl della provincia di Barletta- Andria- Trani. E a breve, non appena saranno formalizzate le procedure, potrebbero arrivarne molte altre.
8-Feb-2021 - AZD1222
NRC- Zuid-Afrika schort vaccinatie op met AstraZeneca-vaccin
De Zuid-Afrikaanse regering heeft zondag het gebruik van het vaccin van fabrikant AstraZeneca (het ‘Oxford-vaccin’) voorlopig opgeschort. Dat deed ze omdat uit pril onderzoek naar voren komt dat het vaccin nauwelijks lijkt te beschermen tegen infectie met de besmettelijkere Zuid-Afrikaanse variant van het coronavirus, B.1.351. Ook blijkt dat de antistoffen die het vaccin opwekt minder goed werken tegen die variant, die voor het eerst opkwam in dat land en daar nu vrijwel alle besmettingen voor zijn rekening neemt.
8-Feb-2021 - GRAd-COV2
La Repubblica - Maggiorenne, sano e consapevole: l'identikit del volontario per il vaccino ReiThera in Puglia
Le prime adesioni sono già arrivate. Si tratta di una decina di manifestazioni di interesse spontanee da parte di coloro che vorrebbero sottoporsi alla sperimentazione del vaccino ReiThera che sarà avviata a marzo dall'Asl della provincia di Barletta- Andria- Trani. E a breve, non appena saranno formalizzate le procedure, potrebbero arrivarne molte altre.
8-Feb-2021 - AZD1222
NRC- Zuid-Afrika schort vaccinatie op met AstraZeneca-vaccin
De Zuid-Afrikaanse regering heeft zondag het gebruik van het vaccin van fabrikant AstraZeneca (het ‘Oxford-vaccin’) voorlopig opgeschort. Dat deed ze omdat uit pril onderzoek naar voren komt dat het vaccin nauwelijks lijkt te beschermen tegen infectie met de besmettelijkere Zuid-Afrikaanse variant van het coronavirus, B.1.351. Ook blijkt dat de antistoffen die het vaccin opwekt minder goed werken tegen die variant, die voor het eerst opkwam in dat land en daar nu vrijwel alle besmettingen voor zijn rekening neemt.
7-Feb-2021 - GRAd-COV2
Siena News- Rappuoli: “Entro la fine del 2021 pandemia sotto controllo ma non tiriamo troppo la corda o si spezza”
“Quanto ci vorrà a fare i vaccini? Questa era la domanda più frequente durante i primi mesi di pandemia. Ebbene, abbiamo battuto tutti i record, a differenza delle aspettative, siamo riusciti a produrre vaccini in 10 mesi”.Queste, le parole di Rino Rappuoli, Chief di Gsk, a margine del convegno virtuale proposto dagli organizzatori di Wine&Siena. Proprio dal padre dei vaccini arriva un messaggio di speranza: “Entro la fine dell’anno avremo controllato la pandemia”.
7-Feb-2021 - GRAd-COV2
Siena News- Rappuoli: “Entro la fine del 2021 pandemia sotto controllo ma non tiriamo troppo la corda o si spezza”
“Quanto ci vorrà a fare i vaccini? Questa era la domanda più frequente durante i primi mesi di pandemia. Ebbene, abbiamo battuto tutti i record, a differenza delle aspettative, siamo riusciti a produrre vaccini in 10 mesi”.Queste, le parole di Rino Rappuoli, Chief di Gsk, a margine del convegno virtuale proposto dagli organizzatori di Wine&Siena. Proprio dal padre dei vaccini arriva un messaggio di speranza: “Entro la fine dell’anno avremo controllato la pandemia”.
7-Feb-2021 - GRAd-COV2
Siena News- Rappuoli: “Entro la fine del 2021 pandemia sotto controllo ma non tiriamo troppo la corda o si spezza”
“Quanto ci vorrà a fare i vaccini? Questa era la domanda più frequente durante i primi mesi di pandemia. Ebbene, abbiamo battuto tutti i record, a differenza delle aspettative, siamo riusciti a produrre vaccini in 10 mesi”.Queste, le parole di Rino Rappuoli, Chief di Gsk, a margine del convegno virtuale proposto dagli organizzatori di Wine&Siena. Proprio dal padre dei vaccini arriva un messaggio di speranza: “Entro la fine dell’anno avremo controllato la pandemia”.
6-Feb-2021 - GRAd-COV2
La Repubblica - Burioni boccia la sperimentazione del vaccino ReiThera in Puglia: "Rischiosa"
Roberto Burioni boccia la sperimentazine del vaccino ReiThera annunciata dall'Asl Bat, che coinvolgerà 40 volontari fra Andria e dintorni nell'ambito di un programma nazionale dell'azienda farmaceutica italiana. Il virologo ha scritto un tweet nel quale spiega che "sottoporre pazienti alla sommistrazione di un vaccino sperimentale è un rischio".
6-Feb-2021 - GRAd-COV2
La Repubblica - Burioni boccia la sperimentazione del vaccino ReiThera in Puglia: "Rischiosa"
Roberto Burioni boccia la sperimentazine del vaccino ReiThera annunciata dall'Asl Bat, che coinvolgerà 40 volontari fra Andria e dintorni nell'ambito di un programma nazionale dell'azienda farmaceutica italiana. Il virologo ha scritto un tweet nel quale spiega che "sottoporre pazienti alla sommistrazione di un vaccino sperimentale è un rischio".
4-Feb-2021 - Covid-eVax
La Repubblica -Il secondo vaccino italiano è pronto per i test. Prodotto da Takis e Rottapharm
Un secondo vaccino italiano è pronto per la sperimentazione sull’uomo. Lo ha messo a punto l’azienda Takis di Castel Romano (Roma), che lavora al suo sviluppo insieme alla Rottapharm Biotech di Monza. L’Aifa, Agenzia italiana del farmaco, ha affidato la richiesta al proprio comitato etico, che darà presto il via libera. Le vaccinazioni di prova potranno partire nel corso del mese e dare risultati in primavera per quanto riguarda la fase uno e in estate per la fase due. I primi 80 volontari sono già stati arruolati in tre ospedali del nord (il san Gerardo di Monza), del centro (lo Spallanzani di Roma) e del sud (l’istituto Pascale di Napoli). “Vogliamo essere un vaccino di tutta l’Italia” sorride Luigi Aurisicchio, amministratore delegato e direttore scientifico di Takis.
29-Jan-2021 – AZD1222
De Telegraaf - Toezichthouder EMA komt met oordeel over derde coronavaccin
Over het vaccin is de laatste tijd veel te doen. De Europese Unie heeft voor dit jaar 400 miljoen doses AZD1222 besteld, waarvan er 11,7 miljoen naar Nederland zouden gaan. Voor eind maart zou AstraZeneca de eerste 80 miljoen doses moeten leveren, waarvan 4,5 miljoen aan Nederland. Tot woede van Brussel zegt de farmaceut nu slechts 31 miljoen doses te kunnen leveren. Dat zou komen door een haperende productie bij een fabriek in Wallonië.
29-Jan-2021 – AZD1222
The Manila Times - AstraZeneca vaccine approved for rollout
The Philippine Food and Drug Administration (FDA) has given Emergency Use Authorization (EUA) to British-Swedish drugmaker AstraZeneca for its coronavirus disease 2019 (Covid-19) vaccine.
29-Jan-2021 – NVX-COV2373
https://www.rtlnieuws.nl/nieuws/nederland/artikel/5211490/corona-covid-vaccin-novavax-effectief
RTL Nieuws - Ook Novavax-vaccin lijkt voor 90 procent effectief
Het vaccin van het Amerikaanse biotechbedrijf Novavax beschermt bij negen op de tien mensen tegen Covid-19, stelt het bedrijf op basis van een klinische test in het Verenigd Koninkrijk. Het is een van de acht vaccins die een rol speelt in de Nederlandse vaccinatiestrategie.
29-Jan-2021 – NVX-COV2373
Het Parool - Ook Novavax claimt coronavaccin met hoge effectiviteit
Het coronavaccin van het Amerikaanse biotechbedrijf Novavax beschermt bij negen op de tien mensen tegen Covid-19, stelt het bedrijf op basis van een klinische test in het Verenigd Koninkrijk. Het middel zou bijna net zo effectief zijn tegen de Britse variant van het virus, zou uit voorlopige resultaten blijken.
29-Jan-2021 -NVX-COV2373
De Volkskrant - Ook Novavax claimt effectiviteit van 90 procent
Het coronavaccin van het Amerikaanse biotechbedrijf Novavax beschermt bij negen op de tien mensen tegen Covid-19, stelt het bedrijf op basis van een klinische test in het Verenigd Koninkrijk. Het middel zou bijna net zo effectief zijn tegen de Britse variant van het virus, zou uit voorlopige resultaten blijken.
29-Jan-2021 – NVX-COV2373
https://edition.cnn.com/2021/01/29/europe/novavax-covid-vaccine-uk-sa-trials-gbr-intl/index.html
CNN- Novavax says Covid-19 vaccine is 89% effective in UK trial, but less so in South Africa
A new Covid-19 vaccine from Novavax was found to be 89.3% effective in a clinical trial conducted in the UK and appears to offer protection against some variants of the coronavirus, the American biotech firm has announced.
29-Jan-2021 – NVX-COV2373
New Scientist - Novavax coronavirus vaccine found 89 per cent effective in trials
A coronavirus vaccine developed by the US firm Novavax has been shown to be 89 per cent effective in preventing covid-19 in phase III clinical trials. The vaccine is made from nanoparticles containing spike proteins from the virus, which are produced by genetically modified insect cells. The nanoparticles cannot replicate or cause covid-19, but they enable the body’s immune system to recognise the viral proteins and make antibodies against them.
29-Jan-2021 – NVX-COV2373
Times of India - Serum Institute applies to conduct local trial for Novavax Vaccine
29-Jan-2021 – NVX-COV2373
https://www.timesofisrael.com/novavax-says-its-vaccine-appears-96-effective-but-less-so-against-variants/
The times of Israel - Novavax says its vaccine appears 96% effective, but less so against variants
Novavax Inc. said Thursday that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well — against new mutated versions of the virus circulating in that country and South Africa.
29-Jan-2021 – AZD1222
https://www.dvhn.nl/extra/Coronavaccin-AstraZeneca-krijgt-positief-oordeel-van-Europese-medicijnwaakhond-maar-nog-altijd-discussie-over-de-levering-26446919.html
Dagblad van het Noorden - Coronavaccin AstraZeneca krijgt positief oordeel van Europese medicijnwaakhond (maar nog altijd discussie over de levering)
Het Europees Geneesmiddelenbureau (EMA) is positief over het coronavaccin dat AstraZeneca en de Universiteit van Oxford hebben ontwikkeld. Daarmee is de weg vrij voor de Europese Commissie om het middel toe te laten. Het is het derde vaccin dat een positief oordeel van de toezichthouder krijgt.
29-Jan-2021 – NVX-COV2373
Bloomberg - Novavax Sees U.K. Vaccine Approval First; in Talks With FDA
A new Covid-19 vaccine from Novavax Inc. is likely to get its first approval in the U.K., and the company is discussing with U.S. regulators whether trial data from other countries could be part of the shot’s review, Chief Executive Officer Stan Erck said.
28-Jan-2021 – AZD1222
https://wnl.tv/2021/01/28/nederland-heeft-bijna-12-miljoen-doses-besteld-bij-astrazeneca/
WNL - Nederland heeft bijna 12 miljoen doses besteld bij AstraZeneca
De farmaceut AstraZeneca lag vorig jaar ruim op kop in de race om als eerste een coronavaccin op de markt te brengen. Voor het kabinet was dat aanleiding om alvast een grote bestelling te doen. Nederland zou in de loop van dit jaar 11,7 miljoen doses van het middel AZD1222 krijgen, waarvan 4,5 miljoen al voor eind maart. Van dat optimisme is nu weinig over: AstraZeneca is afgetroefd door twee rivalen, kan waarschijnlijk minder leveren dan verwacht en tot overmaat van ramp is niet duidelijk of het middel wel genoeg werkt bij ouderen, terwijl dat nou juist de meest kwetsbare groep is.
28-Jan-2021 – NVX-COV2373
Novavax-coronavaccin heeft volgens farmaceut effectiviteit van 90 procent
Nu.nl - Het coronavaccin van het Amerikaanse biotechbedrijf Novavax beschermt negen op de tien mensen tegen het coronavirus, stelt het bedrijf op basis van een klinische test in het Verenigd Koninkrijk. Het middel zou bijna net zo effectief zijn tegen de Britse variant van het virus, beweert het bedrijf op basis van de recentste onderzoeksresultaten.
28-Jan-2021 – NVX-COV2373
https://www.ft.com/content/1978fc50-99f0-4aab-88cb-15dd1ba14c95
Financial Times - Novavax’s Covid-19 vaccine shown to be 89% effective
Novavax’s Covid-19 vaccine is 89 per cent effective and works against new variants of the virus, according to interim data published from clinical trials in the UK and South Africa.
28-Jan-2021 – NVX-COV2373
Forbes - Novavax Covid Vaccine Is Highly Effective Against U.K. Variant But Struggled In South Africa, Data Shows
A Covid-19 vaccine candidate from Novavax offers strong protection against a more contagious coronavirus variant first discovered in the United Kingdom, but it’s somewhat less effective against a rapidly spreading mutation from South Africa, according to early data released Thursday, marking the latest vaccine to face some efficacy issues as new strains of the virus evolve.
28-Jan-2021 – NVX-COV2373
https://www.telegraaf.nl/nieuws/1458711489/live-novavax-claimt-coronavaccin-met-hoge-effectiviteit
De Telegraaf - Novavax claimt coronavaccin met hoge effectiviteit
Ook nu er een begin is gemaakt met vaccineren, blijft het uit China overgewaaide coronavirus mondiaal voor ontwrichting zorgen. De besmettingen en ziekenhuiscijfers zijn in Nederland nog niet extreem, maar de mutanten baren zorgen. De Britse variant houdt op het ’eiland’ flink huis en ook de Braziliaanse en Zuid-Afrikaanse zijn in aantocht. Tegelijkertijd zuchten economie en maatschappij onder verstikkende maatregelen. Volg in dit live-blog het laatste coronanieuws
27-Jan-2021 – AZD1222
https://www.spektrum.de/news/astrazeneca-impfstoff-verwirrung-um-die-wirksamkeit-von-azd1222/1824223
Spektrum- Verwirrung um die Wirksamkeit des AstraZeneca-Impfstoffs
Über 65-Jährige sollen durch den Impfstoff von AstraZeneca (AZD1222) nur unzureichend geschützt sein. Bei ihnen solle die Wirkung nur bei rund acht Prozent liegen. Diese Behauptung war kürzlich in diversen Medienberichten zu lesen. Zwar werde weiterhin damit gerechnet, dass das Mittel in der Europäischen Union zugelassen wird – es sei jedoch möglich, dass es für besagte Altersgruppe nicht in Frage kommt, hieß es etwa im »Handelsblatt« weiter.
27-Jan-2021- GRAd-COV2
https://www.ilfattoquotidiano.it/2021/01/27/reithera-palu-aifa-dopo-settembre-alcune-milioni-di-dosi-del-vaccino-italiano-speranza-giusto-entrare-nel-capitale-con-soldi-pubblici/6079852/
Il Fatto Quotidiano - Reithera, Palù (Aifa): “Dopo settembre alcune milioni di dosi del vaccino italiano”. Speranza: “Giusto entrare nel capitale con soldi pubblici”
Perché il vaccino di Reithera sia disponibile, ha detto il presidente dell'Agenzia italiana del farmaco, "ci vorrà ancora qualche mese" perché "è stata appena conclusa la fase 1". Quindi ha specificato: "Non sarà utile in questa fase critica, ma sicuramente più avanti"
27-Jan-2021 – GRAd-COV2
https://www.thelocal.it/20210127/covid-19-italian-reithera-vaccine-set-to-be-available-from-september
The Local- Covid-19: Italian ReiThera vaccine set to be available from September
A Covid-19 vaccine developed by Italian company ReiThera is expected to be available from September, Italian pharmaceutical agency AIFA said on Wednesday.
26-Jan-2021 – AZD1222
https://www.mdr.de/wissen/corona-impfung-astrazeneca-vektor-virus-100.html
Mitteldeutscher Rundfunk - ASTRAZENECA-IMPFSTOFF: NICHT GEEIGNET FÜR MENSCHEN ÜBER 65?
Am kommenden Freitag entscheidet die EMA über die Zulassung des Corona-Impfstoffs von AstraZeneca und schon vorher gibt es Konflikte. Denn es gibt Lieferschwierigkeiten und Vorwürfe, dass die Impfung bei älteren Menschen nicht wirken würde. Seine Funktionsweise ist anders, als die der schon zugelassenen mRNA-Vakzine.
25-Jan-2021- GRAd-COV2
https://www.meteo.it/notizie/vaccino-italiano-spallanzani-reithera-6900fe3c
Meteo - A che punto siamo con il "vaccino italiano" di Spallanzani e ReiThera
È stato annunciato a inizio gennaio il successo della prima fase di sperimentazione, ma restano ancora diversi aspetti da definire
25-Jan-2021 – mABCo19
Il tirreno - Super farmaco anti-Covid, Rappuoli: "Sarà pronto tra aprile e maggio"
"Il farmaco" anti Covid a base di anticorpi monoclonali "è infialato e pronto per le prove cliniche, e con leggerissimo ritardo dovrebbe essere a disposizione per aprile/maggio". Lo annuncia, nel corso di un evento on line, il professor Rino Rappuoli a capo dell'equipe che nei laboratori senesi della Fondazione Toscana Life Sciences sta lavorando a una terapia anti Covid.
23-Jan-2021 – NVX-COV2373
https://www.entrepreneur.com/article/363991
The entrepreneur - Curevac and Novavax Vaccines Against Covid-19 Will Begin Phase 3 in Mexico
The Secretary of Foreign Affairs, Marcelo Ebrard , shared on his Twitter account that the CUREVAC (German) and Novavax (USA ) vaccines would start phase 3 in Mexico and that the necessary doses for this will arrive next week.
21-Jan-2021 – AZD1222
Der Spiegel - Größter Impfstoffhersteller der Welt meldet Fabrikbrand
In Indien steht ein Produktionsstandort des Serum Institute in Flammen, das auch den Corona-Impfstoff von AstraZeneca herstellt. Laut Firmenangaben soll das Feuer aber keine Folgen für die Produktion haben.
21-Jan-2021 – AZD1222
Bioprocess international - Oxford vaccine fill-finish site threatened by severe floods
Storm Christopher has caused – and continues to cause – severe damage across North Wales, and yesterday hit a facility producing the Oxford-AstraZeneca vaccine (AZD1222) run by Wockhardt UK.
22-Jan-2021 – NVX-COV2373
The Sydney Morning Herald - Sydney startup to help vaccine hopeful Novavax roll out jab
Multibillion-dollar US vaccine maker Novavax has selected a Sydney company to help it secure approval for its coronavirus vaccine and plan for its Australian rollout, in a significant boost for the local biotech sector.
20-Jan-2021 – NVX-COV2373
https://www.fiercepharma.com/vaccines/novavax-sees-covid-vaccine-trial-dropout-as-pfizer-moderna-shots-rollout-gears-up
Fierce Pharma - Novavax sees some COVID-19 vaccine trial dropout as Pfizer, Moderna rollouts gear up
As more supplies of Pfizer-BioNTech and Moderna’s authorized COVID-19 vaccines arrive, many states are expanding their reach beyond the elderly and into the 65-plus crowd. That broader rollout has created some problems for clinical trials of other experimental shots.
18-Jan-2021 – Covivaxx
Hindustan times - SII to dispatch Covishield to multiple countries by month-end
The city-based Serum Institute of India (SII), largest vaccine manufacturer, has provided 11 million Covishield doses to the central government
16-Jan-2021 – AZD1222
https://www.enca.com/news/oxford-scientists-how-we-developed-our-covid-19-vaccine-record-time
ENCA- Oxford scientists: how we developed our COVID-19 vaccine in record time
The pandemic is only a year old, but we already have multiple vaccines available to fight COVID-19 – including the vaccine developed by the team we’re part of at the University of Oxford.
18-Jan-2021- AZD1222
Der Standard- Kurz will rasche Zulassung von Astra-Zeneca-Impfstoff, doch es gibt noch Unklarheiten
In Brüssel herrscht Sorge, ob jenes Vakzin, mit dem man die breite Bevölkerung gegen Covid-19 impfen will, auch für über 55-Jährige zugelassen wird. Dazu kommen Lieferengpässe bei Pfizer
17-Jan-2021 - mAbCo19
Corriere della sera - Covid e variante brasiliana, Rappuoli: «Sono possibili reinfezioni, ma i vaccini dovrebbero difenderci»
L’11 gennaio scorso il ministro della Salute del Giappone ha annunciato di aver isolato una nuova variante di Sars-CoV-2 in 4 persone arrivate dal Brasile. L’ultima, in ordine di tempo. Sabato 16 gennaio l’Italia ha deciso di bloccare i voli da quel Paese, dopo che questa variante (qui tutti i dettagli) ha aggravato la già pesante situazione della pandemia in Brasile (raccontata qui).
17-Jan-2021 - AZD1222
https://www.thenews.com.pk/print/775576-oxford-astrazeneca-s-covid-19-vaccine-allowed-in-pakistan
The news international -Oxford-Astrazeneca’s Covid-19 vaccine allowed in Pakistan
The Drug Regulatory Authority of Pakistan (DRAP) on Saturday gave emergency use authorization to Oxford-Astrazeneca’s AZD1222 in Pakistan following recommendations by a six-member panel of health experts. A private firm has been allowed to import the COVID-19 vaccine in the country.
16-Jan-2021 - AZD1222
https://www.enca.com/news/oxford-scientists-how-we-developed-our-covid-19-vaccine-record-time
ENCA - Oxford scientists: how we developed our COVID-19 vaccine in record time
The pandemic is only a year old, but we already have multiple vaccines available to fight COVID-19 – including the vaccine developed by the team we’re part of at the University of Oxford.
15-Jan-2021- mAbCo19
Abruzzo live - Coronavirus, Rappuoli: su anticorpi gli Usa sono avanti. Per Trump usati 8 grammi, nostre dosi inferiori
L’Aquila. Sugli anticorpi monoclonali le americane Eli Lilly e Regeneron “sono più avanti. Non hanno ancora avuto l’approvazione definitiva, ma la Fda ha dato l’ok per l’emergency use, più o meno l’equivalente del nostro uso compassionevole. Noi invece iniziamo in febbraio la fase 1 e saremo pronti tra aprile e maggio. Prima di giugno potremmo avere l’approvazione”. Lo ha detto all’ANSA Rino Rappuoli, direttore scientifico di Gsk Vaccines e coordinatore della ricerca sugli anticorpi di Toscana Life Sciences.
15-Jan-2021 - NVX-COV2373
Fox21 - U Of M Medical School Participating In Novavax Phase 3 Trials
Clinical trials for Phase 3 of the Novavax COVID-19 vaccine are starting soon.The University of Minnesota Medical School is one of a hundred institutions participating in the study. Medical researchers say after undergoing the first two stages of clinical trials, Novavax vaccine shows promise.
13-Jan-2021 -NVX-COV2373, AZD1222
7 News- What are Australia's COVID-19 vaccines, and when will they be available?
Australians will start to be vaccinated against coronavirus in February, following new advice provided to the federal government. Australia has entered into four separate agreements for the supply of COVID-19 vaccines if they are proven safe and effective
13-Jan-2021- NVX-COV2373
https://www.sueddeutsche.de/politik/coronavirus-weltweit-neuinfektionen-usa-1.5170366
Süddeutsche Zeitung - 226 954 neue Infektionen in den USA
Die EU-Arzneimittelbehörde will bis Ende Januar über Astra-Zeneca-Impfstoff entscheiden.
13-Jan-2021 – mAbCo19
Intoscana - La ricerca contro il Covid-19: dalle Coop in arrivo 1 milione e mezzo di euro per i monoclonali
L’obiettivo era raccogliere 1 milione e mezzo di euro ed è stato superato in poco più di un mese: dal 1 dicembre del 2020 al 10 gennaio sono 150mila le persone che hanno contribuito alla raccolta fondi a sostegno della terapia contro il Covid-19 basata sugli anticorpi monoclonali della Fondazione Toscana Life Sciences.
13-Jan-2021 – mAbCo19
Siena News - Covid, Rappuoli: “Monoclonali e vaccini efficaci contro le varianti inglese e sudafricana”
“Credo che i vaccini e gli anticorpi monoclonali riescano a contenere sia la variante inglese che la variante sudafricana del coronavirus”. Lo ha detto il coordinatore del Mad Lab di Tls Rino Rappuoli durante la conferenza per presentare i risultati della campagna di raccolta fondi promossa da Unicoop Firenze, Coop Alleanza 3.0, Coop Centro Italia, Unicoop Tirreno, Coop Unione Amiatina e Coop Reno a favore della ricerca scientifica della Fondazione Toscana Life Sciences.
12-Jan-2021 – AZD1222
RND - Astra Zeneca: Das ist über den Corona-Impfstoff AZD1222 bekannt
Der britisch-schwedische Arzneimittelkonzern Astra Zeneca hat die Zulassung seines Corona-Impfstoffs in der Europäischen Union (EU) beantragt. Wird das vom Pharmaunternehmen und der Universität in Oxford gemeinsam entwickelte Vakzin genehmigt, wäre es das dritte zugelassene Präparat gegen Covid-19 in der EU. Anders als bei den bisher zugelassenen Vakzinen handelt es sich dabei nicht um einen mRNA-Impfstoff. Und auch in vielen anderen Aspekten unterscheidet sich der Impfstoff AZD1222 von den Präparaten von Biontech/Pfizer und Moderna.
12-Jan-2021 – AZD1222
https://www.gelbe-liste.de/nachrichten/zulassungsantrag-azd1222-astrazeneca
Gelbe Liste - Zulassungsantrag für AZD1222 in EU
Die EMA gab heute bekannt, dass sie einen Antrag auf bedingte Zulassung für das Inverkehrbringen des von AstraZeneca und der Universität Oxford entwickelten Corona-Impfstoffs erhalten hat. Seit Anfang Oktober 2020 befindet sich der Impfstoff im „Rolling-Review“-Verfahren der EMA.
12-Jan-2021 – AZD1222
Free press journal - 'Covishield' FAQ: Serum Institute answers all your queries ahead of COVID-19 vaccination drill
Ahead of the nationwide inoculation exercise against coronavirus disease (COVID-19) across India, the Serum Institute has issued a fact-sheet to answer all the Frequently Asked Questions (FAQs) that vaccine beneficiaries might have in preparation of the drill.
11-Jan-2021 -mAbCo19
https://www.lanazione.it/siena/cronaca/sicurezza-vaccino-covid-1.5902398
La Nazione - Vaccini antiCovid, Rappuoli: "Sulla sicurezza fatti più test del solito"
Nonostante i tempi estremamente rapidi nella sperimentazione dei vaccini anti-Covid, "la quantità di test eseguiti è stata superiore a quelli fatti abitualmente per gli altri vaccini".
11-Jan-2021 – NVX-COV2373
Forbes - Moderna Releases Details Of New Vaccine Deals While Novavax Moves To Phase 3
Novavax, a tiny Maryland-based biotech firm, is hoping 2021 is the year it will reach the major leagues in the global race for a Covid-19 vaccine. While Pfizer, its partner BioNTech, and Moderna received the first vaccine authorizations with mRNA technology, Novavax is hot on their heels with a different option.
11-Jan-2021 – NVX-COV2373
Howard University Newsroom - RECRUITMENT FOR THE HOWARD UNIVERSITY CLINICAL TRIAL IS NOW OPEN TO THE PUBLIC
Howard University announces its participation as a Phase 3 COVID-19 clinical trial site to evaluate the safety and effectiveness of a new coronavirus vaccine developed by Maryland-biotechnology company, Novavax.
11-Jan-2021 – NVX-COV2373
The Economic Times - EU seeks more Moderna COVID-19 vaccines, eyes deals with Valneva, Novavax
The European Union is in talks with Moderna to order more of its COVID-19 vaccine despite the company seeking a higher price, and is also trying to close COVID-19 vaccine deals with Valneva and Novavax, according to two EU officials and an internal document.
10-Jan-2021 – NVX-COV2373
Channel News Asia - Philippines secures 30 million Novavax COVID-19 vaccine doses
The Philippines has secured 30 million doses of a COVID-19 vaccine developed by US drug maker Novavax, officials said Sunday (Jan 10), as the country braces for a surge in infections after a huge religious event.
10-Jan-2021 – mAbCo19
Il Tirreno - Nel laboratorio toscano del super farmaco anti-Covid: i segreti dell'anticorpo J-08, i test sull'uomo e quando sarà pronto
Siena, il team di Rappuoli ha trovato i monoclonali più potenti per mettere a punto una terapia con cui sconfiggere il Coronavirus: come funziona e le previsioni sull'arrivo negli ospedali
8-Jan-2021 – AZD1222
https://www.nytimes.com/interactive/2020/health/oxford-astrazeneca-covid-19-vaccine.html
The New York Times - How the Oxford-AstraZeneca Vaccine Works
The University of Oxford partnered with the British-Swedish company AstraZeneca to develop and test a coronavirus vaccin known as ChAdOx1 nCoV-19 or AZD1222. A clinical trial revealed the vaccine was 62 to 90 percent effective, depending on the initial dosage. Despite some uncertainty over trial results, Britain authorized the vaccine for emergency use in December, and India authorized a version of the vaccine called Covishield on January 3, 2021.
7-Jan-2021 – NVX-COV2373
News4SA- UT Health looking for participants in Phase 3 Novavax COVID vaccine trial
People living in San Antonio will now have the opportunity to participate in the Phase 3 trial for the Novavax COVID-19 vaccine. UT Health and University Health says they started enrolling the first participants Thursday afternoon. They hope to enroll 500 people locally.
7-Jan-2021 – NVX-COV2373
News4Jax- Jacksonville clinical research center begins trials on another COVID-19 vaccine
While the Pfizer and Moderna COVID-19 vaccines continue to be administered across the United States under an emergency authorization status, the Jacksonville Center for Clinical Research has just begun clinical trials for the Novavax vaccine.
7-Jan-2021 – GRAd-COV2
https://tg24.sky.it/salute-e-benessere/2021/01/07/reithera-vaccino-italiano-covid
Sky Tg24- Reithera, Sky TG24 nella fabbrica del vaccino italiano anti-Covid.
L’azienda specializzata in biotecnologie, con sede alle porte di Roma, sta lavorando sul vaccino anti-Covid GRAd-CoV2, che rappresenta la risposta italiana ai vaccini di Pfizer e di Moderna. Dopo la fase 1 di sperimentazione “il vaccino Reithera ha dimostrato di essere sicuro e di avere capacità di indurre risposta immunitaria”, come confermato da Giuseppe Ippolito, direttore scientifico dell'Ospedale Spallanzani di Roma
6-Jan-2021 – NVX-COV2373
Barron’s -Novavax Has Covid-19 Vaccine News Coming Out Soon. That Could Be Good for the Stock.
Covid-19 vaccine makers Moderna and Pfizer are rushing to supply enough vaccine doses to staunch the pandemic’s still-climbing global death toll. Biotech company Novavax may be able to provide a glimmer of hope early this quarter, when data from its first Phase 3 trial of its Covid-19 vaccine is expected to be released.
6-Jan-2021 – AZD1222
Biopharma reporter – Oxford-AstraZeneca COVID-19 vaccine granted emergency use authorization in multiple countries
AstraZeneca officially announced today the Serum Institute of India had obtained emergency use authorization in India for its COVID-19 vaccine.
6-Jan-2021 -GRAd-COV2
Huffpost - ReiThera, prime consegne vaccino italiano entro fine del 2021
“L’obiettivo è quello di concludere la sperimentazione entro l’estate, per poi presentare la richiesta di autorizzazione alle agenzie regolatorie. Ovviamente per fare tutto questo servono le risorse”. Così la presidente di ReiThera Antonella Folgori, l’azienda del vaccino Made in Italy, su La Stampa.
6-Jan-2021 – mAbCo19
https://www.repubblica.it/salute/2021/01/06/news/covid_i_guariti_non_sono_immuni_al_virus_mutato-281310046/
La Repubblica - Covid, cosa succede quando i guariti incontrano il virus mutato
L’immunità naturale, quella sviluppata dopo aver superato la malattia, potrebbe non proteggere da una seconda infezione se Sars-Cov-2 è mutato. Lo dimostra uno studio condotto dal gruppo di Rino Rappuoli. Attenzione, però: è un lavoro in laboratorio e non si riferisce alle persone vaccinate
6-Jan-2021 – GRAd-COV2
https://www.lagone.it/2021/01/06/ben-tollerato-e-sicuro-positivi-i-primi-giudizi-sul-vaccino-italiano-rei-thera/
Lagone - “ben tollerato e sicuro”. positivi i primi giudizi sul vaccino italiano rei thera
Lusinghieri gli esiti della prima fase di sperimentazione. “Oltre il 94% dei soggetti nella fascia d’età 18-55 anni vaccinati con una sola dose ha prodotto anticorpi, ed oltre il 90% ha sviluppato anticorpi con potere neutralizzante nei confronti del virus”.
6-Jan-2021 - GRAd-COV2
https://www.ilmessaggero.it/video/salute/vaccino_italiano_reithera_puntiamo_100_milioni_di_dosi-5682572.html
Il Messagero - Codiv, vaccino italiano Reithera: «Puntiamo a 100 milioni di dosi»
«Puntiamo a sviluppare 100 mln dosi di vaccino per anno. Il vaccino è stabile ad una temperatura tra 2 e 8 gradi». Lo ha detto la presidente dell'azienda Reithera sviluppatrice del vaccino italiano, Antonella Folgore, alla presentazione dei risultati della Fase 1 della sperimentazione del Vaccino GRAd-CoV2
6-Jan-2021- GRAd-COV2
https://www.ilmessaggero.it/video/salute/vaccino_reithera_arcuri_giornata_importante_italia_punta_indipendenza-5682594.html
Il Messagero- Vaccino ReiThera, Arcuri: «Giornata importante, Italia punta a indipendenza»
«È una giornata molto importante. In una situazione come questa dobbiamo cercare di dipendere il meno possibile degli altri e produrre in maniera propria. In queste settimane dipendiamo completamente da vaccini stranieri e combattiamo per avere il maggior numero possibile di vaccini, ma l'Italia punta all'indipendenza». Così il commissario straordinario per l'emergenza COVID-19, Domenico Arcuri, durante la conferenza stampa sugli esiti e risultati della Fase 1 della sperimentazione del vaccino ReiThera GRAd-CoV2. «Il governo ha destinato una quantità di risorse sufficienti per lo sviluppo successivo di Reithera ed entrerà nel capitale dell'azienda per la successiva fase 2 e fase 3. L'azienda ha già presentato una proposta di investimento», ha aggiunto Arcuri.
6-Jan-2021 – GRAd-COV2
https://www.mondopalermo.it/news/il-vaccino-italiano-reithera-e-monodose-e-si-conserva-tra-2-e-8-gradi/
Mondo Palermo - IL VACCINO ITALIANO REITHERA È MONODOSE E SI CONSERVA TRA 2 E 8 GRADI
Ieri all’Istituto Spallanzani di Roma sono stati presentati i risultati della prima fase di sperimentazione del GRAd-COV2, il vaccino italiano prodotto dalla ReiThera di Castel Romano. Erano presenti il commissario straordinario per l’emergenza Covid, Domenico Arcuri e il presidente del Consiglio superiore di sanità (ISS), Franco Locatelli. Si tratta di un vaccino monodose che si conserva ad una temperatura tra i 2 e gli 8 gradi. L‘obiettivo produttivo stimato è di cento milioni di dosi all’anno. Nei soggetti a cui è stato inoculato nella prima fase di sperimentazione sull’uomo, non c’è stato nessun effetto indesiderato o grave.
6-Jan-2021 – AZD1222
https://indianexpress.com/article/india/coronavirus-vaccination-drive-icmr-covaxin-bharat-biotech-7134363/
The Indian Express - Ready for vaccination within 10 days of approval: Ministry
The Union Health Ministry said on Tuesday that stakeholders at the Centre and states were prepared to roll out the mass immunisation programme against Covid-19 within 10 days of the vaccines getting approval.The decision on rolling out India’s biggest adult vaccination drive will, however, be taken by the central government, it said.
5-Jan-2021 – mAbCo19
https://www.lanazione.it/siena/cronaca/mano-tesa-da-unicoop-fi-al-mad-lab-della-fondazione-tls-1.5879751
La Nazione - Mano tesa da UniCoop.Fi al Mad Lab della Fondazione Tls
Uniti nel sostenere i ricercatori del Mad Lab della Fondazione Toscana Life Sciences di Siena, coordinato dal professor Rino Rappuoli, scienziato di fama mondiale. Il noto laboratorio da marzo scorso ha indirizzato le proprie competenze nell’individuazione di anticorpi monoclonali umani capaci di curare il Covid-19.
5-Jan-2021 – GRAd-COV2
https://www.lacnews24.it/italia-mondo/reithera-il-vaccino-anticovid-italiano-e-efficace-come-pfizer-e-moderna_129792/
LACnews24 - ReiThera, il vaccino anti-Covid italiano «è efficace come Pfizer e Moderna»
Il vaccino italiano anti-Covid prodotto da ReiThera è efficace come quello di Pfizer e Moderna. A dirlo il direttore scientifico dell’Inmi Spallanzani di Roma, Giuseppe Ippolito, che ha presentato i risultati della Fase 1 della sperimentazione della cura contro il Covid-19.
5-Jan-2021 – GRAd-COV2
https://www.reuters.com/article/us-health-coronavirus-italy-reithera/italy-to-invest-in-biotech-reithera-to-support-covid-19-vaccine-development-idUSKBN29A17V
Reuters - Italy to invest in biotech ReiThera to support COVID-19 vaccine development
Italy will invest in local biotech company ReiThera to support the development of its COVID-19 vaccine, a senior official said on Tuesday after the government called results of a Phase 1 trial encouraging.
5-Jan-2021- GRAd-COV2
https://uk.reuters.com/article/health-coronavirus-italy-reithera/update-1-italy-to-invest-in-biotech-reithera-to-support-covid-19-vaccine-development-idUKL8N2JG2MB
Reuters- Italy to invest in biotech ReiThera to support COVID-19 vaccine development
Italy will invest in local biotech company ReiThera to support the development of its COVID-19 vaccine, a senior official said on Tuesday after the government called results of a Phase 1 trial encouraging.
4-Jan-2021 – AZD1222
http://www.koreaherald.com/view.php?ud=20210104000871
The Korea Herald - Korea begins approval process for AstraZeneca vaccine
AstraZeneca’s COVID-19 vaccine (AZD1222) will be reviewed for potential approval in South Korea within the next 40 days, Korea’s Ministry of Food and Drug Safety announced Monday
4-Jan-2021 – AZD1222
https://www.zenopa.com/news/2856/vaccine-developers-respond-to-remarks-regarding-their-vaccines-effectiveness-against-the-new-strain-of-covid
Zenopa - Vaccine developers respond to remarks regarding their vaccines' effectiveness against the new strain of Covid
Several vaccine developers have responded to remarks regarding their vaccines' effectiveness against the new strain of COVID-19. Ugur Sahin, BioNTech Chief Executive Officer, whose Pfizer partnered vaccine has been approved in the UK, US and EU, believes the vaccine will continue to work against the new strain.
1-Jan-2021 -AZD1222
https://www.hindustantimes.com/india-news/sii-s-covishield-approval-efficacy-cost-and-all-about-astrazeneca-s-covid-19-vaccine/story-2XrMT3hOEfuMhDOi4GViOK.html
Hindustan Times - SII’s Covishield approval: Efficacy, cost and all about AstraZeneca’s Covid-19 vaccine
A government’s expert panel has reportedly approved the vaccine, developed by AstraZeneca and Oxford University, for emergency use in India to provide immunity against the coronavirus disease (Covid-19). According to news agency Reuters, a subject expert committee, set up by Drugs Controller General of India (DCGI) to vet Covid-19 vaccine proposals, recommended granting emergency use authorisation to AstraZeneca’s vaccine AZD1222, dubbed in India as Covishield.
1-Jan-2020 – AZD1222
https://www.indiatvnews.com/news/world/coronavirus-oxford-astrazeneca-covid-19-vaccine-serum-institute-covishield-all-you-need-to-know-675389
India TV- Here's what you need to know about Oxford Covid-19 vaccine
With the UK giving the green light to the Covid-19 vaccine developed by Oxford University and drugmaker AstraZeneca, India is also expected to follow suit soon as a meeting of the decision-making body began on Friday, giving new hope of beginning the end of the pandemic as the New Year ushers in.
31-Dec-2020 – AZD1222
https://www.biospace.com/article/warp-speed-head-slaoui-predicts-astrazeneca-vaccine-won-t-be-used-in-the-u-s-until-april/
Biospace- AstraZeneca Vaccine Not Likely to Receive U.S. EUA Until April, Warp Speed Chief Says
The United Kingdom authorized AstraZeneca’s COVID-19 vaccine on Wednesday, but it could be April at the earliest before the drug will likely be administered in the United States, Operation Warp Speed’s chief said.
31-Dec-2020 – NVX-COV2373
https://www.nytimes.com/interactive/2020/health/novavax-covid-19-vaccine.html
The NY Times - How the Novavax Vaccine Works
The Maryland-based company Novavax has developed a protein-based coronavirus vaccine called NVX-CoV2373. The vaccine produced strikingly high levels of antibodies in early clinical trials. In September, the vaccine entered a Phase 3 clinical trial in the United Kingdom, and another one in the United States at the end of December. Those trials will show whether the vaccine is safe and effective.
29-Dec-2020 -AZD1222
https://www.lanazione.it/siena/cronaca/coronavirus-1.5861016
La Nazione - "Il virus cambia, andiamo più veloci"
Per ora lo studio è pubblicato su una piattaforma scientifica, ’biorxiv’, che potrebbe essere il passaggio propedeutico alla pubblicazione su Science o su altre riviste prestigiose.
28-Dec-2020 – NVX-COV2373
National Institutes of Health - Phase 3 trial of Novavax investigational COVID-19 vaccine opens
The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by Novavax, Inc., of Gaithersburg, Maryland.
25-Dec-2020 – V591
https://www.verywellhealth.com/merck-covid-19-vaccine-5093294
VeryWellHealth - An Overview of the Merck COVID-19 Vaccine
Merck, one of the largest pharmaceutical companies in the world, focused its early efforts in the fight against the coronavirus disease 2019 (COVID-19) on looking for ways to treat people who were sick. Now, the U.S. company is working on the vaccine development.
23-Dec-2020 – AZD1222
https://www.nst.com.my/news/nation/2020/12/651722/astrazeneca-selling-covid-19-vaccine-malaysia-no-profit
The Straits Times - AstraZeneca selling Covid-19 vaccine to Malaysia at no profit
With Malaysia and AstraZeneca having entered an agreement for the supply of 6.4 million doses of the University of Oxford's potential Covid-19 vaccine called AZD1222, the company confirms they are providing the vaccine at no profit.
22-Dec-2020 – Cape Biologix
https://www.news.uct.ac.za/article/-2020-12-22-uct-spin-off-receives-millions-in-european-funding
UCT spin-off receives millions in European funding
Cape Bio Pharms has received a multimillion-rand capital injection to fast-track the production of affordable plant-based rapid diagnostic COVID-19 test kits.
17-Dec-2020 – NVX-COV2373
https://www.reuters.com/article/us-health-coronavirus-newzealand-novavax-idUSKBN28R01S
Reuters - Novavax enters deal with New Zealand for 10.7 million doses of COVID-19 vaccine candidate
Biotechnology company Novavax Inc said it had entered an agreement with the government of New Zealand for 10.7 million doses of its COVID-19 vaccine candidate.
17-Dec-2020 – NVX-COV2373
Reuters - EU concludes preliminary talks to buy up to 200 million doses of Novavax COVID vaccine
The European Union has concluded preliminary talks with U.S. firm Novavax to secure up to 200 million doses of its COVID-19 vaccine candidate, a Commission spokesman said on Thursday.
17-Dec-2020 – NVX-COV2373
https://investorplace.com/2020/12/nvax-stock-still-make-vaccines-great-again/
Investor Place - Novavax Can Still Make Coronavirus Vaccines Great Again
It was the one-two punch (from the same arm, as it turned out) that chagrined many a novel coronavirus vaccine contender. First, Pfizer (NYSE:PFE) came up with a long-term solution that was 90%-plus effective, then Moderna (NASDAQ:MRNA) followed shortly thereafter. Both utilize messenger-RNA, which greatly contributed to their success over rivals like Novavax (NASDAQ:NVAX). But this approach is also why you can’t completely discount NVAX stock.
17-Dec-2020 – NVX-COV2373
Ekathimerini.com - EU concludes preliminary talks to buy up to 200 mln doses of Novavax Covid vaccine
The European Union has concluded preliminary talks with U.S. firm Novavax to secure up to 200 million doses of its COVID-19 vaccine candidate, a Commission spokesman said on Thursday.
17- Dec-2020 – NVX-COV2373
Dagblad van het Noorden - Europa dicht bij de aankoop van nog een coronavaccin. Het Amerikaanse Novavax moet 200 miljoen doses gaan leveren
De Europese Commissie is dicht bij de aankoop van nog een coronavaccin. De verkennende gesprekken met het Amerikaanse Novavax zijn afgerond, laat de commissie weten. Ze wil 100 miljoen doses kopen en een optie op nog eens zoveel.
17-Dec-2020 – AZD1222
https://www.nytimes.com/interactive/2020/health/oxford-astrazeneca-covid-19-vaccine.html
The New York Times - How the Oxford-AstraZeneca Vaccine Works
The University of Oxford partnered with the British-Swedish company AstraZeneca to develop and test a coronavirus vaccine known as ChAdOx1 nCoV-19 or AZD1222. A clinical trial revealed the vaccine was up to 90 percent effective, depending on the initial dosage. But uncertainty over the results has clouded its prospects.
15-Dec-2020 – AZD1222
https://www.manilatimes.net/2020/12/15/news/headlines/astrazeneca-seeks-vaccine-approval/811014/
The Manila Times - AstraZeneca seeks vaccine approval
After withdrawing its application for clinical trials in the Philippines, AstraZeneca is negotiating with the country’s vaccine regulators for an emergency use authorization (EUA) for its vaccine.
14-Dec-2020 – AZD1222
Europe Pharmaceutical Review - AstraZeneca to test combination of AZD1222 and Sputnik V vaccines
AstraZeneca has agreed to use one of the Sputnik V vaccine components in combination with its own COVID-19 vaccine to try and boost the efficacy of AZD1222 in humans.
“Today we announce a clinical trial programme to assess the safety and immunogenicity of a combination of AZD1222, developed by AstraZeneca and Oxford University, and Sputnik V, developed by Russian Gamaleya Research institute,” AstraZeneca said.
14-Dec-2020 – AZD1222
Hospital Healthcare Europe - AZD1222 vaccine has acceptable efficacy and safety profile
The highly anticipated vaccine (AZD1222) produced by a collaboration between Oxford University and AstraZeneca has become the first to have its interim study data published and appears to be as effective as reported in various media outlets.
14-Dec-2020 – mAbCo19
Siena News - Anticorpi monoclonali, Rappuoli: “Con questa cura guariti dal covid in 2 giorni”
L’ anticorpo monoclonale “in una persona positiva nello stadio iniziale della malattia, velocizza la guarigione in due o tre giorni ed è protetta per sei mesi dal Covid. Poi la protezione svanisce”.
13-Dec-2020 – COVID-eVAX
Il Meteo - CORONAVIRUS: VACCINO, ne arriverà uno tutto ITALIANO, al via la SPERIMENTAZIONE.
In attesa della somministrazione del VACCINO contro il CORONAVIRUS dell'azienda farmaceutica PFIZER, un nuovo vaccino tutto italiano è pronto ad essere testato. Lucio Rovati, presidente e direttore scientifico di Rottapharm Biotech, già durante la prima ondata dell’emergenza sanitaria ha messo a disposizione di Takis, società biotecnologica romana, "il supporto tecnico dei nostri manager scientifici, costituendo un team di elevate competenze cliniche, di tossicologia, farmacologia e nello sviluppo di prodotti biologici".
13-Dec-2020 – PLX-PAD
The Jerusalem Post - Pluristem to terminate Phase III study of critical limb ischemia (CLI)
While the CLI study was unsuccessful, Yanay said the company is maintaining a forward-thinking attitude, looking toward the development of other treatments it has in the works.
11-Dec-2020 – NVX-COV2373
M live - Ann Arbor VA hospital to conduct Novavax COVID-19 vaccine trial
The VA Ann Arbor Healthcare System will be one of two VA medical centers in the nation to launch clinical trials for the investigational COVID-19 vaccine developed by Novavax, according to a release from the U.S. Department of Veterans Affairs.
10-Dec-2020 – PLX-PAD
NASA-partnered Pluristem crashes to Earth as it axes leading therapy
Israeli biotech Pluristem is canning its experimental phase 3 critical limb ischemia therapy after an outside review said it was no good.
10-Dec-2020 - mAbCo19
Libero quotidiano - Coronavirus, fiale di monoclonali per guarire in 48 ore. Il microbiologo Rappuoli: "Basterà una puntura fatta in casa”
Fiale di monoclonali che consentono di guarire dal Covid in 48 ore, "basterà una puntura fatta in casa, poi basta contagi". E' questa la cura cui sta lavorando il microbiologo Rino Rappuoli, coordinatore scientifico del Mad (Monoclonal antibody discovery) della fondazione toscana Life Sciences. Dopo aver raccolto gli anticorpi dal sangue delle persone convalescenti, lo scienziato ha isolato in laboratorio le cellule che producono queste difese naturali e ha selezionato quelle super potenti, per poi riprodurle su scala industriale e poterle reiniettare.
10-Dec-2020 - mAbCo19
Il Sussidiario - https://www.ilsussidiario.net/news/monoclonali-guariscono-covid-in-48-ore-rappuoli-dose-anticorpi-protegge-6-mesi/2103554/
Non solo prevenzione ma anche terapia contro il Covid. Oltre al vaccino, l’attenzione è focalizzata in questo momento anche sull’uso di anticorpi monoclonali. Il microbiologo Rino Rappuoli, coordinatore scientifico del Mad (Monoclonal antibody discovery) della fondazione Life Sciences sta lavorando proprio su questa promettente cura.
10-Dec-2020 - NVX-COV2373
FX street - NVAX Stock Price: Novavax Inc drops as big name biotech companies inch closer to EUA for COVID-19 vaccine
NVAX has been somewhat forgotten in the race for Emergency Use Authorization (EUA) of its COVID-19 vaccine, taking a backseat to some of the biotech giants who are anticipating approval over the next couple of weeks. Novavax dropped 4.08% on Wednesday alongside a broader market selloff as US stimulus talks hit another wall in Congress. Investors do not have much to complain about considering shares are still up nearly 3000% over the past 52-weeks, with more to come in 2021 once its COVID-19 vaccine is approved for distribution.
10-Dec-2020 - NVX-COV2373
Oxford Mail - Novavax Covid vaccine trial recruits in Oxfordshire
US biotech company Novavax is running trials in Oxford as part of more than 15,203 participants recruited across the UK. It is the largest double blind, placebo-controlled Covid-19 vaccine trial to be undertaken in the country so far.
9-Dec-2020 - AZD1222
European Pharmaceutical Review - AZD1222 vaccine for COVID-19 is safe and effective in Phase III trials
An interim analysis reveals the AZD1222 vaccine candidate against COVID-19 is safe and effectively prevents immunised individuals from contracting symptomatic COVID-19 or severe disease requiring hospitalisation. The interim analysis for efficacy was based on 11,636 participants accruing 131 symptomatic infections in Phase III trials conducted in the UK and Brazil by Oxford University.
9-Dec-2020 - NVX-COV2373
https://dc.citybizlist.com/article/642516/why-novavax-stock-crushed-it-in-november
Citybizlist - Why Novavax Stock Crushed It in November
Shares of the COVID-19 vaccine developer Novavax (NASDAQ:NVAX) jumped by a healthy 73% during the month of November, according to data from S&P Global Market Intelligence. To put this sizable northward move into the proper context, the iShares Nasdaq Biotechnology ETF gained a far more modest 10.9% over the course of November.
8-Dec-2020 - PLX-PAD
https://seekingalpha.com/article/4393565-pluristem-moment-of-truth
Seeking Alpha - Pluristem - Moment Of Truth
For a biotechnology company there is always that defining moment where it presents the results of a super critical clinical trial which will define the fate of the company and will determine whether the sometimes decades long research was worth the huge resources and funds or whether it all goes down to the drain.That moment is here and now for Pluristem (PSTI).
8-Dec-2020 – AZD1222
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext
The Lancet - Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
8-Dec-2020 – AZD1222
https://www.handelsblatt.com/unternehmen/industrie/corona-pandemie-zwischenanalyse-impfstoff-von-astra-zeneca-ist-sicher-und-wirksam/26699012.html?ticket=ST-8938600-oidobq9Tr2kI5DQVMEta-ap3
Handelsblatt - Zwischenanalyse: Impfstoff von Astra-Zeneca ist sicher und wirksam
Der britische Pharmakonzern Astra-Zeneca hat die Daten der Zwischenanalyse aus seiner fortgeschrittenen Corona-Impfstoffstudie in der Fachzeitschrift „The Lancet“ veröffentlicht. Damit können Experten in aller Welt die Daten zum gemeinsam mit der Universität Oxford entwickelten Impfstoff einsehen.
8-Dec-2020 – AZD1222
Der Standard - Erste Resultate zu Corona-Impfstoff von Astra Zeneca stimmen zuversichtlich
Zum ersten Mal sind Resultate zur Wirksamkeit eines Covid-19-Impfstoffs in einer begutachteten Fachzeitschrift veröffentlicht worden. Das Vakzin AZD1222 sei sicher und biete nach Gabe zweier Dosen einen Schutz von etwa 70 Prozent gegen die Erkrankung, schreibt das Team um Andrew Pollard von der Universität Oxford im Fachblatt "The Lancet".
8-Dec-2020 – AZD1222
Berliner Zeitung - AstraZeneca: Erstmals Resultate zu Corona-Impfstoff in Fachjournal publiziert
Auf derartige Daten warten Wissenschaftler in aller Welt: Zum ersten Mal sind Resultate zur Wirksamkeit eines Covid-19-Impfstoffs in einer begutachteten Fachzeitschrift veröffentlicht worden. Es ist der Impfstoff AZD1222, den die Oxford University zusammen mit dem Astra-Zeneca-Konzern entwickelt, zu dem nun eine solche Publikation aus der entscheidenden klinischen Phase 3 vorliegt. Ähnliche Veröffentlichungen der beiden ebenfalls weit vorangekommenen Hersteller Moderna und Biontech sind zwar angekündigt, aber noch nicht erschienen.
5-Dec-2020 - Cape Biologix
https://www.biznews.com/news/2020/12/05/inside-covid-19-3
Biz news - Inside Covid-19: Meet two remarkable SA women in the spotlight for putting others first
BizNews journalist Linda van Tilburg looks at an entrepreneurial Cape company that has developed a rapid Covid-19 test from a cousin of the tobacco plant. The company is one of five attracting investment from the University Technology Fund, a South African vehicle aimed at commercialising technologies and innovations developed at home. We speak to Cape Bio Pharms founder Belinda Shaw.
3-Dec-2020 - Cape Biologix
https://www.biznews.com/inside-covid-19/2020/12/03/inside-covid-19-3
Biznews - Inside Covid-19: Meet two remarkable SA women in the spotlight for putting others first
In this episode of Inside Covid-19, we look at two SA success stories as the world fights the biggest global health crisis in living memory. BizNews journalist Linda van Tilburg looks at an entrepreneurial Cape company that has developed a rapid Covid-19 test from a cousin of the tobacco plant.
3-Dec-2020 - COVID-eVAX
Ansa - Covid, in Italia si lavora al vaccino contro le varianti del virus
Dopo la prima generazione, ormai vicina all'approvazione da parte delle agenzie regolatorie, dei vaccini contro il Covid-19, si cominciano già a studiare quelli in grado di contrastare le nuove varianti del virus SARS-CoV-2, La Takis si prepara infatti alla sperimentazione clinica di fase 1 del vaccino COVID-eVax, basato sulla sequenza genetica del virus SARS-CoV-2 circolato in Cina ad inizio 2020.
2-Dec-2020 - NVX-COV2373
https://www.jpost.com/israel-news/two-dozen-red-zones-named-tuesday-as-criteria-changed-650916
The Jerusalem Post - Israel in negotiations with Novavax to purchase COVID-19 vaccine
Israel is in negotiations with the Maryland-based biotech company Novavax to receive its vaccine candidate, Prime Minister Benjamin Netanyahu said Wednesday.
2-Dec-2020 -v591
Fierce Pharma - Merck cashes in on Moderna COVID-19 vaccine enthusiasm with sale of equity stake
When Merck invested $100 million in cash and stock in Moderna back in 2015, and then another $125 million three years later, the term “mRNA” was barely known outside of biotech circles.But now that Moderna’s mRNA vaccine to prevent COVID-19 is nearing the finish line—contributing to the collective worldwide sigh of relief that an end to the pandemic may be in sight—Merck’s early investment in the company looks rather prescient.
30-Nov-2020 - GRAd-COV2
Il Dolomiti - Coronavirus, Mirian Fadelli volontaria per il test sul nuovo vaccino: “Nessun effetto collaterale”
Da Roma arriva il via libera per procedere con la fase 2 per la sperimentazione del vaccino contro il coronavirus dell'italiana Reithera. Tra il primo gruppo di volontari sani, tra 18 e 55 anni, che si sono sottoposti all'inoculazione c’è Mirian Fadelli: “Ho deciso di farlo perché credo fortemente nella scienza e nella medicina”
30-Nov-2020 - NVX-COV2373
Finanzen.net - Corona-Impfstoffstudie von US-Biopharmakonzern Novavax verzögert sich - Novavax-Aktie in Grün
Für die Zulassung in den USA und Mexiko starte die Phase III der klinischen Studie voraussichtlich in den kommenden Wochen, teilte Novavax am Montag in Gaithersburg (Maryland) mit. Bisher hatte das Unternehmen mit dem Start bis Ende November gerechnet. Novavax hat nach eigenen Angaben durch das Impfprogramm der US-Regierung 1,6 Milliarden US-Dollar (1,3 Mrd Euro) erhalten, um die Bereitstellung eines sicheren und wirksamen Vakzins zu beschleunigen. In Großbritannien stünden nun rund 15 000 Teilnehmer für die Phase III der dortigen Versuchsstudie fest.
30-Nov-2020 - mAbCo19
https://www.lanazione.it/covid-rino-rappuoli-anticorpi-monoclonali-pronti-per-marzo-2021-1.5766617
La Nazione - Covid, Rino Rappuoli: "Anticorpi monoclonali pronti per marzo 2021"
Dovrebbero arrivare a marzo le prime dosi di anticorpi monoclonali 'made in Italy' da distribuire alla popolazione. Entro fine anno, infatti, la Fondazione Toscana life sciences inizierà i test sulle persone. A fare il punto e' il coordinatore della ricerca, Rino Rappuoli, questa mattina nel corso di una conferenza stampa indetta da Coop Alleanza 3.0 e Unicoop Firenze. "Stiamo lavorando per avere i monoclonali disponibili su larga scala per marzo 2021", conferma Rappuoli.
30-Nov-2020 - mAbCo19
Contro Radio - Covid: Rappuoli, entro primavera avremo anticorpi potenti e costi accessibili
Gli anticorpi monoclonali “in genere sono per malattie gravi come tumori, malattie
infiammatorie, autoimmuni, e costano tantissimo, a volte decine di migliaia di dollari o euro per trattamento”, invece “i nostri anticorpi sono stati studiati in modo da essere molto potenti, in modo che bastino quantità piccole, quindi i costi saranno molto più accessibili”. Lo ha affermato Rino Rappuoli, direttore
scientifico di Gsk Vaccines e coordinatore del progetto di ricerca sugli anticorpi monoclonali presso Toscana Life Sciences.
30-Nov-2020 - NVX-COV2373
Reuters - Novavax delays U.S. COVID-19 vaccine trial again, now sees start in the coming weeks
Vaccine maker Novavax Inc said on Monday it has pushed back the start of a U.S.-based, late-stage trial for its experimental COVID-19 vaccine and now expects it to begin in the coming weeks instead of November.
26-Nov-2020- AZD1222
Ruhr24.de - Corona-Impfstoffe: Unterschiede zwischen Biontech, Astra Zeneca und Moderna einfach erklärt
Dortmund – Maske tragen, Abstand halten, Kontaktbeschränkungen. Der Wunsch nach Lockerungen und nach einem baldigen Ende der Coronavirus-Pandemieist groß. Aktuell gibt es drei heiße Impfstoff-Kandidaten, die die angespannte Corona-Dynamik vielleicht bald entspannen könnten. Die drei Wirkstoffe wurden von verschiedenen Firmen entwickelt und unterscheiden sich in der Wirkweise.
25-Nov-2020 – AZD1222
https://www.gv.com/news/vaccitech-adrian-hill-covid-19-vaccine/
GV- Vaccitech Co-Founder Professor Adrian Hill on Developing a COVID-19 Vaccine
Following this week's news that AstraZeneca, the University of Oxford, and our portfolio company Vaccitech's vaccine for COVID-19 is highly effective and safe, my colleague Vidu Shanmugarajah and I invited Vaccitech co-founder Professor Adrian Hill to talk with our portfolio CEOs about the battle against the pandemic. Here Adrian recounts the story behind his search for a vaccine, results from late-stage clinical trials, the challenges of manufacturing and global distribution — and what has to happen next to stop the virus.
25-Nov-2020 - VPM1002
Neue Presse - MHH testet Corona-Impfstoff – besser als Biontech & Co.?
Derzeit überschlagen sich die Meldungen über Corona-Impfstoffe. Dabei könnte es sein, dass es ihn schon längst gibt. Die MHH forscht jetzt mit der Fortentwicklung eines bewährten Tuberkulose-Mittels. Und dieser Impfstoff könnte viel besser wirken als die angekündigten Mittel gegen Covid-19.
25-Nov-2020 - AZD1222
RTL- Warum der Impfstoff von Astrazeneca die Welt endlich von Corona befreien könnte
Die Biotech-Pioniere Biontech und Moderna beherrschen mit ihren Covid-19-Impfstoffen die Schlagzeilen. Diese Medikamente werden wohl hauptsächlich an die reichen Industrieländer gehen. Die Hoffnung vor allem ärmerer Länder ruht unter anderem aber viel mehr auf Astrazeneca und der Universität Oxford.
24-Nov-2020 -AZD1222
AstraZeneca: Halbe Dosis – bessere Wirksamkeit
AstraZeneca hat neue Daten zu seinem Corona-Impfstoffkandidaten vorgelegt. Das Besondere: Die beiden untersuchten Impfschemata scheinen unterschiedlich wirksam zu sein: Zwei volle Dosen schützen mit einer rund 70-prozentigen Wahrscheinlichkeit vor Covid-19. Wird bei der ersten Injektion nur die halbe Dosis verabreicht, so entsteht ein Infektionsschutz von 90 Prozent.
24-Nov-2020 - AZD1222
https://www.n-tv.de/wissen/Die-drei-Top-Corona-Impfstoffe-im-Vergleich-article22189430.html
NTV -Die drei Top-Corona-Impfstoffe im Vergleich
Kampf mit dem Coronavirus Sars-CoV-2 scheint sich das Blatt zugunsten der Menschheit zu wenden: Innerhalb von rund zwei Wochen geben die westlichen Entwickler Biontech/Pfizer, Moderna und Astrazeneca/Universität Oxford Erfolge mit ihren Impfstoffkandidaten bekannt. Das Positive: Alle drei Vakzine wirken gegen den Erreger. Dennoch gibt es markante Unterschiede zwischen den drei Impfstoffen.
24-Nov-2020 -AZD1222
https://www.n-tv.de/wirtschaft/Astrazeneca-macht-den-Impfstoff-fuer-die-Massen-article22187188.html
NTV - Astrazeneca macht den Impfstoff für die Massen
Die Biotech-Pioniere Biontech und Moderna beherrschen mit ihren Impfstoffen die Schlagzeilen. Diese Medikamente werden wohl hauptsächlich an die reichen Industrieländer gehen. Die Hoffnung vor allem ärmerer Länder ruht unter anderem aber viel mehr auf Astrazeneca und der Universität Oxford.
24-Nov-2020 - AZD1222
https://indianexpress.com/article/explained/simply-put-how-far-from-a-vaccine-now-7063054/
Explained: How far are we from a Covid-19 vaccine now?
AstraZeneca Oxford vaccine trials put efficacy at 62% when two full doses are given, and 90% when first shot is half a dose. How does it compare to other vaccines, and what does it mean for Covishield in India?
24-Nov-2020 - GRAd-COV2
Corriere Etneo - Coronavirus, va avanti il vaccino italiano di Reithera: “E’ ben tollerato e induce risposta immunitaria”
ReiThera fa sapere infatti che il suo candidato vaccino Grad-Cov2 contro Covid-19 “è ben tollerato e induce risposta immunitaria nei soggetti sani di età compresa tra i 18 e i 55 anni”. La Fase 1 – che valuta il candidato vaccino su 90 volontari sani – avanza ora nei soggetti più anziani, tra i 65 e gli 85 anni.
24-Nov-2020 - GRAd-COV2
Il Fatto Quotidiano - Vaccino Covid, Reithera: “Nostro candidato ben tollerato e induce risposta immunitaria. Ora al via i test sugli anziani”
Lo studio è stato disegnato ed è condotto in collaborazione con l’Istituto nazionale per le malattie infettive Lazzaro Spallanzani di Roma. "L'arruolamento dei volontari più anziani sta procedendo come previsto e prevediamo di comunicare entro la fine dell’anno i primi risultati dello studio" dice l'ad Antonella Folgori
24-Nov-2020 - GRAd-COV2
https://www.ilmessaggero.it/salute/focus/vaccino_covid_azienda_roma_reithera_news-5604983.html
Il messaggero - Vaccino Covid, Reithera: «Ben tollerato, ora Fase 1 sui soggetti più anziani»
Sul vaccino anti Covid avanza anche la ricerca italiana. ReiThera, azienda di Castel Romano, fa sapere infatti che il suo candidato vaccino Grad-Cov2 contro Covid-19 «è ben tollerato e induce risposta immunitaria nei soggetti sani di età compresa tra i 18 e i 55 anni». La Fase 1 - che valuta il candidato vaccino su 90 volontari sani - avanza ora nei soggetti più anziani, tra i 65 e gli 85 anni. L'azienda ha comunicato infatti oggi l'aggiornamento sullo studio clinico di Fase 1 del suo candidato vaccino, attualmente in corso.
24-Nov-2020 - GRAd-COV2
https://www.scienceboard.net/index.aspx?sec=ser&sub=def&pag=dis&ItemID=1754
Science Board - ReiThera touts phase I COVID-19 vaccine results
ReiThera is highlighting positive phase I clinical trial results for its COVID-19 vaccine candidate, GRAd-COV2. The first phase of the trial includes a cohort of healthy volunteers between the ages of 18 and 55. This phase is now advancing to include healthy subjects between the ages of 65 and 85; its phase II/III will explore effective vaccine dose. The vaccine is based on a proprietary replication-defective simian adenoviral vector that encodes the full-length coronavirus spike protein, according to the firm.
23-Nov-2020 - mAbCo19
Siena News- Covid, Rappuoli: “Vaccini e anticorpi monoclonali nel 2021 ci ridaranno la nostra libertà”
“Nel 2021 saremmo capaci di controllare la pandemia da covid grazie ai vaccini e agli anticorpi monoclonali”, lo ha detto in una videoconferenza il microbiologo e scienziato senese Rino Rappuoli ospite all’Accademia dei Fisiocritici per parlare di vaccini e anticorpi monoclonali che verranno usati contro il coronavirus.
23-Nov-2020 - AZD1222
Deutsche Apotheker Zeitung - AZD1222 erzeugt robuste Immunität auch bei Senioren
Der Corona-Impfstoff von AstraZeneca scheint auch bei älteren Menschen eine robuste Immunität zu erzeugen und tendenziell verträglicher zu sein als bei Jüngeren, zu diesem Fazit kommen Wissenschaftler bei einer Zwischenauswertung von ChAdOx1 nCoV-19 (AZD1222) in „The Lancet“. Dies ist in zwei Punkten interessant: Denn ältere Menschen haben ein erhöhtes Risiko für schwere und tödliche COVID-19-Verläufe, jedoch reagiert ihr Immunsystem aufgrund von Immunoseneszenz meist schlechter auf eine Impfung als das von jüngeren Menschen.
23-Nov-2020 - AZD1222
The Japan Times - AstraZeneca and Oxford say COVID-19 vaccine shows 70% efficacy
British drug group AstraZeneca and the University of Oxford on Monday said their jointly-developed vaccine against COVID-19 has shown “an average efficacy of 70 percent” in trials.
22-Nov-2020 - NVX-COV2373
Daily Mail - Novavax vaccine stops coronavirus spreading between monkeys – raising hopes of a jab that will eliminate virus as well as stopping people falling ill
A company in the global race to produce a Covid-19 vaccine has raised hopes that its jab could stop humans spreading the virus to each other following successful trials in monkeys. Novavax told The Mail on Sunday that its vaccine 'prevented infection' between rhesus macaque monkeys in testing
20-Nov-2020 - AZD1222
https://www.genengnews.com/news/astrazeneca-oxford-covid-19-vaccine-shows-positive-phase-ii-results/
Gen eng news - AstraZeneca-Oxford COVID-19 Vaccine Shows Positive Phase II Results
Researchers from AstraZeneca, the University of Oxford, and several collaborating institutions have published Phase II data showing that their COVID-19 vaccine candidate AZD1222—one of several leading vaccines in development against the virus—has similar immunogenicity across all age groups after the second “boost” dose, including older adults where the vaccine showed fewer adverse effects.
20-Nov-2020 -AZD1222
Cambridge Network - AstraZeneca's COVID-19 vaccine shows promise among older people in trials
Strong immune responses were demonstrated across all age groups and boosted after a second dose.Interim results from the ongoing Phase II/III COV002 trial of AZD1222 in the UK, led by the University of Oxford demonstrated lower local and systemic reactions in older adults (≥56-69 years and ≥70 years) than younger adults (≥18-55 years) and generated similar robust immune responses against the SARS-CoV-2 virus across all adult age groups.
20-Nov-2020 - AZD1222
http://www.koreaherald.com/view.php?ud=20201120000748
Korea Herald- AstraZeneca vaccine results to be out around Christmas, SK Bioscience already manufacturing
AstraZeneca and Oxford University’s co-developed COVID-19 vaccine AZD1222 has shown immune response in older adults enrolled in a phase 2 clinical trial of the drug.
Phase 3 clinical trial results are anticipated to be released around Christmas, the researchers said Friday.
20-Nov-2020 - AZD1222
Nasdaq -AZN's Covid Jab & Immunosenescence, PFE/BNTX To Seek Emergency Nod For Vaccine, QURE Aces HOPE-B
Today's Daily Dose brings you news about the encouraging immune response triggered by AstraZeneca's Covid-19 vaccine candidate in older adults, the first combination regimen authorized for emergency use by FDA for COVID-19, Pfizer/BioNTech mulling to file for emergency use approval of their COVID-19 shot, and uniQure's gene therapy trial results in Hemophilia B patients.
20-Nov-2020 - mAbCo19
Il Giornale -Un super anticorpo anti Covid "Pronti a distribuirlo in Italia"
Starebbe arrivando un super anticorpo capace di combattere il Covid e presto potrebbe essere distribuito in Italia.
20-Nov-2020 - mAbco19
https://www.today.it/scienze/anticorpi-monoclonali-italia-quando.html
Today - Anticorpi monoclonali: quando arriva la cura contro il coronavirus in Italia
Lo scienziato Rino Rappuoli ha annunciato che è in corso di definizione un accordo con il Ministero della Salute per la distribuzione da marzo (ma solo in casi di emergenza)
17-Nov-2020 - AZD1222
https://in.reuters.com/article/uk-factcheck-vaccine-idUSKBN27W2I7
Reuters- Fact check: Lung tissue of an ‘aborted male foetus’ is not in the vaccine for coronavirus
A Facebook video discussing the Oxford AstraZeneca vaccine for COVID-19 has falsely claimed it contains tissue from an aborted human foetus.
16-Nov-2020 - GRAd-COV2
https://www.radioradio.it/2020/11/ranucci-vaccino-coronavirus-di-lorenzo-big-pharma/?cn-reloaded=1
RadioRadio- Contratti segreti sul vaccino: lo Stato italiano paga, Big Pharma guadagna miliardi ► Ranucci (Report)
Tutti lo cercano, tutti attendono il fatidico annuncio: la caccia al vaccino contro il coronavirus sarebbe forse come lo sbarco sulla Luna per la nazione che lo trovasse. Non si spiegherebbero altrimenti le estenuanti ricerche nei laboratori di tutto il mondo che in queste ore fanno i conti con Big Pharma. La celebre multinazionale starebbe infatti provando ad attribuire gli oneri di un risarcimento dovuto a disfunzioni o effetti collaterali agli Stati nazionali: una lotta in cui è inclusa anche l’Italia.
11-Nov-2020 - NVX-COV2373
Washington Business Journal - Novavax mulls up to $500M raise as Covid, flu programs move forward
Novavax has experienced “accelerated expansion … in every functional area,” CEO Stanley Erck said on a Nov. 9 company earnings call.
11-Nov-2020 - NVX-COV2373
https://www.kbtx.com/2020/11/10/novavax-covid-19-vaccine-receives-designated-fast-track-from-fda/
KBTX-TV - Novavax COVID-19 Vaccine receives designated fast track from FDA
Novavax vaccine is the latest company to get fast track designation from the U.S Food and Drug Administration (FDA).This is the same company that will use the FUJIFILM Diosynth biotechnologies and the Texas A&M Innovation Center to help manufacture their product.
11-Nov-2020 - mAbCo19
In Toscana - Toscana Life Sciences: a Siena il polo d’eccellenza nella ricerca farmacologica
Arriva da Siena la nuova speranza di cura e prevenzione contro il Covid-19. La Fondazione Toscana Life Sciences infatti ha individuato gli anticorpi monoclonali in grado di combattere il Coronavirus, grazie al lavoro del Monoclonal Antibody Discovery (MAD) Lab della fondazione senese, coordinato dallo scienziato e pioniere dei vaccini Rino Rappuoli che riceverà, insieme al presidente di TLS Fabrizio Landi, il Pegaso d’Oro della Regione Toscana.
11-Nov-2020 - COVID-eVAX
https://www.ilgiorno.it/monza-brianza/cronaca/covid-vaccino-1.5701818
Il Giorno - Covid: vaccino made in Monza, a gennaio la sperimentazione
Vaccino anti-Covid, pronti allo studio clinico sui primi volontari. "In questi giorni invieremo la documentazione alle autorità sanitarie e a inizio gennaio partiremo con la Fase 1 al San Gerardo di Monza, allo Spallanzani di Roma (che si occuperà anche di tutte le valutazioni di laboratorio) e all’oncologico Pascale di Napoli".
9-Nov-2020 - NVX-COV2373
Bloomberg - Prognosis: Novavax Covid-19 Vaccine Gets Fast-Track Tag From FDA
Novavax Inc.’s experimental Covid-19 vaccine received a fast-track designation from U.S. regulators as the drugmaker prepares to launch a large, late-stage study before the end of the month, the company said on Monday.
9-Nov-2020 - AZD1222
Morningstar- CSL Begins Manufacturing Of Astra's AZD1222 Covid-19 Vaccine Candidate
CSL Ltd on Sunday confirmed it will start manufacturing the AZD1222 Covid-19 vaccine candidate from the University of Oxford and AstraZeneca PLC at its advanced manufacturing facility in Broadmeadows, Australia.
5-Nov-2020 - AZD1222
BioPharma Reporter - Only ‘small chance’ of distributing the AZD1222 vaccine in the UK before Christmas
Late-stage trial results on Astra Zeneca’s Covid-19 Vaccine could be ready by December
5-Nov-2020 - AZD1222
Sixth tone - COVID Vaccines, Tests Take Center Stage at Shanghai Trade Expo
With the COVID-19 pandemic still spreading rapidly across the globe, several companies are showcasing their health care-related products and services at the third annual China International Import Expo (CIIE), which kicked off Thursday in Shanghai.
5-Nov-2020 - AZD1222
Finanztreff.de - Astrazeneca erwartet noch 2020 Studienergebnis zu Covid-19-Impfstoff
LONDON (Dow Jones)Der Pharmakonzern Astrazeneca befindet sich mit seiner klinischen Studie zu einem Impfstoff gegen das Coronavirus im Plan. Ergebnisse sollen noch in diesem Jahr vorliegen, und eine Auslieferung der Impfdosen soll nach einer Genehmigung durch die Behörden "schnell" erfolgen, wie der britische Konzern ankündigte.
5-Nov-2020 - AZD1222
https://www.thelocal.it/20201105/italy-seeks-volunteers-for-covid-19-vaccine-trial
The Local It - Italy seeks volunteers for Covid-19 vaccine trial
Volunteers in Italy could receive the first doses in December, as scientists begin a Phase 3 clinical trial of the vaccine developed by Oxford University and AstraZeneca pharmaceutical group and partly manufactured and bottled by two Italian companies near Rome.
5-Nov-2020 - NVX-COV2373
Brisbane times - Experts hail addition of two more vaccines to Australia's virus 'portfolio'
The expert in charge of two separate Australian clinical trials of coronavirus vaccine candidates says the latest vaccine agreement announced by the federal government is vital in helping the country eventually reopen fully next year.
4-Nov-2020 - AZD1222
Fierce Biotech - Trial chief tips AstraZeneca COVID-19 vaccine for 2020 data drop
AstraZeneca has a good chance of delivering late-phase data on its COVID-19 vaccine this year, the chief investigator of the Oxford Vaccine Trial said. The timing gives AstraZeneca a “small chance” of being able to start distributing the AZD1222 vaccine in the U.K. before Christmas.
3-Nov-2020 - mAbCo19
https://www.theflorentine.net/2020/11/03/covid-19-monoclonal-antibody-treatment-developed-in-siena/
The Florentine -Covid-19: Monoclonal antibody treatment developed in Siena
A monoclonal antibody treatment to heal Covid-19 patients and prevent infection is being developed in Siena, Tuscany. The announcement was made on television programme “Che tempo che fa?” by Professor Rino Rappuoli, Chief Scientist and Head External R&D di GSK Vaccines in Siena.
2-Nov-2020 - AZD1222
Pharma Forum - UK could get COVID-19 vaccines early next year, ahead of European countries
COVID-19 vaccines could be approved and available early next year in the UK ahead of European countries, after its national regulator began its own rolling reviews of shots from AstraZeneca and Moderna.
2-Nov-2020 - NVX-COV2373
Washington business journal - Novavax buys new real estate as Covid-19 program drives growth
Gaithersburg’s Novavax Inc. has secured new real estate to support its growth, fueled by its Covid-19 and seasonal flu programs. The local biotech said early Monday it has purchased a 9.7-acre parcel at 14 Firstfield Road in Gaithersburg through its affiliate, 14 Firstfield Holdings LLC. There, Novavax “plans to develop in the future to accommodate growth of the Company.” It did not immediately disclose a purchase price, which is not yet public.
2-Nov-2020 - NVX-COV2373
WTOP News - Novavax to expand in Montgomery County, add hundreds of jobs
Gaithersburg, Maryland-based Novavax, one of several companies advancing a potential COVID-19 vaccine, will open a new research and development and manufacturing facility in Gaithersburg, and will add at least 400 new jobs, the majority of them by next spring.
2-Nov-2020 - AZD1222
https://www.fr.de/wissen/kein-kompletter-schutz-aber-ein-kuerzerer-infekt-90088168.html
Frankfurter Rundschau - Kein kompletter Schutz – aber ein kürzerer Infekt
Die ersten Impfstoffe werden wohl kaum die Ansteckung eines Geimpften mit dem neuen Coronavirus verhindern. „Die Daten aus den Tierstudien deuten darauf hin, dass nur im Einzelfall einen Schutz vor Infektion mit Sars-CoV-2 durch die Impfung erreicht wird“, sagt Klaus Cichutek, Präsident des Paul-Ehrlich-Institutes, der deutschen Behörde, die für die Zulassung von Impfstoffen zuständig ist. Warum ist das so und was bringt ein Impfstoff dann überhaupt?
1-Nov-2020 - AZD1222
VOA News - Britain Starts Accelerated Review for AstraZeneca's Potential COVID-19 Vaccine
AstraZeneca Plc said on Sunday Britain's health regulator had started an accelerated review of its potential coronavirus vaccine."We confirm the MHRA's (Medicines and Healthcare Products Regulatory Agency) rolling review of our potential COVID-19 vaccine," an AstraZeneca spokesman said.
, coordinato da Rino Rappuoli a Siena. Si è arrivati alla scelta del candidato migliore su cui puntare durante la fase di sviluppo e produzione dei tre anticorpi migliori (selezionati a luglio scorso), che valuta sia la capacità dell'anticorpo di legare la proteina spike e di inattivare il virus, sia la resa da un punto di vista dello sviluppo e produzione della terapia contro il virus.
30-Oct-2020 - AZD1222
Geneng News - U.S. Army Awards $599M in Contracts for AstraZeneca Vaccine, Lilly Antibody vs. COVID-19
The U.S. Army will spend a combined $599 million to procure two leading COVID-19 candidates—AstraZeneca’s vaccine AZD1222, co-developed with the University of Oxford and a spinout company; and Eli Lilly’s neutralizing antibody bamlanivimab (LY-CoV555).
30-Oct-2020- AZD1222
Indian Express - Explained: Is death in Brazil a blow for AstraZeneca-Oxford Covid-19 vaccine candidate?
There has been a death in the late-stage clinical trials of a Covid-19 vaccine being developed by University of Oxford and Swedish-British drugmaker AstraZeneca. What happened and what does this mean for the trials of the closely watched candidate, a version of which is at the forefront of India’s own Covid-19 vaccine race?
30-Oct-2020 - VPM1002
Money Control - Explainer: What the ICMR study tells us about the effectiveness of the BCG vaccine against Covid-19
Governments around the world are keen to know if the nearly century-old vaccine can be used to prevent Covid-19. It’s not hard to see why — the safety of the BCG vaccine has long been established. Moreover, it is very cheap and production can be scaled up easily
29-Oct-2020 - AZD1222 & NVX-COV2373
Pharmalive - pharma companies strike deals to deliver millions of covid-19 vaccines by 2021 leading pharmaceutical giants – including moderna, pfizer and astrazeneca – are racing ahead to develop and distribute a covid-19 vaccine.
29-Oct-2020- mAbCo19
AGI - "Ancora 3 mesi e avremo la cura con anticorpi". La revisione di Rappuoli
L'amministratore delelgato di Glaxo Vaccines è fiducio: "Dopo l'arruolamento in un mese-un mese e mezzo contiamo di avere i risultati in base ai quali poter chiedere l'autorizzazione al commercio"
29-Oct-2020 -mAbCo19
055 Firenze - Pegaso d'Oro a Rino Rappuoli e a Fabrizio Landi della Fondazione Toscana Life Sciences
Il primo Pegaso d'Oro della nuova Giunta regionale della Toscana, guidata da Eugenio Giani, sarà consegnato allo scienziato Rino Rappuoli e al presidente della Fondazione Toscana Life Sciences, Fabrizio Landi. Entrambi, spiega la Regione, sono al centro di una nuova strategia scientifica per sconfiggere il Covid 19, su cui lo stesso Governo italiano sta investendo in modo significativo, per accelerare i risultati della ricerca di un vaccino, che dovrebbe proteggerci definitivamente dalla pandemia in corso.
29-Oct-2020 - GRAd-COV2
I24 News - Israel agrees to buy coronavirus vaccines from Italy
Rome-based biotech company ReiThera is currently developing a coronavirus vaccine at the capital's Spallanzani Institute for infectious diseases. Human trials, expected to last six months, began in August.
27-OCt-2020 - V591
Business Standard -Merck says early data from Covid-19 vaccines expected this year
Merck & Co Inc on Tuesday said it expects to report results from early-stage studies of two potential COVID-19 vaccines before the end of the year and has advanced an experimental antiviral drug into late-stage testing.
28-Oct-2020 - AZD1222
https://www.dw.com/en/covid-19-difficult-trade-offs-in-astrazeneca-vaccine-development/a-55421164
DW - COVID-19: Difficult trade-offs in AstraZeneca vaccine development
The Oxford vaccine ChAdOx1 is seen as a promising candidate to combat COVID-19. But critics believe that research is going too fast and that risks could be being played down. What is true about the accusations?
27-Oct-2020 - AZD1222
The Guardian - Oxford Covid vaccine works in all ages, trials suggest
One of the world’s leading Covid-19 experimental vaccines produces an immune response in older adults as well as the young, its developers say, raising hopes of protection for those most vulnerable to the coronavirus that has caused social and economic chaos around the world.
27-Oct-2020 - v591
Business standard - Merck says early data from Covid-19 vaccines expected this year
Merck & Co Inc on Tuesday said it expects to report results from early-stage studies of two potential COVID-19 vaccines before the end of the year and has advanced an experimental antiviral drug into late-stage testing.
27-Oct-2020- NVX-COV2373
CNBC- Novavax delays U.S. trial of Covid-19 vaccine candidate to November
Novavax on Tuesday delayed the start of a late-stage U.S. trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing process.
27-Oct-2020 -NVX-COV2373
https://www.deaandeelhouder.nl/nieuws/2020/10/27/novavax-breidt-coronavaccinstudie-in-vk-uit/
De aandeelhouder -Novavax breidt coronavaccinstudie in VK uit
Novavax heeft ruim 5.500 proefpersonen gerekruteerd voor de Fase 3 studie naar een coronavaccin die het in Verenigd Koninkrijk uitvoert en wil dit onderzoek uitbreiden naar 15.000 vrijwilligers. Dit meldde het Amerikaanse farmaceutische bedrijf dinsdagmiddag.
27-OCt-2020 - mAbCo19
https://startupitalia.eu/139528-20201027-rappuoli-chi-e-biografia
Startup Italia - Rino Rappuoli, chi è il “papà” dei super anticorpi contro il Covid
Rino Rappuoli è uno dei più importanti e riconosciuti microbiologi italiani e mondiali. Noto alla comunità scientifica per la scoperta del vaccino contro meningococco B e C e quello contro la pertosse, oggi Rappuoli è a capo del progetto della fondazione non profit Toscana Life Sciences – TLS -, per la ricerca sugli anticorpi monoclonali in grado di rendere immuni per sei mesi dal Covid. Sempre in Toscana, lo scienziato direttore scientifico e capo del comparto di ricerca e sviluppo nella divisione vaccini della casa farmaceutica britannica GlaxoSmithKline– GLS – a Rosia, in provincia di Siena.
26-Oct-2020 - AZD1222
Aljazeera -Oxford vaccine prompts immune response in elderly: AstraZeneca
An experimental COVID-19 vaccine being developed in the United Kingdom produces an immune response in both younger and older adults, British drug maker AstraZeneca said, raising hopes in the fight against the coronavirus pandemic.
26-Oct-2020 - AZD1222
https://pharmaphorum.com/news/az-jj-coronavirus-vaccine-trials-okay-to-restart-in-us/
PharmaPhorum - AZ, J&J COVID-19 vaccine trials okay to restart in US
US trials of AstraZeneca’s experimental COVID-19 vaccine AZD1222 have been cleared to restart by the FDA, several weeks after testing was suspended following a serious adverse reaction in one patient who received the shot.
26-Oct-2020 - AZD1222
Scandasia - AstraZeneca to produce COVID-19 vaccine AZD1222 for Thailand and South East Asia
The Swedish Embassy, on 12 October 2020, expressed that they were delighted to witness the signing ceremony of the Letter of Intent on the manufacturing and supply of the University of Oxford’s potential COVID-19 vaccine AZD1222 for Thailand and South East Asia among the Thailand’s Ministry Of Public Health, Siam Bioscience Co., Ltd., SCG and British – Swedish biopharmaceutical company, Astrazeneca (Thailand) Ltd. Photo from the signing ceremony on 12 October 2020 at Thailand’s Ministry of Public Health
26-Oct-2020 - AZD1222
Pharmazeutische Zeitung -Astra-Zenecas Corona-Impfstoffstudie in den USA läuft wieder
Nach einer fast siebenwöchigen Unterbrechung setzt der Pharmakonzern Astra-Zeneca seine klinischen Studien für den mit der Universität Oxford entwickelten Corona-Impfstoff AZD1222 auch in den USA wieder fort.
25-Oct-2020 -
mAbCo19
RAI TV Che Tempo Che Fa - Rino Rappuoli, scientific director of the vaccines division of GSK of Rosia (Siena)
25-Oct-2020 - PLX-PAD
The Jerusalem Post - Pluristem names members of coronavirus Steering Committee
Israeli bio-pharmaceutical firm Pluristem officially formed a Steering Committee for its clinical program for its treatment of coronavirus complicated by acute respiratory distress syndrome (ARDS).
25-Oct-2020 - mAbCo19
Siena News - Covid, Rappuoli: “A marzo prime dosi del farmaco con anticorpi monoclonali”
“Incominciare le prove cliniche prima di Natale, finirle entro febbraio e a marzo avere il farmaco a disposizione, le prime decine di migliaia di dosi e poi averne sempre di più”, così è intervenuto nella trasmissione “Che tempo che fa?” il direttore scientifico della divisione vaccini Gsk e capo del laboratorio Mad Lab Rino Rappuoli. Il progetto di ricerca sugli anticorpi monoclonali contro il covid è iniziato questa primavera e vi collaborano INMI Spallanzani, Toscana Life Sciences, VisMederi, università di Siena e Imperial College di Londra.
25-Oct-2020 -mAbCo19
Corriera Dell Umbria - Coronavirus, Rappuoli (Gsk), annuncia a Che Tempo che fa: "Farmaco a marzo, migliaia di dosi" | Video
23-Oct-2020 - AZD1222, NVX-CoV2373
India Today - Readying 1 billion doses of 5 coronavirus vaccines, says SII's Adar Poonawalla
Serum Institute of India (SII) is reportedly readying one billion doses of five coronavirus vaccines worldwide with CEO Adar Poonawalla saying that the plan is to launch at least one vaccine every quarter likely by 2021 beginning.
23-Oct-2020 - AZD1222
Frankfurter Allgemeine - Corona-Impfung mit Fragezeichen
Weltweit wird in Rekordtempo an einem Corona-Impfstoff geforscht. Doch die Zulassungsstudien werden von einem Todesfall und quälenden Unsicherheiten überschattet.
23-October-2020 - AZD1222
Republic World - Oxford COVID-19 Vaccine Doing 'everything Expected'; Says Study Calling It 'good News'
The Oxford University COVID-19 vaccine, which is currently undergoing Phase III, clinical trial with Pharma Giant AstraZeneca is doing “everything expected”, an independent analysis stated on October 22. The analysis, which was conducted by researchers from Bristol University, examined vaccine candidates ChAdOx1 and also AZD1222, to see “what it does when it gets inside a human cell.”
22-Oct-2020 - AZD1222
https://www.aerztezeitung.de/Nachrichten/Toter-bei-COVID-19-Impfstoffstudie-413949.html
AerzteZeitung - Toter bei COVID-19-Impfstoffstudie?
Der COVID-19-Impfstoffkandidat „AZD1222“ von der Universität Oxford und AstraZeneca gilt als einer der vielversprechendsten Kandidaten weltweit. Nun soll in der klinischen Phase-III-Studie ein Proband gestorben sein.
21-Oct-2020 - AZD1222
PMLive - AZ’s US-based COVID-19 vaccine trial could restart this week
The US arm of AstraZeneca’s (AZ) COVID-19 vaccine, which was put on hold in September after a study participant developed a serious illness, could resume this week.
20-Oct-2020 - V591
Oe24 - Corona-Impfung: Wiener war Österreichs erster Tester
Die erste Corona-Impfung hat Alex P. (32) aus Wien bereits schadlos überstanden. Insgesamt nehmen 25 Probanden aus ganz Österreich an der Studie teil.
19-Oct-2020 - PLX-PAD
https://www.calcalistech.com/ctech/articles/0,7340,L-3862812,00.html
Ctech - The Genesis Prize Foundation and Start-Up Nation Central announce finalists in COVID-19 startup competition
21 of Israel's most promising startups are shortlisted for a competition highlighting the global potential of Israeli innovation. “The shortlisted companies epitomize the best of what Israeli innovation has to offer to help tackle the global crisis.”
19-Oct-2020 - PLX-PAD (from minute 7.20, in Hebrew)
https://www.youtube.com/watch?v=QL2AlnLUtPM&ab_channel=כאןחדשות-תאגידהשידורהישראלי
Israeli TV Channel 11 - CEO and President, Yaky Yanay’s COVID19 interview on the World Today program broadcast on Israeli TV Channel 11
15-Oct-2020 -PLX-PAD
The Jerusalem Post - Pluristem to enroll participants for GvHD treatment at Sourasky
Israeli biotech company Pluristem received clearance to move forward with Cohort II enrollment for its investigator-led Phase I/II study for the treatment of steroid-refractory chronic graft vs. host disease (GvHD).
14-Oct-2020 - mAbCo19
https://www.lanazione.it/siena/cronaca/anticorpi-monoclonali-1.5609119
La Nazione - Covid, a Siena individuato l'anticorpo monoclonale più potente. Al via test
Si chiama MAD0004J08, ed è l'anticorpo monoclonale che si è dimostrato più potente contro il virus: i test clinicipartiranno entro fine 2020. Lo annuncia il Monoclonal Antibody Discovery Lab di Fondazione Toscana Life Sciences, coordinato da Rino Rappuoli a Siena. Si è arrivati alla scelta del candidato migliore su cui puntare durante la fase di sviluppo e produzione dei tre anticorpi migliori (selezionati a luglio scorso), che valuta sia la capacità dell'anticorpo di legare la proteina spike e di inattivare il virus, sia la resa da un punto di vista dello sviluppo e produzione della terapia contro il virus.
17-Oct-2020 -mAbCo19
Sienanews - Coronavirus, Rappuoli: “Fuori dalla pandemia nel 2021”
Così, risponde Rino Rappuoli, capo della ricerca sui vaccini all’Imperial College di Londra, a una intervista del Quotidiano.net. Il riferimento è, ovviamente, a riguardo del coronavirus, tema tornato di grande attualità, purtroppo, a causa della forte impennata dei contagi nel nostro Paese, ma anche nel resto d’Europa. Ebbene, il professore e Chief Scientist and Head External R&D di Gsk Vaccines a Siena ha rassicurato un po’ la popolazione relativamente a una possibile cura del Covid-19.
17-Oct-2020 - mAbCo19
https://www.blitzquotidiano.it/salute/rino-rappuoli-vaccini-3228490/
Blitz quotidiano - Rino Rappuoli, il prof dei vaccini: “Fuori dalla pandemia entro il 2021 grazie a vaccini e anticorpi monoclonali”
Rino Rappuoli non ha dubbi, il nostro Paese tornerà a respirare tra un anno: “Fuori dalla pandemia entro il 2021 grazie a vaccini e anticorpi monoclonali”. Secondo Rino Rappuoli, microbiologo italiano, Medaglia d’oro al merito della sanità pubblica nel 2005, l’Italia uscirà dalla pandemia entro il 2021 grazie a vaccini e anticorpi monoclonali.
19-Oct-2020 - J.POD
Manager Magazin - Gates-Stiftung steckt Geld in Covid-19-Forschung von Evotec
Prominente Unterstützung für den MDax-Konzern Evotec: Für die Forschung gegen die Corona-Krankheit Covid-19 erhält das Unternehmen eine Finanzspritze der Stiftung von Microsoft-Gründer Bill Gates.
19-Oct-2020 - J.POD
https://www.finanztreff.de/nachrichten/evotec-und-bill-gates+erste-kaufsignale/22120859
Finanztreff.de - Evotec und Bill Gates – erste Kaufsignale
Der Wirkstoff-Forscher Evotec bekommt eine Förderung von der Stiftung von Microsoft-Gründer Bill Gates. Anleger reagieren positiv – und die Evotec-Aktie liefert erste Kaufsignale.Mit der Geldspritze, über deren Höhe keine Angabe gemacht wurde, soll die Entwicklung und Herstellung von Antikörpern gegen die Lungenkrankheit Covid-19 in den USA vorangetrieben werden, wie Evotec am Montag mitteilte.
19-Oct-2020 - J.POD
pharmiweb - JUST - EVOTEC BIOLOGICS RECEIVES GRANT TO ENABLE AN ANTIBODY PRODUCT FOR THE PREVENTION OF COVID-19
Evotec SE today announced that its Seattle-based subsidiary, Just - Evotec Biologics, Inc., received a grant from the Bill & Melinda Gates Foundation (Seattle, WA) as part of the COVID-19 Therapeutics Accelerator to enable the development and production of monoclonal antibody ("mAb") candidates for the prevention of severe COVID-19 in vulnerable populations in low and middle income countries.
17-Oct-2020 - AZD1222
Live mint - COVID-19 vaccine may be ready by December, to be available in market by March: SII official
Serum Institute of India can produce 700-800 million vaccine dosages every year once things are streamlined, executive director of SII said. The vaccine is likely to provide protection for about a year, AstraZeneca CEO Pascal Soriot said
16-Oct-2020 - mAbCo19
OKSiena - INDIVIDUATO A SIENA ANTICORPO MONOCLONALE PIÙ POTENTE CONTRO COVID-19
Scelto l’anticorpo monoclonale più potente contro il coronavirus e, per questo, candidato farmaco per la terapia per sconfiggere Covid-19. Ad annunciarlo il Monoclonal Antibody Discovery Lab di Fondazione Toscana Life Sciences con sede a Siena e coordinato dallo scienziato Rino Rappuoli.
13-Oct-2020 - AZD1222
https://www.sknvibes.com/news/newsdetails.cfm/113257
SKN Vibes - Mexico ensures vaccine for more than 100 million Mexicans
The Government of Mexico formalized pre-purchase contracts for COVID-19 vaccine with AstraZeneca, CanSino Biologics and Pfizer to cover more than 100 million Mexicans. In the framework of the press conference led by President Andrés Manuel López Obrador, the Secretary of Foreign Affairs, Marcelo Ebrard Casaubon, reported on the progress in Mexico's strategy to guarantee universal access and fair prices to the vaccine against COVID- 19. This week, the Government of Mexico signed three pre-purchase contracts with the pharmaceutical companies AstraZeneca, CanSino Biologics and Pfizer to acquire sufficient doses of vaccines to cover, together with those obtained in the COVAX mechanism, up to 116 million Mexican people.
13-Oct-2020 - NVX-CoV2373
Yorkshire Evening Post - Hundreds take part in Novavax Covid-19 vaccine study in University of Leeds The Edge sports hall
The trial is the first Phase Three study to test the effectiveness of the new Novavax COVID-19 vaccine.Volunteers will be receiving the vaccine in the University of Leeds' The Edge Sports Hall.Half of the volunteers will be given the vaccine and the other half a placebo, or "dummy" injection.
9-Oct-2020 - NVX-CoV2373
FXstreet- NVAX Stock Price: Novavax Inc. gains as COVID-19 vaccines hit front-page news after President Trump’s recovery
It has been a historic year for biotech firms as the emergency need for a COVID-19 vaccine has put many small firms on the radars of investors. NASDAQ:NVAX is at the top of that list and after gaining over 4600% year to date, the stock still could have room to move if the results of its Phase 3 clinical trials are successful.
9-Oct-2020 - NVX-CoV2373
CBS Baltimore - 10K Volunteers Participating In Novavax COVID-19 Vaccine Trial In UK
A big step in the race for a coronavirus vaccine- Gaithersburg-based Novavax has kicked off the late-stage trial of its potential vaccine in the UK. It’s testing the effectiveness of the shot among 10,000 people.
8-Oct-2020 – AZD1222
https://ipolitics.ca/2020/10/08/canada-could-order-astrazenecas-covid-vaccine-before-end-of-2020/
iPolitics - Canada could order AstraZeneca’s COVID vaccine before end of 2020
The Canadian government could pre-order doses of the COVID-19 vaccine that’s furthest along in Health Canada’s authorization process before the end of the year, if the vaccine continues to show promising results in its clinical trials.
8-Oct-2020 – Chorus
Radio Siena TV- Diesse Diagnostica Senese, nuovo test per la diagnosi sierologica precoce di Covid-19
Prosegue l’impegno di DIESSE nella lotta alla pandemia, offrendo un nuovo ed efficace supporto all’identificazione dello stato di salute dei pazienti. Il nuovo test sierologico sviluppato da DIESSE consente di rilevare la presenza di anticorpi totali (IgG, IgM ed IgA) contro il virus SARS-CoV-2 con valori di sensibilità e specificità superiori al 99% con metodica automatizzata sulla piattaforma Chorus.
8-Oct-2020 – Chorus
https://www.gonews.it/2020/10/08/covid-diesse-kit-diagnosi/
Go news - Covid-19, dalla senese Diesse un nuovo kit per la diagnosi
Prosegue l’impegno di DIESSE nella lotta alla pandemia, offrendo un nuovo ed efficace supporto all’identificazione dello stato di salute dei pazienti. Il nuovo test sierologico sviluppato da DIESSE consente di rilevare la presenza di anticorpi totali (IgG, IgM ed IgA) contro il virus SARS-CoV-2 con valori di sensibilità e specificità superiori al 99% con metodica automatizzata sulla piattaforma Chorus.
7-Oct-2020 -PLX-PAD
The Jerusalem Post - Phase II COVID-19 placenta cellular therapy trial to launch in Israel
The Haifa-based company Pluristem announced announced Wednesday that it has received approval from the Health Ministry to expand an existing Phase II clinical trial of its treatment for COVID-19 to Israel.
6-Oct-2020 – AZD1222
https://www.fool.com/investing/2020/10/06/astrazenecas-coronavirus-vaccine-is-already-being/
The Motley Fool - AstraZeneca's Coronavirus Vaccine Is Already Being Reviewed for Approval in Canada and Europe. Why Not in the U.S.?
It wasn't all that long ago that many people saw AstraZeneca (NYSE:AZN) as the leader in the race to develop a coronavirus vaccine. The U.K.-based drugmaker partnered with the University of Oxford and got off to a fast start.
6-Oct-2020 – AZD1222
Fierce Pharma - Oxford Biomedica earns U.K. nod for 4th manufacturing suite to boost COVID-19 production
Among the contract manufacturers enjoined in the race for a COVID-19 vaccine, Oxford Biomedica has forged a close relationship with AstraZeneca given its choice location. Now, the company is one step closer to running at full speed with the U.K.'s nod for a new production suite.
3-Oct-2020 – PLX-PAD
Gulf News - Abu Dhabi Stem Cells Centre collaborating with Israeli firm for COVID-19 therapies
Abu Dhabi: UAE's Abu Dhabi Stem Cells Centre (ADSCC) is collaborating with Israeli regenerative medicine company, Pluristem, to advance COVID-19 therapies.
In a statement, ADSCC said it was working to administer Pluristem developed PLX cells via a nebuliser to COVID-19 patients. The collaboration will allow ADSCC to expand its stem cell therapy options with the novel PLX cells, while also enabling Pluristem to leverage the ADSCC’s nebuliser administration experience to develop a new treatment delivery model for PLX cells.
2-Oct-2020 – AZD1222
Market Screener - AstraZeneca : COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India
The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
2-Oct-2020 – PLX-PAD
The Jerusalem Post -Israeli and Emirati companies join forces to develop COVID-19 treatment
Israeli Pluristem Therapeutics Inc. (PSTI,) and Emirati Abu Dhabi Stem Cells Center (ADSCC) unveiled their first joint projects at the Malta Conferences Foundation, a global conference that brings together scientists and researchers from Middle East countries in order to improve the quality of life and regional political stability, while meeting the scientific and technological challenges of the region.
1-Oct-2020 – GRAd-COV2
Start Magazine - Sanofi, Irbm, Reithera: il ruolo dell’Italia per il vaccino anti Covid
Anche l’Italia ha un ruolo chiave per lo sviluppo, la produzione e il confezionamento dei vaccini anti Covid. Oggi lo stabilimento Sanofi di Anagni ha inaugurato le linee di produzione del farmaco sviluppato dalla francese Sanofi in collaborazione con la casa farmaceutica britannica Gsk (che ha lo zampino anche nella fondazione Tls che sarà finanziata dal governo Conte). In Italia verrà infialato, presso la Catalent di Anagni, il vaccino messo a punto dall’Università di Oxford in collaborazione con l’italiana Irbm e prodotto da Astrazeneca. E sempre in Italia, Reithera, di proprietà di Keires Ag, società del settore finanziario con sede a Basilea, ha sviluppato, in collaborazione con lo Spallanzani, un vaccino che viene testato e prodotto nel nostro Paese.
30-Sep-2020 – NVX-COV2373
Bioprocess international - Novavax and J&J ink COVID-19 vaccine fill/finish deals
As Novavax progresses its COVID-19 vaccine candidate through the clinic, the firm has inked numerous deals with contract development and manufacturing organizations (CDMOs) to ensure it will be ready for large-scale production.
The latest focuses on the fill and finish of the Phase II candidate, NVX-CoV2373, with a deal in place with Par Sterile Products – a subsidiary of Endo International.
29-Sep-2020 – NVX-COV2373
The New Indian Express- COVID-19: Mysuru’s JSS Hospital likely to start human trials of Novavax
Mysuru’s JSS Hospital is likely to start phase 2 and 3 trials of the Covid-19 vaccine candidate, Novavax.
The hospital consented to carry out the trial after Pune-based Serum Institute of India approached the hospital, adding another feather to its cap.
23-Sept-2020 – VPM1002
Frankfurter Rundschau - Kampf gegen Corona: Alter Impfstoff könnte den Durchbruch bringen
Ein altbekanntes Vakzin verhindert laut einer Studie Atemwegsinfekte – und könnte auch gegen Mutationen des Coronavirus wirksam sein. Ein gegen Tuberkulose entwickelter Impfstoff könnte auch gegen das Coronavirus helfen. In verschiedenen klinischen Studien soll jetzt die Wirksamkeit gegen Covid-19 getestet werden. Auch ein in den USA entwickelter Antikörper könnte den Durchbruch in der Forschung für einen Impfstoff bringen.
23-Sept-2020 – mAbCo19
Il Cittadino - Coronavirus: AchilleS Vaccines è partner strategico di TLS
SIENA. AchilleS Vaccines e Fondazione Toscana Life Sciences (TLS) hanno siglato un Joint Venture Agreement orientato al finanziamento e alla gestione dello sviluppo industriale del prodotto MAbCo19, frutto della ricerca su anticorpi monoclonali umani come soluzione terapeutica al SARS-CoV-2.
21-Sept-2020 – AZD1222
The week – Human trials of Oxford coronavirus vaccine paused over ‘spinal-cord disease fears’
Human trials of the Oxford coronavirus vaccine are facing delays in the US after a participant suffered a rare neurological condition, according to a leaked document.
15 Sept-2020 – NVX-COV2373
Fierce Pharma - Novavax adds antigens to COVID-19 production pact with Indian vaccines giant
Despite a lackluster history of taking vaccines to market, Maryland's Novavax is streaking through clinical trials for its promising COVID-19 shot candidate. Going commercial is a whole other beast, however, and Novavax is now expanding one of its key manufacturing deals to aid the cause.
14-Sept-2020 – AZD1222
Fierce Biotech - AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine
Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the U.K.
Announced over the weekend, the U.K. Big Pharma said its vaccine, known as AZD1222, “has resumed in the U.K. following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.”
14-Sept-2020 – GRAd-Cov2
ADNKronos - Covid, ReiThera: "Per vaccino corsa contro il tempo"
ReiThera è "coinvolta a pieno ritmo nel raggiungimento di questo importante obiettivo: si tratta di una vera e propria corsa contro il tempo per verificare la sicurezza, l’immunogenicità e l’efficacia del vaccino sull’uomo affinché possa essere messo a disposizione di tutto il Paese nel più breve tempo possibile".
12-Sept-2020 – V591
Reuters - Merck starts recruitment for COVID-19 vaccine trial
U.S. drugmaker Merck & Co Inc has begun recruiting participants to its early-stage COVID-19 vaccine study, according to the government database clinicaltrials.gov.
12-Sept-2020 – AZD1222
https://www.channelnewsasia.com/news/world/astrazeneca-trials-of-covid-19-vaccine-resuming-13105804
Channel News Asia - AstraZeneca resumes UK trials of COVID-19 vaccine halted by patient illness
AstraZeneca has resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs, the company said on Saturday (Sep 12).
09-Sep-2020- AZD1222
The Wire (India) COVID-19: AstraZeneca Halts Oxford Vaccine Trial After a Report of Adverse Effects
The British-Swedish pharma company AstraZeneca has temporarily halted phase 3 clinical trials of the AZD1222 COVID-19 vaccine after a trial participant reportedly developed severe adverse reactions, STAT News has reported. Reuters quoted company spokeswoman Michele Meizell: “Our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee.”
09-Sep-2020- AZD1222
The Conversation AU: Halting the Oxford vaccine trial doesn’t mean it’s not safe – it shows they’re following the right process
Only days after the federal government announced a A$1.7 billion vaccine deal to roll out COVID-19 vaccines to Australians in 2021, one of the two candidates has halted its phase 3 trials after a participant became ill. The AZD1222 vaccine, considered one of the frontrunners in the global race for a COVID-19 vaccine, was developed by the University of Oxford and has been undergoing testing with British-Swedish pharmaceutical company AstraZeneca.
09-Sep-2020- Grad-Cov 2
https://www.rfi.ro/social-124714-italia-accelereaza-testarea-propriul-vaccin-anticovid
RFI Romania: Italia accelerează testarea pe om a propriul vaccin anticovid (Italy is accelerating human testing for its own vaccine)
Italy is accelerating the human testing of Grad-Cov 2 vaccine. The vaccine is produced and patented by a company in Rome and would be approved for widespread use in the spring, if the test results allow. Meanwhile, more and more volunteers from the age of 18 are receiving doses of the Italian vaccine. At the Borgo Roma hospital in Verona, 6 volunteers aged between 18 and 54 have already received their dose of Grad-Cov 2 vaccine, developed, produced and patented by the Italian biotechnology company, ReiThera. This is the first of three phases of the Italian human vaccine testing. Tomorrow the number of vaccinated volunteers will be double so that a total of 43 people will receive the vaccine at the hospital in Verona. One third of the volunteers are doctors, nurses or medical students. Volunteers will be monitored for six months and if during this time they did not register side effects and produced antibodies - "we can say that we are on the right track in finding the vaccine," says Stefano Milleri, director of the Center for Clinical Research.
07-Sep-2020- mAbCo19
http://www.quotidianosanita.it/regioni-e-asl/articolo.php?articolo_id=87730
Quotidiano Sanità: Speranza in visita al polo Toscana Life Sciences. Rossi: “Verrà da Siena il nuovo farmaco per curare il coronavirus”(Speranza visits the Toscana Life Sciences hub. Rossi: "The new drug to cure the coronavirus will come from Siena")
The new drug that will allow Covid to be treated will come from Siena. The president of the Tuscany Region, Enrico Rossi, is convinced of this , and today he visited together with the Minister of Health, Roberto Speranza, the headquarters of Toscana Life Sciences, the Sienese technology and research center, financed iby the Tuscany Region. For Rossi, “TLS is the only center in Italy that can boast hundreds of pharmaceutical patents and that can compete globally with all the countries that are fighting against Covid”.
07-Sep-2020-mAbCo19
Siena News: L’Italia punta su Tls, 50 milioni di euro per la produzione del farmaco anticovid (Italy is betting on Toscana Life Sciences (Tls), 50 million euros for the production of the anticovid drug)
Fifty million euro funding for the anticovid drug, with a potential to rise to 80 million. These are the funds that the Italian Government will invest in the project to be developed in the Tls laboratories. The drug will be produced in the Menarini plants in Florence.
07-Sep-2020- nvx-cov2373
http://www.koreabiomed.com/news/articleView.html?idxno=9129
Korea BioMedical review: Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
The New England Journal of medicine published the paper "Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine". The results show that at 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum.
01-Sep-2020- AZD1222
European Pharmaceutical review: Phase III testing of AstraZeneca’s AZD1222 vaccine has begun in the US
A multi-site, Phase III clinical trial evaluating AZD1222, an investigational COVID-19 vaccine, has begun in the US. The trial will enrol approximately 30,000 adult volunteers (aged 18 plus) at 80 US sites to evaluate if the candidate vaccine can prevent symptomatic COVID-19. The 30,000 participants in the double-blind US trial will be randomly assigned to either the investigational vaccine group or the placebo group in a ratio of 2:1. After an initial screening, participants will receive two injections of either the investigational vaccine or a saline placebo approximately four weeks apart. The trial is primarily designed to determine if AZD1222 can prevent symptomatic COVID-19 after two doses. However, it will also evaluate if the vaccine candidate can prevent SARS-CoV-2 infection regardless of symptoms and if it can preclude severe COVID-19. It will also assess if the experimental vaccine can reduce the incidence of emergency department visits due to COVID-19.
31-Aug-2020 - AZD1222
BusinessWire: Development of COVID-19 Vaccine AZD1222 Expands Into US Phase III Clinical Trial Across All Adult Age Groups
AZD1222 development expanded into a Phase III clinical trial in the US to assess its safety, efficacy and immunogenicity. Trial centers across the US are recruiting up to 30,000 adults aged 18 years or over from diverse racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions, including those living with HIV, and who are at increased risk of infection from the SARS-CoV-2 virus.
31-Aug-2020 - Grad-CoV2
Sputnik News: Grad-CoV2, candidato vaccino italiano in sperimentazione al Policlinico di Verona (Grad-CoV2, Italian vaccine candidate being tested at the Verona Polyclinic).
The trial of the Italian Grad-CoV2 vaccine candidate to verify the immune response to the Sars-CoV2 virus, starts on Monday 31 August at the Policlinico di Verona. Today the first three volunteers will receive the injection, out of a total of 70 chosen from the many applicants.
31-Aug-2020 - NVX-CoV2373
NASDAQ: Novavax Inks Deal With Canadian Government To Sell Up To 76 Mln Doses Of Its COVID-19 Vaccine
(RTTNews) - Biotechnology company Novavax, Inc. (NVAX) announced Monday it has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, Novavax' COVID-19 vaccine. Novavax and Canada expect to finalize an advance purchase agreement under which Novavax will supply doses of NVX-CoV2373 to Canada beginning as early as the second quarter of 2021.
31-Aug-2020 - NVX-CoV2373
CNBC: Canada to purchase 76 million doses of Novavax coronavirus vaccine.
The company says Novavax said it expects to finalize an agreement that would see it begin to supply Canada with doses “as early as the second quarter of 2021,” the company said. The company’s vaccine, called NVX-CoV2373, is currently in phase two trials. Novavax has previously said it could begin late-stage trials as early as October.
29-Aug-2020 - PLX-PAD
Jerusalem Post: FDA clears Haifa-based Pluristem’s COVID-19 Expanded Access Program
The US Food and Drug Administration has approved the use of Pluristem’s PLX-PAD cells in patients who are suffering from acute respiratory distress syndrome brought on by COVID-19, but who do not qualify for the company’s clinical trial.
26-Aug-2020 - Grad-CoV2
EU Reporter: Mexico signs up to Italian vaccine trial for Coronavirus – minister
Mexico is due to take part in clinical trials of an Italian vaccine GRAd-COV2 being developed by the National Institute for Infectious Diseases ‘Lazzaro Spallanzani’ in Rome.against the coronavirus. The Lazzaro Spallanzani institute this week announced it would conduct trials on 90 volunteers over the coming weeks, with the hope a vaccine may be available by spring of next year. Ebrard did not say when Mexico would begin the trials of the vaccine.
24-Aug-2020- Grad-CoV2
S.I.R. Agenzia D’Informazione: Coronavirus Covid-19: iniziata allo Spallanzani la sperimentazione sull’uomo di GRAd-CoV2, il candidato vaccino italiano contro Sars-CoV-2 (Coronavirus Covid-19: human experimentation of GRAd-CoV2, the Italian vaccine candidate against Sars-CoV-2, started at Spallanzani)
The human trial of GRAd-CoV2, the Italian vaccine candidate against Sars-CoV-2, began this morning at the National Institute of Infectious Diseases (Inmi) "Lazzaro Spallanzani" in Rome. made, produced and patented by the Italian biotechnology company ReiThera. The experiment, developed by a team of Spallanzani researchers and clinicians in collaboration with ReiThera, will be carried out on ninety volunteers divided into two age groups: 45 between 18 and 55 years, as many over the age of 65.
24-Aug-2020- NVX-CoV2373
Globe NewsWire: Novavax Initiates Phase 2 Portion of Phase 1/2 Clinical Trial of COVID-19 Vaccine
Novavax, Inc. a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the first volunteers have been enrolled in the Phase 2 portion of its ongoing clinical trial to evaluate the immunogenicity and safety of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The Phase 2 clinical trial expands on the age range of the Phase 1 portion by including older adults 60-84 years of age as approximately 50 percent of the trial’s population.24-Aug-2020 – GRAd-COV2
Corriere della sera - Vaccino anti Covid allo Spallanzani: oggi iniziano i test di Reithera sull’uomo
Antonella Folgori, ad di Reithera, annuncia l’avvio della sperimentazione del vaccino per il coronavirus pensato in Italia che sarà condotta dallo Spallanzani con dosi studiate e preparate nello stabilimento di Castel Romano
24-Aug-2020 – NVX-COV2373
Reuters - Novavax starts enrollment for phase two of COVID-19 vaccine trial
Novavax Inc said on Monday it has begun enrolling volunteers for the second phase of an ongoing clinical trial of its COVID-19 vaccine candidate, with interim data expected in the fourth quarter of 2020.
20-Aug-2020 – NVX-COV2373
Washington Business Journal - Novavax lease brings newly converted Gaithersburg lab building to full occupancy
Gaithersburg-based Novavax Inc. (NASDAQ: NVAX), which has secured a multibillion-dollar commitment to develop a Covid-19 vaccine, recently inked a lease for lab space at 704 Quince Orchard Road, co-owner Scheer Partners announced Thursday.
19-Aug-2020 – PLX-PAD
https://www.israel21c.org/israelis-and-emiratis-to-develop-covid-stem-cell-therapy/
Israel21c- Israelis and Emiratis to develop Covid stem-cell therapy
Fast on the heels of the agreement between Israel and the United Arab Emirates (UAE) to establish full diplomatic relations, Haifa-based Pluristem Therapeutics signed a non-binding memorandum of understanding (MoU) with the Abu Dhabi Stem Cells Center to advance cell therapies for diseases including Covid-19.
17-Aug-2020 – PLX-PAD
https://en.globes.co.il/en/article-pluristem-teams-with-1001339557
Globes - The two sides have signed an MOU on cooperation in developing stem cell-based therapies for coronavirus and other diseases.
The normalization agreement between Israel and the United Arab Emirates (UAE) has not yet been signed, but several Israeli healthcare companies from the two countries are cementing scientific and business ties that they had already started forming discretely.
17-Aug-2020 – NVX-COV2373
MarketWatch - Novavax starting trial of COVID-19 vaccine in South Africa
Novavax NVAX, +6.15% said it's beginning a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, its COVID-19 vaccine candidate. The Bill & Melinda Gates Foundation providing $15 million grant toward trial, said Novavax, which last week agreed to sell its vaccine to the U.K. government if successful.
17-Aug-2020 – NCX-COV2373
Biopharma-reporter – UK strikes deals with J&J, Novavax to source 90m COVID-19 vaccines
UK government reaches agreements to buy millions of COVID-19 vaccines from Johnson & Johnson and Novavax, bringing total stockpile up to 340 million.
17-Aug-2020 – NVX-COV2373
Washington Business Journal - Novavax is racking up Covid-19 vaccine deals for global markets. And the stock shows.
This agreement is the latest in a string the Gaithersburg biotech has inked in the past week.
17-Aug-2020 – NVX-COV2373
The Hill - Novavax coronavirus vaccine candidate begins phase two trials
Novavax on Monday announced it would proceed with phase two clinical trials to determine if its coronavirus vaccine candidate showed positive results for patients.
17-Aug-2020 – NVX-COV2373
The Wall Street Journal - Covid-19 Vaccine Candidate From Novavax Starts Midstage Trial
The Phase 2 study will test the safety and efficacy of the vaccine in South Africa, with 2,665 healthy adults and another 240 who are HIV positive
17-Aug-2020 – PLX-PAD (in Hebrew)
N12 - An interview with Pluristem’s CEO, Yaky Yanay, on Israeli TV
N12 News Israel, discuss the latest milestone #UAE #Israel collaboration with ADSCC Abu dhabi Stem Cells Center to advance cell therapies for the benefit of patients throughout the world.
16-Aug-2020 – AZD1222
Yahoo finance - AstraZeneca Clinches First Supply Deal With EU For Covid-19 Vaccine
AstraZeneca has reached an agreement with the European Commission (EC) to supply up to 400 million doses of its AZD1222 COVID-19 vaccine candidate. AstraZeneca (AZN) said that the agreement builds on the existing accord with Europe’s Inclusive Vaccines Alliance spearheaded by Germany, France, Italy and the Netherlands. The new agreement will give all EU member states the option to access the vaccine candidate in an equal manner at no profit during the coronavirus pandemic. The terms also allow EU member states to redirect doses to other European countries.
14-Aug-2020 – NVX-COV2373
Washington Business Journal- Novavax is racking up Covid-19 vaccine deals for global markets. And the stock shows. (paid content)
14-Aug-2020 – AZD1222
https://www.fiercepharma.com/pharma/astrazeneca-europe-ink-covid-vaccine-supply-deal-for-400m-doses
Fierce Pharma- Busy AstraZeneca inks yet another big COVID-19 vaccine deal, this time with EU
As Johnson & Johnson, Sanofi and GlaxoSmithKline move ahead in advanced COVID-19 vaccine supply negotiations with the EU, AstraZeneca has signed into the union’s first finalized agreement.
14-Aug-2020 – AZD1222
https://www.wsj.com/articles/eu-secures-coronavirus-vaccine-deal-with-astrazeneca-11597418453
The Wall Street Journal - EU Secures Coronavirus Vaccine Deal With AstraZeneca
The European Union, seeking to catch up with other parts of the world for access to coronavirus treatments, agreed with AstraZeneca PLC to buy as many as 400 million doses of the U.K. drugmaker’s Covid-19 vaccine now in development.
14-Aug-2020 – VPM1002
The Economic Times – TB vaccine shows encouraging results against coronavirus in phase-3 clinical trials
India may have hope in a fourth vaccine being tested as a preventive and immunity booster against Covid-19. VPM1002, a tuberculosis vaccine, is showing encouraging results against the coronavirus infection in Phase-III clinical trials being conducted in Germany.
14-Aug-2020 - NVX-COV2373
Reuters - Novavax to deliver 60 million doses of COVID-19 vaccine candidate to UK
U.S. drug developer Novavax Inc (NVAX.O) said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373.
14-Aug-2020 – NVX-COV2373
Yahoo finance - Novavax Inks UK Supply Deal For 60M Doses Of Its Covid-19 Vaccine Candidate
Novavax said on Friday that the US drug developer has entered into a purchase agreement with the UK government for the supply of 60 million doses of NVX-CoV2373, its COVID-19 vaccine, sending shares up 6% in pre-market trading.
13-Aug-2020 – NVX-COV2373
https://en.yna.co.kr/view/AEN20200813009500320?section=news
Yonhap news - SK Bioscience to manufacture Novavax's coronavirus vaccine candidate
SEOUL, Aug. 13 (Yonhap) -- SK Bioscience Co., a vaccine unit of South Korea's SK Group, said Thursday that it has secured a deal to manufacture a component of the U.S.-based biotechnology company Novavax Inc.'s experimental coronavirus vaccine.
10-Aug-2020 – NVX-COV2372
Boston Business Journal - Takeda enters Covid-19 vaccine race with $285M manufacturing deal
After declining to develop a Covid-19 vaccine of its own, Takeda Pharmaceutical Co. Ltd. is lending its manufacturing expertise in the field to another startup.
8-Aug-2020 – AZD1222
Business Standard - Serum Institute to provide Covid vaccine to 92 countries at Rs 250 a dose
Serum Institute of India (SII) has inked a pact with the Bill and Melinda Gates Foundation, as well as Gavi, The Vaccine Alliance, to make 100 million doses of a potential vaccine. This is for low- and medium-income countries, and with a price cap of Rs 250 a dose.
7-August-2020 – GRAd-COV2
Italia Sera - Vaccino antiCovid: dal 24 agosto lo Spallanzani avvierà i primi test sull’uomo del ‘Grad-Cov2’
”Sono arrivate le prime dosi del vaccino made in Italy” all’Istituto Spallanzani di Roma per la “sperimentazione sull’uomo” che, ha aggiunto, prenderà il via “dal 24 agosto”.
7-Aug-2020- AZD1222
Deutsche Apotheker Zeitung - AstraZeneca will Covid-19-Vakzine zum Selbstkostenpreis anbieten
Es ist noch nicht so weit mit einem Corona-Impfstoff. Trotzdem müssen sich die Regierungen schon jetzt Gedanken über den Zugang zu den Vakzinen und über die voraussichtlichen Kosten machen. Aus Sicht der Hersteller ist der Preis auch ein wesentliches Wettbewerbsinstrument. AstraZeneca meint, dass sein COVID-19-Impfstoff eventuell nur ein paar Dollar kosten könnte. Damit könnten Moderna und Pfizer wohl bei weitem nicht mithalten.
5-Aug-2020 - NVX-CoV2373
https://www.nytimes.com/2020/08/04/world/coronavirus-cases.html#link-1228a480
The New York Times - Novavax sees encouraging results from two studies of its experimental vaccine.
Novavax, the little-known Maryland company that received a $1.6 billion deal from the federal government for its experimental coronavirus vaccine, announced encouraging results in two preliminary studies on Tuesday.
5-Aug-2020 - NVX-CoV2373
Handelsblatt - Hersteller Novavax: Gute Ergebnisse nach ersten Tests von Corona-Impfstoff
Ein experimenteller Coronavirus-Impfstoff der US-Biotech-Firma Novavax hat nach Angaben des Herstellers bei ersten Tests ermutigende Ergebnisse gezeigt. In der ersten Phase der klinischen Tests hätten alle Probanden Antikörper gegen den Erreger Sars-CoV-2 entwickelt, erklärte das Unternehmen am Dienstag (Ortszeit). Bei den 131 Teilnehmern im Alter von 18 bis 59 Jahren habe es keine schweren Nebenwirkungen gegeben, hieß es weiter. Die Ergebnisse der in Australien durchgeführten Tests wurden jedoch noch nicht von unabhängigen Forschern geprüft und veröffentlicht.
5-Aug-2020 - NVX-CoV2373
https://video.foxbusiness.com/v/6178362555001/?playlist_id=3166411554001#sp=show-clips
Fox Business - Novavax R&D head: ‘Hopeful’ coronavirus vaccine can be deployed in December
Novavax Research and Development President Dr. Gregory Glenn on the next steps for the company’s coronavirus vaccine.
4-Aug-2020 – V591 (formerly COVAX)
Bioprocess International - Merck betting on ‘swish-and-swallow’ and single administration COVID vaccines
A recombinant vesicular stomatitis virus-based COVID-19 vaccine may be active when administered orally, says Merck as it begins clinical manufacture from facilities in Pennsylvania.
4-Aug-2020 – GRAd-COV2
Gazetta delle milia - UniCredit eroga il primo finanziamento leasing in Italia con Garanzia Sace a favore di ReiThera Srl
Le nuove risorse finanziarie saranno utilizzate sempre nell’ambito degli investimenti sul fronte della ricerca scientifica di un vaccino contro il virus Covid-19 e per l’acquisto di specifici macchinari destinati alla produzione, al confezionamento e distribuzione del vaccino stesso.
3-Aug-2020 - PLX-PAD
Disney-ABC - Broadway Set Designer Survives Covid-19 After 46 Days On Ventilator
Ed Pierce and his wife Pixie talk about his “Hail Mary” life-saving treatment that they both credit with saving his life during his COVID-19 battle.
30-July-2020 – AZD1222
https://uk.reuters.com/article/us-astrazeneca-results-vaccine-liability-idUKKCN24V2EN
Reuters - AstraZeneca to be exempt from coronavirus vaccine liability claims in most countries
AstraZeneca has been granted protection from future product liability claims related to its COVID-19 vaccine hopeful by most of the countries with which it has struck supply agreements, a senior executive told Reuters.
27-July-2020 – VPM1002
Express Pharma - SII enrols 6000 subjects for efficacy trial of rBCG vaccine, VPM1002 against COVID-19
The DBT-BIRAC supported trial aims to evaluate the ability of VPM1002 in reducing infection incidence and severe disease outcomes of COVID-19 among high-risk persons of advanced age or co-morbidities and high-exposure healthcare workers
27-July-2020 – mAbCo19
OMAR- Tre diversi anticorpi monoclonali anti-SARS-CoV-2 saranno prodotti per i primi test sull’uomo
Il MAD (Monoclonal Antibody Discovery) LAB di Fondazione Toscana Life Sciencesannuncia di aver terminato la fase di discovery di anticorpi monoclonali umani in risposta all’infezione da SARS-CoV-2, per l’impiego a scopo profilattico/terapeutico e come esca molecolare per la ricerca di antigeni per lo sviluppo di vaccini. Sono 3 gli anticorpi selezionati a partire da più di 4000 candidati ottenuti dal sangue di pazienti convalescenti o guariti da COVID-19, ricevuto grazie alla collaborazione con INMI Spallanzani e, successivamente, con la Azienda Ospedaliero-Universitaria Senese e che, dopo essere stati oggetto di domanda di brevetto, potranno essere prodotti per i test clinici.
27-July-2020 – NVX-CoV2373
bizjournals - Novavax adds Fujifilm to growing manufacturing roster for Covid-19 vaccine
Novavax Inc. (NASDAQ: NVAX) is looking to get its Covid-19 vaccine through clinical trials with help from global contract development and manufacturing organization Fujifilm Diosynth Biotechnologies.
24-July-2020 – mAbCo19
La Nazione Siena - "I nostri anticorpi prima del vaccino La cura senese contro l’epidemia"
La dottoressa Sala a capo del laboratorio Tls che ha individuato tre proteine monoclonali molto efficaci.
24-Jul-2020
Reuters - EU eyes COVID-19 vaccines at less than $40, shuns WHO-led alliance
The European Union is not interested in buying potential COVID-19 vaccines through an initiative co-led by the World Health Organisation as it deems it slow and high-cost, two EU sources told Reuters, noting the bloc was in talks with drugmakers for shots cheaper than $40.
22-July-2020 – mAbCo19
https://www.gazzettadisiena.it/anti-covid-19-rappuoli-a-siena-vogliamo-fare-qualcosa-di-speciale/
Gazzetta di Siena - Anti Covid 19, Rappuoli: “A Siena vogliamo fare qualcosa di speciale”
Lo scienziato sugli anticorpi monoclonali: “A Siena abbiamo effettivamente selezionato tre anticorpi che sono mille volte più potenti degli altri”
21-July-2020
Times of India - Possible but not certain Covid-19 vaccine rolled out this year – Oxford developer
The university of Oxford’s possible Covid-19 vaccine could be rolled out by the end of the year but there is no certainty that will happen, the lead developer of the vaccine said on Tuesday.
21-July-2020 – AZD1222
The New York Times - South Korea's SK Bioscience in Deal With AstraZeneca on Vaccine
South Korea's SK Bioscience has agreed to manufacture AstraZeneca's experimental COVID-19 vaccine to help the British company build global supplies of the vaccine that has shown promise against the new coronavirus, it said on Tuesday.
21-July-2020 – AZD1222
Hindustan Times - How was AZD1222 made, when is first dose expected: Things to know about Oxford University’s Covid-19 vaccine
The researchers on Monday announced the results of the first phase of a Covid-19 vaccine developed by the University of Oxford. The vaccine appears safe and induces a strong immune response within the body, the results published in leading scientific journal The Lancet show.
20-July-2020 – plant based protein
https://allafrica.com/stories/202007200987.html
South Africa: UCT to Boost COVID-19 Testing Capability in SA
The University of Cape Town's (UCT) Biopharming Research Unit (BRU), under the leadership of Professor Ed Rybicki, has received government funding to assist in the production of diagnostic reagents for COVID-19.
20-July-2020 – AZD1222
https://www.pharmaceutical-business-review.com/news/azd1222-astrazeneca-oxford-trial/
Pharmaceutical business review - AZD1222 delivers strong immune response in phase I/II Covid-19 vaccine trial
AstraZeneca said that the AZD1222 vaccine candidate (formerly ChAdOx1 nCoV-19) licensed from the Oxford University has shown strong immune responses against the SARS-CoV-2 virus in all participants in a phase I/II trial.
20-July-2020 – AZD1222
NRC - Vaccins uit China en Oxford zijn veilig en roepen afweerreactie op
De eerste proeven in vrijwilligers met twee experimentele vaccins tegen Covid-19 laten zien dat beide middelen een krachtige afweer oproepen tegen het nieuwe coronavirus SARS-CoV-2 en dat ze veilig zijn zonder al te veel bijwerkingen. Dat is het hoopvolle nieuws dat maandag online werd gepubliceerd door het medische vakblad The Lancet.
20-July-2020 – AZD1222
The Economist - Trials of a vaccine and new drug raise hope of beating covid-19
IN EARLY JANUARY researchers at Oxford University started work on a vaccine for covid-19. At that time the illness was a tiny outbreak without a proper name. Six months on, with more than 600,000 people dead, the Oxford team is leading a race to develop a vaccine that could halt the pandemic. The vaccine has been raced into production around the world by AstraZeneca, a British-Swedish drug company, and billions of doses are planned. But two key questions remain: is it safe and does it work? The first glimmers of the answers have just arrived, with the publication in the Lancet on July 20th of a paper about a trial of the Oxford vaccine, which began in April and involved 1,000 volunteers.
20-July-2020 -AZD1222
Bloomberg - Oxford Vaccine Shows Early Promise But Market Is Unconvinced
A coronavirus vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, and is now set to move into larger trials that are likely to be decisive on how effective they truly are.
20-July-2020 -AZD1222
RTL Nieuws - Veelbelovende eerste resultaten van coronavaccin dat Nederland heeft besteld
Het coronavaccin dat al in grote hoeveelheden door Nederland is ingekocht is veilig, heeft weinig bijwerkingen en zorgt ervoor dat het immuunsysteem het virus aanvalt. Dat blijkt uit de eerste testresultaten van de Universiteit van Oxford.
20-July-2020 – AZD1222
Times Now News - Oxford’s COVID-19 vaccine phase 1 data expected today; Serum Institute to begin human trials from next month
The Lancet medical journal is expected to publish the phase 1 clincial trial data of Oxford and AstraZeneca's COVID-19 vaccine candidate, AZD1222 COVID-19 vaccine, formerly called ChAdOx1 nCoV-19, today, July 20. On Thursday, July 16, media reports in the UK said the team of researchers at Oxford have discovered that the vaccine could offer ‘double protection’ against the novel coronavirus (SARS-CoV-2) following early stage human trials. Meanwhile, vaccine maker Serum Institute of India (SII) has reportedly said it would start human trials of the Oxford- AstraZeneca’s coronavirus vaccine candidate from next month.
20-July-2020 – AZD1222
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext
The Lancet - Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2.
20-July-2020 – VPM1002
Welt - Wie ein Tuberkulose-Impfstoff auch gegen Covid-19 helfen könnte
In Studien wird aktuell untersucht, ob der Tuberkulose-Impfstoff auch gegen Sars-CoV-2 Viren helfen kann. Prof. Stefan Kaufmann erklärt, wie man auf diese Idee gekommen ist.
19-July-2020 – AZD1222
News Medical Life Sciences - Oxford University and AstraZeneca to publish eagerly-anticipated COVID-19 trial results today
The coronavirus pandemic is still rapidly spreading across the globe, infecting more than 14.44 million people. With more than 188 countries and territories affected, scientists are racing to develop a vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19).
18-July-2020 – AZD1222
Financial Express - Oxford-AstraZeneca Coronavirus vaccine: Serum Institute says it will take a long time to reach everyone
“It will be a long time before everyone gets a vaccine because of the number of doses that needs to be administered,” said Adar Poonawalla, CEO, Serum Institute, who has partnered with Oxford-AstraZeneca to support in COVID-19 vaccine development.
18-July-2020 -mAbCo19
Canale3 - COVID-19: conclusa la fase di discovery per il progetto MabCo19 di Toscana Life Sciences: 3 gli anticorpi monoclonali che saranno prodotti per i test clinici.
Il MAD (Monoclonal Antibody Discovery) LAB di Fondazione Toscana Life Sciences annuncia di aver terminato la fase di discovery di anticorpi monoclonali umani in risposta all’infezione da SARS-CoV-2, per l’impiego a scopo profilattico/terapeutico e come esca molecolare per la ricerca di antigeni per lo sviluppo di vaccini. Sono 3 gli anticorpi selezionati a partire da più di 4000 candidati ottenuti dal sangue di pazienti convalescenti o guariti da COVID-19, ricevuto grazie alla collaborazione con INMI Spallanzani e, successivamente, con la Azienda Ospedaliero-Universitaria Senese e che, dopo essere stati oggetto di domanda di brevetto, potranno essere prodotti per i test clinici.
17-July-2020 – PLX-PAD
https://www.calcalistech.com/ctech/articles/0,7340,L-3840111,00.html
Ctech- Israel third only to U.S. and China in Covid-19 solutions, says life sciences expert
We don't talk anymore about devices or drugs. We talk about healthtech convergence, which for me is the future," explains Dr. Laurent Choppe, Managing Partner at Cukierman & Co. Life Sciences
16-July-2020 – NVX-CoV2373
https://www.nytimes.com/2020/07/16/health/coronavirus-vaccine-novavax.html
The New York Times - How a Struggling Company Won $1.6 Billion to Make a Coronavirus Vaccine
Novavax just received the Trump administration’s largest vaccine contract. In the Maryland company’s 33-year history, it has never brought a vaccine to market.
16-July-2020 – VPM1002
MDR Thüringen - Thüringer Forscher testen Tuberkulose-Mittel gegen Covid-19
Ein Erfurter Forschungs-Institut testet einen Tuberkulose-Impfstoff gegen die Covid-19-Infektion. Wie das Unternehmen Socratec der Thüringer Allgemeinen mitteilte, wurde das Mittel eigentlich gegen Tuberkulose entwickelt. Bei den Tests soll nun herausgefunden werden, ob es auch bei einer Infektion mit dem Corona-Virus wirkt. Die Forscher hoffen demnach, dass ein schwerer Verlauf der Corona-Infektion abgemildert werden kann. Das Mittel soll bei älteren Menschen und Mitarbeitern von Krankenhäusern und Arztpraxen getestet werden.
15-July-2020 – AZD1222
Bloomberg - Covid Vaccine Front-Runner Is Months Ahead of Her Competition
The University of Oxford candidate, led by Sarah Gilbert, might be through human trials in September. AstraZeneca has lined up agreements to produce 2 billion doses. Could this be the one?
14-July-2020 – AZD1222
Fierce Biotech - AstraZeneca taps IQVIA to 'warp speed' its U.S. pandemic vaccine research
Operation Warp Speed is living up to its name as, under the project, one of the COVID-19 vaccine front-runners AstraZeneca is teaming up with life science services company IQVIA to boost its work on the shot.
11-July-2020 – AZD1222 & NVX-CoV2373
India Today- The vaccine candidates that come as a ray of hope during the Covid pandemic
More than 150 vaccine candidates from 12 countries, including India, are in the race to counter the deadly Covid-19 that has infected over 1.2 crore people and killed more than 5.5 lakh worldwide in a little over six months. Of them, a dozen vaccines have entered the clinical trial phase.
10-July-2020 – NVX-CoV2373
Yahoo Finance - Can Novavax Win FDA Approval for COVID-19 Vaccine Before Year End? Analyst Weighs In
After initially being excluded from the U.S. government’s Operation Warp Speed (OWS) program, Novavax (NVAX) joined the list of companies eligible for federal support.
On July 7, the vaccine specialist announced it will receive $1.6 billion from the federal government to support the development of its COVID-19 vaccine candidate, NVX-CoV2373.
8-July-2020 - NVX-CoV2373
15min.lt (source BNS): AV skyrė 2 mlrd. JAV dolerių dviem bendrovėms, kuriančioms vaistus nuo COVID-19. (The US has allocated $ 2 billion. USD for two companies developing COVID-19 drugs)
The U.S. federal government has allocated $ 2 billion. USD to two pharmaceutical companies to support the development and production of experimental drugs and a possible vaccine against coronavirus infection COVID-19. After receiving this funding, the company intends to produce 100 million. vaccine doses - this is expected to happen by the end of this year.
8-July-2020 - NVX-CoV2373
https://www.apteka.ua/article/554207
Apteka Online: Правительство США финансирует создание вакцин и биопрепаратов против COVID-19. (The US government finances the creation of vaccines and biological products against COVID - 19)
The US government is funding the development of vaccines and biological products. Novavax reportedly received 1.6Billion dollars to finance the development and launch of the large-scale production of an experimental vaccine against COVID-19.
8-July-2020 - NVX-CoV2373
https://finance.sina.com.cn/stock/usstock/c/2020-07-08/doc-iirczymm1279040.shtml
Sina.com.cn: 开盘：关注疫情与复苏前景 美股小幅高开. (US stocks opened slightly higher following the epidemic situation and recovery prospects)
Novavav is working on a vaccine that is one of more than 130 candidate coronavirus vaccines worldwide. If the clinical trial is successful, it will provide 100 million doses of vaccine by the end of 2020. The US epidemic situation is grim, with more than 60,000 newly diagnosed cases yesterday, of which nearly half came from 4 states including Arizona.
8-July-2020 - NVX-CoV2373
https://www.industriepharma.fr/covid-19-novavax-recoit-1-6-mrd-du-gouvernement-americain,112331
Industrie Pharma: Covid-19 : Novavax reçoit 1,6 Mrd $ du gouvernement américain. (Covid-19: Novavax receives $ 1.6 billion from the US government)
After CEPI (Coalition for Epidemic Preparedness Innovations) last June , the American government has provided funding to the American biotech Novavax for its Covid-19 vaccine project. Called "Warp Speed", this operation includes aid amounting to 1.6 billion dollars (1.4 billion €), ensuring the United States gets the first 100 million doses in the event of proven effectiveness. This funding will be used to complete the clinical development of NVX-CoV2373, a vaccine candidate developed from antigens derived from the SARS-Cov-2 protein Spike. The phase III clinical trial of this active ingredient is scheduled for fall 2020, after the phase I / II immunogenicity and safety results expected by the end of July, and should include up to 30,000 participants.
8-July-2020 - NVX-CoV2373
El Pais (Brazil): EUA pagam 1,6 bilhão de dólares à Novavax para acelerar a produção de uma vacina contra a covid-19 (US pays $ 1.6 billion to Novavax to accelerate the production of a vaccine against covid-19)
The United States government has allocated $ 1.6 billion (about $ 8.61 billion) to the biotechnology company Novavax to accelerate its production of the coronavirus vaccine. The investment is part of the Operation Warp Speed program , created in mid-May to provide financial support to companies that are developing the most promising treatments to control the pandemic. Novavax, which has never launched a product on the market, said on Tuesday that it will use the money to complete studies of the latest testing stages, manufacture on a large scale and deliver 100 million doses in late 2020 and early 2021, if the test results show that the vaccine (NVX-CoV2373) is safe and effective.
8-July-2020 - NVX-CoV2373
NASDAQ: CRVS, HEPA Jump On COVID-19 Drug Bandwagon, LVGO In Good Health, NVAX Joins $100 Stock Price Club
Shares of Novavax Inc. (NVAX) climbed more than 30 percent on Tuesday, following news that the Company has been selected to participate in Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 in 2021. The Company's COVID-19 vaccine candidate NVX-CoV2373 is under a phase I/II trial, with preliminary immunogenicity and safety results from the phase I portion of the trial expected in July 2020. If the results are promising, the phase II portion of the trial will be initiated quickly. The Coalition for Epidemic Preparedness Innovations has provided up to $388 million in funding to support the phase I/II trial.
8-July-2020 -mAbCo19
Siena News: Covid-19, Rino Rappuoli: “Stiamo facendo progressi, a fine anno potremmo avere il vaccino” (Rino Rappuoli: We’re making progress. By the end of the year we could have a vaccine)
We are making progress on the new vaccine and if we are lucky we will have it ready by the end of the year says Rino Rappuoli, CEO of GSK Vaccines during the presentation of the new Smart Lab structure of the company. Rappuoli is considered one of the top experts in the world.
07-July-2020 – AZD1222
DAZ.online - COVID-19-Impfstoffe: ein Kandidat in Phase 3, zweiter folgt
Nach der aktuellen „Draft landscape of COVID-19 candidate vaccines“ der WHO vom 6. Juli 2020 hat die Zahl der COVID-19-Impfstoffkandidaten, die in der klinischen Erprobung angekommen sind, weiter zugenommen. Mittlerweile sind es 19 Kandidaten, davon zehn in den Phasen 3, 2 und 1/2.
07-July-2020 – NVX-COV2373
Bloomberg - Novavax Covid Vaccine Gets $1.6 Billion in U.S. Funding
Novavax Inc., one of the front-runners in the race to develop a Covid-19 vaccine, will receive $1.6 billion from the U.S. government, the biggest contribution yet from the Operation Warp Speed program.
6-July-2020 – PLX-PAD
https://www.israel21c.org/13-promising-covid-treatments-emerging-from-israel/
Israel21c - 13 promising Covid treatments emerging from Israel
In parallel to vaccine research, there’s an urgent need for effective treatments for the respiratory disease caused by the SARS-CoV-2 coronavirus.
5-July-2020- PLX-PAD
https://www.tikkunolamisrael.com
Tikkun Olam: Israel vs COVID-19
How is one of the planet's smallest countries helping to tackle the world's biggest challenge?
5-July-2020 – AZD1222
News medical life sciences - Oxford COVID-19 vaccine trials move to stage 3 human trials
Scientists across the globe are racing to develop an effective and safe vaccine against severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2). The coronavirus pandemic has marked its 11th million cases, and without a vaccine, cases are expected to continue to rise for the foreseeable future. Sarah Gilbert, professor of vaccinology at the University of Oxford, and one of the scientists leading the vaccine initiative told the U.K.'s Science and Technology Committee last week that their candidate vaccine has progressed to the phase III trial in the United Kingdom.
5-July-2020 – NVX-CoV2373
The Print - CanSino, Moderna, Novavax: A list of Covid vaccines under clinical trials across the world
New Delhi: With the coronavirus pandemic continuing to claim thousands of lives across the globe every day, the Indian Council of Medical Research (ICMR) has decided to fast-track clinical trials of the indigenous Covid-19 vaccine, which it is producing with the Bharat Biotech International Limited (BBIL).
4-July-2020 – AZD1222
First post - Oxford's vaccine offers ‘good duration of immunity’ to COVID-19 compared to no vaccine: lead researcher
Oxford University, experts think, is the most likely to come up with a viable vaccine candidate for COVID-19, which has caused havoc around the world. Even the World Health Organisation has pegged them as the leading candidate for a viable vaccine.
2-July-2020 – NVX-CoV2373
Yahoo Finance - Novavax Announces Updates to Leadership Team
Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Frank Czworka as Senior Vice President, Global Sales, with responsibility for leading sales planning and distribution. Novavax also announced the promotion of Brian Webb to Senior Vice President, Manufacturing, with responsibility for overseeing antigen manufacturing and supply activities in support of Novavax’ vaccine candidates.
1-July-2020 - AZD1222
Reuters - Oxford COVID-19 vaccine developers encouraged by immune response but cautious on timeframe
A leading scientist behind the University of Oxford’s potential COVID-19 vaccine said on Wednesday the team has seen the right sort of immune response in trials but declined to give a firm timeframe for when it could be ready.
1-July-2020 - AZD1222
International Business Times - WHO Reveals Coronavirus Vaccine 'Leading Candidate', Already In Phase 3 Clinical Trials
For the World Health Organization (WHO), however, the winner is clear -- AZD1222 from the University of Oxford and AstraZeneca. WHO chief scientist Dr. Soumya Swaminathan revealed AZD1222 appears "probably the leading candidate." She gave two reasons for her statement.
30-June-2020- NVX-CoV2373
Fierce Pharma - Novavax hires new manufacturing chief to take COVID-19, flu vaccine hopefuls across the finish line
With its COVID-19 vaccine hopeful cycling through clinical trials, shot maker Novavax is working to flesh out its executive team to help lead the company to the commercial stage. But you can't get regulatory approval without a sturdy manufacturing operation—and now Novavax has hired an exec to get that operation in order.
29-June-2020 – AZD1222
Fierce Pharma - AstraZeneca reaches supply deal with Brazilian government to produce millions of doses of COVID-19 shot
As COVID-19 continues to rampage across the globe, Brazil stands alongside the U.S. as the countries hardest hit with new infections and deaths. But AstraZeneca and its vaccine hopeful could be coming to save the day now that the drugmaker and Brazilian government have reached a new supply pact.
26-June-2020 – GRAd-COV2
The New York Times - Brazil University in Talks to Test Italian Coronavirus Vaccine
The Federal University of Sao Paulo (Unifesp) is in talks to test a potential coronavirus vaccine developed by Italian researchers, the dean of the Brazilian university told Reuters.
25-June-2020 – PLX-PAD
Theater Mania - Edward Pierce's Miracle: How a Broadway Set Designer Beat Covid and Made Medical History
Pierce is the first American to receive a placental cell transplant to fight the insidious virus that left him on a ventilator for five weeks.
25-June-2020 - GRAd-COV2
Startmag.it – Reithera, chi è l’azienda finanziata da Unicredit per il vaccino anti Covid
Unicredit scommette sul vaccino anti-Covid dell’azienda biotecnologica italiana Reithera (prodotto in collaborazione con Sgs). Dal gruppo bancario capeggiato dall’amministratore delegato, Jean-Pierre Mustier, è arrivato un finanziamento di 5 milioni di euro per accelerare nella ricerca dell’antidoto. Tutti i dettagli.
23-June-2020 – GRAd-COV2
Affari Italiani – Reithera, chi è l’azienda finanziata da Unicredit per il vaccino anti Covid
Liberare il potenziale dei progetti innovativi. Questo l’obiettivo di ReiThera srl che ottiene da UniCredit un finanziamento da 5 milioni di euro, grazie alle garanzie rilasciate dal Fondo Centrale di Garanzia, per nuovi investimenti sul fronte della ricerca scientifica innovativa mirata all’individuazione di un vaccino contro il virus Covid 19.
23-June-2020 – AZD1222
https://www.sciencefocus.com/news/oxford-vaccine-trial-on-pigs-boosts-coronavirus-immune-response/
BBC Science Focus – Oxford vaccine: trial on pigs ‘boosts coronavirus immune response’
Two doses of a coronavirus vaccine candidate created by UK researchers produce a greater antibody response than a single dose, a study in pigs has shown. The ChAdOx1 nCoV-19 (AZD1222) vaccine, developed by the University of Oxford, is currently undergoing human trials and it is hoped an effective vaccine could be ready later this year.
23-June-2020 – AZD1222
Euro weekly news - Coronavirus Vaccine: UK Scientists “very positive” after Trials with Two Doses
After a study in pigs, it was found that two doses of a coronavirus vaccine made by UK researchers produced a greater antibody response than a single dose.
The technical name for the drug is ChAdOx1 nCoV-19 (also known as the AZD1222) vaccine and was developed by the University of Oxford.
23-June-2020 – VPM1002
VPM - Hope for the elderly in the corona pandemic – First participants receive VPM1002 in a late-stage phase III clinical trial in Germany
Vakzine Projekt Management GmbH (VPM) announces that the first participants have been enrolled last week in the phase III trial to test the efficacy of the vaccine candidate VPM1002 in preventing COVID-19 and other respiratory diseases. The large-scale, multicentre clinical trial has started in Berlin and will soon be rolled out to other sites in Germany. The clinical trial will include elderly participants.
22-June-2020 – NVX-COV2373
Washington Business Journal - Novavax charges ahead with $200M in fresh capital — and a familiar face on its board
Novavax Inc. plans to advance its Covid-19 vaccine candidate with new additions to the company and about $200 million in new funds from selling convertible preferred stock — the latest cash infusion for the Gaithersburg vaccine maker.
19-June-2020 – mAbCo19
https://www.bioworld.com/articles/435911-other-news-to-note-for-june-19-2020
Bioworld - Other news to note for June 19, 2020
Achilles Vaccines srl, of Siena, Italy, has received an investment from the EU Malaria Fund (EUMF) that will support development of a novel malaria vaccine produced on its technology platform designed to transform bacteria into an efficient delivery system of bio antigenic molecules to produce low-cost, safe and self-adjuvanting fit-for-purpose vaccines. The funding, with support from Fondazione TLS, will also be used to advance the company’s project to develop a human monoclonal antibody against COVID-19.
19-June-2020 – mAbCo19
La Nazione- Rossi e l’orgoglio di Fondazione Mps La corsa di AchilleS
"Siamo particolarmente soddisfatti di essere la prima fondazione italiana a partecipare al Malaria Fund, con un milione di euro". Carlo Rossi, presidente della Fondazione MPS. "Un investimento importante, con una visione di lungo termine, che ci consente di perseguire due obiettivi in questo delicato momento: continuare a sostenere la ricerca scientifica, in particolare su quelle malattie con elevato impatto in termini di salute pubblica, ed attrarre nuove risorse sul nostro territorio con benefici durevoli a favore della comunità. – prosegue Rossi - Siamo molto soddisfatti, inoltre, della decisione di destinare parte delle risorse alla ricerca su Covid-19, un’altra sfida sanitaria globale che richiede un enorme impegno collettivo".
19-June-2020 – mAbCo19
La Nazione - "L’Europa ha bisogno di impianti Pronti a investire 280 milioni"
Holm Keller, manager del Malaria Fund, alla consegna dei finanziamenti per la start up senese sui vaccini
19-Jun-2020 - mAbCo19
Canale 3 TV - Eu Malaria Fund: presentato a Siena il primo investimento europeo in Italia in AchilleS Vaccines per la lotta contro malaria e Covid -19
EU Malaria Fund (EUMF) ha presentato oggi a Siena, nella sede della Fondazione Monte dei Paschi di Siena, il suo primo investimento in AchilleS Vaccines. Un finanziamento per lo sviluppo di un nuovo vaccino contro la malaria, attraverso l’utilizzo di una piattaforma tecnologica combinata, in grado di trasformare i batteri – portatori di molecole potenzialmente nocive per la salute umana – in un efficiente sistema di distribuzione di molecole bio-antigene, in grado di produrre vaccini a basso costo, sicuri ed autoimmunizzanti.
19-Jun-2020 - mAbCo19
Antenna Radio Esse - 46 milioni ad AchilleS Vaccines da EU Malaria Fund per la ricerca su Covid-19 e malaria
La start up senese AchilleS Vaccines usufruirà per i suoi progetti di un finanziamento di 46 milioni da parte del nuovo fondo europeo Malaria Fund. Uno di questi riguarda proprio lo sviluppo di un anticorpo monoclonale contro il coronavirus, mentre l’altro progetto riguarda la realizzazione di un nuovo vaccino a basso costo contro la malaria.
18-Jun-2020 - mAbCo19
Radio Siena TV - L’Europa premia i vaccini senesi con 46 milioni: AchilleS Vaccines riceve finanziamenti per lotta a malaria e Covid
EU Malaria Fund ha presentato oggi nella sede della Fondazione Monte dei Paschi di Siena il suo primo investimento in AchilleS Vaccines: Italia primo paese a beneficiarne
17-June-2020 – NVX-CoV2373
Benzinga - Novavax Beefs Up Executive Team As It Sprints In The Coronavirus Vaccine Race
The company said Wednesday it has appointed AstraZeneca plc veteran Filip Dubovsky as SVP and Chief Medical Officer, overseeing its medical and clinical affairs and related activities
16-June-2020 – AZD1222
Daily Mail - AstraZeneca boss claims Oxford University's experimental Covid-19 vaccine is likely to protect humans for a YEAR
The boss of British pharma giant AstraZeneca today claimed its unproven Covid-19 vaccine may protect people from catching the disease for a year. Its AZD1222 jab, developed by Oxford University, is currently being trialled on more than 10,000 people but there is no scientific evidence it works.
16-June-2020 – NVX-CoV2373
https://baltimore.cbslocal.com/2020/06/16/novavax-coronavirus-vaccine-latest/
CBS Baltimore - Gaithersburg-Based Novavax Raising $200M To Fund COVID-19, Flu Vaccine Efforts
The Gaithersburg-based company Novavax announced this week it plans to raise around $200 million to not only fund its coronavirus vaccine work, but also its flu vaccine, NanoFlu.
16-June-2020 – AZD1222
Skynews - Coronavirus: Oxford University vaccine to provide protection 'for about a year', says drugmaker
A coronavirus vaccine being developed in the UK will provide protection against the disease "for about a year", according to the drugmaker currently carrying out trials.
14-June-2020 - AZD1222
https://www.timesofisrael.com/astrazeneca-agrees-to-make-experimental-covid-19-vaccine-for-europe/
The Times of Israel - AstraZeneca agrees to make experimental COVID-19 vaccine for Europe
Drugmaker AstraZeneca struck a deal Saturday to supply up to 400 million doses of an experimental COVID-19 vaccine to European Union countries, the latest in a series of agreements as scientists, governments and pharmaceutical companies race to combat the virus.
13-June-2020 - AZD1222
https://www.bnnbloomberg.ca/astrazeneca-reaches-vaccine-supply-deal-with-four-eu-nations-1.1449944
BNN Bloomberg - AstraZeneca reaches vaccine supply deal with four EU nations
AstraZeneca Plc and four European Union countries said they reached an agreement to distribute a coronavirus vaccine. The Netherlands, Germany, France and Italy concluded a contract with the U.K. drugmaker to provide 300 million to 400 million doses of a possible vaccine in stages starting from the end of 2020, the Dutch government said in a statement on Saturday.
13-June-2020 - AZD1222
De Volkskrant - Nederland sluit aan in de rij: het eerste mogelijke coronavaccin is gereserveerd
Als het de universiteit van Oxford en medicijnenfabrikant AstraZeneca lukt om nog dit jaar een vaccin tegen het coronavirus te ontwikkelen, staat Nederland vooraan in de rij. Samen met Duitsland, Frankrijk en Italië zijn bij voorbaat 300 miljoen doses gereserveerd. Dat heeft minister De Jonge (Volksgezondheid) zaterdag aan de Tweede Kamer geschreven.
12-June-2020 – mAbCo19
Milano Finanza - EU Malaria Fund e Fondazione Mps finanziano AchilleS Vaccines
La scale-up italiana, incubata presso Toscana Life Sciences, si aggiudica tre progetti di ricerca sulla malaria e altre malattie infettive, e uno sul Covid-19 da parte del fondo EU Malaria Fund
11-June-2020 - mAbCo19
Corriere di Siena - Siena, arrivano 10 milioni per la Achilles Vaccines: progetti contro Coronavirus e malaria
Quarantasei milioni di euro in cinque anni, oltre dieci subito, destinati a tre progetti di ricerca sulla malaria e altre malattie infettive e uno relativo al Covid-19.
11-June-2020 - PLX-PAD
Streetinsider - Pluristem Therapeutics (PSTI) Reports Activation of Clinical Sites & Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial
Pluristem Therapeutics Inc. (NASDAQ: PSTI) announced today the activation of clinical sites and initiation of enrollment in its Phase II U.S. Food and Drug Administration (FDA) study of PLX cells for the treatment of severe COVID-19 complicated by Acute Respiratory Distress Syndrome (ARDS). The Company is focused on expanding to clinical sites throughout the U.S. in accordance with the changing dynamic spread of the COVID-19 pandemic, using its advanced operational capabilities and cold chain agility. The trial is expected to include up to 25 sites.
9-June-2020 - mAbCo19
MedicalExcellence.tv -Ricerca malaria e Covid-19: EU Malaria Fund finanzia AchilleS Vaccines con il sostegno di Fondazione MPS
AchilleS Vaccines, scale-up italiana incubata presso Toscana Life Sciences, si aggiudica il finanziamento di ben tre progetti di ricerca sulla malaria e altre malattie infettive, e di uno relativo al Covid-19, da parte del fondo EU Malaria Fund, grazie anche ad un importante investimento della Fondazione Monte dei Paschi di Siena.
9-June-2020- AZD 1222/ NVX-CoV2373
https://abcnews.go.com/Health/lab-peoples-arms-list-covid-19-vaccines-studied/story?id=71145250
ABC News - Out of the lab and into people’s arms: A list of COVID-19 vaccines that are being studied in clinical trials
The world's leading drug companies, universities and governments are racing to develop a vaccine for COVID-19, the disease that has taken more than 400,000 lives globally. Of the 133 candidates being explored, ten have been approved for human trials, according to the World Health Organization.
9-June-2020- NVX-CoV2373
https://finance.yahoo.com/news/novavax-inks-dod-contract-operation-235503847.html
Yahoo Finance - After Novavax Inks DoD Contract, Is Operation Warp Speed Ahead? Top Analyst Weighs In
On June 4, Novavax (NVAX) revealed it will receive $60 million from the U.S. Department of Defense (DoD) to further the advancement of its experimental vaccine candidate, NVX-CoV2373, in the U.S., through JPEOCBRND-EB (Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies). As per the terms of the agreement, NVAX will work with multiple biologics contract development manufacturing organizations (CDMO) based in the U.S. to increase the scale of antigen and Matrix-M adjuvant production, which are both components of the vaccine. The end goal is to produce 10 million doses for the DoD in 2020, which will then be used in either a Phase 2/3 trial or under an Emergency Use Authorization (EUA).
9-June-2020- AZD 1222
Times of India - Coronavirus vaccine latest update: AstraZeneca close to "rolling out" COVID-19 vaccine, Oxford vaccine gets the go-ahead for clinical trials in Brazil and more updates
COVID-19 cases have topped the seven million mark today (June 08) globally. India too is seeing a surge in the number of cases every day. While there still is a long way to go before we put the pandemic behind us, trials and research are going on at warp speed to attend to the crisis at large. Many potential treatments have shown promising results in the clinical trial stage, while some are carrying on production. We recap all the recent development as the world waits for a COVID-19 vaccine with bated breath
9-June-2020 – mAbCo19
Radio Siena TV - Ricerca Covid-19: l’Europa investe nella ricerca senese con il finanziamento a AchilleS Vaccines
Il più grande finanziamento start-up del biotech italiano: 46 milioni in 5 anni, l’EU Malaria Fund finanzia AchilleS Vaccines con il sostegno di Fondazione Mps e la collaborazione di TLS
8-June-2020- VPM 1002
https://www.modernghana.com/news/1007659/jymwrites-using-tb-vaccine-in-treating-the-new.html
Modern Ghana - JymWrites: Using TB Vaccine In Treating The New COVID 19
The Bacillus Calmette-Guérin (BGC) vaccine has been protecting against the deadliest forms of tuberculosis (TB) for the past 100 years. Even though the safety and effectiveness of the vaccine were hugely debated over the decades, research indicates that its effectiveness level is around 70-80% against the most severe forms of TB. A dose of the vaccine is given to newborn babies living in countries with a high TB rate.
Also, scientists in Germany have developed a new tuberculosis vaccine (VPM1002) by genetically modifying the BGC that could help control the new coronavirus. Several studies have been initiated and the results are promising, the BCG has already proven to be effective against other infections. Given that the world is urgently looking for ways to treat and prevent the new coronavirus until we can develop a vaccine, attention is being turned to the BCG vaccine and the new VPM1002
8-June-2020 – mAbCo19
https://www.lanazione.it/siena/cronaca/il-malaria-fund-della-ue-punta-risorse-su-siena-1.5198836
La Nazione - Il Malaria Fund della Ue punta risorse su Siena
I segreti della AchilleS Vaccines la start up senese che è riuscita ad avere il finanziamento più ingente per il suo progetto
5-June-2020 – NVX-CoV2373
Washington Business Journal - Novavax’s latest win? A $60M contract for its Covid-19 vaccine
Novavax Inc. just scored even more support for its coronavirus vaccine program. The Gaithersburg company said late Thursday it won a Department of Defense contract worth up to $60 million to help manufacture its Covid-19 vaccine candidate, NVX CoV2373. The funding, from the Defense Health Program, would back the production of multiple pieces of the vaccine, to be manufactured in the U.S., according to Novavax’s (NASDAQ: NVAX) announcement.
5-June-2020 – AZD1222
Daily Mail - Pharmaceutical giant AstraZeneca reveals it is ALREADY manufacturing Oxford University's experimental vaccine in India, the UK and Europe amid plans to distribute 2BILLION doses as early as September if it works
A British pharmaceutical giant is already manufacturing an unproven coronavirusvaccine as it hopes to dish out hundreds of millions of doses by September.
AstraZeneca has started to mass-produce the experimental AZD1222 jab, developed by Oxford University, at factories in India, Oxford, Switzerland and Norway.
5-June-2020 – AZD1222
The next web - Bill Gates commits $750M to help Oxford vaccinate the world against COVID-19
The Bill and Melinda Gates Foundation has contributed $750 million towards the manufacturing and distribution a potential COVID-19 vaccine developed by Oxford University.
4-June-2020 – NVX-CoV2373
Bloomberg - Overlooked Covid-19 Vaccine Runners Up Defended by Wall Street
Don’t give up hope for Novavax Inc. and Inovio Pharmaceuticals Inc., Wall Street analysts said after the two failed to appear on a Trump administration list of Covid-19 vaccine developers picked for Operation Warp Speed.
4-June-2020 – AZD1222
The Guardian - AstraZeneca doubles capacity for potential Covid-19 vaccine to 2bn doses
AstraZeneca has doubled the manufacturing capacity for its potential Covid-19 vaccine to 2bn doses after striking a number of deals that include two health organisations backed by Bill and Melinda Gates.
4-June-2020 – NVX-CoV2373
Welt - Schützt eine ausrangierte Tuberkuloseimpfung vor Covid-19?
Um Patienten vor schweren Verläufen von Covid-19 zu schützen, greifen Forscher zu ungewöhnlichen Mitteln. In Hannover soll nun ein Impfstoff verwendet werden, der sich in seinem ursprünglichen Einsatzgebiet nicht gut bewährt hat. Er soll jedoch die Körperabwehr verbessern.
4-June-2020 - AZD1222
The Telegraph - How close are we to a coronavirus vaccine? Latest news on UK and US trials
Alok Sharma, the Business Secretary, said that the clinical trial at the University of Oxford is progressing well and, if it proves successful, the doses could be ready by the end of the summer.
3-June-2020 – NVX-CoV2373
Financial Post – Novavax partners with contract drugmaker for COVID-19 vaccine manufacturing
An add-on component of Novavax’s vaccine that could help enhance the immune response against the coronavirus would be manufactured by privately held AGC Biologics, the contract drugmaker said. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Saumyadeb Chakrabarty)
3-June-2020 - COVID-eVax
Ansa - Takis, Rottapharm in vaccine deal
Italian biotech companies Takis and Rottapharm Biotech on Wednesday reached a deal to develop a vaccine against the coronavirus conceived by Takis and called COVID-eVax.
Within the framework of the accord, a statement said, Rottapharm Biotech will place at Takis's disposal its experience in the development of innovative drugs and financial support up to at least the completion of phases one and two of clinical trials.
2-June-2020 - AZD1222
Daily Mail - Drugs to treat Covid-19 are 'essential' because a vaccine will take YEARS to roll out and multiple waves of the virus are inevitable when air travel resumes, Wellcome Trust expert warns
British firm AstraZeneca said it fully expected to have millions of doses of its AZD1222 vaccine, being developed by Oxford University, ready by September.
28-May-2020 - Plant based protein production
https://www.news.uct.ac.za/article/-2020-05-28-harnessing-plant-power-to-curb-covid-19
University of Cape Town News - Harnessing plant power to curb COVID-19
Here’s a different reason for tobacco to be in the news. Cape Bio Pharms, a biotech company with its origins in the Biopharming Research Unit (BRU) at the University of Cape Town (UCT), has joined the global effort to create a fast and affordable antibody test for COVID-19, using a relative of the tobacco plant.
28-May-2020 - AZD1222
The New York Times - AstraZeneca Partners With Oxford Biomedica to Expand COVID-19 Vaccine Manufacturing Capacity
AstraZeneca has partnered with British cell therapy company Oxford Biomedica to make its experimental COVID-19 vaccine, as the drugmaker looks to bolster its manufacturing capacity to produce one billion doses.
28-May-2020 - COVAX
https://de.reuters.com/article/idDEKBN2341SX
Reuters- Wiener Biotechfirma Themis verspricht weltweiten Zugang zu Corona-Impfstoff
Der vom US-Pharmariesen Merck & Co übernommene österreichische Impfstoffhersteller Themis Bioscience will das von ihm entwickelte potentielle Covid-19-Medikament weltweit zur Verfügung stellen.
27-May-2020 - NVX-CoV2373
Reuters - Novavax aims to make one billion COVID-19 vaccine doses after buying plant
Novavax Inc is buying a manufacturing plant from privately held Serum Institute of India, the world’s largest maker of vaccines by volume, as the U.S. company aims to produce 1 billion doses of its COVID-19 vaccine candidate next year.
27-May-2020- PLX-PAD
Cell & Gene Therapy Insights - Cell therapy’s role in defeating Covid-19
YAKY YANAY was appointed as President from February 2014 and as CEO from June 2019, after a period of being Co-CEO since March 2017. Mr Yanay served in variety of executive positions in Pluristem since 2006 including Chief Financial Officer, Chief Operating Officer and Executive Vice President. He is the former Co-Chairman and current board member of Israel Advanced Technology Industries (IATI), the largest umbrella organization representing Israel’s life science and high-tech industries.
26-May-2020 - VPM1002
Vakzine Projekt Management - SARS-CoV-2 study kicks off in Germany: First participant enrolled in Phase III clinical trial of VPM1002 focused on healthcare workers battling the COVID-19 pandemic
Vakzine Projekt Management GmbH (VPM) announced that the first participant has been enrolled on May 25th in a phase III study to investigate whether the vaccine candidate VPM1002 is effective against respiratory diseases like COVID-19.
26-May-2020 - NVX-CoV2373
CNBC - Front-line coronavirus workers could be vaccinated as soon as this year, Novavax CEO says
Workers on the front lines of the coronavirus pandemic will be first to receive a vaccine and that could come as soon as later this year, Stanley Erck, CEO of vaccine development company Novavax, said Tuesday.
26-May-2020 – COVAX
Reuters - Merck to buy Austrian vaccine maker as it jumps into COVID-19 race
Merck & Co Inc (MRK.N), which has largely kept to the sidelines of the race for COVID-19 treatments, said it was buying Austrian vaccine maker Themis Bioscience and would collaborate with research nonprofit IAVI to develop two separate vaccines.
26-May-2020 – NVX-CoV2373
https://www.wsj.com/articles/novavax-coronavirus-vaccine-begins-human-testing-11590438240
Bloomberg - Novavax Coronavirus Vaccine Begins Human Testing
Novavax Inc. said Monday it started the first human study of its experimental coronavirus vaccine, making it one of at least 10 shots now being tested in people globally for Covid-19.
26-May 2020 – NVX-CoV2373
https://www.sbs.com.au/news/first-australian-human-trials-of-potential-coronavirus-vaccine-start-in-melbourne
SBSNews - First Australian human trials of potential coronavirus vaccine start in Melbourne
More than 100 volunteers in Melbourne and Brisbane have been lined up to take part in the first phase of a human trial of a potential coronavirus vaccine.
26-May-2020 – COVAX
Bloomberg - Merck Unveils Virus Vaccine Candidates While Warning on Timeline
Merck & Co. moved to bolster the global fight against the coronavirus, unveiling plans for a pill to treat the infection and two vaccines to prevent it.
26-May-2020 – COVAX
Forbes - Merck Jumps Into The Race For A Coronavirus Vaccine
New Jersey-based pharmaceutical Merck announced three initiatives Tuesday to fight the novel coronavirus, including teaming up with nonprofit scientific research firm IAVI to develop a vaccine, as companies around the world race to find an effective treatment against the virus.
26-May-2020 – COVAX
https://www.wsj.com/articles/merck-does-deals-to-develop-coronavirus-vaccines-drug-11590489902
The Wall Street Journal - Merck Does Deals to Develop Coronavirus Vaccines, Drug
Drugmaker is buying a privately held Austrian company to obtain one vaccine, joining with other groups on a second vaccine and an antiviral
25-May-2020 – NVX-CoV2373
Bloomberg - Novavax Jumps After Starting Covid-19 Vaccine Study
Novavax Inc. jumped at much as 18% on Tuesday after initiating testing of its coronavirus vaccine candidate in people. The biotech anticipates providing a first look in July at what sort of immune responses are generated.
25-May-2020 – VPM1002
Göttinger Tageblatt - MPI-Forscher: Tuberkulose-Impfstoff könnte gegen Corona-Virus helfen
Stefan Kaufmann wird Emeritus-Direktor am Göttinger Max-Planck-Institut für biophysikalische Chemie. Er entwickelte einen Impfstoff gegen Tuberkulose, der als Zwischenlösung bei Covid-19 dienen könnte.
25-May-2020 – NVX-CoV2373
Forbes - Novavax Is Beginning Clinical Trials Of Its Coronavirus Vaccine
Novavax, a biotech company focused on developing vaccines against infectious diseases, announced Monday that it is beginning a phase 1 clinical trial of its Covid-19 vaccine candidate in Australia. Results of the trial are expected in July 2020.
25-May-2020 - COVAX
https://www.mrknewsroom.com/news-release/research-and-development-news/merck-acquire-themis
Merck - Merck to Acquire Themis
Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur.
24-May-2020 – AZD1222
Hindustan Times - Oxford’s Covid-19 vaccine trial has 50% chance of success: Project leader
The University of Oxford’s Covid-19 vaccine trial has only a 50% chance of success as the coronavirus seems to be fading rapidly in Britain, the professor co-leading the development of the vaccine has said. Oxford’s Jenner Institute has tied up with biopharma major AstraZeneca Plc to produce the vaccine on a mass scale if the results are successful. The experimental vaccine, known as ChAdOx1 nCoV-19, is one of the front-runners in the global race to provide protection against the new coronavirus causing the coronavirus pandemic.
24-May-2020 – AZD1222
Bloomberg - Oxford University Vaccine Trials Run Into Hurdle
The Oxford University team in charge of developing a coronavirus vaccine said a decline in the infection rate will make it increasingly difficult to prove whether it’s been successful, the Telegraph reported. “It’s a race against the virus disappearing, and against time,” Professor Adrian Hill, director of the university’s Jenner Institute, told the newspaper. “We said earlier in the year that there was an 80% chance of developing an effective vaccine by September. But at the moment, there’s a 50% chance that we get no result at all.”
22-May-2020 - ChAdOx1 nCoV-19, COVAX, NVX-CoV2373
The Times of India - How one Indian company could be world's door to a Covid-19 vaccine
If the world is to gain access to a vaccine for Covid- 19, there's a good chance it will pass through the doors of Serum Institute of India.
22-May-2020 - ChAdOx1 nCoV-19
http://www.ox.ac.uk/news/2020-05-22-oxford-covid-19-vaccine-begin-phase-iiiii-human-trials
Oxford University - Oxford COVID-19 vaccine to begin phase II/III human trials
niversity of Oxford researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers.
22-May-2020 - ChAdOx1 nCoV-19
The Telegraph - Coronavirus latest news: Vaccine trial extended to 10,000 people including over 70s and children
Researchers have begun recruiting volunteers for the next two phases in clinical trials they hope could bring a coronavirus vaccine this year. Work began in January on the vaccine, which uses a virus taken from chimpanzees and has been developed by the University of Oxford's Jenner Institute and the Oxford Vaccine Group. Now scientists want to recruit up to 10,260 people across the country for phases II and III, which involve vastly increasing the number of volunteers and expanding the age range to include older adults and children.
22-May-2020 - mAbCo19
Corriere Di Siena - Vaccino Coronavirus, professor Rappuoli: "Nostro patto per riuscire a produrre un miliardo di dosi". Il video
Un patto tra giganti della farmaceutica per arrivare a produrre un miliardo di dosi di vaccino anti Coronavirus entro il 2021. E’ stato Rino Rappuoli, direttore scientifico e responsabile delle ricerche sui vaccini di Gsk, a svelare l’ambizioso progetto durante Meet the future, programma online de La Repubblica. Parlando dell’emergenza per il Covid-19 e della ricerca di un vaccino, in corso praticamente in tutto il mondo, Rappuoli si è detto abbastanza fiducioso: a suo avviso saranno più di uno i progetti che andranno a buon fine. Un problema non indifferente, però, sarà l’altissimo numero di dosi di cui si avrà bisogno se davvero la campagna di vaccinazione dovrà essere mondiale. Occorrono miliardi di fiale. La soluzione a cui sta pensando Gsk è quella di utilizzare gli adiuvanti che permettono di garantire l’effetto di un vaccino pur usando solo un decimo della dose.
22-May-2020 - ChAdOx1 nCoV-19
The Print India - Covid vaccine could come by 2020-end but realistic time-frame would be 2 yrs: Adar Poonawalla
Vaccines for Covid-19 are at least two years away, but a few may get ready by the end of the year, said Adar Poonawalla, chief executive of Serum Institute of India, the world’s largest vaccine producer. Pune-based SII, which produces 150 crore vaccine doses a year across the globe, is working on three vaccine candidates developed by the UK’s University of Oxford, US-based Codagenix and Austrian biotech firm Themis. Of these, if the vaccine currently under trials by Oxford University in collaboration with British pharma giant AstraZeneca succeeds, it may become the first to come out by the end of the year.
22-May-2020 - ChAdOx1 nCoV-19
Live Mint - Vaccine development is like a rollercoaster, says Serum Institute CEO
Adar Poonawalla, CEO, Serum Institute of India (SII), said on Thursday that developing a vaccine is like a rollercoaster ride with ups and downs. " Sometimes we fail, sometimes we succeed, but we must be patient and not jump to conclusions too early. We must wait for all phase 3 trials to be completed," Poonawalla said in a tweet. There have been reports that one of the strong candidates for a potential vaccine for Covid-19 being tested by researchers at the Oxford University has failed to protect monkeys from being infected by the virus. However, the potential vaccine helped to protect the monkeys from pneumonia.
22-May-2020 - ChAdOx1 nCoV-19
Times of India - Coronavirus vaccine current update: Oxford vaccine failure to Moderna's favourable results, here is the latest status of COVID-19 vaccines and drugs
The vaccine being developed by Oxford University uses a weakened strain of the common cold virus, known as adenovirus which causes infections in Chimpanzees. They have combined it with the genetical material of the spike protein of SARS-CoV-2. The vaccine candidate was developed within 3 months and showed promising results in animal trials. However, recent reports have confirmed that the potential vaccine ‘ChAdOx1 nCoV-19’, ’was not able to prevent infection in rhesus macaque monkeys. As of now, the vaccine seems to be partially effective as it protected the animals from developing viral pneumonia but could not stop the COVID-19 infection.
21-May-2020 - NVX-CoV2373
https://finance.yahoo.com/news/novavax-covid-19-vaccine-candidate-001437548.html
Yahoo Finance - Novavax’s COVID-19 Vaccine Candidate Could Be the One, Says Top Analyst
Wall Street has been looking at Novavax (NVAX) of late, and investors clearly like what they see. Over the past 5 months, Novavax stock skyrocketed over 1000% (that's not a typo) and remains relatively close to its 52-week high. The company’s speedy development of a possible COVID-19 vaccine has been behind the stock’s dazzling performance. The company developed vaccines against coronaviruses such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS), for which preclinical testing demonstrated strong immunogenicity and 100% protection. This was also the case for Ebola, with the NVAX vaccine candidate proving effective in primate studies.
21-May-2020 - ChAdOx1 nCoV-19
https://www.nytimes.com/2020/05/21/health/coronavirus-vaccine-astrazeneca.html
New York Times - $1.2 Billion From U.S. to Drugmaker to Pursue Coronavirus Vaccine
The Trump administration announced a grant to AstraZeneca, which has licensed a potential vaccine that is in trials by Oxford University. Scientists at Oxford University are proceeding on an accelerated timetable for a potential coronavirus vaccine in Britain, in partnership with AstraZeneca. Expanding its pursuit of an inoculation against the coronavirus, the U.S. Department of Health and Human Services said on Thursday it would provide “up to $1.2 billion” to the drug company AstraZeneca to develop a potential vaccine from a laboratory at Oxford University. The deal with AstraZeneca is the fourth and by far the largest vaccine research agreement that the department has disclosed. The money will pay for a Phase 3 clinical trial of a potential vaccine in the United States this summer with about 30,000 volunteers.
21-May-2020- ChAdOx1 nCoV-19
https://www.ft.com/content/4b216c2e-2558-4308-b9c2-bf805b08e949
Financial Times - AstraZeneca books orders for 400m doses of Oxford vaccine
Drugmaker AstraZeneca has secured orders for at least 400m doses of an as yet unproven Covid-19 vaccine being developed with Oxford university and would begin delivering them in September. The company said it had also received more than $1bn in funding from the Biomedical Advanced Research and Development Authority (Barda), a unit of the US health department, to develop the coronavirus vaccine.
21-May-2020 - PLX-PAD
The Daily Beast - How Edward Pierce, Broadway ‘Wicked’ Designer, Fought COVID-19—and Made Medical History
Broadway designer Edward Pierce is the first American to receive placental cell treatment for COVID-19. He and wife Pixie tell Tim Teeman about survival, guilt, and making history.
21-May-2020 - PLX-PAD
The Daily Mail - Broadway set designer makes medical history after becoming first American to receive placental cell treatment for coronavirus under FDA's 'compassionate use' rules
Edward Pierce, 49, is acclaimed Broadway scenic designer for plays like Wicked. Pierce fell ill with COVID-19 and was treated at a hospital in Teaneck, New Jersey . Doctors grew concerned as his condition deteriorated due to organ failure. There was little hope, so his wife agreed to use an untested method. Pierce was administered placental cells in around 15 parts of his body. Within 10 days, he was off a ventilator and breathing on his own. The placental cell therapy was developed by an Israeli biotechnology firm. Pierce was given treatment as part of 'compassionate use' .
20-May-2020- NVX-CoV2373
https://www.skynews.com.au/details/_6157799654001
Sky News - COVID-19 vaccine trial to begin human testing in Australia
Phase one of a coronavirus vaccine trial - which will see 131 people from Melbourne and Sydney injected with the trial drug - is set to begin in less than a week. The vaccine was developed in the United States and is the first human clinical trial to run in Australia.
18-May-2020 - ChAdOx1 nCoV-19
TimesNowNews India - Potential Oxford COVID-19 vaccine fails to prevent coronavirus infection in animal trials
New Delhi: Oxford University’s COVID-19 vaccine failed to prevent the monkeys from being infected with the novel coronavirus in trials, dashing the UK's hopes of a safe and effective vaccine this year. The vaccine is among the top candidates that are currently being tested on humans. But detailed results from the animal trials showed that the ChAdOx1 nCoV-19 vaccine did not stop rhesus macaque monkeys from contracting the virus, and it does not stop the animals from spreading the infection to others as well.
18-May-2020 - PLX-PAD
TrialSite News - Regenerative Therapy out of Israel Shows Promise for COVID-19 Patients Fighting ARDS
75% of those COVID-19 patients treated by the company’s regenerative therapy were off any mechanical ventilation after 28 days of treatment. Under a compassionate use program in Israel, in addition to an FDA Single Patient Expanded Access Program in the United States, treated patients were in Intensive Care Units (ICU), on invasive mechanical ventilation and were suffering from Acute Respiratory Distress Syndrome (ARDS) at the time of treatment.
18-May-2020 - ChAdOx1 nCoV-19
The Telegraph - Doubts over Oxford vaccine as it fails to stop coronavirus in animal trials
Experts warn that vaccine may only be 'partially effective' after results of a trial in rhesus macaque monkeys.
18-May-2020 - ChAdOx1 nCoV-19
sky news - Coronavirus vaccine: How is Oxford vaccine being trialled and when will we know if it works?
The government says 30 million doses could be available across the UK in September if the medical trial turns out well.
18-May-2020 - mAbCo19
About Pharma - Produzioni del vaccino per Covid, Rappuoli: “Bisogna investire milioni sugli impianti”
Per preparare milioni se non miliardi di dosi serviranno investimenti titanici e tutto dipenderà da questo. Rino Rappuoli, direttore scientifico GlaxoSmithKline Vaccines spiega come la sperimentazione non sia l’unico ostacolo da superare, bensì anche la capacità produttiva delle singole aziende. Non tutte potranno farlo e la selezione rischia di essere impietosa.
17-May-2020 - ChAdOx1 nCoV19
NASDAQ/RTT News: AstraZeneca To Make 30 Mln Doses Of Coronavirus Vaccine By Sept If Successful
AstraZeneca will make up to 30 million doses of the Oxford coronavirus vaccine by September if the vaccine is successful. As part of a global licensing agreement between Oxford University and AstraZeneca, the UK-based pharmaceutical company will deliver 100 million doses in total. Sharma announced a new funding of 84 million pounds for two universities to increase production of their potential vaccines.
17-May-2020 - AZD1222
The Times - Race to find coronavirus vaccine has rivals working together
Vaccitech, which was founded by two Oxford professors, Adrian Hill and Sarah Gilbert, in 2016, is part of a consortium that is, so far, Britain’s best hope in the race to find a vaccine. In partnership with Oxford University, Astra Zeneca and other biotech companies, Vaccitech wants to deliver millions of doses of the vaccine.
17-May-2020 – AZD1222
Bloomberg - AstraZeneca Aims for 30 Million U.K. Vaccine Doses by September
AstraZeneca Plc will make as many as 30 million doses of coronavirus vaccine available to the U.K. by September and has committed to delivering 100 million doses this year. The U.K. will be the first country to get access to the vaccine should it be successful.
16-May-2020 - PLX-PAD
The Jerusalem Post - Israel’s Pluristem: 75% of treated COVID-19 patients off ventilators
The Haifa-based regenerative medicine company that has been treating COVID-19 patients with its biological therapeutic products reported that 75% of those treated were off any mechanical ventilation within 28 days.
16-May-2020 - Plant-based protein production
IOL - South African researchers making giant strides in fight against Covid-19
Cape Bio Pharms used a distant cousin of tobacco, Nicotiana benthamiana, as a bioreactor to produce antibodies and antigens
15-May - ChAdOx1 nCoV19
NIH: Investigational ChAdOx1 nCoV-19 vaccine protects monkeys against COVID-19 pneumonia
A single dose of ChAdOx1 nCoV-19, an investigational vaccine against SARS-CoV-2, has protected six rhesus macaques from pneumonia caused by the virus, according to National Institutes of Health scientists and University of Oxford collaborators. The findings posted in preprint server bioRxiv are not yet peer-reviewed but are being shared to assist the public health response to COVID-19. Based on these data, a Phase 1 trial of the candidate vaccine began on April 23 in healthy volunteers in the United Kingdom.
15-May-2020 – NVX-CoV2373
Bloomberg TV - Novavax Could Deliver 100M Covid-19 Vaccine Doses By End of Year, Says R&D Head
Novavax Inc.'s vaccine is one of at least 100 potential candidates trying to curb the spread of the virus that causes Covid-19. The biotech company recently received a funding of $388-million from the Coalition for Epidemic Preparedness Innovation, making it the biggest investment ever from the group. Dr. Gregory Glenn, Novavax's president of research and development, speaks on "Bloomberg Technology."
14-May-2020 PLX-PAD
https://www.nytimes.com/2020/05/14/theater/patti-lupone-marianne-elliott-company.html
The New York Times - The Show’s Delayed, but They’re Still Keeping ‘Company’
By trans-Atlantic email, Patti LuPone and the Broadway director Marianne Elliott talk fear, sadness, camaraderie and the ethics of buying eggs from a Trump supporter; ith a side note on the Pluristem PLX-PAD clinical trial.
14-May-2020 – mAbCo19
https://horizon-magazine.eu/article/aim-find-monoclonal-hunt-antibody-treat-covid-19.html
Horizon Magazine - The aim is to find the monoclonal’: the hunt for the antibody to treat Covid-19
Transfusing antibodies from Covid-19 survivors into seriously ill patients could provide a quick treatment win, but a more selective approach may both treat and prevent the disease. A single, highly-effective antibody that is mass-produced like a drug could combine the benefits of antivirals and a vaccine for at-risk individuals such as health workers.
14-May-2020 – mAbCo19
https://www.lanazione.it/siena/cronaca/coronavirus-anticorpi-1.5147927
La Nazione- Trovati 17 anticorpi che uccidono il virus
I primi successi della ricerca Fondazione Tls-Spallanzani. Le anticipazioni di Rappuoli, le speranze della ’senior scientist’ Claudia Sala
14-May-2020 – PLX-PAD
Israeli Life Sciences - Pluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, today reported an update on the status of COVID-19 infected patients treated with PLX cells under a compassionate use program in Israel and the FDA Single Patient Expanded Access Program in the U.S. All treated patients were in Intensive Care Units (ICU), on invasive mechanical ventilation and suffered from Acute Respiratory Distress Syndrome (ARDS) at the time of treatment. As of today, a total of 18 patients were treated in Israel and in the U.S., of which 8 (1 in the U.S. and 7 in Israel) so far have completed a 28-day follow up period.
13-May-2020 – ChAdOx1-nCoV19 - NVX-CoV2372
CNBC - Scientists race to find a cure or vaccine for the coronavirus. Here are the top drugs in development
Below is a list of the leading vaccines and drugs in development to battle Covid-19.
13-May-2020 - mAbCo19
Corriere di Siena - Farmaco anti Coronavirus, Tls conferma importanti progressi. Il punto sulla ricerca a Siena
Farmaco anti Coronavirus, Toscana Life Sciences conferma gli importanti progressi nella ricerca annunciati dal coordinatore del gruppo di lavoro, Rino Rappuoli, nel corso di una intervista a RaiNews24.
13-May-2020 - mAbCo19
il Cittadino - Covid-19: tra qualche mese pronto un farmaco contro l’infezione
Gsk, Tls e Spallanzani stanno lavorando agli anticorpi monoclonali
12-May-2020 – NVX-CoV2372
CNBC - Novavax CEO talks receiving $384 million in CEPI funding for coronavirus vaccine candidate
Novavax CEO Stanley Erck discussed the biotech company’s efforts to develop a Covid-19 vaccine, including millions in funding to help clinical trials and production
12-May-2020 - mAbCo19
RAI News - Rappuoli: funzionano i nostri anticorpi monoclonali, la cura contro il Covid19
C'è una importante svolta sul fronte della cura di Covid19: Rino Rappuoli, uno dei microbiologi più citati e noti al mondo, il padre del vaccino contro meningococco B e C e quello contro la pertosse, è riuscito a trovare degli anticorpi monoclonali che funzionano contro il nuovo coronavirus. Spiega di cosa si tratti e le prospettive per arrivare ad un vaccino nell’intervista a Gerardo D’Amico
12-May-2020 – Plant based protein production
News24 - WATCH | CT company uses plants to create antigens to test for Covid-19
Cape Bio Pharms is using biotechnology to manufacture Covid-19 proteins in plants. These proteins, called antigens, are used in rapid diagnostic test kits that detect antibodies against the virus in a person's blood, indicating whether they have been exposed to the virus.
12-May-2020 - mAbCo19
https://www.ilsole24ore.com/art/la-cura-made-italy-il-sangue-guariti-ADbVV3P?refresh_ce=1
isole24ore - La cura made in Italy con il sangue dei guariti
Dalla partnership tra Spallanzani e Fondazione Toscana Life Science lo sviluppo di un farmaco. Si punta a produrlo per la primavera del 2021, ma ora servono gli investimenti dell’industria. Di Barbara Gobbi
12-May-2020 – COVAX
https://science.orf.at/stories/3200746/
ORF - Mit dem Masernvirus zum Covid-Impfstoff
Zahlreiche Forschungsgruppen weltweit arbeiten intensiv an einem Impfstoff gegen SARS-CoV-2, auch in Österreich. Die Wiener Biotech-Firma Themis verwendet das Masernvirus, um das Immunsystem auf das neuartige Coronavirus aufmerksam zu machen.
11-May-2020 - VPM1002
https://www.dw.com/en/can-a-tuberculosis-vaccine-help-combat-covid-19/a-53388220
Deutsche Welle - Can a tuberculosis vaccine help combat COVID-19?
VPM1002 is the name of a new tuberculosis vaccine that could possibly help control the novel coronavirus. Scientists at Germany's Max Planck Institute for Infection Biology have developed the vaccine by genetically modifying BCG. Now, scientists are also testing the vaccine for its efficacy against COVID-19. Its precursor has already proven to be effective against other infections. Several studies have been initiated and seem promising.
11-May-2020 - ChAdOx1 nCoV-19
https://indianexpress.com/article/explained/coronavirus-covid-19-vaccine-6402085/
The Indian Express - Covid-19 vaccine: The search for a coronavirus cure
The University of Oxford is researching whether a vaccine that was originally developed for MERS, another coronavirus, could be administered during this pandemic. Called ChAdOx1 nCoV-19, this vaccine would help the body recognise the “spikes” of the virus which are made of protein. As it was already being developing for MERS, it passed the initial stages and is now in the clinical trial phase.
10-May-2020 - GRAd-COV2
Il tempo - Coronavirus, presto test sull'uomo per il vaccino tutto made in Italy
ReiThera Srl ha annunciato i risultati ottenuti dai test del suo vaccino anti-COVID19 negli animali. Stefania Capone, direttore della ricerca preclinica di ReiThera ha dichiarato che una singola somministrazione di vaccino ha indotto una forte risposta immunitaria sia per quanto riguarda gli anticorpi contro il Coronavirus, che sono in grado di prevenire l'infezione, sia per quanto riguarda le cellule T che eliminano il virus già entrato nell'organismo.
10-May-2020 - PLX-PAD
https://en.globes.co.il/en/article-fda-covid-19-trial-nod-boosts-pluristem-1001327952
Globes - FDA Covid-19 trial nod boosts Pluristem
The FDA has cleared Pluristem's application for a Phase II study of its PLX cells in the treatment of severe Covid-19 cases. Pluristem has been treating patients suffering from severe complications caused by COVID-19, such as ARDS and inflammatory complications, in the US and Israel through compassionate use programs. Preliminary data from these compassionate use programs in Israel were reported on April 7, 2020. A Clinical Trial Authorization (CTA) has also been filed in Europe for a Phase II COVID-19 trial, with the first European clinical sites planned in Germany and Italy.
9-May-2020 - ChAdOx1 nCoV-19
https://thenewdaily.com.au/life/wellbeing/2020/05/09/oxford-coronavirus-vaccine-trial/
The New Daily - Coronavirus vaccine trial: Oxford scientists shoot for one million doses by September
Can the safety of a vaccine be established in large enough numbers within the next four to five months? This is the plan of the Oxford University team who are working at unprecedented speed to develop a vaccine against COVID-19. By September, all going well, the Oxford scientists will begin jabbing a million arms with their new vaccine called ChAdOx1 nCoV-19.
8-May-2020 - PLX-PAD
The Jerusalem Post - Israel's Pluristem FDA approved for study in treatment of severe COVID-19
Israel’s Pluristem Therapeutics’ PLX cells therapy has been cleared by the US Food and Drug Administration for a Phase II study in the treatment of severe COVID-19 cases complicated by Acute Respiratory Distress Syndrome.
7-May-2020 PLX-PAD
https://sciencebusiness.net/covid-19/regenerating-bodys-healing-mechanisms-covid-19-patients
Science Business - Regenerating the body’s healing mechanisms for COVID-19 patients
EU-backed Israeli biotech company treats COVID-19 patients with innovative cell therapy. An innovative treatment developed by Pluristem, a regenerative medicine company based in Israel, is showing promise. The company recently signed a non-dilutive financing agreement of €50 million with the European Investment Bank to support the further development of Pluristem’s regenerative cell therapy platform, with a focus on the company’s COVID-19 treatment.
6-May-2020 – PLX-PAD
http://www.xinhuanet.com/english/2020-05/06/c_139033131.htm
Xinhua net - Roundup: Israeli hi-tech firms focus on seeking solutions to COVID-19 challenges
In face of the challenges posed by the COVID-19 pandemic, the Israeli hi-tech industry has focused its efforts on seeking innovative solutions. Pluristem Therapeutics, a company based in the northern Israeli city of Haifa, announced last week it had received a grant of 50 million U.S. dollars from the European Investment Bank (EIB) to further advance its stem cell therapy in curing COVID-19 patients. Pluristem specializes in creating regenerative medicines using full-term placenta cells.
6-May-2020 – plant based protein production
https://ewn.co.za/2020/05/06/covid-19-claims-10-more-lives-in-sa-bringing-death-toll-to-148
Eyewitness News - COVID-19 CLAIMS 10 MORE LIVES IN SA, BRINGING DEATH TOLL TO 148
‚In the Western Cape - Biotechnology firm , Cape Bio Pharms (a spin-off of the Biopharming Research Unit at UCT) is producing plant-based antigens. to be used in conjunction with rapid diagnostic test kits’
5-May-2020 - PLX-PAD
https://www.eib.org/en/stories/placenta-cell-therapy-cure-covid-19
EIB Blog - Placenta cells to fight COVID-19
Can placenta cell therapy cure COVID-19? Israeli-European firm Pluristem is on track to show how placenta cells help the body heal itself.
5-May-2020: Plant-based protein Production
Creamer Media’s Engineering News - Cape Town company joins global efforts to develop plant-based Covid-19 test kits
Cape Bio Pharms, a spin-off company of the Biopharming Research Unit at the University of Cape Town, has partnered with international biotechnology companies to address the international problem of accessibility to affordable reagents and rapid Covid-19 serology testing, with the launch of its Plants Against Corona initiative.
4-May 2020 – ChAdOx1 nCoV-19
https://www.nrc.nl/nieuws/2020/05/04/welk-vaccin-gaat-ons-verlossen-van-dit-virus-a3998583
NRC - De wedloop om hét vaccin
Het is de heilige graal, dé uitweg uit deze pandemie: een coronavaccin. Meer dan negentig prototypen zijn op dit moment in ontwikkeling in laboratoria in een kleine twintig landen. Deze race tegen de klok moet alle records breken. Maar gaat het ook lukken? En vooral: wanneer?
2-May-2020 - ChAdOx1 nCoV-19
Libero Quotidiano - Giuseppe Conte "ha detto no". Dagospia, bomba sul governo: il vaccino anti-coronavirus poteva essere italiano
Il vaccino anti-coronavirus poteva essere italiano, ma Giuseppe Conte ha detto no. E ora, forse, ci ritroveremo a doverlo chiedere alla Gran Bretagna. Dagospia, con un pesantissimo Dago-report, sgancia la bomba sul governo accendendo i fari sulle ricerche condotte in partnership tra lo Jenner Institute della Oxford University e la società IRBM di Pomezia, uno dei fiori all'occhiello della scienza di casa nostra che ha iniziato a lavorare fin da subito per trovare l'arma contro il Covid19.
2-May-2020 - PLX-PAD
https://www.mako.co.il/news-channel12?subChannelId=52d3d5d1b5331710VgnVCM100000700a10acRCRD&vcmid=fd695d064a6d1710VgnVCM100000700a10acRCRD (original in hebrew)
https://www.pluristem.com/pluristem-video/ (original with English subtitles provided by the company)
N12 - Israeli treatment of Corona based on placental cells
Weekend prime time TV news
1-May-2020 - ALL
WHO - WHO and European Investment Bank strengthen efforts to combat COVID-19 and build resilient health systems to face future pandemics
In the context of the COVID-19 pandemic, the EIB is currently assessing over 20 projects in the field of vaccine development, diagnostic and treatment, leading to potential investments in the 700 million EUR range.
30-April-2020 -PLX-PAD
https://www.calcalistech.com/ctech/articles/0,7340,L-3814051,00.html
Ctech - European Investment Bank, Israel Innovation Authority Collaborate on Medical Investments
As part of the collaboration, European Investment Bank has provided Pluristem GmbH, the German subsidiary of Israel-based medical company Pluristem, with a debt loan of €50 million (approximately $54 million)
30-Apr-2020 - VPM1002
The Lancet - Considering BCG vaccination to reduce the impact of COVID-19
By Tedros A Ghebreyesus, among others. In addition to its specific effect against tuberculosis, the BCG vaccine has beneficial nonspecific (off-target) effects on the immune system that protect against a wide range of other infections and are used routinely to treat bladder cancer.1, 2 This has led to the suggestion that vaccination with BCG might have a role in protecting health-care workers and other vulnerable individuals against severe coronavirus disease 2019 (COVID-19).
30-Apr-2020 - PLX-PAD
http://www.israelnationalnews.com/News/News.aspx/279444
Israel National News 7 - €50 loan from European Investment Bank to Israeli company Pluristem
Pluristem is a regenerative medicine company with a focus on novel biological products.
30-Apr-2020 - PLX-PAD
https://www.my9nj.com/video/679516
my9 news - NJ hospital pioneers COVID-19 treatment
Holy Name Medical Center in Teaneck, NJ, is the first to use a breakthrough COVID-19 treatment.
30-Apr-2020 - PLX-PAD
Jerusalem Post - European Investment Bank to assist Israeli bio-convergence research
The European Investment Bank (EIB) and the Israel Innovation Authority (IIA) signed a cooperation agreement on Thursday to pursue investment in the field of bio-convergence for healthcare.
30-Apr-2020 - PLX-PAD
European Commission - New collaboration in innovation and therapies for COVID-19 with Israel
On 30 April 2020 the European Investment Bank (EIB) and the Israel Innovation Authority (IIA) signed a cooperation agreement (MoU) to jointly pursue investment opportunities in the domain of bio-convergence in health.
30-Apr-2020 – ChAdOx1 nCoV-19
BBC News - Oxford 'started developing coronavirus vaccine in January'
Pharmaceutical giant AstraZeneca is to manufacture and distribute a coronavirus vaccine that is being developed by the University of Oxford, if the treatment proves effective. AstraZeneca's chief executive Pascal Soriot tells the BBC why his firm has chosen to back Oxford in developing a vaccine.
28-Apr-2020 - ChAdOx1 nCoV-19
The Economist - An Indian firm starts mass-producing an unproven covid-19 vaccine
On April 21, Adar Poonawalla, boss of the Serum Institute of India, one of the world’s largest producers of vaccines, arrived at work full of optimism about a new vaccine for covid-19, created by the Jenner Institute at Oxford University. In normal times the products that Mr Poonawalla manufactures are proven, effective vaccines. They have regulatory approval, and an order has been placed for them. These are not normal times.
28-Apr-2020 - ChAdOx1 nCoV-19
Algemeen Dagblad - ‘Coronavaccin met Nederlands tintje mogelijk in september al op de markt’
Hoopvol nieuws in sombere coronatijden: wetenschappers van de universiteit van Oxford zeggen dat ze in september een werkend vaccin tegen het virus op de markt kunnen brengen. Er zitten meerdere Nederlandse tintjes aan het vaccin.
27-Apr-2020 – ChAdOx1 nCoV-19
https://www.nytimes.com/2020/04/27/world/europe/coronavirus-vaccine-update-oxford.html
The New York Times - In Race for a Coronavirus Vaccine, an Oxford Group Leaps Ahead
As scientists at the Jenner Institute prepare for mass clinical trials, new tests show their vaccine to be effective in monkeys.
27-Apr-2020 - PLX-PAD
Deutschlandradio - Informationen am Morgen: Kurz vor Impfstoff?
Israel sieht sich als Forschungshochburg gegen COVID-19.
26-April-2020 – NVX-CoV2373
https://www.thesun.co.uk/news/11482679/one-third-americans-think-government-hiding-coronavirus-cure/
The Sun - CORON-SPIRACY - One-third of Americans think government hiding virus cure despite no evidence
SUSPICIOUS Americans reckon a coronavirus vaccine has been created, but that it's being "withheld from the public", a joint study shows
24-Apr-2020 - PLX-PAD
Jerusalem Post - Israel's Pluristem secures €50m. EU financing to boost COVID-19 treatment
Haifa-based Pluristem has secured €50 million ($54m.) in financing from the European Union's European Investment Bank (EIB) to advance its pioneering regenerative cell therapy platform, with a focus on the clinical development of a placenta-based treatment for complications associated with COVID-19.
24-April-2020 – VPM1002
Reuters - Reasons for hope: the drugs, tests and tactics that may conquer coronavirus
With much of the world living in lockdown, the spread of the new coronavirus, SARS-CoV-2, that was first detected in China late last year is beginning to slow in some places. As of April 23, 2.7 million had been infected and 192,000 killed by COVID-19, the disease caused by the virus.
23-Apr-2020 – ChAdOx1 nCoV-19
The New York Times - European Firms Step Up COVID-19 Vaccines Work, UK Team Starts Human Trials
Scientists in Britain began clinical trials of a potential COVID-19 vaccine on Thursday as other vaccine developers across Europe also stepped up work on experimental shots against the disease caused by the new coronavirus.
23-Apr-2020 - ChAdOx1 nCoV-19
BBC - Coronavirus: First patients injected in UK vaccine trial
The first human trial in Europe of a coronavirus vaccine has begun in Oxford. Two volunteers were injected, the first of more than 800 people recruited for the study. Half will receive the Covid-19 vaccine, and half a control vaccine which protects against meningitis but not coronavirus.
23-Apr-2020 - COVAX
https://tvthek.orf.at/profile/Eco/11523082/Eco/14049277
ORF - Magazin ECO: Wettlauf der Forscher, teure Suche nach dem Wirkstoff
Weltweit forschen unzählige Teams an Universitäten und in Pharma-Unternehmen mit Hochdruck an einem Impfstoff oder einem Medikament gegen das Coronavirus. Üblicherweise dauert es zehn bis 15 Jahre bis neue Mittel marktreif sind. Diesmal muss es viel schneller gehen. Auch in Österreich stellt die Regierung Geld zur Verfügung, um die Entwicklung von Medikamenten voranzutreiben.
20 Apr-2020 - ChAdOx1 nCoV-19
Daily Mail - Oxford scientist leading Britain's coronavirus vaccine race urges Government to help produce millions of doses amid hopes jab could be ready by September
An Oxford scientists leading Britain's coronavirus vaccine race has urged the Government to help produce millions of doses before it has proven to be effective.
19-Apr-2020 - ChAdOx1 nCoV-19
https://www.bbc.co.uk/iplayer/episode/m000hk96/the-andrew-marr-show-19042020
(available inside the UK only)
BBC: The Andrew Marr Show
Andrew Marr is joined by Professor Sarah Gilbert, vaccinologist at Oxford University
17-Apr-2020 - VPM1002
https://magazin-forum.de/de/node/18512#article
FORUM: „Etwa 50 Impfstoffe in der Entwicklung“
Prof. Dr. Stefan H. E. Kaufmann hat einen Tuberkulose-Impfstoff entwickelt, der gute Aussichten auf einen Einsatz gegen SARS-CoV-2 hat. Mit FORUM spricht der Biologe über die Entwicklung von spezifischen Impfstoffen sowie Einsatzmöglichkeiten seines Impfstoffs VPM1002.
16 April 2020 - PLX-PAD
https://newyork.cbslocal.com/2020/04/16/coronavirus-placenta-cell-therapy-treatment/
CBS: Coronavirus Update: Hospital In New Jersey Is First In USA To Try Placenta Cell Therapy On A COVID-19 Patient
A New Jersey hospital is the first in the country to try a therapy on a coronavirus patient that utilizes cells from new moms.
Photos from inside Holy Name Medical Center’s ICU show a historic effort to fight the coronavirus: A 49-year-old patient is injected with placenta cells derived from a healthy live birth.
16 April 2020 -PLX-PAD
Bloomberg: Holy Name Medical Center Uses Placenta Cells to Treat Covid-19
Michael Maron, chief executive officer at Holy Name Hospital in Teaneck, New Jersey, discusses progress on an experimental treatment the hospital is using. He speaks with Bloomberg's Emily Chang.
14-April-2020 – PLX-PAD
https://video.foxbusiness.com/v/6149349682001/#sp=show-clips
Fox Business - Placenta coronavirus treatment offers hope: Dr. Ravit Barkama
Holy Name Medical Center Clinical Development Assistant Vice President Dr. Ravit Barkama provides insight into a possible new coronavirus treatment that uses cells taken from a placenta after a baby is born
14 April 2020 - PLX-PAD
Jerusalem Post: Israeli COVID-19 treatment with 100% survival rate tested on US patient
After one week, six critically ill patients in Israel survived. Four of them showed improvement in respiratory parameters.
13 April 2020 - PLX-PAD
https://nypost.com/2020/04/13/could-stem-cells-from-a-babys-placenta-treat-covid-19/#content-wrapper
New York Post: Stem cells from a baby’s placenta may save life of coronavirus victim in NJ
Doctors in New Jersey are battling the coronavirus in one 49-year-old male patient with a revolutionary new treatment — injections of cells from babies’ placentas. The procedure, which was approved by the Food and Drug Administration only on Friday, was carried out Saturday and may be the first of its kind to take place in the entire US.
12-April-2020 -PLX-PAD
The Jerusalem Post - Israeli COVID-19 treatment shows 100% survival rate - preliminary data
Six critically ill coronavirus patients in Israel who are considered high-risk for mortality have been treated with Pluristem’s placenta-based cell-therapy product and survived, according to preliminary data provided by the Haifa-based company.
11 April - ChAdOx1 nCoV-19
Bloomberg: Prognosis. Coronavirus Vaccine Could Be Ready in Six Months: Times
A vaccine against the coronavirus could be ready by September, according to a scientist leading one of Britain’s most advanced teams.
Sarah Gilbert, professor of vaccinology at Oxford University, told The Times on Saturday that she is “80% confident” the vaccine would work, and could be ready by September. Experts have warned the public that vaccines typically take years to develop, and one for the coronavirus could take between 12 to 18 months at best.
11 April - ChAdOx1 nCoV-19
The Times: ‘Many of us have been saying for years that we need more vaccines’
But the Oxford professor closing in on a treatment for Covid-19 isn’t angry, she just wants to do her bit to help.
10 April – NVX-CoV2372
https://www.fox5dc.com/news/montgomery-county-biotech-company-working-on-covid-19-vaccine
FOX5: Montgomery County biotech company working on COVID-19 vaccine
A biotech company in Montgomery County says it's ready to start taking its coronavirus vaccine program to a new phase earlier than they expected, as the company is still working on securing more funding and support for the program.
9-April-2020
BioSpace - Preliminary Data from Pluristem’s PLC Cell Program Shows Promise in COVID-19
The world continues to wait with bated breath for a treatment for COVID-19, and Pluristem Therapeutics appears to be on the cusp of providing some hope. Preliminary data from Israel is showing promise for the company’s experimental treatment.
8 April - PLX-PAD
The Jerusalem Post: Israeli COVID-19 treatment shows 100% survival rate - preliminary data
Six critically ill patients in Israel who were considered high-risk for mortality have been treated with Pluristem’s placenta-based cell-therapy product and survived, according to preliminary data. The patients were treated at three different Israeli medical centres for one week under the country’s compassionate use program and were suffering from acute respiratory failure and inflammatory complications associated with COVID-19. Four of the patients also demonstrated failure of other organ systems, including cardiovascular and kidney failure.
8 April – NVX-CoV2373
https://www.nytimes.com/2020/04/08/health/coronavirus-vaccines.html
The New York Times: More Coronavirus Vaccines and Treatments Move Toward Human Trials
Just three months after the start of the coronavirus pandemic, several biotech companies are beginning trials of promising vaccines and treatments.
7 April – Hydroxychloroquine & Quinine
https://www.zdf.de/verbraucher/volle-kanne/medikamente-gegen-covid-100.html
ZDF: Medikamenten-Tests gegen Covid-19. Ein Lösungsansatz mit altbekannten Mitteln?
Europäische Forschungseinrichtungen beginnen mit klinischen Tests von vier Methoden zur Behandlung von Covid-19-Patienten. Dafür nehmen rund 3200 Probanden Medikamente gegen Ebola, Malaria und HIV ein. Dr. Christoph Specht ist hierzu im Gespräch.
7 April – PLX-PAD
Reuters: Pluristem Reports 100% Survival Rate In 7 COVID-19 Patients
PLURISTEM REPORTS PRELIMINARY DATA FROM ITS COVID-19 COMPASSIONATE USE PROGRAM, TREATING SEVEN PATIENTS WITH ACUTE RESPIRATORY FAILURE
7 April – PLX-PAD
Wallstreet-online: Pluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure
All treated patients were in Intensive Care Units (ICU) on ventilators and suffered from Acute Respiratory Distress Syndrome (ARDS). 100% survival rate for all seven patients.
6 April - VPM1002
https://www.zdf.de/nachrichten/heute-journal/heute-journal-vom-06042020-100.html ZDF Heute Journal: Immun-Booster gegen Sars COV2
magazin coverage at 19:39 min
3 April - VPM1002
CNN: Germany testing tuberculosis drug as coronavirus treatment
A microbiologist in Germany believes that the use of an updated version of a 100-year-old Tuberculosis vaccine may work as an intermediate treatment for Covid-19. CNN's Frederik Pleitgen reports.
3 April - COVAX
Wiener Zeitung: Impfstoff mit Österreich-Komponente
Das Wiener Bioscience-Unternehmen Themis spielt bei der Entwicklung eines Covid-19-Impfstoffs eine Schlüsselrolle.
3 April - VPM1002
Frankfurter Allgemeine Zeitung: Die Zwischenlösung im Kampf gegen Covid-19
Ein alter Impfstoff gegen Tuberkulose soll nun Ärzte und Pflegekräfte vor schweren Verläufen von Covid-19 schützen. Damit er wirksamer ist, wurde er jetzt aufgerüstet. Doch der Wirkstoff ist nur eine Zwischenlösung.
2 April - VPM1002
Reuters: Explainer - How an old tuberculosis vaccine might help fight the new coronavirus
There is no vaccine against the novel coronavirus, called SARS-CoV-2, that is spreading rapidly around the world. But scientists in several countries are testing a century-old tuberculosis (TB) vaccine to see if it might boost the immune system to reduce respiratory symptoms in people who get new coronavirus infections.
1 April - COVAX
https://www.nytimes.com/2020/04/01/world/europe/coronavirus-science-research-cooperation.html
The New York Times: Covid-19 Changed How the World Does Science, Together
Never before, scientists say, have so many of the world’s researchers focused so urgently on a single topic. Nearly all other research has ground to a halt.
1 April– VPM1002
Berliner Zeitung: Hilfe gegen Covid-19: Neue Impfung soll Abwehr gegen Corona verbessern
Sein in Berlin entwickelter Tuberkulose-Impfstoff könnte gefährdete Personengruppen vor einer Corona-Infektion schützen, sagt der Immunologe Stefan Kaufmann. Es handle sich dabei aber nur um eine Übergangslösung.
30 March – PLX-PAD
The Jerusalem Post: Israeli company uses placenta cells to treat critical COVID-19 patients
Pluristem Therapeutics, a Haifa-based regenerative-medicine company, has treated its first three coronavirus patients in Israel with its placenta-based cell-therapy product.
28 March 2020 - Hydroxychloroquine & Quinine
https://www.makanisi.org/coronavirus-la-rdc-terre-du-quinquina-au-centre-des-enjeux-mondiaux/
Makanisi: Coronavirus. la RDC, terre du quinquina, au centre des enjeux mondiaux
Face au Covid-19, des traitements associant la chloroquine, produit synthétique inspiré de la formule chimique de la quinine, seraient prometteurs. La RDC dispose, au Kivu, de vastes plantations de quinquina, un arbre dont l’écorce contient de la quinine, réputée pour ses propriétés antipaludiques. Dans la crise sanitaire actuelle, le pays pourrait avoir une carte à jouer. Les explications d’Etienne Erny, directeur général de la Pharmakina, le géant de cette filière dans le pays
27 March – Hydroxychloroquine & Quinine
Frankfurter Allgemeine Zeitung : Bisher nur grobe Vermutungen
Der Tropenmediziner Peter Kremsner will herausfinden, ob ein Malariamittel gegen Covid-19 hilft.
25 March - Hydroxychloroquine & Quinine
Radio Okapi: Coronavirus. la Task force va réfléchir sur l'opportunité d’appuyer la PHARMAKINA pour fabriquer la chloronique
Le Président de la République, Felix Tshisekedi a promis, mardi 24 février, que la « Task force » qu’il dirige va réfléchir avec le comité de pilotage de la lutte contre le coronavirus sur les contours et l’opportunité d’appuyer la PHARMAKINA.
21 March - ChAdOx1 nCoV-19
ITV: Coronavirus - How scientists are racing to find a Covid-19 vaccine
The first steps towards a coronavirus vaccine in the UK start next week, but a vaccine for all is still a year away at best. Scientists at Public Health England invited the cameras in to their usually off-limits Porton Down research labs. They’re the highest containment laboratories in the UK that handle the really nasty stuff, like Ebola, Marburg disease and the much milder, but much more threatening SARS-CoV-2, the virus that causes COVID-19.
20 March - ChAdOx1 nCoV-19
https://www.newsweek.com/countries-coronavirus-vaccine-trials-covid-19-before-end-year-1493362
Newsweek: 3 Countries Starting Coronavirus Vaccine Trials in global race to stop COVID-19 before end of year.
In the three months since the covid-19 pandemic started, scientists around the world have raced to create the first vaccine against it, with trials either starting or poised to in the U.S., China, and Europe.
20 March - ChAdOx1 nCoV-19
https://www.mirror.co.uk/news/uk-news/coronavirus-vaccine-trials-starting-uk-21723248
Mirror: Coronavirus vaccine trials starting in UK next month in major pandemic breakthrough
Trials of a coronavirus vaccine could begin within the next month, the Government's health agency has said, as it prepares to start evaluating a drug developed by Oxford University. Scientists at Public Health England could give the go-ahead for human testing well ahead of the usual time frame for drug development.
20 March - ChAdOx1 nCoV-19
https://www.telegraph.co.uk/news/2020/03/20/coronavirus-vaccine-trials-could-start-uk-within-month/
The Telegraph: Coronavirus vaccine trials could start in UK within a month
Trials of a coronavirus vaccine could begin within the next month, the Government's health agency has said, as it prepares to start evaluating a drug developed by Oxford University.
20 March– Cape Bio Pharms
https://www.enca.com/news/watch-race-covid-19-local-test-kits
ENCA: The race for COVID-19 local test kits
Diagnostic test kits for the coronavirus are in high demand - but all of them are imported.
A South African company is looking to potentially change that and fast. A cheaper, locally produced kit would separate the seasonal flu sufferer from a person infected with COVID-19, alleviating the strain on our healthcare system. Cape Bio Pharm is introducing spike proteins into plants, which are reproducing them but to what end?
20 March– VPM1002
https://magazin.spiegel.de/SP/2020/14/170213712/index.html
Der Spiegel No 14: Alarm im ganzen Körper
Der Berliner Max-Planck-Forscher Stefan Kaufmann hat einen neuen Impfstoff gegen Tuberkulose entwickelt. Der könnte vielleicht sogar vor Covid-19 schützen.
No preview available
19 March– ChAdOx1 nCoV-19
https://www.theguardian.com/society/2020/mar/19/uk-drive-develop-coronavirus-vaccine-science
The Guardian: Trials to begin on Covid-19 vaccine in UK next month
Researchers at Oxford University, led by Prof Sarah Gilbert, are planning a safety trial on humans of what is expected to be the UK’s first coronavirus vaccine next month. Provided that it goes smoothly, they will move directly into a larger trial to assess how effective the vaccine is at protecting against the infection.
17 March– PLX-PAD
Reuters: Israel to weigh "compassionate use" of Pluristem therapy for COVID-19
Israel’s Health Ministry has approved a request by Pluristem Therapeutics to seek case-by-case permission for compasstional treatment of COVID-19 patients with its stem cell therapy, the company said on Tuesday.
15 March – PLX-PAD
The Jerusalem Post: Israeli cell therapy could treat respiratory effects caused by coronavirus
A regenerative medicine company based in Haifa, Israel, says its placenta-based cell therapy product could be used to treat hundreds of patients who are suffering from respiratory and inflammatory complications associated with the COVID-19 coronavirus.